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Natural product biosynthetic pathways produce a plethora of biologically active compounds, 
including antibiotics. These secondary metabolites are produced by a number of enzyme fam-
ilies found within bacteria, fungi and plants. These enzymes can be large, multidomain, com-
plexes harbouring an intricate series of precisely controlled structural and functional interac-
tions. Once their chemical products are liberated, a wide variety of tailoring enzymes perform 
complex and often understudied chemical reactions to create the final, active, biomolecule. 
This study aims to further our understanding of these processes through the characterisation of 
a number of enzymes within the abyssomicin C biosynthetic pathway. Type I polyketide syn-
thases act in a concerted manner to create a linear chain, which is functionalised before cy-
clisation by the bona fide natural Diels-Alderase, AbyU, eventually leading to the potent anti-
biotic, abyssomicin C. A structural characterisation of the modular polyketide synthase AbyB3 
via X-ray crystallography and cryo-EM methods aims to reconcile existing models for polyke-
tide synthase architecture and mechanism, whilst an in-depth mechanistic characterisation of 
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Since the first demonstration of the antibacterial activity of penicillin by Sir Alexander 
Fleming in 1928,
1
 antibiotics have grown to become a cornerstone of modern medicine. They 
are an irreplaceable tool in our fight against infectious disease and are used globally to treat 
bacterial infections in both human and animal populations. They are also used extensively as a 
prophylactic, for example in livestock, where they used to be fed year-round as common prac-
tice to mitigate the spread of infection.
2
 Within human populations they are employed during 
and following surgical procedures, and are prescribed for individuals within  high risk infection 
groups, including those who are immunosuppressed or are undergoing treatment for cancer. 
Their prevalence in developed medicine is such that almost 30 % of patients in Europe, either 
within a hospital or at the GP, are in receipt of a course of antibiotics at any one time.
3
 This 
figure rises sharply within groups who are more susceptible to infection, such as the elderly 
and infants. In the developing world, antibiotics are often not as widely available to the local 
population, despite their effectiveness. This lack of availability has a huge effect on the health 
of the local population as well as on mortality rates and their causes. In conjunction with a 
number of other factors including hygiene, living conditions and lower vaccination rates, a lack 
of access to antimicrobial agents drives infection based mortality, and increases risks associated 
with routine medical procedures such as childbirth. In western society individuals now have 
limited memory of a time when infectious disease was a leading cause of death, whereas in 
Africa, infectious diseases account for 5 of the top 6 causes of death and 36.6% of all deaths in 
total. In South East Asia 3 of the top six causes of death are attributable to infectious diseases, 
and 14.3% of total deaths. In Europe, where antibiotics are freely accessible, this number falls 
to 2.7% of deaths.
4
 These figures serve to highlight the crucial role of antibiotics in the 
healthcare system. Following their wider adoption at the end of the Second World War, average 
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life expectancy has increased by more than 65 %, from 47 years to 79 years at birth.
5
 Our length 
and quality of life, along with economic prosperity all correlate with antibiotic accessibility. 
 
1.1.1 Antibiotic Resistance 
Our reliance upon antibiotics has always been tempered by the fact that bacteria develop 
resistance to these molecules. This is not a new phenomenon, and has been well documented 
since the first clinical use of antibiotics in 1940.
6
 In this sense antibiotics are much like most 
therapeutic agents, in that if they are unable to cure the patient completely, they are only suc-
cessful until resistance or tolerance has developed. This frequently occurs within oncology, as 
well as during virus or parasite infection. Although antimicrobial resistance (AMR) has existed 
for as long as antibiotics have been in use, it has grown in severity and prominence recently. 
The discovery of multi-drug resistant (MDR) and extensively-drug resistant (XDR) strains of 
bacteria
7
 have made headlines and brought attention to this emerging public health crisis. The 
emergence of AMR has been classified as a major global public health concern by the World 
Health Organisation (WHO), the US based Centre for Disease Control (CDC) and the European 
Centre for Disease Prevention and Control (ECDC). This recognition has largely occurred as a 
result of both the current and future health and economic burdens imposed by AMR. In the 
European Union (EU) there were 400,000 drug-resistant infections recorded in 2007, which 
led to 25,000 deaths and an estimated €1.5 billion cost to the economy.
8
 Similarly, the CDC 
reports 23,000 annual AMR related deaths in the USA. Predictions of the future consequences 
of AMR paint a bleak picture, with a 2014 UK review predicting 10 million deaths by 2050, 
and an economic impact of up to $10 trillion worldwide, if nothing is done to limit the preva-
lence of AMR.
9
    
 
1.1.2 Antibiotic Modes of Action 
The proliferation of AMR has led to a significant investment of time, money and expertise 
into the identification and development of new antimicrobial drugs. This has involved scien-
tists, both in academia and industry, working to understand both the mechanisms of action of 
candidate molecules and the process of resistance emergence. On a molecular level, antibiotics 
typically target enzymes or proteins that perform critical functions in nucleic acid or protein 
synthesis, or in the construction of the cell wall. For example, β-lactams inhibit bacterial cell 
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wall biosynthesis, quinolones interfere with nucleic acid synthesis and tetracyclines inhibit 
protein synthesis.
10
 Alternatively, some classes of antibiotics, such as antimicrobial peptides, 
create pores in the bacterial membrane, initiating lysis.
11
 The most attractive targets for anti-
bacterial intervention are those that are implicitly required for bacterial survival, with inhibition 
resulting in either cell death or severely impeding bacterial growth.  
 
1.1.3 Antibiotic Resistance Mechanisms 
It is now known that resistance significantly predates the human exploitation of antibiotics, 
and as such is a phenomenon that should always be of concern whenever antibiotics are used. 
Evolutionary studies have shown that the β-lactamase-encoding blaOXA genes are in fact sev-
eral million years old.
12
 Similarly a sequencing study of  bacteria isolated from the Antarctic 
permafrost identified > 180 resistance genes spread across twenty three families of bacteria, 
accounting for every known mode of antibiotic resistance.
13
 Resistance genes were developed 
and conserved in order to avoid attack by other microorganisms, and to mitigate issues of self-
toxicity, brought about through the biosynthesis of bioactive molecules designed to target other 
bacteria and thus providing a competitive advantage.  
Bacteria use a number of different strategies to negate the potency of antibiotics.
14
 These 
fall into four key categories, each of which has been outlined in the literature. The first method 
employed involves making modifications to the antibiotic itself. A prominent example of this 
is the expression of β-lactamase enzymes, which cleave a key amide bond within β-lactam 
antibiotics, thereby opening the β-lactam ring essential for activity (Figure 1.1).
15
 The second 
mechanism of resistance hinges on modifying the antibiotic target binding site. This can occur 
directly through the acquisition of point mutations
16
 or via post-translational modifications 
such as methylation.
17
 Alternatively the target binding site may be indirectly protected by 
mechanisms such as the imposition of steric hinderence.
18
 Bacteria are also known to replace 
the individual targets, including through the acquisition of genes encoding redundant enzymes 
capable of performing the role of the enzyme targeted by the antibiotic.
19
 Thirdly, bacteria can 
take measures to reduce the size of the cytoplasmic antibiotic pool. Bacteria have been shown 
to prevent internalisation access by reducing membrane permeability,
20
 or, alternatively, export 
compounds following cell entry. This is usually achieved by efflux pumps, which are complex 
bacterial proteins that can eject toxic compounds in both a highly efficient and specific man-
ner.
21
 Finally, some bacteria are capable of instigating global changes throughout their cells to 
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evade some potent antibiotics, including vancomycin and daptomycin. Although these wide-
ranging responses are not yet fully understood, they involve synergistic mutations in multiple 
enzymes and regulatory elements governing a whole process, such as cell membrane compo-





Figure 1.1 Penicillin Inactivation by b-Lactamases. The b-lactam ring is hydrolysed pre-
venting interaction with the bacterial cell wall.  
 
Crucially, populations of bacteria are not restricted to the acquisition of antibiotic resistance 
solely through internal processes. They are able to acquire resistance elements via horizontal 
gene transfer, a process by which genetic material is actively transferred between individual 
bacterial cells. This process expedites the spread of resistance, and enables MDR strains to 
emerge with greater frequency, particularly within closed systems, such as the gastrointestinal 




1.1.4 Combatting Antimicrobial Resistance 
A number of strategies have consequently been developed to counter both the spread and 


















portfolio, and efforts to limit antibiotic use to only those cases where they are explicitly re-
quired. This later approach is founded on the principle that a key factor in the spread of AMR 
is the exposure of bacteria to low and frequent, or high and infrequent, doses of antibiotics. 
This provides enough of a selection pressure to drive mutation, horizontal gene transfer and 
the proliferation of those individual bacterial cells which are better able to withstand individual 
antibiotics, without killing the population in its entirety. There have been multiple efforts to 
reduce unnecessary antibiotic prescriptions and to reduce non-compliance with the prescribed 
dose. Whilst these efforts can drastically slow the spread of AMR, they will not lead to its 
eradication. Consequently, there is a pressing need to establish as diverse an arsenal of clini-
cally viable antibiotics as is possible, comprising molecules with a panoply of different modes 
of action. Since the 1940s there have been a number of strategies employed to develop new 
antibiotics, which can be broadly divided into two general approaches. 
 
1.1.5 Antibiotic Discovery 
The first strategy is that pursued by the early pioneers of antibiotic discovery including 
Fleming, Duchesne and Lister. Duchesne reported the inhibition of E. coli by Penicillium glau-
cam a full 30 years before Fleming and became the first person to isolate the active compound. 
Similarly, Lister, 28 years prior to Duchesne, demonstrated the cure of a nurse’s infected flesh 
wound using P. glaucam extract, after noticing that it inhibited bacterial growth.23 This discov-
ery route involves identifying strains of microorganisms which are able to inhibit the growth 
of others. The active compound(s) are then isolated, and their effectiveness determined. Com-
pounds isolated via this route are subsequently tested extensively and optimised for activity 
against their biological target. This method of drug discovery has been by far the most prolific, 
yielding 20 different classes of antibiotic between the 1940s and 1970s.
24
  
The second route to antibiotic drug discovery was largely enabled by advances in synthetic 
chemistry and seeks to develop de novo antibiotics able to engage ‘druggable’ molecular tar-
gets. Targets are usually a single protein or enzyme with a key function in an essential bacterial 
process required for survival. A prerequisite of this approach is that identified targets must be 
validated and well characterised, both in vivo and in vitro. Ideally, they are proteins without 
direct relatives within humans, which serves to minimise the potential for off target effects. 
This method of ‘rational’ drug design, had some notable early successes, leading to the devel-
opment of sulphonamides and quinolones amongst others. The last new class of antibiotic 
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discovered via this route was the Oxazolidinones in 1987, during a period when > 20 pharma-
ceutical companies were directly engaged in antibiotic discovery.
24
 In addition to developing 
new antibiotics from first principles, there have also been some successes reported repurposing 




Of all the antibiotics discovered to date, the majority have been isolated from fungi or bac-
teria. Around half of all commercially licensed antibiotics in use today are based on molecules 
isolated from Streptomyces spp.24 This relative abundance is due to the wide variety of antimi-
crobial compounds produced by many bacterial species, which form an important component 
of the producing microorganism’s secondary metabolome. Unlike the products of primary met-
abolic pathways, these compounds are chemically diverse and are an unequalled source of bi-
oactive potential. For these reasons, such natural products remain one of the preeminent 




1.2 Natural Products 
Natural products (NPs) include any product or compound produced by a living organ-
ism.
28,29
 They include both primary metabolites and secondary metabolites, though are gener-
ally considered to be comprised predominantly of the latter. Secondary metabolites have di-
verse roles within plants, animals, fungi and microbes. They are considered to convey a com-
petitive advantage to the natural producer, and hence provide an enhancement in fitness. Sec-
ondary metabolites include, but are not limited to, toxins, molecules with roles in intercellular 
signalling and quorum sensing, defensive compounds, and those necessary for symbiosis and 
other ecological interactions such as harvesting minerals or metals from the environment.
30
 
The vast majority of secondary metabolite NPs are predicted to be currently unknown to sci-
ence, and although the majority of those that have been isolated and characterised are not ac-
tively used by mankind, a significant number have been exploited for use in a variety of indus-




 in personal care prod-
ucts
34
 and as agrochemicals.
35
 Importantly, these compounds also represent an abundant source 







 and enzyme inhibitors.
48,49
 NPs have also 
been employed extensively in food preservation.
50
 Whilst initial attempts to isolate NPs from 
their host species resulted in the ‘golden age’ for antibiotic discovery, the pace at which new 
compounds were characterised declined rapidly from the 1980s onwards. This was due to the 
misguided belief that microbes had been exhausted as a source of novel therapeutic lead com-
pounds, a move that coincided with the emergence of the target driven approach for drug dis-
covery.  
 
1.2.1 Natural Product Discovery 
The last two decades have, however, seen a resurgence in the field of NP discovery and 
exploitation; a consequence of major improvements in the ease and accessibility of DNA se-
quencing and allied technologies.
51
 These technological advances enabled the sequencing and 
subsequent construction of the Streptomyces coelicolor and Salinispora tropica genomes, 
which revealed that > 70 % of their complement of NP producing biosynthetic pathways were 
cryptic and previously unknown.
52,53
 This observation, in conjunction with a recognition that 
there are many bacterial species unculturable under conventional laboratory conditions, has led 
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to recent estimates of the potential existence of > 10 billion unique NPs.
54
 The ability to com-
bine genome sequencing with novel approaches for bacterial cell culture
55
 and the exploration 
of ever more remote geographies, with their highly specialised and unique life forms,
56
 has led 
to an explosion in the number and diversity of natural compounds characterised. For example, 
in 2017 >1490 compounds were isolated from marine microorganisms alone, an increase of 
>17 % from 2016.
57
 These numbers are expected to grow yet further in the coming years, with 
studies in the Antarctic revealing large numbers of NP encoding genes endemic to the region.
58
 
The emergence of AMR, in combination with recent high profile success in the identifica-
tion of ‘new’ bioactive NPs
36
 has led to a surge in interest in the development of new NP based 
antimicrobials. Using an innovative microbial culturing device termed the Isolation Chip 
(iChip),
59
 developed in 2010 to enable researchers to “culture unculturable bacteria”, Ling et 
al. were able to isolate the NP antibiotic teixobactin. This compound inhibits cell wall biosyn-
thesis,
60
 and possesses highly potent bactericidal activity against Gram-positive bacterial 
strains resistant to vancomycin and methicillin, whilst exhibiting no toxicity against mamma-
lian cells and without the detectable emergence of resistance. Despite repeated passages of S. 
aureus bacteria in concentrations of teixobactin below the minimum inhibitory concentration 
(MIC) over 27 days, no resistant colonies could be recovered. Culp et al. recently used a bio-
informatic approach, with the knowledge that genetic information encoding NP-producing en-
zymes is normally co-located on the host genome, to identify biosynthetic gene clusters (BGCs) 
without the presence of observable known resistance determinants.
61
 This led to the discovery 
of a novel glycopeptide antibiotic, corbomycin, which also has activity against methicillin, 
daptomycin and vancomycin resistant strains of S. aureus and Enterococcus. Corbomycin elic-
its its bioactivity by interfering with peptidoglycan biosynthesis, but not by blocking an enzyme 
involved in constructing the cell membrane, rather one responsible for peptidoglycan remod-
elling.
61
 Most recently, Stokes et al. reported the discovery of halicin, named after the Heuris-
tically Programmed ALgorithmic Computer (HAL) from the 1968 film 2001 – A Space Odys-
sey.
62
 Halicin is so named due to its discovery using a deep neural network approach. Artificial 
intelligence was trained in a supervised manner to identify the key attributes for a successful 
antibiotic. This program then analysed libraries containing over 107 million different chemical 
compounds. Halicin displays activity against both Gram-positive and Gram-negative bacteria, 
including against Acinetobacter baumannii, which is regarded by the WHO as one of the “pri-
ority pathogens”; bacteria for which antibiotics are most urgently required. Halicin has been 
demonstrated to kill pan-resistant A. baumannii in mice models,62 leading to hopes that off-
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target effects are minimal. Whilst it is not derived from a natural product, it does highlight the 
value of computational approaches in modern antibiotic discovery processes. Together, these 
studies constitute high profile exemplars of the novel approaches being applied to discover 
novel antibiotics, in particular those of NP origin. These innovative methods have yielded 
structurally unique antibiotics with previously unreported modes of action and broad spectrum 
activity against multiple MDR clinical isolates. A lack of discernible resistance when investi-
gated is also extremely encouraging. 
Another attractive approach for NP discovery is to encourage the production of NPs from 
gene clusters that are inactive, or ‘silent’, under standard laboratory conditions. With the ge-
nomes of many well-studied species of Streptomyces encoding up to 40 individual gene clus-
ters, each with the potential to produce a distinct secondary metabolite,
54
 it is easy to conceive 
of the vast untapped NP potential of these bacteria. In order to unambiguously establish what 
compounds a BGC might produce, predict their structure and efficacy computationally, and to 
produce more chemically distinct derivatives, the enzymology of the biosynthetic pathways 
used to produce these compounds must be understood. The pathways used to produce NPs are 
incredibly diverse, due in part to the fact that secondary metabolite production is generally 
strain-specific.
63
 This contrasts with primary metabolism where there is significant conserva-
tion within the molecular machineries employed, due to the essential nature of these processes. 
This diversity means that many BGCs remain unclassified or poorly understood, with many 




1.2.2 Natural Product Families 
A wide range of secondary metabolite families have been identified in bacteria, classified 
based on commonalities in their chemical origins and biosynthetic pathways used to produce 
them. The collinearity between nucleic acid sequence and product chemistry often enables pre-
diction of NP structure based on BGC sequence. Saccharides are the most common secondary 
metabolite produced by bacteria (Figure 1.2), encoded within 93% of bacterial genomes.
64
 This 
is unsurprising due to the universal role that these metabolites play in biology, acting as signal-
ling molecules and forming major components of cell membranes.
65
 Terpenes are the most 
structurally and chemically diverse group of NPs recorded to date; they are produced by both 
prokaryotes and eukaryotes for a variety of functions.
66
 They include carotenoids for photo-
synthesis
67
 and, in humans, bacteria in the gut microbiome are crucial for the production of 
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retinoids such as Vitamin A.
68
 Terpenes are particularly abundant in plants and include the 
antimalarial compound artemisinin,
69






Figure 1.2 The Distribution of NP Secondary Metabolites in Bacteria. Over 1150 bacte-
rial genomes were analysed and BGCs identified and categorised by product. ‘Other’ includes over 
1000 BGCs that were unable to be classified, as well as a number of rarer, known secondary metabolite 
BGCs. In a third of the bacterial genomes analysed, Saccharides made up over half of the BGCs present, 
whilst they represent over 40% of all BGCs identified. Adapted from Cimermancic et al.64 
 
Ribosomally synthesised and post-translationally modified peptides (RiPPs) are a less well 
studied family of NPs, though these molecules possess potential for use across a range of ap-
plication areas. In these systems, a precursor peptide, attached to a short leader sequence, is 
biosynthesised by the ribosome. This molecule is subsequently recognised by downstream en-
zymes which post-translationally modify the peptide core to generate the mature metabolite. 
Whilst the antibiotic thiostrepton is used in complex ointments, the use of RiPPs as therapeutics 
has been hampered by their poor bioavailability and solubility. This notwithstanding, the prom-
iscuity displayed by RiPP tailoring enzymes shows tremendous potential for use in bioengi-
neering approaches.
71
 These enzymes recognise the leader sequence and then act upon the 
highly variable core of the peptide, creating a structurally diverse suite of biomolecules without 




With respect to clinically proven therapeutic NPs, non-ribosomal peptides (NRPs) and 
polyketides (PKs) are the two most exploited families of secondary metabolites. They are cur-
rently used as immunosuppressive drugs, anti-cancer agents, and are some of our most effective 
and well known antibiotics (Figure 1.3). Clinically relevant NRPs include the anti-cancer drug 
actinomycin D,
73
 the antibiotic vancomycin
74
 and the antiparasitic avermectins.
75
 PKs include 
the antibiotic erythromycin,
76
 whilst hybrid NRP-PKs, which are comprised of building blocks 
originating from both pathways, have also proven to be exploitable therapeutic agents. Exam-
ples include bleomycin, which is used to treat a wide range of carcinomas and lymphomas,
40
 
and rapamycin and its analogues, which exhibit immunosuppressive, anti-cancer, anti-fungal, 
anti-aging and neuroprotective activities
47,77
. The NRP-PK epothilone has also found clinical 
use as an anti-tumour agent, due to its capacity to stabilise microtubules and induce apoptosis.
78
 
Polyketides and hybrid NRP-PKs systems in particular have proved to be highly successful 
sources for pharmaceutical drugs.
79
 As of 2005 > 20 of these agents were available commer-
cially for clinical use, equating > 0.3 % of all known molecules of this class. This compares 
extremely favourably to the < 0.001 % success rate reported from target based drug discovery 
screening programmes.
80
 Thus, the case for PKs, NRPs and their hybrids as priority drug leads 
is a compelling one. In addition to traditional NP discovery methods, there is further  hope that 
synthetic biology approaches will enable the identification and functional optimisation of these 
compounds.
63
 With this as a goal, the field of metabolic engineering aims to construct unnatural 
biosynthetic pathways, both within cells and in vitro, to produce molecules with specific chem-
istry and function. These approaches hope to counter some of the limitations of synthetic chem-
istry; using enzymes to perform one pot biotransformations that might take a synthetic chemist 






1.3 Natural Product Biosynthesis 
1.3.1 Exploiting Natural Product Biosynthetic Pathways 
NP biosynthetic pathways are considered attractive targets for exploitation and re-engineer-
ing, often outside of their natural context. For example, RiPP tailoring enzymes have recently 
been shown to be highly promiscuous, leading to the creation of non-natural hybrid RiPP prod-
ucts.
83
 This has enabled the assembly of chimeric peptides with leader sequences specific for 
a plethora of tailoring enzymes, including those not encoded within the natural pathway. The 
tailoring enzyme then recognises its cognate leader sequence and acts upon its fused partner 
peptide. This capacity for a mix-and-match approach shows promise accessing rationally de-
signed peptide products with predefined functionality. Similarly, non-ribosomal peptide syn-
thetases (NRPSs) and polyketide synthases (PKSs) are both considered attractive targets for 
re-engineering, due in part to their distinctive modular architectures. Both use predictable and 
conserved classes of enzymes to select and install starter and extender unit substrates, assem-
bling a product chain via sequential, pre-programmed condensation reactions, in a manner 
analogous to fatty acid biosynthesis.
84
 The resulting product backbone is then liberated from 
the assembly line-like enzyme and further modified by downstream tailoring enzymes. The 
level of conservation within these classes means that both NRPS and PKS gene clusters can be 
readily identified in silico. Genome sequencing data can then in turn be used as a proxy to 
predict the chemistry of the final pathway product, by aligning the sequence with the sequence 
of known BGCs.
85
 This approach is, however, not without its limitations. Key pharmacological 
nuances, such as compound stereochemistry, or compound modification by trans-acting en-
zymes are sometimes impossible to predict.
86
 
PKSs and NRPSs differ principally in the substrate starter and extender units that they use 
(Figure 1.4). PKSs incorporate predominantly malonyl- and methylmalonyl-CoA building 
blocks, whereas NRPS enzymes have specificity for a much wider range of amino acid sub-
strates. These include all 20 naturally occurring amino acids, in addition to many hundreds of 
non-proteinogenic and unnatural amino acids, and aryl acids.
87,88
 PKSs, which are the focus of 
the work outlined in this thesis, may be classified into one of three distinct families, termed  





Figure 1.3 Biosynthetically Constructed, Therapeutically Relevant, NPs. a) NRPS de-













































































































































































1.3.2 Type I Polyketide Synthases 
Type I PKSs are the largest and most sophisticated family of NP biosynthetic enzymes and 
are broadly divided into two subgroups, iterative PKSs (iPKSs) common to fungi, and modular 
PKSs (mPKS), found predominantly in bacteria. A detailed discussion of Iterative systems goes 
well beyond the scope of this thesis, and thus these systems will not be discussed here.  
mPKS are encoded by large open reading frames (ORFs), that encode for gigantic multi-
domain polypeptides. In most instances each domain within the synthase acts only once during 
the biosynthetic possess, rendering these systems inherently non-iterative. Individual PKS do-
mains are arranged into distinct modules within the PKS, with each module minimally com-
posed of three domains, a ketosynthase (KS), an acyltransferase (AT), and an acyl carrier pro-
tein (ACP). The AT is usually highly selective, functioning as a gatekeeper by dictating the 
choice of acyl-CoA derived substrate to be loaded at each module. Catalytically, these enzymes 
employ a nucleophilic serine residue, housed within the enzyme active site, to attack the thioe-
ster of the selected acyl-CoA substrate, facilitating substrate transfer to the neighbouring ACP 
via a ping-pong mechanism.
89
 KS domains are responsible for catalysing Claisen-like conden-
sation reactions, which link the AT-selected extender unit to the growing polyketide chain. The 
ACPs act as way stations, presenting either the AT-loaded extender units or the extended prod-
uct chain for downstream modification. Both substrates and intermediates are attached to ACPs 
via a phosphopantetheine arm, post-translationally added to a conserved serine residue, which 
attaches the acyl-O-enzyme intermediate via its terminal thiol group.
88,90
 Each module thus 
serves to extend the product chain by two carbon atoms. Following extender unit incorporation, 
the β-branched ketone of this substituent can be selectively reduced to an alcohol, alkene or 
alkane through the action of module specific ketoreductase (KR) domains, dehydratase (DH) 
domains, and enoylreductase (ER) domains, respectively. Each module has a defined compli-
ment of reductive domains, which allows defined control over the oxidation state of product 
incorporated monomers. In addition to these core domains, terminal modules within PKSs of-
ten incorporate a thioesterase (TE) domain, which acts to liberate the immature polyketide 
product from the synthase assembly line.  
The paradigm example of this type of canonical mPKS is the 6-deoxyerythronolide B syn-
thase (DEBS).
91
 It has been studied extensively for over 50 years and is described in greater 
detail below. Although a multitude of synthases have been recently reported that deviate from 
this prototypical canonical architecture, most notably the trans-AT family of PKSs,89 these are 
 36 
of only tangential relevance to the work outlined herein and will thus not be described in sig-
nificant detail in this introduction. Importantly Polyketide synthases of the cis-AT class, which 
adhere to the formal principles outlined above are considered to conform to the ‘Principal of 
Collinearity’. This dictates that the chemistry of the synthase product itself is defined by the 
order and composition of the PKS assembly line, which is in turn dictated by the nucleotide 




Figure 1.4 Commonly Used Starter and Extender Molecules in Polyketide and Non-
Ribosomal Peptide Synthesis. 
 
In contrast to Type I mPKSs, Type I iterative systems act in a cyclical manner, assembling 
their polyketide product using a single set of enzymatic domains to perform multiple rounds of 
chain elongation, typically using malonyl-CoA extender units (Figure 1.5). These systems are 
similarly able to control the degree of product reduction through the action of KR, DH and ER 
domains, but in contrast to mPKS enzymes, these modifications take place during predefined 
cycles of chain extension.
93
 Importantly, studies have reported the presence of semi-iterative 
and iterative modules embedded within mPKSs, in addition to the presence of non-canonical 
domains, casting doubt on the accuracy of making predictions of product chemistry based 


































Figure 1.5 Schematic Representation of Polyketide Biosynthesis. Each domain is repre-
sented by a labelled circle. Type I mPKSs consist of many modules split amongst long polypeptide 
chains, which could each contain 1 to 4 modules. Type I iPKSs consist of a single 6 domain module. 
Type II PKSs also work iteratively, although the domains are expressed individually. Type III PKSs do 
not interact with ACPs in order to create the polyketide chain, instead interacting directly with acyl-
CoA.95 
 
1.3.3 Type II Polyketide Synthases 
Type II polyketide synthases are responsible for the biosynthesis of an array of bioactive 
aromatic polyketides, including the anticancer anthracyclines. They are almost exclusively 
found in actinomycetes bacteria.
96
 The principal difference between type II and type I systems 
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is that type II systems comprise a series of dissociable enzyme domains, which are the products 
of individual ORFs. A minimal type II module consists of an ACP, which anchors the growing 
polyketide chain, and two KS subunits, KSα and KSβ (also known as the chain length factor, 
CLF). The two KS subunits strongly associate to form a heterodimer, and link to the ACP, with 
the KSα domain catalysing the Claisen condensation reaction necessary to extend the product 
chain.
97
 The KSβ domain is the primary determinant of the length of the product chain synthe-
sised and forms a cavity with the KSα domain which is, in turn, occupied by the nascent polyke-
tide chain. This amphipathic tunnel simultaneously prevents any spontaneous cyclisation and 
strictly controls the final chain length.
98,99
 Although the majority of type II PKSs exclusively 
use malonyl-CoA as the starter and extender units, there have recently been reports of systems 
which are capable of using alternative starter units, such as 5-carbon 2-methylbutyryl-CoA in 
the biosynthesis of trioxycarcin.
100
 Once assembled, Type II PKS products are  then further 
modified by downstream enzymes including aromatases, cyclases, oxygenases and transferases 




1.3.4 Type III Polyketide Synthases 
Polyketides produced by Type III systems are typically found in plants, although it is now 
accepted that there are also widespread examples to be found in bacteria.
102
 They are structur-
ally the smallest and simplest of the PKSs, conducting all reactions necessary to construct the 
polyketide product in a single active site. This exists within each monomer comprising the 
functional homodimer.
103
 Similarly to other PKSs, they iteratively catalyse Claisen condensa-
tion reactions, building a polyketide chain from acyl-CoA building blocks, usually malonyl-
CoA. Intramolecular cyclisation catalyses the release of the completed polyketide chain from 
the PKS. Despite their simplicity, type III PKS products are highly diverse and exhibit a wide 
range of bioactivities.
95
 This includes their integral role in mycobacterium biofilm formation 
and pathogenesis.
104
 The structural and functional diversity of these molecules originates in the 
variety of starter and extender units employed during biosynthesis and the nuances of the chain 
cyclisation process, with this latter regulated by the shape of the active site cavity.
95
 Notably, 
extender units used by the Type III system can be widely varied (Figure 1.4), for example, C22-
C26 FAS products are used as starter units for the production of phenolic lipids in Azotobacter 
vinelandii. Crucially, the FAS established a highly specific protein-protein interaction with the 




1.3.5 Non-Ribosomal Peptide Synthases 
NRPSs are analogous to type I mPKSs in that they are composed of large multi-domain 
polypeptides that operate in a non-iterative fashion to assemble a NP scaffold, although NRPS 
biosynthesis relies on the use of amino acid, rather than carboxylic acid, building blocks. Min-
imally, a single NRPS module consists of the adenylation (A) domain, a peptidyl carrier protein 
(PCP) domain and a condensation domain (C). The A domain functions in a manner analogous 
to a PKS AT, selecting the extender or starter unit and loading it onto the terminal thiol of a 
phosphopantetheine arm attached to an ACP equivalent PCP domain. The C domain then ca-
talyses the formation of a peptide bond between the pre-formed peptide intermediate and 
loaded amino acid extender unit, resulting in chain elongation, in a manner akin to a PKS KS 
domain. The chain can then be further modified by accessory domains including methyltrans-





1.3.6 The DEBS Paradigm 
The work outlined in this thesis is primarily concerned with bacterial type I mPKSs, the 
tailoring enzymes that they employ, and the NPs that they produce. In order to establish a foun-
dational understanding of the core principles of mPKS enzymology it is necessary to illustrate 
these features using a paradigm exemplar. The DEBS polyketide synthase, which biosynthe-
sises the 6-deoxyerythronolide B (6-dEB) core of erythromycin, is most studied and best un-
derstood of the mPKSs.
90
 In the early 1990s multiple high-impact papers concerning the do-
main architecture and modular organisation of DEBS were published, along with successful 
expression studies of DEBS within heterologous hosts, including E. coli.107–110 These findings, 
and subsequent clarifications, are summarised diagrammatically in Figure 1.6. They represent 
the first successful attempts to provide a comprehensive understanding of PKS enzymology at 
a molecular level. Importantly these studies themselves build on decades of prior research ex-
ploring the molecular genetics of the natural erythromycin producer Saccharopolyspora ery-
threa.111,112  
DEBS is constructed from three large polypeptide chains, each encoded by its own ORF; 
DEBS1, DEBS2 and DEBS3. These three protein chains assemble a single 14-carbon polyke-
tide product, employing a primary loading domain on DEBS1, two extender modules on each 
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of DEBS1, 2 and 3, and an additional terminal TE domain on DEBS3. Each module further 
contains a KR domain, although the KR domain of module 3 is catalytically inactive. Module 
4 contains additional DH and ER domains, resulting in a fully reduced portion of the polyketide 
backbone. The TE domain of DEBS3 facilitates the liberation of the immature polyketide chain 
from the assembly line, via cyclisation, to form the 6-dEB macrocycle. In summary, 28 active 
sites are arranged across 29 enzyme domains within three large polypeptide chains. This foun-
dational understanding of the molecular organisation of DEBS has been used to guide efforts 
in the determination of molecular structures, interactions and kinetic processes for multiple 
type I mPKSs. For example, it is now known that KS-AT didomains assemble to form homodi-
meric protomers, in a manner dictated by the KS domain, with key intramolecular protein-
protein interactions observed between domains.
91,113,114
 It is also known that linker regions are 
required to control module–module interactions both within and between individual polypep-
tides. a-helical docking domains allow the highly specific passage of the polyketide chain be-
tween adjacent modules.
115,116
 Further flexible linkers differentiate individual domains within 
polypeptides, facilitating substrate-induced conformational changes. Investigation into the 
rules defining the substrate specificity of individual AT domains have been undertaken, in ad-





Figure 1.6 Schematic Diagram of the DEBS mPKS Architecture. Intra-polypeptide link-
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1.4 Engineering Natural Product Assembly Lines 
1.4.1 “Legoization” of Polyketide Synthase Domains 
The insights provided by these detailed enzymological studies of DEBS served to drive ef-
forts towards the rational engineering of this synthase, aiming to access a functionally opti-
mised variant of erythromycin by interchanging domains and modules. This approach has been 
described as the “Legoization” of mPKSs.
118
 The principle idea behind this approach is that 
each domain might be used much like a LEGO
â
 building block, combined with other domains 
to lead to the construction of a designer PKS, biosynthesising similarly bespoke polyketides. 
Ultimately, it is hoped that such an approach could lead to the establishment of huge libraries 
of random combinatorial polyketides. Indeed, theoretical studies show that by only using chem-
istry native to the synthesis of 6dEB, it should be possible to generate >100,000 possible chem-
ical structures, once the number of elongation steps, possible starter molecules, possible ex-
tender molecules and their possible chirality, and the level of reduction is taken into account.
119
 
Once all naturally occurring chemical possibilities present in other known pathways are taken 
into account, this scales to > 800 million theoretically possible polyketides, of which only 
10,000 had been reported as of 2005. Another potential avenue of exploration lies in the pro-
spect of using a semi-synthetic semi-biosynthetic approach to further diversify these com-
pounds. A chemo-biosynthetic approach should in principle lead to an even greater chemical 
diversity. 
There were some notable early successes re-engineering DEBS, with McDaniel et al. pro-
ducing a library of over 50 different erythromycin analogues in 1999, by using single, double 
and triple domain alterations. These relied predominantly on AT substitutions, insertions of 
additional reductive domains and/or removal of reductive domains.
120
 The yield of these ana-
logues was, however, noticeably lower than for the authentic natural product, with yields so 
low that product mass determination proved problematic. Further progress was made by Men-
zella et al., who successfully cloned 14 separate modules from 8 different mPKS clusters and 
assembled them into > 150 different combinations.
121
 In vivo analysis in E. coli allowed deter-
mination of those combinations that were biosynthetically active, resulting in the isolation of a 
number of novel unnatural natural products. Fewer than half of the constructs produced detect-
able product, however, and all were at a lower yield than the parent PKSs. Unfortunately, the 




1.4.2 Engineering Acyltransferase Domains 
Significant efforts were made to swap AT domains between mPKS modules, as this repre-
sents an inherently attractive route to accessing novel products. If an alternative extender mod-
ule can be inserted into a polyketide backbone at a defined position, the prospects for accessing 
new natural product chemistry increase significantly. Initial efforts sought to exploit the natural 
promiscuity exhibited by the loading module of the avermectin biosynthetic pathway, which 
installs both 2-methylbutyryl-CoA and isobutyryl-CoA to generate avermectins A and B. Early 
feeding studies showed that this AT could incorporate > 40 different starter units,
122
 and that 
some of this promiscuity could be readily translated into the DEBS system.
123
 Other studies 
successfully used point mutations to knock out cis-AT activity in DEBS, replacing this essential 
function with surrogate trans-acting AT domains from other systems. This approach has deliv-
ered successes both in vivo,124 and in vitro,125 and mostly without appreciable loss of activity. 
Other researchers have succeeded in using this complementation approach to insert fluorine 
atoms into erythromycin analogues in vivo.126 These studies served to set the benchmark for 
PKS engineering, though there have been more failures than successes and the true potential 
of PKS re-engineering is yet to be fully realised.  
In addition to conducting complete AT domain swaps between PKSs, efforts have also fo-
cussed on attempts to selectively alter the substrate specificity of these enzymes. The exact 
mechanism by which ATs achieve substrate selectivity for malonyl- or methylmalonyl-CoA is 
currently not fully understood, and nor is the basis for AT substrate promiscuity.
127
 For exam-
ple, in the lipomycin PKS system, the initial loading and extender modules exhibit remarkably 
broad specificity for a number of propionyl analogues, but are unable to accept malonyl-CoA 
as a starter or extender unit.
128
 Such ambiguities may, however, be resolved, through the pro-
vision of a detailed molecular description of these AT domains, both alone and in the context 
of the PKS modules within which they reside.  
 
1.4.3 Obstacles to Polyketide Synthase Engineering  
Despite some successes, the frequent failure of efforts to achieve the problem-free substrate 
transfer and assembly of PKs by non-natural PKS assembly lines only serves to highlight the 
oversimplified initial view of PKS enzymology. In reality individual domains have preferred 
upstream and downstream partners, and distinct substrate specificities.
80
 The mechanism by 
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which this selectivity is conferred is influenced by a multitude of factors at the domain, module 
and intact PKS level. It has been shown, for example that successive PKS polypeptides use 
terminal a-helical docking domains to form highly specific complexes with their partner 
poylpeptides.
129
 Any alteration of these sequences results in dramatically reduced product 
yields, as do attempts to mismatch these key elements.
115
 Chen et al. demonstrated that they 
could improve non-natural module activity by preserving the interactions within KS-AT 
didomains, using alternative ACP-substrate partners. This resulted in catalytic activity at a level 
of 70% of that of the wild type module.
128
  
In other attempts to assemble individual modules de novo, extensive module skipping was 
observed. This phenomenon occurs when the polyketide chain is transferred directly between 
ACP domains, bypassing KS and associated reducing domains, and delivering truncated 
polyketide products.
130,131
 It is apparent that a failure to account for the contributions made to 
the biosynthetic processes by complex conformational interactions is likely to translate into 
aberrantly functioning engineered PKSs. Further, and in light of these observations, it is also 
clear that in order to successfully apply a mix and match approach by swapping domains and 







1.5 The Structure of Polyketide Synthases 
1.5.1 The Architectures of Individual Domains  
Initial structural studies of mPKSs relied on the use of limited proteolysis experiments to 
isolate the constituent parts of the DEBS PKS, which could in turn be subjected to high reso-
lution structural studies.
133
 The first mPKS domain to be successfully crystallised was the TE 
domain from DEBS, with the structure of this protein subsequently determined by single crys-
tal X-ray diffraction.
134
 This structure revealed a dimerised domain architecture consistent with 
the known oligomeric state of the intact mPKSs. The 1.79 Å crystal structure of the KR domain 
from DEBS module 1 was the next structure to emerge.
135
 This was rapidly followed by crystal 
structures of two KS-AT didomains. The first of these structures was from DEBS module 5,
113
 
which was followed by the structure of the equivalent didomain from DEBS module 3.
114
 These 
were particularly significant, as they gave insights into both individual domain architectures 
and interdomain protein-protein interactions. Both structures revealed homodimeric complexes 
with an extensive dimerisation interface between the two KS monomers. They also disclosed 
the nature of the KS-AT linker regions and the a-helical docking domain on the N-terminus of 
module 5 (Figure 1.7a). These structures show that the AT domains are arranged horizontally, 
relative to the central KS dimer, implying that major structural reorganisation was required to 
enable the ACP domains to engage both the AT and KS domains.
91
 Interestingly, these struc-
tures were consistent with equivalent structures reported from porcine FAS,
136
 and led to the 
theory that their modular architectures could be consistent.  
The structure of the first mPKS ACP domain, that from DEBS module 2, was determined 
by nuclear magnetic resonance (NMR) spectroscopy. This approach was used in preference to 
X-ray crystallography due to the modest size (~10 kDa) and flexibility of these domains.
137
 To 
date, no crystal structure incorporating a free ACP has been determined, although the structure 
of an ACP in complex with its cognate AT, enabled through the use of  chemical cross linkers, 
has been reported.
138
 The structure of the DH domain of DEBS module 4 was reported in 2008, 
again showing notable similarities to mammalian FAS.
139
 A structure of the final core mPKS 
domain was reported in 2012 by Keatinge-Clay and co-workers, who reported an ER-DH do-
main crystal structure from module 2 of the spinosyn biosynthetic pathway.
140
 This time a no-
table divergence from the structure of the FAS ER was observed, with a deviant dimerisation 
orientation between ER monomers revealed. These investigations allowed the construction of 
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a widely accepted model for the organisation of a complete mPKS module (Figure 7a). Im-
portantly, however, this was derived from structures of isolated domains and not informed by 
detailed studies of mPKS intact modules.  
 
1.5.2 The Architecture of Intact Polyketide Synthase Modules 
In 2014 the first structures of intact modules from mPKS systems were published. The first 
of these studies employed cryo-electron microscopy (cryo-EM) to elucidate the architecture of 
PikAIII from the pikromycin synthase.
141,142
 The second study used solution X-ray scattering 
(SAXS) to elucidate the low resolution structure of DEBS module 3 fused to the DEBS TE 
domain, and that of DEBS modules 5 and 6, similarly fused to its cognate TE domain.
143
 The 
DEBS SAXS structures, elucidated by Khosla and co-workers, were consistent with their pre-
viously reported crystal structures. The researchers used a rigid body fitting approach to for-
mulate a pseudoatomic model of both the DEBS complexes investigated (Figure 5b). The 
SAXS structure was in sharp contrast to the Cryo-EM structure of PikAIII. This structure was 
determined to a maximum resolution of 7.3 Å, insufficient to derive a native atomic model, but  
appropriate for close fitting of DEBS-based homology models of individual PikAIII do-
mains.
141
 This structure revealed an arch-shaped symmetric conformation, with the KS dimer 
located at the apex of the complex and the AT and KR domains extending vertically down-
wards. The two ACP domains were found to occupy one of two distinct locations a solvent 
exposed cavity within the core of the complex. These conformations occurred in an approxi-
mate 1:1 ratio, engaging either the KR or AT domains (Figure 5c). In a companion paper, 
Skiniotis, Smith, Sherman and co-workers also interrogated the structural rearrangements that 
accompany the different stages of polyketide chain elongation during the PikAIII’s catalytic 
cycle.
142
 This was achieved by incubating recombinant PikAIII with its pentaketide substrate, 
both alone and in conjunction with methyl-malonyl-CoA and/or NADPH. In this way, the re-
searchers were able to elucidate a number of PikAIII structures in a series of intermediate cat-
alytic states. They solved structures with substrate bound to the KS and bound to the ACP both 
pre- and post-reduction by the KR domain. Multiple conformational changes were observed, 
including flipping of the KR domain and movement of the ACP within the central cavity of the 
module. Subsequent SAXS studies from the Weissman lab, focusing on intact modules from 




 although it remains unclear as to how comparable these studies are given the 
established differences between cis-and trans-AT systems.  
 
1.5.3 Interpreting Structure-Function Relationships in Polyketide Synthases 
The Cryo-EM studies of Whicher et al. provide compelling support for the hypothesis that 
protein-protein interactions and conformational reorganisation are essential components of 
mPKS module catalysis, consistent with the turnstile mechanism previously proposed by Kho-
sla, Cane and others.
146
 This theory offers an explanation as to why, during the vectoral syn-
thesis of polyketides, there is no stuttering or skipping as is observed in engineered systems. It 
proposes that the linkers and interfaces between individual domains act to instigate conforma-
tional changes as opposed to playing a purely structural role.
79
 In this way, conformational 
changes prevent the loading of the KS with a new polyketide prior to completion of an in 
progress catalytic cycle.  
Together, these studies serve to pose more questions regarding mPKS module function than 
they provide answers. Can the PikAIII structure be considered a universal model for mPKS 
architecture given its apparent disparity with SAXS studies of other mPKS polypeptides? Is 
the horseshoe topology observed in the PikAIII structure not seen in KS-AT didomain X-ray 
structures as these latter proteins lack necessary ACP directed protein-protein interactions to 
adopt this conformation? Would the SAXS data, if refined using the PikAIII cryo-EM structure 
as a starting model, give a structural description more closely mirroring this architecture?
147
 A 
number of excellent reviews have debated relative merits and apparent disparities between each 
of these studies, with each arriving at the same  conclusion: that further structural information 








Figure 1.7 Alternative mPKS Structural Models. a) 2009 hybrid DEBS modular structure 
based on structural analysis by the Khosla and Keatinge-Clay groups (based on Khosla et al.132). The 





























(bright yellow), the flexible KS-AT linker (light yellow), and the post-AT linker (pink) forms the core 
of the assembly. The NMR resolved structure from DEBS module 2 and the KR domain from module 
1 were docked to this computationally. Only one ACP domain is shown for clarity. b) SAXS structure 
of DEBS module 3 connected to a TE domain.143 c) Structure of the porcine FAS solved by Maier et al. 
to a 3.2 Å resolution.152 d) Cryo-EM structure of PikAIII and the molecular DEBS-based atomic map 
fit to the structure.141 Colouring is consistent to the Khosla model, with the pre-KS docking domain in 
bright yellow and the KS-AT linker in light yellow. The post-AT linker is not resolvable and hence is 
not shown. KR0 = pseudo-ketoreductase (facilitates dimerisation but is inactive), MAT = malonyl-acetyl 
transferase (analogous to AT in PKS), ME0 = pseudo-methyltransferase (inactive and homologous to 
methyltransferases). 
 
1.5.4 Biochemical Characterisation of mPKS Domains 
In tandem with structural studies of mPKSs, biochemical and biophysical investigations 
have also served to further our understanding of mPKS enzymology. These have included de-
termining the stereoselectivity of a variety of isolated mPKS domains. For example, Valenzano 
et al. investigated the DH domain of DEBS module 4, demonstrating that it is unable to process 
substrates with alternative stereochemistries, such as those generated by KR domains within 
non-cognate DEBS modules or from alternative mPKSs.
153
 Likewise, ER domains from a num-
ber of pathways have been found to exhibit absolute stereoselectivity for their DH generated 
substrates; though exceptions do exist, such as ER4 from DEBS.
154
 Similarly, in vitro studies 
of ACP and AT domains have established some of the determinants of substrate and partner 





1.6 Recent Advances in mPKS Understanding 
1.6.1 Protein-Protein Interaction-Based mPKS Engineering Approaches 
In light of recent progress in the structural and functional characterisation of mPKSs, re-
engineering efforts have refocused to account for these important observations. A number of 
groups have opted to attempt to engineer PKS pathways without overtly interfering with critical 
protein-protein interactions. This typically involves active site mutagenesis, and results in 
small, but positive outcomes. Sherman and co-workers successfully used this approach to mod-
ify the TE domain from PikAIV to catalyse the macrocyclisation of an unnatural, but closely 
related, substrate, when attached to PikAIII.
155
 Similarly, the specificity of a KS domain from 
the mycolactone biosynthetic pathway was relaxed using structure guided mutagenesis,
156
 
while Jianting Zheng’s lab has successfully probed the stereoselectivity of ER and AT domains 
using similar approaches.
157,158
 This approach is not, however, a guarantee of success, as is 
illustrated by the disabling of KR, DH and ER domains in the premonesin biosynthetic path-
way.
159,160
 Whilst a library of 22 non-natural metabolites was produced, the highest titre was 
~10 times less than for the wild type synthase.   
AT exchanges have also been explored in greater detail recently, with Yuzawa et al. success-
fully delineating the precise boundaries of the AT domain in vitro, allowing for the most effi-
cient translocation of an AT domain to date.
161
 This method attempts to relocate the precise AT 
linker region, allowing for function of the AT without impacting KS activity. This culminated 
in a series of AT domain swaps that didn’t suffer from compromised productivity. The Williams 
lab has reported the successful creation of a chimeric mPKS which sequentially installs two 
non-natural extender units.
162
 This study was significant, as previous attempts at to achieve 
sequential modifications only generated systems producing stalled intermediates, which could 
not be processed by down-stream modules within the PKS. This study exploited the domain 
boundary prediction approach of Yuzawa et al., but despite this still delivered a system that 
showed compromised product yields vs. the non-engineered synthase. These methods were 
applied to enable AT domain swaps within PikAIII and PikAIV, investigating the inherent sub-
strate promiscuity of the domains within these modules.
162
 Similar substitutions could also be 
made into DEBS module 6, which is now known to be highly substrate promiscuous as com-
pared to other modules. These experiments revealed the important roles played by the KS and 
KR domains in substrate selection.  
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These studies are also driving investigations into the potential for producing commodity 
chemicals and biofuels using engineered mPKSs.
127
 Hagan et al. have successfully combined 
domains from 6 separate mPKS modules to produce adipic acid.
163
 Notably, however, attempts 
at creating true chimeras in vitro have still been generally beset by reduced turnover rates as 
compared to wild type synthases, implying that issues associated with the disruption of protein-




1.6.2 High-Throughput Polyketide Synthase Re-Engineering  
In addition to structure-guided approaches, there have also been a number of attempts at 
randomised engineering of NP assembly lines. Whilst these high-throughput methods are lo-
gistically challenging to implement, there have been some notable successes, albeit mostly 
confined to NRPSs.
164,165
 For mPKSs, Kasey et al. have developed a transcription-factor based 
reporting system to detect the expression of macrolides, such as erythromycin.
166
 Wlodek et al. 
have used a recombination-based method to generate libraries of rapamycin analogues in vivo, 




1.6.3 Reclassifying Polyketide Synthase Modules 
In tandem with these re-engineering studies, researchers have also begun to re-evaluate the 
fundamental classification of PKS modules and the domains therein. Keatinge-Clay, building 
on the work of Zhang et al. exploring the evolutionary origins of mPKSs,168 has become a 
proponent of an alternative modular description of mPKSs (Figure 1.8). This is derived from 
studies mapping the evolutionary movement of PKS modules between pathways, with the AT 
typically moving with the downstream KS as opposed to its upstream neighbour.
169
 Initial in-
dications are that the adoption of this description is translating into more efficient module 
swapping, enabling the creation of multiple active venemycin-pikromycin chimeras.
170
 It re-
mains to be seen, however, whether this alternative modular arrangement will expedite further 
engineering efforts and overcome existing bottlenecks in the de novo design of mPKSs.  
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Figure 1.8 Alternative mPKS Module Classification Schemes. Schematic representations 
of an mPKS assembly line, with every domain in a module coloured identically. Distinct polypeptides 
are represented by gaps. a) Traditional module assignment, in line with polypeptide chains. b) Module 
assignment proposed by Keatinge-Clay. Modules are spread between polypeptides with the KS being 
evolutionarily attached to the AT domain preceding it.  
 
1.6.4 Future Goals for Polyketide Synthase Research 
Efforts to rationally design and build mPKSs appear destined to continue at pace over the 
coming years. Our capacity to build mPKSs from first principles is still some way from being 
a tractable proposition with a number of fundamental questions regarding the enzymology of 
these systems still to be satisfactorily answered. A unified structural description of an intact 
module is still needed, with the acquisition of additional structural information viewed as a 
high priority. Ideally such studies should employ a hybrid approach leveraging complimentary 
methods, including cryo-EM, crystallography, biological NMR and solution scattering. Beyond 
this, the structure of a multi-module mPKS polypeptide remains an ambitious target. The 
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b)













































































precise mechanism of vectoral biosynthesis and the process by which polyketide intermediates 
are transferred between modules remain largely unexplored, with this information critical in 
informing future pathway engineering efforts. Recent studies redefining module boundaries 
appear to have positively impacted re-engineering approaches, but it too early to assess their 
significance with any great confidence. In vitro studies are also at a premium, with most inves-
tigations to date carried out in vivo. Expanding the scope and complexity of in vitro studies will 
allow for robust quantitative biochemical analysis, and the application of steady-state and tran-
sient kinetic methods. Finally, it is desirable to widen our knowledge of mPKS systems, with 
current dogma derived largely from studies of only the erythromycin and pikromycin syn-
thases. It is unlikely that studies of these two systems alone will fully capture the peculiarities 




1.7 Biosynthetic Tailoring Enzymes 
Downstream tailoring enzymes are ubiquitous in all secondary metabolite biosynthetic path-
ways, and are capable of performing intriguing chemical transformations. These tailoring en-
zymes can alter the activity and pharmacodynamic properties of the pathway product, and are 
often critical in ensuring the stability, solubility and bioactivity of NPs.
171
 Tailoring enzymes 
commonly include oxygenases, reductases, halogenases, cyclases, ATs and glycosyltransfer-
ases (GTs), amongst others.  
 
1.7.1 Redox Enzymes in Natural Product Biosynthesis 
Redox enzymes are commonly found performing tailoring reactions in polyketide pathways. 
Those that catalyse the insertion of oxygen atoms into the NP scaffold are usually found as 
monooxygenases, which transfer one oxygen atom and reduce the second to water, although 
dioxygenases do exist.
172
 Flavoprotein oxygenases, whose activities are reliant on FMN or 
FAD cofactors, have evolved to use molecular oxygen as a substrate, rather than suppressing 
interactions between the reduced flavin core and oxygen, as is common to most flavopro-
teins.
173
 Monooxygenases are capable of performing a diverse set of reactions including Bae-
yer-Villiger oxygenation, yielding a rare carbonate moiety within the NP scaffold, for example 
in the case of CcsB from the fungal cytochalasin E pathway. These enzymes typically employ 
NADPH as a source of reducing potential, inserting an oxygen atom into a carbonyl group to 
form an ester. Other flavin-dependent proteins have evolved to insert halogens into NPs. This 
is an incredibly powerful tool in biosynthesis, frequently enhancing bioactivity, as is the case 
for vancomycin (Figure 1.3).
171
 Of particular note is the enzyme RebH, which, along with its 
flavin-dependent partner RebF, catalyses the insertion of chlorine during the biosynthesis of 
rebeccamycin (Figure 9).
174
 The RebH/RebF couple also illustrate the potential for tailoring 
enzymes to become industrial biocatalysts. Canonically they halogenate tryptophan, but have 





 These enzymes can also be engineered to enhance product yield and 
activity. For example, the halogenase CtcP, involved in the biosynthesis of the broad spectrum 
antibiotic chlortetracycline, has been subjected to structure guided mutagenesis to enable ele-
vated production of chlortetracycline by 1.7 fold in vivo.177  
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1.7.2 Radical SAM Enzymes in Natural Product Biosynthesis 
S-adenosylmethionine (SAM) dependent enzymes also perform tailoring roles as part of NP 
biosynthetic clusters, particularly in the synthesis of RiPPs.
178
 Radical SAM enzymes can func-
tion as methyltransferases, as in the synthesis of the antibiotic anti-tumour agent thiostrepton 
A,
179
 or as halogenases. For example, SalL catalyses chlorination of the proteasome inhibitor 
salinosporamide A, a marine NP isolated from S. tropica.180 This enzyme has also been shown 





1.7.3 Engineering Transferases from Natural Product Biosynthetic Pathways 
GTs and ATs from biosynthetic pathways have also been developed as industrially relevant 
biocatalysts.
171
 Xie and Tang successfully demonstrated a single step production of simvastatin 
from monacolin J, a process that otherwise requires a five step synthesis, en-route to the pro-
duction of this cholesterol lowering agent (Figure 1.9).
182
 Researchers have also demonstrated 
the capacity for significant improvement in the catalytic performance of tailoring enzymes 
from this pathway, with engineered variants of the AT LovD exhibiting a > 11x enhancement 
in catalytic efficiency vs. the wild type enzyme.
183
 GTs can facilitate significant modifications 
in NP scaffolds. These enzymes are found in a plethora of biosynthetic pathways, modifying a 
number of clinically relevant NPs.
184
 Whilst these enzymes do not normally display substrate 
promiscuity, the GT involved in oleandomycin biosynthesis, OleD, which was isolated from S. 
antibioticus, has been shown capable of accepting non-natural substrates following extensive 
modification via directed evolution.
185
 The directed evolution screen used during this study 
was subsequently employed to select for further engineered variants of OleD that were em-
ployed in the synthesis of multiple functionalised sugar-nucleotides. The best performing OleD 
variant was capable of incorporating 6 functionalised sugars and 5 nucleoside diphosphate ac-
ceptors, yielding a library of 30 distinct sugar-nucleotides.
186
 Similarly, Parajuli et al. have 
used promiscuous GTs to diversify existing NPs, aiming to increase solubility and bioactivity. 
In this study the GT YijiC was shown to be capable of producing 6 non-natural glycosylated 





1.7.4 Standalone Cyclases in Natural Product Biosynthesis 
Although TE domains within mPKS generally considered to be the primary driver of prod-
uct cyclisation during the biosynthesis of polyketide NPs, many biosynthetic pathways also 
incorporate stand-alone cyclases in their compliment of tailoring enzymes. Terpene biosyn-
thetic clusters contain a multitude of cyclases that are amongst the most well understood.
188
 
Cyclases in PKS and NRPS systems are less well characterised, though there have been a num-
ber of interesting candidates identified. SpnF, a cyclase involved the biosynthesis of the insec-
ticide spinosyn A, has been shown to catalyse a [4 + 2] cycloaddition reaction, producing a 
cyclohexene product, in a process analogous to a formal Diels-Alder (DA) reaction (Figure 
1.9).
189,190
 Other cyclases, such as the anthracycline cyclase Snoal, use an aldol condensation 





Figure 1.9 Selected Tailoring Reactions Performed During the Biosynthesis of NPs. 
 
Undoubtedly, there is a significantly greater diversity in the structures and functions of NP 
pathway tailoring enzymes than is observed in core NP pathway synthases. They represent 
viable targets for rational engineering once fully characterised and are often more tractable to 
work with in heterologous hosts due to their modest size. Substrate specificity can be altered, 
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with particularly impressive results achieved using high-throughput directed evolution tech-
niques. They do, however, lack the inherent modularity and potential predictability of mPKSs. 
The study and engineering of these biocatalysts is of high priority and has the potential to 




1.8 Abyssomicin C 
1.8.1 The Isolation of Abyssomicin C 
As part of an ongoing effort to address the antibiotic crisis through the discovery of new 
NPs from unusual environments, in 2004 Bister et al. reported the discovery and isolation of 
abyssomicins B, C, and D from Verrucosispora sp. AB 18-032 (Figure 1.10).192 Recently, how-
ever, the formal classification of this actinomycete strain as Verrucosispora maris was revised 
to Micromonospora maris, as part of a major reclassification of the actinomycetes in their en-
tirety by Göker, Goodfellow and co-workers.
193
 M. maris was first isolated from a sediment 
sample obtained at a depth of almost 300 m off the coast of Japan. During the isolation and 
testing of these three compounds, abyssomicin C was found to represent the major product, as 
well as being the most bioactive of the three, exhibiting potent bioactivity against a variety of 
Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and 
vancomycin resistant S. aureus (VRSA) isolates.194 The potential value of abyssomicin C as an 
antibiotic lead was further enhanced following the establishment of its mode of action, which 
was found to be via inhibition of the key  para-aminobenzoic acid (pABA) biosynthesis en-
zyme PabB. pABA is a precursor required for the biosynthesis of tetrahydrofolate, itself essen-
tial for the production of aromatic amino acids via the folate biosynthetic pathway.  
 
1.8.2 Atrop-Abyssomicin C 
Following the isolation of abyssomicin C, a stereoisomer, atrop-abyssomicin C, was syn-
thesised by Nicolaou and Harrison, and shown to have an increased potency against MRSA 
(Figure 1.10).
195
 It was also demonstrated that incubation of abyssomicin C with a strong acid, 
including those frequently used in high performance liquid chromatography (HPLC) separa-
tion, would catalyse the conversion of atrop-abyssomicin C to abyssomicin C. Careful re-anal-
ysis of M. maris extracts confirmed atrop-abyssomicin C as the principle compound produced, 
and with the most potent inhibitory effect.
196,197
 There have been difficulties, however, in pre-
cisely assigning this atrop-isomerism. Various sources represent the isomerism between the 
ketone at position 7 and the end of the alkene system at position 10 differently.
197–201
 The de-




Figure 1.10 Chemical Structures of Key Abyssomicin and Neoabyssomicin NPs. Num-
bering is consistent for abyssomicins B – D and consistent between abyssomicin 2, neoabyssomicin A 









































































1.8.3 The Folate Biosynthetic Pathway 
The folate biosynthetic pathway is comprised of the shikimate, chorismate and folic acid 
(SCF) pathways (Figure 1.11). pABA is biosynthesised from chorismate, which is in turn gen-
erated through the shikimate pathway. pABA biosynthesis requires two enzymes, 4-amino-4-
deoxychorismate synthase (ADCS), which is comprised of the PabA and PabB monomers, and 
4-amino-4-deoxychorismate lyase (ADCL), also known as PabC. pABA is, in turn, required 
for folic acid biosynthesis, where it is condensed to pteridine by the enzyme dihydropteroate 
synthase (DHPS). Synthesis of folate via this well-studied pathway is ubiquitous in prokaryotes 
and some lesser eukaryotes, but is not present in higher eukaryotes, including humans, who 
obtain folate through consumed nutrients.
202
 The SCF pathway has therefore long been consid-
ered an attractive target for inhibition by antimicrobials, due to its essential nature in microbes 
and anticipated reduced off-target effects in humans. The enormously successful chemical pes-
ticide glyphosate is itself an inhibitor of the shikimate pathway and the sulphonamides repre-
sent clinically approved inhibitors of the folic acid biosynthetic pathway. The antibiotic trime-
thoprim, another example of a successful fully synthetic antibiotic,
203
binds to dihydrofolate 
reductase, preventing the production of tetrahydrofolate (THF). There was, however, until the 
identification of the abyssomicins, no known NP based inhibitor of folate biosynthesis.
201
 A 
combination of pathway validation by the two synthetically derived drugs, along with the emer-




 further enhanced 
the attractiveness of this pathway as an antimicrobial target. The sulphonamides act as a com-
petitive inhibitor of the enzyme DHPS, mimicking the structure of pABA. A common mode of 
sulphonamide resistance is to increase the synthesis of pABA, outcompeting the sulphonamide 
inhibitor. This meant that the identification of atrop-abyssomicin C as an inhibitor of ADCS, 
specifically PabB, via a Michael addition reaction to an active site cysteine (Figure 1.12), rep-
resented the identification of a novel mode of action with the potential to complement sulphon-
amide based therapies, whilst circumventing established resistance mechanisms.
196,201
 The Mi-
chael addition reaction of abyssomicin C with PabB had been predicted based on the chemical 
structure of this compound, as the inactive abyssomicins B and D lack the Michael system 
adjacent to the ketone group. This means that these compounds, which are worse Michael ac-




Figure 1.11 Schematic representation of folate biosynthesis through the SCF pathways. 
ADC, amino-dechorismate; ADCL, amino-dechorismate lyase; ADCS, amino-dechorismate synthase; 
DHF, dihydrofolate; DHP, dihydropteroate; E-4-P, erythrose-4-phosphate; GAT, glutamine amido-
transferase; GTP, guanosine-5’-triphosphate; PEP, phosphoenolpyruvate; THF, tetrahydrofolate.  
 
1.8.4 Abyssomicin Bioactivities 
Abyssomicin C and its atrop-isomer are both defined as small spirotetronates. The small 
spirotetronates consist of a core, comprising a tetronic acid ring spiro-linked to cyclohexene, 
embedded in an 11 carbon macrocycle. There may also be additional ring structures present.
198
 
Within the small spirotetronates there are a number of close analogues of 2 with reported bio-
activities.
201
 Atrop-abyssomicin C has also been shown to display potent bioactivity against 
tuberculosis (TB) strains, as has the analogue abyssomicin J.
207,208
 Abyssomicin J retains ac-
tivity against TB isolates despite having lost the crucial Michael system. Instead this dimer of 
abyssomicins acts as a prodrug, undergoing oxidative activation to yield atrop-abyssomicin C.  






























Figure 1.12 Mechanism of Action by Abyssomicin C and its Atrop-Isomer. Abyssomicin 
C and atrop-abyssomicin C inhibit folate biosynthesis through irreversible binding to the active site 
cysteine of PabB. This occurs due to the two Michael acceptor systems present in 1 and 2 (coloured 
red). Figure adapted from Savic.200 
 
The Neoabyssomicins A & B were recently isolated from Streptomyces koyangenesis, an-
other marine bacterial strain, and were shown to possess a dilactone bridge, differentiating 
them from previously reported abyssomicins (Figure 1.10).
209,210
 Although these intriguing 
scaffolds do not yet have any assigned therapeutic uses, the precursor to neoabyssomicin B, 
abyssomicin 2, has been shown to re-activate latent human immunodeficiency virus (HIV).
211
 
This unusual activity is of interest to those seeking to cure HIV-infected patients, enabling the 
virus to be identified both by the immune system and by other retroviral drugs.
212
 In January 
2020, Zhang et al. reported the isolation of abyssomicin Y and its analogues. This compound 
was shown to have potent antiviral activity, specifically against influenza type A.
213
 
 These recent insights into abyssomicins lacking a Michael system indicate the potential of 
this core NP scaffold as a therapeutic lead. Unfortunately, abyssomicin C has been shown to 
exhibit cytotoxic effects on human cell lines, precluding clinical use. In an effort to address 
this issue, atrop-O-benzyl-desmethylabyssomicin C, featuring a protective benzene group and 
lacking the two methyl groups protruding from the macrocyclic ring, was synthesised by the 
Saicic group.
214
 This molecule exhibits a much lower cytotoxic effect on human cells, but re-
tains activity against clinical isolates of MRSA, giving hope that the cytotoxic mechanism of 
action differs from the Michael addition reaction necessary to inhibit PabB. Further reduction 































1.8.5 Synthesis of Atrop-Abyssomicin C 
The therapeutic potential and novel mode of action of atrop-abyssomicin has resulted in this 
compound being considered an attractive target for total synthesis, with a number of different 
groups having now developed syntheses of this compound and its analogues. The first synthesis 
completed was that of Sorensen and co-workers, and was quickly followed by an alternative 
synthesis completed by Nicolaou and Harrison.
195,216
 Both of these reported routes made use 
of Diels-Alder (DA) reactions to form the central chiral atom. Further synthetic attempts in-
cluded the synthesis of (−)-atrop–abyssomicin C by Bihelovic et al., resulting in an enantiose-
lective product, albeit at only 1.8% yield.
199
 The earlier, non-enantioselective syntheses oc-
curred at similar yields, although with fewer than the 21 steps used by Bihelovic et al. Moti-
vated by these studies  attention began to turn to establishing the biosynthetic origins of the 





1.9 Abyssomicin Biosynthesis 
1.9.1 Characterising the Abyssomicin C Biosynthetic Gene Cluster 
The abyssomicins are not only of interest due to their potential clinical value, but also for 
their unique and varied chemical structures that appear to incorporate many unusual biosyn-
thetic steps.
198
 Upon initial isolation, abyssomicin C was formally classified as a polyketide 
antibiotic,
192
 however, it took until 2011 for a formal investigation into the biosynthesis of 
abyssomicin C to take place. By this time the mechanism of action for abyssomicin C had been 
determined,
196
 and three total syntheses had been reported, though none with a final yield above 
4%.
216–219
 A rigorous growth condition assessment of M. maris had not been undertaken, and 
bacteria from the now redundant genus Verrucosispora had never before been successfully ge-
netically manipulated in the laboratory. Süssmuth and co-workers successfully combined in-
terrogation of the BGC encoding abyssomicin C with C
13
 labelled substrate feeding studies.
220
 
These revealed that abyssomicin C was constructed from 5 acetate units, two propionate units 
and a glucose based 2-carbon molecule. This fits well with the genetic profiling, which identi-
fied the Type I mPKS genes abyB1, abyB2 and abyB3 as containing 7 modules, predicted to 
insert the 5 malonyl-CoA and 2 methylmalonyl-CoA starter and extender units required to form 
the linear carbon chain. Module 5 was predicted to contain inactive KR and DH domains in 
order to maintain collinearity, and genetic analysis determined that inactivating mutations were 
present in their active sites.  
Downstream of the mPKS modules, a variety of tailoring enzymes were identified. Inacti-
vation of any of the enzymes AbyA1 – AbyA4 proved to be catastrophic for the production of 
abyssomicin C, and, for these reasons, as well as genetic comparisons to the Chlorothricin and 
Kijanimicin BGCs,
221,222
 they were predicted to be involved in the formation of the tetronate 
moiety, inserting a glycolytic pathway-generated 2-C molecule. In addition to this, a number 
of genes hypothesised to be involved in the export of the antibiotic molecule (abyF1 – abyF4) 
were identified, along with a cytochrome P450 system (abyV, abyW and abyZ), regulators and 
monooxygenases. Notably, however, Gottardi et al. were unable to identify any enzyme 
thought capable of catalysing the intramolecular DA reaction necessary to cyclise the linear 
polyketide chain 5. 
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1.9.2 Subsequent Characterisation of Individual Enzymes in the Abyssomicin C Biosyn-
thetic Gene Cluster  
Following the first analysis of the abyssomicin C BGC, further studies have elucidated the 
function, structure and mechanisms by which the mPKS gene products and associated tailoring 
enzymes assemble the active compound, atrop-abyssomicin C. An up-to-date overview of this 
pathway is shown in Figure 1.13. The entire BGC is ~57 kb long, of which abyB1 accounts for 
> 17 kb (around 30 %), abyB2 > 11 kb and abyB3 ~3 kb. Whilst the three mPKS genes com-
prise > 55 % of the BGC, there are a minimum of 24 further putative enzymes involved in the 
biosynthesis and export of 2, not all of which have been fully characterised to date. Due to 
many of the issues already discussed the mPKS proteins encoded, AbyB1-3, have only recently 
been subjected to any level of in vitro characterisation.223 Heterologous expression of AbyB3 
has been achieved, the details of which are outlined in the results section of this thesis. While 
not comprehensively studied, the route to the tetronate moiety has been elucidated through 
comparative genomic studies. AbyA3 has been identified as a standalone ACP, responsible for 
reducing glycerate in conjunction with AbyA2, and transferring the product to the polyketide 
backbone. AbyA1 catalyses C-C bond formation, simultaneously forming the tetronate ring 
and liberating the AbyB3 tethered polyketide chain.
198,224
 Once the tetronate ring has installed, 
AbyA4 is hypothesised to acetylate the linear chain via attack at the hydroxyl moiety. This 
prepares the chain for modification by an acetate lyase, AbyA5. This class of enzyme is unique 
to the formation of spirotetronate/spirotetramate NPs, creating the dienophile necessary for DA 
cyclisation. AbyA5 has recently been shown to be a stereo-specific catalyst, efficiently elimi-
nating acetate without the production of hydrolysis products in the natural system.
225
 This lin-
ear chain, 5, now contains the diene system in the hydrocarbon tail and the dienophile, created 
by AbyA5, both of which are necessary for an enzyme-catalysed [4 + 2] cyclisation by a Diels-
Alderase (DAase). This enzyme, AbyU, was reported in 2015 by Byrne et al., and was the first 
reported natural enzyme specifically evolved to catalyse a DA reaction.
224
 AbyU, like all spi-
rotetronate cyclases, does not share any sequence similarity with putative DAases from other 
systems and hence was not included in the original BGC annotation by Gottardi et al. It was 
shown to catalyse the [4 + 2] cycloaddition reaction via a concerted asynchronous DA reaction. 
This will be further elaborated in Chapter 5. The final steps in the conversion of the cyclised 
pre-abyssomicin 6 are not yet fully understood. It is anticipated that a combination of AbyV 
and E create an epoxide group at the expense of the hexene double bond. This highly reactive 
intermediate is then quickly processed to become 2. Subsequent ring opening and formation of 
 66 
a heteromeric, bicyclic, 6-membered ring system is probably catalysed and controlled by fur-




Figure 1.13 A Schematic of the Abyssomicin C Biosynthetic Pathway in M. maris. 
 
1.9.3 Neoabyssomicin Biosynthesis 
Abyssomicin 2 (4), a close analogue of abyssomicin C, is biosynthesised by a highly anal-
ogous enzymatic pathway (Figure 1.14). Further tailoring steps are then possible to produce 
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Similarly to the abyssomicin C pathway, the neoabyssomicin pathway comprises 3 multi-
modular mPKS polypeptides, housing 7 modules. 4 of these are located on AbmB1, 2 on 
AbmB2 and a single minimal module resides on AbmB3. Each module performs the same level 
of reduction on the growing polyketide chain as in the biosynthesis of abyssomicin C. There 
are, however, distinct differences in the substrate specificity of modules 2 and 6. Module 2 
loads methylmalonyl-CoA instead of malonyl-CoA, and module 6 loads malonyl-CoA as op-
posed to methylmalonyl-CoA. These two small changes in chain decoration, in combination 
with the alternative stereoisomer generated during DA catalysed cyclisation, translate to a mod-
ified bioactivity, with abyssomicin 2 exhibiting potent antiviral rather than antibiotic activity. 
The product of the PKS assembly line is similarly modified by the addition of a tetronate head 
group, installed by the enzymes AbmA1 – AbmA5 (analogous to AbyA1-A5). AbmU is then 
hypothesised to catalyse the intramolecular DA reaction, yielding the cyclised isomer of 7. The 
epoxide necessary to create the final ring system is formed through action by AbmV and E, 
before formation of the tetracyclic 3 by AbmV and AbmZ.201,226 In order to convert 3 into 4, a 
Baeyer-Villiger reaction takes place, inserting an oxygen atom into the macrocycle. AbmE2 
and AbmZ have recently been shown to catalyse this interesting reaction, acting in concert, 
with AbmZ functioning as a reductase, allowing AbmE2, a luciferase-like monooxygenase, to 
perform the oxygenation step.
227
 Together these constitute a Type II Bayer-Villiger monooxy-





Figure 1.14 A Schematic of the Neoabyssomicin Biosynthetic Pathway from S. ko-
yangenesis. The only mPKS difference in comparison to the abyssomicin C biosynthetic path-
way is in the loading specificity for methylmalonyl-CoA at module 2 and malonyl-CoA at 
module 6. The resulting change in chain decoration is coloured blue throughout.  
 






































































1.10 Research Aims  
NP biosynthetic pathways are rich sources of novel chemistries and exploitable enzyme bi-
ocatalysts. The abyssomicin C biosynthetic pathway represents an opportunity to further our 
understanding of Type I PKSs, their products, and the suite of tailoring enzymes that are em-
ployed to create the functional biomolecule. Progress made in addressing the significant gaps 
in our understanding of these pathways will facilitate future engineering attempts to exploit 
and improve their products, potentially leading to novel, clinically relevant, compounds. This 
thesis aims to address these gaps in our understanding through the interrogation of two critical 
enzyme classes represented within the abyssomicin C biosynthetic pathway: The Type I PKS 
assembly lines and the DAase AbyU. Specifically, studies have been performed to develop 
cloning and expression protocols for the mPKS polypeptides AbyB2 and AbyB3. Subsequently, 
AbyB3 was subjected to a structural characterisation using complementary X-ray crystallog-
raphy and cryo-EM methods. AbyU has been mechanistically interrogated using transient tech-
niques to determine a deceptively complex reaction mechanism, with further understanding 
developed through the application of high-pressure structural and functional analyses. The 
studies performed herein on AbyU represent the first mechanistic characterisation of its kind 
for a [4 + 2] cyclase or enzyme displaying a b-barrel architecture, whilst the structural charac-
terisation of AbyB3 presents a significant step towards reconciling the conflicting theories of 
mPKS modular architectures. As such the work has potential to significantly improve our un-





2.1  Bioinformatic Analyses 
The following software programmes and online tools were used to conduct bioinformatic 
analyses of target nucleic acid and protein sequences, and for primer design and gene codon 
optimisation. 
• Benchling: https://benchling.com/ 
• Clustal Omega Multi-Sequence Alignment: https://www.ebi.ac.uk/Tools/msa/clustalo/ 
• DNA-DNA Hybridization: http://ggdc.dsmz.de/home.php 
• Emboss Needle Pairwise Sequence Alignment: https://www.ebi.ac.uk/Tools/psa/em-
boss_needle/ 
• Expasy Translate: https://web.expasy.org/translate/ 
• M. maris Genome: https://www.ncbi.nlm.nih.gov/nuccore/NC_015434.1 
• Prot pi Bioinformatics Calculator: https://www.protpi.ch/ 
• ThermoFisher GeneArt Primer and Construct Design Tool: https://www.ther-
mofisher.com/order/oligoDesigner/ 





2.2 Microbiological Techniques 
2.2.1 Polymerase Chain Reaction 
DNA sequences encoding target enzymes were either ordered from ThermoFisher GeneArt 
as synthetic genes, or directly amplified from M. maris genomic DNA. Gene amplification was 
performed using polymerase chain reaction (PCR). PCR reaction mixes were established as 
outlined in Table 2.1. In all cases master mix solutions were employed, comprising pre-mixed 
dNTPs, buffer, thermostable DNA polymerase enzyme and hot start antibody, included to min-
imise non-specific amplification. Unless otherwise specified, CloneAmp HiFi Master Mix 
(Takara Bio) was used for PCR reactions, employing the amplification conditions listed in Ta-
ble 2.2.  
 
Component Volume (µL) Concentration 
Total Volume 25 / 50 - 
2x Master Mix 12.5 / 25 - 
Template DNA 1 / 2 1 ng/µL 
Forward Primer 0.75 / 1.5 10 pMol 
Reverse Primer 0.75 / 1.5 10 pMol 
ddH2O 10 / 20 - 
 
Table 2.1 Typical PCR Reaction Mix Composition. 
 
Temperature (°C) Time (s) Cycles 
98 10 1 
98 5 
30 62 30 
72 30 
72 300 1 
 
Table 2.2 Typical PCR Amplification Conditions. 
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2.2.2 Agarose Gel Electrophoresis 
PCR products were visualised using agarose gel electrophoresis. 1 % agarose gels were 
made by dissolving 0.5 g of agarose powder in 50 mL of Tris/acetate/EDTA (TAE) buffer (40 
mM Tris base, 20 mM acetic acid and 1 mM EDTA) supplemented with 5 µL of SYBR SafeTM 
dye (ThermoFisher, 10,000 x concentration). PCR reactions were mixed with 6x concentrate 
DNA gel loading dye (ThermoFisher) prior to gel loading and electrophoresis. 2 µL of each 
PCR reaction was used for sample analysis, with entire reaction mixes (50 µL) used for gel 
extraction. Gels were electrophorised at 120 V for 25 minutes in a TAE buffer. Gels were vis-
ualised under UV light to assess sample quality and quantity. DNA extractions from agarose 
gels were performed using the QIAquick PCR purification kit (Qiagen), following the manu-
facturer’s instructions.  
 
2.2.3 Plasmid Preparation 
Purified PCR products were inserted into destination plasmids (Appendix Table A2) via 
homologous recombination, employing the In-Fusion cloning kit (Takara Bio), as per the man-
ufacturer’s instructions. 5 µL samples of each recombination mix were transformed into chem-
ically competent E. coli DH5a Stellar cells (Clontech) by 45 s heat shock at 42 °C for 50 
seconds. Following heat shock, cells were subjected to a 45 min outgrowth in LB broth before 
transfer to agar plates. Agar plates were prepared by dissolving 12 g of granular agar in 1 L LB 
broth, followed by supplementation with either 100 µg/mL carbenicillin (Carb) or 50 µg/mL 
kanamycin (Kan), dependent on the antibiotic selection marker present in the host plasmid. 
Plates were incubated at 37 °C for 18h before a single colony was picked and used to inoculate 
10 mL LB broth supplemented with appropriate antibiotic as above. Cultures were grown for 
18h at 37 °C with shaking, following which cells were harvested by centrifugation and plas-
mids were isolated using the QIAprep plasmid miniprep kit (Qiagen), following the manufac-
turer’s instructions. 1 µL of each purified plasmid was used to transform 20 µL of a chemically 
competent E. coli expression strain, typically E. coli BL21 (DE3) (NEB) or E. coli BL21 (DE3) 
BAP1 cells (prepared in-house, see 2.2.4) via the heat shock method. Transformed cells were 
plated onto LB-agar plates as outlined above in preparation for protein expression studies.  
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2.2.4 Preparation of Chemically Competent E. coli Cells 
E. coli cells of the desired strain were plated onto LB-agar plates and grown overnight at 37 
°C. Single colonies were picked and grown in 10 mL LB broth without antibiotic. 0.5 mL was 
used to inoculate 50 mL of fresh LB broth, which was subsequently grown with vigorous shak-
ing to an OD600 nm of 0.4 – 0.6. Cells were subsequently harvested by centrifugation at 4 °C. 
All subsequent preparation steps were conducted in a constant temperature room at  4 °C. Cell 
pellets were gently resuspended in 5 mL TBF I buffer (30 mM potassium acetate, 100 mM 
rubidium chloride, 50 mM manganese chloride, 10 mM calcium chloride, 15% glycerol, pH 
5.8) and left on ice for 10 minutes. Cell suspensions were then centrifuged at 1500 x g and 
supernatants removed. Resulting cell pellets were gently resuspended in TBF II buffer (10 mM 
MOPS, 10 mM rubidium chloride, 75 mM calcium chloride, 30 % glycerol, pH 6.5), before 50 




2.3 Protein Expression, Purification and Analysis  
2.3.1 Small Scale Expression Testing 
0.5 mL of pre-transformed E. coli cell culture was used to inoculate 50 mL of growth media, 
either LB, Terrific Broth (TB) or autoinduction TB (TBAI) broth, supplemented with appro-
priate antibiotic. Cultures were grown to at 37 °C with shaking at 180 rpm to an OD600 nm of 
either 0.4-0.6 for cultures grown in LB, or ~1 for those grown in TB. Once the required optical 
density had been reached, cultures were transferred to a shaking incubator at 20 °C, followed 
by induction with up to 1 mM IPTG. The addition of IPTG was not required for cultures grown 
in autoinduction media. Following induced growth for 18h, aliquots of cell cultures were re-
moved, cells harvested by centrifugation, and samples visualised by SDS-Polyacrylamide gel 
electrophoresis (SDS-PAGE) as outlined below. 
 
2.3.1 Large Scale Protein Expression  
E. coli transformants were grown on agar plates supplemented with appropriate antibiotic. 
Single colonies from these plates were used to inoculate 10 mL of LB broth supplemented with 
appropriate antibiotic. Cultures were grown overnight to turbidity at 37 °C, with shaking at 180 
rpm. These starter cultures were subsequently used as a 1 % inoculant for 1 L of the required 
growth media, LB broth for AbyU or TB for AbyB3 and AbyB3DACP. All growth media were 
supplemented with 100 µg/mL Carb. Cultures were grown at 37 °C with shaking at 180 rpm to 
either an OD600 nm of 0.4-0.6 for LB based cultures or ~1 for TB based cultures. Once the re-
quired OD had been reached, cultures were induced (1 mM IPTG for AbyU, 0.2 mM IPTG for 
AbyB3 and AbyB3DACP) and grown at 20 °C with shaking at 200 rpm for 18 h prior to being 
harvested by centrifugation. Resulting cell pellets were stored at -70 °C prior to lysis. 
 
2.3.2 Protein Purification 
Cell pellets were thawed and resuspended in His Load buffer (20 mM Tris-HCl, 150 mM 
Sodium Chloride, 20 mM Imidazole, pH 8). Cell suspensions were homogenised and passed 
through a cell disruptor (Constant Systems Ltd), with resulting cell lysates clarified by centrif-
ugation at 39,000 x g for either 30 mins (LB based cultures) or 45 mins (TB based cultures). 
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Supernatants were removed and passed through a 5 mL HiTrap HP column (GE life sciences) 
pre-charged with nickel. The column was washed with Load buffer before bound protein was 
eluted over 40 mL using a linear gradient of 0-50% Load to Elute buffer (150 mM NaCl, 20 
mM Tris-HCl, 1 M imidazole, pH 8), with 1.5 mL fractions collected throughout. The absorb-
ance of the column eluent was monitored throughout at 280 nm, with all peak fractions sub-
jected to SDS-PAGE analysis. Eluted fractions containing the protein of interest at > 75 % 
purity were pooled and concentrated to 2 mL. Concentrated proteins were subsequently loaded 
onto either a GE Healthcare 16/60 S75 column for AbyU, or a GE Healthcare 16/60 S200 
column for both AbyB3 and AbyB3DACP. Both columns were pre-equilibrated in size exclu-
sion chromatography (SEC) buffer (150 mM NaCl, 20 mM Tris-HCl, pH 7.5) prior to sample 
loading. This buffer system was also used for protein elution, which was performed at 1 
mL/min, with the absorbance of the column eluent monitored throughout at 280 nm. All peak 
fractions were subjected to SDS-PAGE analysis to assess protein purity and quantity. Protein 
fractions determined to be of > 95 % purity were pooled and concentrated using a Vivaspin 20 
mL centrifugal concentrator (Sartorius). A 10 kDa molecular weight (MW) cut-off was used 
for AbyU and a 50 kDa MW cut-off used for AbyB3 and AbyB3DACP. 
 
2.3.3 SDS-PAGE 
Proteins were resolved using either precast 4-20 % acrylamide gels (BioRad or NuSep), or 









Solution 7 % Resolving 
gel (µL) 
12 % Resolving 
gel (µL) 
15 % Resolving 
gel (µL) 
5 % Stacking gel 
(µL) 
Acrylamide 40 % 175 300 375 125 
Tris-HCl 1.5 M 
pH 8.8 
250 250 250 ----- 
Tris-HCl 0.5 M 
pH 6.8 
----- ----- ------ 250 
Water 555 430 355 605 
AMPS 10 %  8  8  8  12  
TEMED  0.7  0.7  0.7 1.4  
 
Table 2.3 Polyacrylamide Gel Preparation. Each column describes the quantities necessary 
to make 1 mL of gel mix. Typically, 2 gels were cast simultaneously using a combined 8 mL resolving 
solution and 2 mL stacking solution. AMPS, ammonium persulphate; TEMED, Tetramethylethylenedi-
amine.  
 
For sample analysis 2 µL from each fraction to be analysed was added to 5 µL SDS-PAGE 
loading dye (4% SDS, 125 mM Tris-HCl pH 6.8, 20 % Glycerol, 0.004 % Bromophenol Blue, 
0.02% 2-mercaptoethanol) and denatured by heating at 95 °C for 5 minutes. Samples were 
subsequently loaded into the wells of the gel and subject to electrophoresis at 220 V for 35 
minutes. Gels were then stained using Coomassie blue solution (40% MeOH, 7% Acetic acid, 





Heterologous Production of Recombinant 
Polyketide Synthase Modules and Multi-
Modular Polypeptides  
 
3.1 Introduction 
3.1.1  Heterologous Expression and Model Organisms 
The ability to express individual genes and entire gene clusters within hosts aside from their 
native producers has been a cornerstone of biotechnology and medicine for decades. This tech-
nology allows us to study proteins, enzymes and pathways of interest within tractable and well-
characterised host organisms.
228
 Within the plant world, Arabidopsis thaliana has become the 
model organism of choice,
229,230
 affording a proxy for basic research into plant biology, struc-
ture and function. It has also enabled extensive research into the natural biology of crops, as 
well as their genetic modification to increase nutritious value or resilience.
231–233
 In the animal 
and particularly mammalian world, the development of well characterised human cell lines and 
animal models, frequently mice,
234,235
 have proven similarly transformative in establishing the 
fundamentals of animal biology
236
 and in the identification of therapeutic candidates prior to 
the commencement of clinical trials.
237,238
 Saccharomyces cerevisiae have been developed as 
the simplest of eukaryotic model organisms,
239
 whilst E. coli is the undisputed model organism 
of the prokaryotic world.
240
  
There are several prerequisites for the establishment of a viable and universal model organ-
ism. They must be cheap to maintain (relatively speaking), quick to grow and genetically trac-
table. Crucially, they must also provide a viable imitation of the natural producer or molecular 
target for drug efficacy trials.
241
 This means that it is preferential to use as simple a model as 
possible for the work to be undertaken, whilst preserving key characteristics necessary for 
comprehensive analysis. For investigating complex therapeutic responses or disease 
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characteristics in humans, primate species are frequently required,
242
 however, if investigating 
the mechanism of a human enzyme, one would first be inclined to express such a target recom-
binantly within E. coli,243 or if unsuccessful S. cerevisiae,244 then insect cells,245 and only if 
explicitly required, mammalian cell lines.
246,247
 Bacterial enzymes and proteins are commonly 
expressed within E. coli cells, as their frequent lack of requirement for post-translational mod-
ifications renders them more easily expressed.
240
 Complex proteins, however, do often require 
co-expression with chaperones or regulatory enzymes that are absent in E. coli, to enable pro-




3.1.2 The Heterologous Expression of Natural Products 
The study of NP biosynthetic pathways outside of their cognate host organisms has long 
presented a significant challenge in the field of biosynthesis. Polyketides and other NPs are 
often highly complex molecules that are extremely difficult, if not impossible, to access via 
synthetic methodology.
108
 Due to their therapeutic potential, large scale fermentation of NP 
producers has become the method of choice for the production of numerous NP based active 
pharmaceutical ingredients. For example, S. erythraea has been used to produce erythromycin 
in industrial quantities for as long as this antibiotic has been in clinical use.
249
 This parent strain 
has been ‘improved’ through multiple cycles of optimisation over many years.
250
 Despite recent 
successes in producing this antibiotic in E. coli.,251,252 S. erythraea remains the preferred route 
to industrial scale erythromycin production. In general, complex NP producers, largely the ac-
tinomycetes and related families, are difficult to culture under standard laboratory condi-
tions.
248
 We often have a limited understanding of the correct culturing conditions required to 
both grow and facilitate NP production from host strains.
253
 Even in instances where laboratory 
scale culture has been proven viable, producers are often extremely slow growing and, in most 
cases, the molecular tools required for genetic manipulation are poorly developed, if at all.
160,248
 
In addition, the advent of functional genomics, previously discussed in its relevance to the 
discovery of novel BGCs, enzymes and products, has allowed us to identify multiple BGCs 
that are not expressed under laboratory conditions.
254
 Heterologous expression of BGCs in 
more tractable model organisms is, therefore, generally preferable to working with the native 
producers themselves.  
The selection of a suitable host organism for heterologous NP pathway expression is chal-
lenging. In order to produce a functional PKS or NRPS, the host organism must be capable of 
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expressing and folding large polypeptide chains encompassing multiple enzyme active sites. 
In addition, they must be capable of supporting post-translational modification of these pro-
teins, through the introduction of the phosphopantetheinyl arm necessary for ACP function.
108
 
To facilitate the heterologous production of PKS NPs a number of Streptomyces species have 
been investigated, modified and developed as potential surrogate hosts.
255–257
 Streptomyces are 
the most well studied of the actinomycetes and hence tend to contain much of the biosynthetic 
machinery necessary for the correct production of polyketides, as well being a physiologically 
closer match to the native producer. Early attempts to reproduce PKS function in heterologous 
hosts centred on S. coelicolor and S. lividans.258,259 Many of the current genetic techniques used 
to facilitate the study of BGCs within Streptomyces species were developed using these 
hosts.
260
 Recent studies, however, have sought to use alternative strains to overcome some of 
the difficulties presented by S. coelicolor and S. lividans. These alternative Streptomyces strains 
have been selected on the basis of their rapid growth rate and genetic tractability.
257
 Many also 
possess abbreviated genomes,
261
 meaning that fewer genetic modifications are needed to gen-




3.1.3 E. coli as a Heterologous Host for the Production of PKS Enzymes and Products 
Despite significant progress in strain optimisation, heterologous Streptomyces expression 
hosts are still some way from being the ideal chassis microorganism for PKS expression. Their 
comparatively slow growth rate, along with the modest toolbox of genetic parts and techniques 
available for their manipulation and their large genomes rich in BGCs, all represent significant 
obstacles that still need to be overcome.
263
 E. coli, by contrast, is in principle an ideal heterol-
ogous host. This bacterium is fast growing, is highly amenable to genetic manipulation using 
well established tools and possesses a well characterised metabolome, allowing for standard-
ised characterisation of NPs produced from this host.
263,264
 E. coli is, however, not without its 
limitations. It is physiologically distant from the actinomycetes, and lacks the post-translational 
machinery required to catalyse phosphopantetheinyl transfer. 
In an effort to circumvent these issues, Pfeifer et al. generated a genetically engineered strain 
of E. coli termed BAP1.108 The feasibility of using this strain to produce intact PKSs was 
demonstrated through the expression of a functional DEBS pathway in this host, which in turn 
delivered modest quantities of 6-dEB, with yields subsequently improved, via strain engineer-
ing, to levels comparative to heterologous Streptomyces hosts.265 In order to achieve this, 
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Pfeifer et al. increased the quantities of the DEBS substrate, methylmalonyl-CoA, present in 
the cell by upregulation of the propionyl-CoA synthetase, deleting a propionate catabolism 
gene cluster and co-expressing a propionyl-CoA carboxylase. Crucially, the team also inserted 
the gene for a promiscuous phosphopantetheinyl transferase enzyme from Bacillus subtilis into 
the E. coli, under the control of the T7 inducer.  
The generation of E. coli BAP1 has facilitated many of the most significant advances in the 
understanding of PKS (bio)chemistry, as well as proving a key tool in efforts to re-engineer 
PKS enzymology. Without exception, the structural characterisation of intact PKS modules 
from the erythromycin and pikromycin pathways has relied on the use of E. coli BAP1 to gen-
erate functional protein.
141–143
 Kalkreuter et al. used E. coli BAP1 to produce pikromycin mod-
ules capable of installing sequential non-natural extender units
162
 and Zhang et al. used it in 
the production of erythromycin analogues.
266
 BAP1 cells have also been used to investigate 
and improve the function and interactions of specific domains within PKSs
155,267
 and to inves-
tigate substrate selectivity in vivo.268 In addition to the well-studied pikromycin and erythro-
mycin PKSs, BAP1 has also been deployed successfully in investigations of the minimal fungal 
polyketide synthase LovB
269
  hybrid fungal polyketide synthase modules
270
 and type I iPKS 
modules.
271
 This strain has also been used to express functional NRPS modules, both alone and 
as components of hybrid systems.
272
 An overwhelming body of evidence suggests that, cur-
rently, E. coli BAP1 or analogous strains,170 represent the optimum host system for the recom-
binant production of PKS polypeptides. 
 
3.1.4 Additional Challenges in the Heterologous Expression of mPKSs 
Despite its advantages, E. coli BAP1 is still some way from being a universal chassis for 
the heterologous expression of mPKS modules.
264
 Notwithstanding the success a small number 
of labs and their alumni have had interrogating PKS modules from the erythromycin and pikro-
mycin pathways,
108,141,148
 there remains a dearth of information regarding PKS modules from 
non-model systems. Non-model gene clusters are often identified in, and isolated from, a more 
diverse set of microorganisms, which themselves are often isolated from diverse and evermore 
hostile environments.
57,58
 Many of these strains are extremely slow growing or impossible to 
culture, and even when this is possible, the isolation of good quality genomic DNA from Strep-
tomyces and related species can be challenging.223 Even when successful genomic DNA puri-
fication is achieved, it can still be extremely challenging to work with. Modular PKSs are by 
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definition repetitive, especially if multiple modules are encoded on a single gene. This presents 
challenges when attempting to use standard molecular cloning techniques such as PCR or ho-
mologous recombination, due to the mismatch of primers or homologous regions of sequence. 
These issues can be further complicated by very high (or very low) GC content within the 
genome. For example, the genes abyB1, abyB2 and abyB3 from the abyssomicin biosynthetic 
pathway have an average GC content of 76 %. Not only does this create significant repetition 
within the genes, but it also leads to a necessary codon usage very different to that of E. coli.  
Codon bias is a well-documented phenomenon, where bacteria use a sub-set of codons far 
more frequently than others to encode specific amino acids.
273
 Bacterial species can display 
remarkably different biases towards certain codons, which is reflected by the availability of the 
cognate tRNA within the cell. This bias and availability of tRNAs was identified as the most 
important factor in determining successful heterologous expression.
274
 One potential route to-
wards solving this issue is to take an approach as outlined by Maschio et al.223 This involves 
commercially synthesising genetic material, codon optimised for the target producer, encoding 
each PKS polypeptide in as a series of DNA fragments, which are then assembled into an intact 
coding sequence, to be subsequently inserted into an expression vector and transferred to E. 
coli BAP1. This approach could expedite the recombinant expression of intact polyketide syn-




All general molecular biology methods were performed as described in Chapter 2, with any 
deviation from these methods highlighted in the text, such as the use of an alternative DNA 
polymerase. Experimental methods specific to the study outlined in this chapter are outlined 
below.  
 
3.2.1 Colony PCR 
Colony PCR screening was performed using a modified version of the general PCR protocol 
described in Chapter 2, Section 2.1. Individual colonies were picked from the agar plates using 
sterile pipette tips. Tips were subsequently dipped into 5 µL of ddH2O, before being submerged 
in 10 mL of LB broth supplemented with Carb. The 5 µL ddH2O was subsequently used as a 
template for PCR screening reactions. Screening PCRs were performed using the protocol out-
lined in 2.1, employing GoTaq Green master mix (Promega). PCR conditions were amended 
to include an initial 5 minute denaturation step at 95 °C, to ensure comprehensive lysis of the 
bacterial cells present in the template mixture. Resultant PCR products were analysed by aga-
rose gel electrophoresis as described previously. 
 
3.2.2 Small Scale Protein Expression Tests 
Agar plates and growth media used for the propagation of E.coli transformants harbouring 
pOPINF derived plasmids (developed by the Oxford Protein Production Facility, UK, specifi-
cally for use with the InFusion cloning kit used
275
) were supplemented with 100 µg/mL Carb, 
whilst plates and media used for the growth of cells transformed with pET28a derived plasmids 
were supplemented with 50 µg/mL Kan. Cultures were inoculated and grown as described in 
Section 2.3.1. Further details of the conditions explored during expression testing are summa-
rised in Section 3.4.1. Following overnight growth, cells were harvested by centrifugation at 
3,400 x g for 20 minutes. Harvested cells were subsequently re-suspended in 2 mL of His Load 
buffer. 1.5 mL of this suspension was lysed by sonication on ice. Suspensions were then clari-
fied by centrifugation at 19,000 x g for 20 minutes at 5 °C. Recovered supernatants and pellets 
were separated and analysed by SDS-PAGE. These samples were prepared as follows: for 
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supernatants,  2 µL samples were mixed with 5 µL of SDS-PAGE loading buffer before dena-
turation at 95 °C for 5 minutes; for pellets, a scraping of the cell pellet was taken and resus-
pended in 100 µL of 8 M urea, with 1 µL of this sample then added to 9 µL of SDS-PAGE 
loading buffer before denaturation at 95 °C for 10 minutes. All samples were loaded and elec-
trophoresed as described previously.  
 
3.2.3 Tryptic Digest MALDI Mass Spectrometry of AbyB3 
The identity of recombinant AbyB3 was confirmed using tryptic digest MALDI mass spec-
trometry. All analyses were performed by the University of Bristol Proteomics Facility. Indi-
vidual SDS-PAGE gel bands with masses corresponding to that of AbyB3, were excised, 
washed in ddH2O and summitted for characterisation. 
 
3.2.4 Expression and Purification of AbyB3 
AbyB3 was cloned as described in Section 3.4. Following transformation using the heat 
shock method described in Chapter 2, three colonies of E. coli BL21 (DE3) BAP1, transformed 
with AbyB3::pOPINF, were used to inoculate a single 10 mL solution of LB broth, supple-
mented with 1 % glucose and 100 µg/mL Carb. 1 L of Modified TB (Melford) medium was 
prepared according to the manufacturer’s instructions, including the addition of 5 mL of glyc-
erol. The media should then be precisely autoclaved, also according to the manufacturer’s in-
structions, as any overheating of the glycerol added results in a lack of expression. The over-
night culture is then used as a 1 % inoculant for the prepared media in a baffled flask. The 
culture is then grown at 37 °C, with shaking at 180 – 200 rpm until an OD600 nm of ~1 is reached. 
If no significant growth is observed after 4 h the culture should be disposed of. Once OD has 
been reached, the culture is placed at 20 °C with shaking at 200 rpm for 1 hour. The culture is 
then inoculated with a final concentration of 200 µM IPTG and left for 18 h.  
The cells were harvested and lysed as described in Chapter 2. The purification also pro-
ceeded as outlined in Chapter 2, with the following modifications. AbyB3 was purified by 
nickel affinity chromatography using a HEPES Load Buffer (50 mM HEPES, 250 mM NaCl, 
20 mM Imidazole pH 8) and a HEPES Elute Buffer (50 mM HEPES, 250 mM NaCl, 1 M 
Imidazole pH 8). It was subsequently purified by SEC using HEPES Buffer (50 mM HEPES, 
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250 mM NaCl, pH 7.5) and a GE Healthcare 16/60 S200 column. AbyB3 was typically used 
within 3 days of purification, or flash frozen in liquid nitrogen, in the presence of 10 % glycerol, 
for storage at -70 °C. 
 
3.2.5 Native PAGE Analysis 
Protein samples to be analysed by blue native PAGE were mixed with 4x NativePAGE sam-
ple buffer (ThermoFisher Scientific) on ice. 500 mL Novex NativePAGE Running Buffer and 
200 mL Novex NativePAGE Cathode Buffer (both 20x, Invitrogen) were prepared according 
to the manufacturer’s instructions. A Novex Tris-Glycine Native PAGE gel (ThermoFisher Sci-
entific) was prepared by first rinsing and then filling each well of the gel with Cathode Buffer, 
prior to transfer of the gel into the electrophoresis apparatus. Protein samples were then loaded, 
and the central reservoir of the apparatus filled with 1x Cathode buffer. The outer reservoir of 
the gel apparatus was filled with 1x Running Buffer. Electrophoresis was conducted at 150 V 
for 100 minutes. Gels were rinsed with ddH2O and de-stained as outlined for SDS-PAGE gels.  
 
3.2.6 Negative Stain Electron Microscopy 
AbyB3 was purified by SEC using a non-phosphate based buffer, typically 50 mM HEPES, 
250 mM NaCl, pH 7.5. A 300-mesh nickel grid, coated with an ultra-thin layer of carbon, ~ 5 
nm thick (Electron Microscopy Sciences), was glow-discharged at 15 mA for one minute using 
a Leica EM ACE600. On a sheet of parafilm, two 50 µL drops of HEPES buffer and one 5 µL 
drop of 3 % uranyl acetate solution were prepared. The glow-discharged grid was carefully 
taken by the rim, and a 5 µL drop of protein solution, at a concentration of 10 µg/µL was 
applied and left for 2 minutes. After this incubation, the remaining protein solution was re-
moved by blotting using a Whatman No.1 Filter paper. Following blotting, grids were placed 
face down on a drop of HEPES buffer, followed by a second blotting step to remove excess 
buffer. Grids were then placed face down on the drop of uranyl acetate, for one minute. Excess 
uranyl acetate was removed by blotting and grids washed again in HEPES buffer before a final 
blotting step, and were then left to dry completely at room temperature. Grids were imaged 
using a 200 kV Technai T20 Microscope, equipped with an Eagle 4 x 4k CCD camera, using a 
magnification of 60,000 x.  
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3.3 Results: abyB1-3 Gene Cloning 
3.3.1 Domain Assignment and Sequence Analysis  
The aby mPKS genes were originally identified and reported by Gottardi et al.220 This study 
also reported a bioinformatic based assignment of individual modules and domains within each 
of the genes abyB1, abyB2 and abyB3. No subsequent studies have been published with focus 
on the characterisation of these genes or their gene products. In order to interrogate these ORFs 
further, their sequences were subjected to additional bioinformatic characterisation. Due to 
their inherent size and complexity, it was decided to focus efforts on abyB2 and abyB3 at least 
in the first instance.  
Domain assignments were conducted using an online tool developed by Bachmann and 
Ravel,
276
 allowing for the construction of a schematic map ascribing individual amino acid 
residues to specific domains, or inter-domain and inter-module linkers (Figure 3.1). It should 
be noted that this study predates the more recent recommendations of Keatinge-Clay,
169
 and 
proposals around domain assignment based upon evidence of improved in vitro function.170 In 
addition, it is still unclear whether these new boundary definitions facilitate or hinder the puri-
fication and structural study of mPKS modules, which was the primary aim of the project. 
The assignment studies conducted revealed that, in general, each domain within individual 
Aby modules is flanked by linker regions, which are known, based on studies of other PKSs, 
to be flexible, thus allowing the movement of domains and the passage of the substrates and 
intermediates between synthase active sites.
115,116
 The 20 amino acid linker between the ACP 
of M5 and the KS of M6 is of particular interest. Given the necessity for the ACP to travel 
between the KS and AT of M5 and the KS of M6, this short linker is a clear indication of the 
close spatial arrangement of M5 and M6. Other identified short linking sequences indicate 
relative constraint between the inactive DH and KR domains in module 5 and the ER and KR 
domains in module 6. There are sizeable linkers of > 75 amino acids between each of the three 
domains in AbyB3. Amino acid sequences for AbyB2 and AbyB3 are provided for reference in 




Figure 3.1 Schematic Diagram Illustrating the Domain Architectures of AbyB2 and 
AbyB3. The domain architecture of AbyB2 (3645 amino acids) and AbyB3 (992 amino acids) is shown 
with amino acid sequence numbering included for clarity. In an alignment consistent with Keatinge-
Clay’s proposal169 the ACPs would each be ascribed to the upstream neighbouring module. Pre-KS 
docking domains, post-ACP dimerisation helices and inter-domain linkers are shown in yellow, with 
the inter-module linker in AbyB2 indicated by a dotted line. Sequence numbering is based on that de-
fined by Bachmann & Ravel’s analysis tool.276 Inactive domains, as identified by Gottardi et al.,220 are 
indicated by an asterisk and a surrounding dotted outline.  
 
3.3.2 Design and synthesis of DNA fragments 
In order to study individual Aby PKS polypeptides, and to facilitate easier downstream en-
gineering approaches, the heterologous expression of the abyB2 and abyB3 genes was priori-
tised. The first challenge to overcome was that of the considerable length of the individual 
genes encoding these proteins. Attempts to clone the entire abyB2 gene via a conventional PCR 
amplification approach proved unsuccessful, likely due to the length (11 kb) and high (76%) 
GC content of this ORF (Appendix A2.1). In order to mitigate this, a strategy was devised 
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amplify these fragments from M. maris genomic DNA proved unsuccessful, with multiple mis-
priming events observed. This was a likely consequence of the high GC content and repetitive 
nature of these sequences. 
 
 
Table 3.1 Fragments Designed to Span the Entirety of the abyB2 Gene. Fragments were 
synthesised commercially by ThermoFisher GeneArt. The length of the fragments when amplified with 
the required forward and reverse primers for Type IIs assembly is shown in addition to the fragment 
size (See Table A1 for primer list). 
 
Following repeated unsuccessful attempts at DNA amplification from M. maris genomic 
DNA, six synthetic codon optimised DNA fragments spanning the entire abyB2 gene were 
ordered from a commercial supplier (ThermoFisher GeneArt; Table 3.1). Such an approach has 
only recently become viable due to the rapidly decreasing costs of gene synthesis.
277
 This ap-
proach presents a number of significant advantages. Firstly, codon optimisation can be per-
formed (Appendix A2.1), prioritising codons most frequently used by E. coli, our expression 
host organism of choice. This can be used to significantly reduce the GC content of a target 
gene; in the case of abyB2, from 76.0% to 56.6%. This both reduces the melting temperature 
of the DNA, making PCR reactions more tractable (at 76% GC content only 2-step PCR reac-
tions are possible), and reduces the likelihood of mis-priming events.  
 
3.3.3 Assembly of the abyB2 Gene 
Despite the reduction in repetition and GC content, assembly via a standard homologous 
recombination approach using the In-Fusion system (Takara),
278
 gave only truncated AbyB2 
Fragment Nucleotides Fragment Size (bp) 
AbyB2_Frag1 1 - 1844 1844 / 1874 
AbyB2_Frag2 1845 - 3684 1840 / 1870 
AbyB2_Frag3 3685 - 5530 1846 / 1876 
AbyB2_Frag4 5531 - 7373 1843 / 1873 
AbyB2_Frag5 7374 - 9199 1826 / 1856 
AbyB2_Frag6 9200 - 10 938 1739 / 1773 
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coding sequences. These were found to be being generated due to the sequence complementa-
rity between AbyB2_Frag1 and AbyB2_Frag6. In an effort to circumvent this problem, a 
golden-gate based assembly method was employed (Figure 3.2).
279–281
 This assembly method 
uses the ability of Type IIs restriction enzymes, in this case BsaI, to cut DNA at a defined 
distance away from their recognition site. BsaI does this whilst also generating a four nucleo-
tide 5’ overhang. This means that, with careful design, fragments can be created that generate 
highly specific overhangs, which are complimentary to equivalent terminal sequences in neigh-
bouring DNA fragments sequences. The BsaI recognition site is neatly excised during this pro-
cess, allowing the formation of a scarless join when incubated with T4 DNA ligase.  
To create the necessary recognition sequences and overhangs, the ThermoFisher GeneArt 
Primer and Construct Design tool was used. This automatically analyses different possible 
combinations of overhangs, excluding those which present too great a chance of mis-priming. 
It also designs overhangs for a recipient vector, pType-IIs, specifically designed for use in these 
reactions and provided with the Type IIs assembly kit sold by ThermoFisher GeneArt. The 
pType-IIs vector contains ampicillin and chloramphenicol resistance genes, as well as re-
striction sites for the Type IIs enzymes BsaI, BbsI and AarI. During this study, a one pot reac-
tion, involving a master-mix of buffer, T4 DNA ligase, BsaI and all six aby DNA fragments, 
PCR amplified to contain the necessary recognition and overlap sequences, was performed at 
37 
o
C for 1 hour, followed by 5 minutes at 55 
o
C. This reaction mix was then used to transform 




Figure 3.2 Schematic Representation of the Assembly of the abyB2 Gene. Each synthe-
sised abyB2 fragment was amplified by PCR using the requisite primers to generate a BsaI restriction 
site (Table A1) and a unique homology region, compatible with upstream and downstream fragments. 
Fragments and the pType-IIs vector are digested to generate the requisite overhangs, following which 
all six fragments are assembled in the correct order in the same one-pot reaction. BsaI restriction sites 
are highlighted in grey. 
 
A number of minor modifications were made to recommended protocols to ensure correct 
assembly of the abyB2 gene at a reasonable cost. Although the assembly of > 4 fragments is 
recommended to be undertaken using discrete shuttle vectors containing each fragment, with 
assembled genes recommended to be no more than 10 kb in length, we opted to disregard these 
recommendations in an effort to streamline the assembly process. Due to the expected low 
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assembly rates and reduced fidelity, a total of 24 E. coli transformants were recovered from 
agar plates and screened by colony PCR (Figure 3.3). This enabled the identification of the 
presence of a single 1.5 kb section of the abyB2 gene, spanning the AbyB2_Frag2 and 
AbyB2_Frag3 join, thus confirming the presence of at least two fragments assembled in the 
correct order. Plasmid DNA from the five most promising candidate transformants (5, 6, 9, 13 
and 18; Figure 3.3) was miniprepped and subjected to further analysis. 
 
 
Figure 3.3 Colony PCR Screening of Fragment Assembly and Insertion into pType-
IIs. Twenty four colonies were picked and the presence of a 1517 bp fragment, spanning the join be-
tween AbyB2_Frag2 and AbyB2_Frag3, was confirmed by colony PCR.  
 
Purified plasmids were subsequently used as the template for further PCR analysis. Ampli-
fication reaction were performed to confirm the presence of 1.5 kb sections of abyB2, spanning 
AbyB2_Frag1 and AbyB2_Frag2, AbyB2_Frag3 and AbyB2_Frag4, and AbyB2_Frag5 and 
AbyB2_Frag6 (Figure 3.4). This enabled confirmation of the presence of each fragment within 
the gene, as well the correct order between AbyB2_Frag1 – AbyB2_Frag4 and AbyB2_Frag5 
– AbyB2_Frag6. A final, full length, PCR reaction (Figure 3.5) then enabled confirmation of 
1 2 3 74 5 6 8 9 10 11 12




the connection of AbyB2_Frag1 and AbyB2_Frag6 to pType-IIs, and hence the fidelity of the 
order for all fragments within the assembled ORF.  
 
  
Figure 3.4 Verification of the Presence of abyB2 DNA Fragments by PCR. Plasmids 
were isolated from the five candidate colonies previously shown to contain AbyB2_Frag2 and 
AbyB2_Frag3. The presence of all fragments was determined by PCR amplification of ~1.5 kb frag-
ments spanning the join between AbyB2_Frag1 and AbyB2_Frag2 (1-2), AbyB2_Frag3 and 
AbyB2_Frag4 (3-4), and AbyB2_Frag5 and AbyB2_Frag6 (5-6).  
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Figure 3.5 PCR Amplification of the Intact abyB2 Synthetic Gene. abyB2 was amplified in 
duplicate from the plasmids obtained from colonies 5, 13 and 18 by PCR, using LongAmp Taq DNA 
polymerase (NEB). Amplified fragments were purified and inserted into pOPINF or pET28 by 
homologous recombination.  
 
Following assembly, the intact synthetic abyB2 gene was inserted into either the expression 
vector pOPINF or pET28A (Table A1.2), with successful insertion confirmed by colony PCR 
from plasmid transformants recovered from agar plates. Plasmids originating from colonies 13 
and 18 were submitted for DNA sequencing. Sequencing primers were designed in both for-
ward and reverse directions, complementing central DNA sequences within each abyB2 gene 
fragment. In addition, the pType-IIs plasmids containing genes 13 and 18 were sent for se-
quencing in the forward direction (using all designed forward primers and T7 forward, Table 
A1), whilst equivalent pOPINF constructs were sent for sequencing in the reverse direction 
(using all designed reverse primers and T7 Term). Sequencing results revealed all six fragments 
were assembled in the correct order. The abyB2::pOPINF plasmid derived from colony 18 was 
determined to be >99.9% sequence correct, with the remaining 0.1 % of the gene sequence 
equating to regions where there was poor sequencing coverage.  
 
3.3.4 Cloning abyB3 
The abyB3 gene, at 2979 bp long, is much shorter than abyB2, which allowed the synthesis 
of a single codon optimised coding sequence (ThermoFisher GeneArt). In addition, the gene 
could be successfully amplified from genomic DNA, despite its high (75%) GC content (Figure 
3.6). Genomic and codon optimised abyB3 was inserted into pOPINF by homologous recom-
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Figure 3.6 PCR amplification of abyB3 from genomic DNA. A temperature gradient during 




3.4 Results: Heterologous Expression of AbyB2 and AbyB3 
3.4.1 Protein Expression Trials 
The plasmids abyB2::pOPINF, abyB2::pET28a, abyB3::pOPINF and abyB3::pET28A were 
transformed into a variety of E. coli cell lines for expression testing (Table 3.2). Once the re-
quired cell was transformed, expression of the target polypeptide was assessed under a variety 
of expression conditions, including the in the presence of varying concentrations of IPTG, at 
different growth temperatures, and by varying the length of time that cells were left to grow 
post-induction. Initially, E. coli BL21 (DE3) cells were trialled for expression, as these have 
previously been used successfully for the production of inactive mPKS polypeptides in the 
erythromycin and pikromycin systems, without the insertion of a phosphopantetheinyl arm. 
The majority of expression trials for AbyB3 in E. coli BL21 (DE3) cells and E. coli BL21 
(DE3) pLysS cells, were undertaken by Dr. Alice Parnell, although these unfortunately failed 
to generate recombinant protein. AbyB2 expression trials in E. coli BL21 (DE3) cells and 
pLysS cells were undertaken by myself, as detailed in Table 2, as were complimentary AbyB2 
and AbyB3 expression trials using BAP1 and Vmax cells. These are a commercially sourced 
strain of Vibrio natriegens (SGI-DNA), purported to be a superior expression host to E. coli, 
delivering higher yields of overexpressed protein per litre of culture and with a faster doubling 
time.
282,283
 Initially, these cells were only available in electrocompetent form; successful trans-
formation proved all but impossible, despite fastidious adherence to the manufacturer’s proto-
col. The later release of chemically competent cells did little to improve transformation effi-
ciency, prohibiting a full characterisation of expression conditions to be undertaken using this 
cell line. abyB2::pET28a and abyB3::pOPINF were the only plasmids that could be success-
fully transformed into this cell line, though in both cases there was no evidence of recombinant 
protein expression following growth in the presence of the chemical inducer IPTG. 
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Table 3.2 Expression Conditions Tested for AbyB2 and AbyB3. The only conditions observed to give successful protein expression were those that 
employed E. coli BAP1 cells. Additional unsuccessful expression testing of AbyB3 was carried out by Dr. Alice Parnell. Substantial issues transforming Vmax 





AbyB2 pOPINF BL21 (DE3) LB 20 500 4h, O/N  With and without 10 min ice shock pre-induction 
AbyB2 pOPINF BL21 (DE3) TBAI 37 - 4h, O/N With and without 10 min ice shock pre-induction 
AbyB2 pOPINF pLysS LB 20 500 4h, O/N  
AbyB2 pOPINF pLysS TBAI 37 - 4h, O/N  
AbyB2 pET28 BL21 (DE3) LB 20 500 4h, O/N  
AbyB2 pET28 pLysS LB 20 500 4h, O/N  
AbyB2 pET28 Vmax VM  30 1000 1h, 4h, O/N  
AbyB2 pET28 Vmax LBv2  30 1000 1h, 4h, O/N  
AbyB2 pOPINF BL21 (DE3) TB 20 200 4h, O/N 1h at 20oC pre-induction 
AbyB2 pET28 BL21 (DE3) TB 20 200 4h, O/N 1h at 20oC pre-induction 
AbyB2 pOPINF BAP1 TB 20 200 4h, O/N 1h at 20oC pre-induction 
AbyB2 pET28 BAP1 TB 20 200 4h, O/N 1h at 20oC pre-induction 
AbyB2 pOPINF pLysS TB 20 200 O/N Co-transformed with Sfp plasmid 
AbyB2 pOPINF pLysS TBAI 20 - O/N Co-transformed with Sfp plasmid 
AbyB2 pOPINF Arctic Express TB 12 200 24 h Co-transformed with Sfp plasmid 
AbyB2 pOPINF Arctic Express TBAI 12 - 24 h Co-transformed with Sfp plasmid 
AbyB3 pOPINF Vmax VM  30 1000 1h, 4h, O/N  
AbyB3 pOPINF Vmax LBv2  30 1000 1h, 4h, O/N  
AbyB3 pOPINF BL21 (DE3) TB 20 200 4h, O/N 1h at 20oC pre-induction 
AbyB3 pOPINF BAP1 TB 20 200 4h, O/N 1h at 20oC pre-induction 
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cells prevented full characterisation. BAP1, BL21 (DE3) BAP1 cells108 (a gift from Mr. Christian 
Hobson, University of Warwick); LB, Luria-Bertani broth (Thermofisher); LBv2, LB broth with V2 
salts added; O/N, overnight; pLysS, BL21 (DE3) pLysS cells (Agilent); TB, Terrific Broth (Melford); 
TBAI, Auto-Induction Terrific Broth (Formedium); VM, Vmax Enriched Growth Medium (SGI-DNA); 
Vmax, Vibrio natriegens (SGI-DNA). 
 
Successful expression of both genomic and codon optimised AbyB3 was observed in E. coli 
BL21 (DE3) BAP1 cells (a gift from Mr. Christian Hobson, Warwick; Figure 3.7). This cell 
line originates from the parental strain lineage generated by Khosla and co-workers.108 Expres-
sion was observed in these cells but interestingly not from standard BL21 (DE3) cells under 
the same conditions. This leads to the intriguing possibility that, in this system, folding and/or 
stability of the multidomain complex might somehow be dependent on the insertion of a phos-
phopantetheine arm and the upregulation of cellular levels of propionyl-CoA, the precursor for 
the methylmalonyl-CoA extender unit incorporated by AbyB3. Successful expression of 
AbyB2 was not observed under the same conditions (Figure 3.7). Expression of the correct 
AbyB3 construct was confirmed by tryptic digest MS, performed by the Bristol University 
Proteomics Facility. Further investigations into the expression of AbyB2 in the presence of the 
B. subtilis phosphopantetheinyl transferase Sfp did not yield positive results, even at low tem-






Figure 3.7 Expression Trials of AbyB2 and AbyB3 in E. coli BAP1 Cells. Overexpression 
of AbyB3 is observed for B3.2 and B3.3. The expected position of AbyB3 on the SDS-PAGE gel based 
on amino acid composition is indicated by an arrow. Overexpression bands in B3.2 and B3.3 were 
excised and verified to be AbyB3 by tryptic digest and mass spectrometry. B3 Pellet, insoluble pellet 
produced by B3.2; B3.1, genomic abyB3 DNA inserted into pOPINF; B3.2, genomic abyB3 gene (sep-




3.4.2 Large-Scale AbyB3 Expression and Purification 
Due to the increased overexpression levels observed for the abyB3::pOPINF construct con-
taining the authentic M. maris sequence in E. coli BAP1 cells, this plasmid and strain combi-
nation were taken forward for large scale expression studies. When following the protocol out-
lined in Section 3.2.4, high level recombinant AbyB3 expression could be readily achieved. 
This was dependent on following the outlined expression protocol explicitly. Small deviations 
from this protocol e.g. not growing the BAP1 cells at 20 oC for 1 h prior to induction, or auto-






















expression. In addition, significant variation was observed in expression levels from different 
colonies recovered from transformation reactions. Initial slow growth at 37 oC proved to be a 
reliable indicator that overexpression of AbyB3 would not be observed. Two growths from 
different colonies picked from the same plate of transformants frequently yielded radically dif-
ferent levels of target protein.  
Once a formalised overexpression protocol for AbyB3 had been finalised, purification of 
this protein was performed using a combination of nickel affinity chromatography and SEC. 
This yielded recombinant AbyB3 protein of > 95 % purity (Figure 3.8). AbyB3 was observed 
to resolve at a molecular weight slightly higher than that predicted based in its amino acid 
composition by SDS-PAGE, indicative of the presence of some regions of intrinsic disorder.  
 
 
Figure 3.8 SDS-PAGE gel of purified AbyB3. Samples from across an AbyB3 elution peak 
recovered during SEC purification are shown. Samples were run on a 4-20 % SDS-PAGE gel (NuSep), 
with fractions loaded in the order of elution from left to right. 
 
3.4.3 Preliminary Analysis of AbyB3 
Given the well-reported potential for mPKS modules to dimerise via their KS domains,113,114 
the oligomeric state of AbyB3 in solution was investigated by native PAGE (Figure 3.9). This 
revealed an unexpected mixture of dimer and tetramer. No tetrameric mPKS species have been 
reported to date, although it is possible that those that have been successfully expressed and 








appeared in all samples of protein analysed following SEC, indicating that there was a dynamic 
equilibrium between the species, and initial investigations did not reveal large changes to the 
ratio of dimer to tetramer upon concentration of the sample. 
 
 
Figure 3.9 Blue Native PAGE Gel of Purified AbyB3. Purified AbyB3 was resolved on a native 
PAGE gel immediately following SEC. Bands are observed that correspond approximately to the 
expected size of a dimer (213 kDa) and tetramer (426 kDa). Fractions from across the peak were used 
for analysis to investigate the possibility of different sized populations of AbyB3 being eluted at 
different times. A concentrated sample was also loaded on the gel to determine the effect of AbyB3 
concentration on its oligomeric state.  
 
Further analysis of purified AbyB3 was conducted via negative stain electron microscopy 
(NSEM), and revealed a sample containing what appears to be a mixture of dimeric and te-
trameric particles (Figure 3.10). These particles initially look to be pure and homogenous, and 
exhibit a slightly round appearance, with, in some cases an observable central cavity. These 
initial results are consistent with those reported by Dutta et al.,141 who similarly observe a 
compact rounded object, as opposed to an architecture more analogous to that observed in por-
cine fatty acid synthase.136 
 










Figure 3.10 Analysis of Purified Recombinant AbyB3 by Negative Stain Electron Microscopy. 
Micrographs were obtained on a Technai T20, with a magnification of 60,000 x. Example dimers (red 






3.5.1 Heterologous Expression of mPKS Modules 
The work outlined in this chapter sought to develop a cloning and expression methodology 
to enable to the high-level production of recombinant multi-domain polypeptides from the 
abyssomicin C PKS. These studies focused specifically on the proteins AbyB2 and AbyB3 as 
test cases for the establishment of such a methodology. Due to the size and complexity of these 
coding sequences it was anticipated that conventional molecular cloning techniques would 
have limited value, hence a decision to exploit recent innovations in DNA synthesis and as-
sembly. Modern gene synthesis techniques have opened up new avenues from which to ap-
proach complex projects involving large genes with repetitive sequences or high GC content. 
These advances have also translated into significantly reduced synthesis costs,277 for example, 
the genes used in this study were synthesised at 14 p per base. 
Although significant effort was committed to attempting to clone the abyB2 gene from ge-
nomic M. maris DNA, this ultimately proved intractable and without the option to commer-
cially synthesise this coding sequence the project would have been halted. The codon optimi-
sation performed prior to synthesis is also of considerable value, reducing the protein produc-
tion burden on the host bacteria. Although recombinant AbyB2 was ultimately not produced 
during this study, this work is now ideally positioned for future optimisation. The benefit of 
codon optimisation to increasing the tractability of working with high GC content sequences 
is also considerable, as is evidenced in this study. It considerably reduces the Tm of any primer 
designed to work with a target gene, allowing more reliable 3-step PCR reactions to be per-
formed. Nevertheless, despite the synthetic DNA being far easier to work with, fragment as-
sembly by traditional digestion and ligation methods, or even more modern homologous re-
combination methods proved challenging, at least in the work outlined herein. By contrast, 
Golden Gate based assembly methods were found to be ideally suited to the demands of this 
project. By extension, it is apparent that these methods will of major value in facilitating access 
to a plethora of mPKSs from lesser-known bacterial and fungal pathways.112,284  
Once expression plasmids for both AbyB2 and AbyB3 had been assembled and verified, a 
number of expression protocols were trialled in an effort to access recombinant target polypep-
tides. Unfortunately, the vast majority of the approaches trialled during this project proved 
unsuccessful. Undoubtedly, the physiological disparities between E. coli and M. maris will 
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have impacted on the success, or not, of this work. Despite this, strict adherence to an in-house 
formulated bespoke expression protocol enabled the production of AbyB3 at in good yield. E. 
coli BAP1 cells not only provide a facile way to express active mPKS modules, and, as evi-
denced by this study, support the expression of the large, multi-component protein complexes. 
It is unclear whether, without the added propionyl-CoA carboxylase, cellular levels of 
methylmalonyl-CoA are increased, and whether this had any impact on AbyB3 expression. If 
deletion of the propionyl-CoA metabolism cluster, through the insertion of the Sfp gene, does 
facilitate expression, it would be desirable to knockout acetyl-CoA metabolism for the expres-
sion of AbyB2. Further expression testing of AbyB2 in E. coli Arctic Express and pLysS cells 
with the addition of Sfp through co-transformation, gives good evidence that this alone is not 
sufficient to enable heterologous expression. The significant variability in AbyB3 expression 
yields clearly indicates a requirement to operate in a Goldilocks expression window. It high-
lights the need for rigour when investigating potential expression conditions, as minor changes 
can have significant effects on the success of the trial. In addition, the variability of the colony 
picked post transformation means that duplicate or triplicate trials should always be run for 
each change in condition. Together, these data give some confidence that equivalent expression 
protocols could be readily developed for AbyB2 during future studies. 
The successful expression of AbyB3 provided a sound foundation for the production of ho-
mogeneous recombinant AbyB3 at scale. Based on these studies a two-step purification proto-
col was developed for this protein, which delivered > 95 % purity material in sufficient quan-
tities to enable structural characterisation. To date, no standalone minimal PKS module has 
been successfully expressed and purified for analysis, and only modules from the erythromy-
cin, pikromycin and venemycin pathways have been produced.108,141,170 This later system, iso-
lated from S. venezuelae, is a simple, three-module mPKS which is yet to be subjected to struc-
tural or functional characterisation. Notably during this study, it was proven comparatively 
straightforward to purify AbyB3 to homogeneity, with the inclusion of reducing agents in the 
SEC buffer used affording greater stability of the protein, thus enabling longer term sample 
storage. A relatively high yield of AbyB3, and the ability to purify it to homogeneity provides 




Initial characterisation of recombinant AbyB3 revealed that the polypeptide adopts an un-
expected tetrameric oligomeric state in vitro. Although it is unlikely that the tetrameric form of 
this protein represents the bona fide natural conformation, it does make analysis by electron 
microscopy more viable. For high resolution structural characterisation by cryo-EM, multi-
meric complexes with more axes of symmetry lead to higher resolution structures, as do larger 
protein complexes. From the NSEM analysis of AbyB3 reported herein it is evident that there 
is good potential for further structural characterisation of this polypeptide via cryo-EM. Initial 
inspection of the particles observed by NSEM indicate that the conformation adopted by 
AbyB3 is consistent with those previously reported by Dutta et al. and Whicher et al. for 
PikAIII. With this in mind, a decision was made to initiate a Cryo-EM study of AbyB3, studies 





Structural Characterisation of AbyB3 
 
4.1  Introduction 
4.1.1  Crystallographic Studies of PKS Didomains 
Current structural models of intact mPKS modules are derived from a small number of stud-
ies of multi-domain mPKS polypeptides. These studies present conflicting evidence for the 
conformational arrangement of individual domains within the mPKS module, but each are not 
without merit. It is the hypothetical interpretations of these data that leads to the reported dis-
crepancies. The first model, that proposed by Khosla and co-workers,143 and adopted later by 
Keatinge-Clay and others,143,170 is primarily based on the crystal structure of the KS-AT 
didomain from DEBS M5 (Figure 4.1a and b).113 An analogous crystal structure of the DEBS 
M3 KS-AT didomain was published soon after by the same group.114 These high resolution 
crystal structures enabled a significant step forward in the understanding of both the structure 
and the function of mPKS domains and modules. For the first time, active sites were identified, 
and models for the interaction of the ACP with both the AT and KS domains were developed. 
These advances provided good evidence for the protein-protein interactions postulated to be 
essential for correct mPKS function.80 It is unsurprising, then, that Khosla and co-workers used 
these didomain structures as the basis for the formulation of a molecular model of mPKS ar-
chitecture, which was supported by SAXS studies of DEBS M3-TE.143 These analyses was 
performed using a rigid body fit, as opposed to an ensemble-state calculation, as their data 
showed that DEBS M3-TE “did not sample a wide range of conformational states”. In light of 
this, it is necessary to examine the crystal structures underpinning these data and the assump-
tions that were made during analysis. The structure of the DEBS M5 didomain was solved with 




constraints within the crystal that may prevent the didomain from exhibiting a conformation 
representative of the authentic intact module. When viewed as an entire asymmetric unit we 
can see significant crystal contacts within the lattice. Whilst this is a common constraint in 
crystallography, it is well known to restrict the flexibility of target macromolecules.285 These 
crystal contacts could, theoretically, prevent the didomain structure adopting a conformation 







Figure 4.1 X-ray Crystal Structure of DEBS M5 KS-AT Didomain. a) Side-on view of the 
didomain structure. The pre-KS docking domains are in yellow, the KS dimer is in blue, the KS-AT 
linker in light yellow, the AT in green and the post-AT linker in pink. b) The same structure rotated 90°. 
This time the one KS monomer is coloured cyan and the dimerisation interface is visible. c) A solid 
rendering of two KS dimers in the unit cell, with colouring consistent with part a. Extensive crystal 
contacts are visible between the KS in dimer 1 and the AT in dimer 2, as well as the pre-KS docking 















4.1.2  Analysis of SAXS-derived mPKS Module Structures 
Edwards et al.143 addressed the issue of didomain confirmation, albeit indirectly, through 
SAXS modelling of the solution structures of the individual domains contained within DEBS 
M3-TE (Figure 4.2a). The high resolution crystal structures of the individual domains fit well 
into their respective SAXS envelopes, though the KS-AT dimer adopts a more planar confor-
mation, as opposed to that imposed in the crystal lattice, with each AT domain angled towards 
the pre-KS docking domain. Whilst this structure gives good evidence that the KS-AT dimer 
does not adopt a significantly altered conformation in solution, it does hint towards the need to 
model some flexibility into the linker region between the two domains. In contrast, the SAXS 
analysis of intact DEBS M3-TE is highly ambiguous. The resolution reported is low, ~40 Å, 
and there is a high degree of conformational flexibility within the particle. Three distinct con-
formational arrangements are given for the KR, ACP and TE domains, which are reported to 
move significantly, relative to each other, in solution (Figure 4.2b). Despite this flexibility, 
none of the determined structural models appear to convincingly fill the density identified in 
the SAXS model (Figure 4.2c), with no attempts made to dock high resolution structures of 
these domains into the experimental SAXS envelope. The KS-AT dimer, however, is consist-
ently modelled as a rigid body, without any flexibility. This is particularly surprising given the 
flexibility observed in the rest of the complex, the existence of the KS-AT linker region, and 
the well-documented protein-protein interactions necessary for correct function. By modelling 
the KS-AT dimer as a rigid body, these factors were largely ignored. The presence of additional 
domains within the module would be expected to impact the global structure observed. Given 
that enzymes often only adopted a fully ordered conformation upon substrate binding,286 the 
addition of multiple catalytic domains is likely to have considerable conformational impact. 
The approximated oval shape of the module, and the low resolution reported, means that it is 
conceivable that an alternative, more convincing, model may have been generated if ensemble-
state calculations had been employed, or if the structure of Dutta et al. had been available and 
used in these analyses.  
A similar study, published by Davison et al.144 investigating the trans-AT PKS virginiamy-
cin M5, adds an additional layer of complexity. This structure, consisting of a KS dimer and 
two pairs of ACP domains, adopts an arch like global conformation in solution, as revealed by 
SAXS analysis. Although trans-AT PKS assembly lines are thought to have evolved inde-
pendently of cis-AT PKSs,287 and hence structural comparisons should be approached with 




by Davison et al. appears immediately more convincing than that of Edwards et al., with greater 
structural definition observed and supported by the docking of high resolution mPKS domain 
structures into the SAXS envelope (Figure 4.2d). This model reveals a global conformation 
which matches more closely to that reported by Dutta et al. It is worth noting that Edwards et 
al. were unable to generate a convincing pseudo atomic model of DEBS M3-TE by docking of 
domain structures into the SAXS envelope, consistent with significant dynamic heterogeneity 
within the module. The data obtained by Davison et al. reveals minimal flexibility in vir-
giniamycin M5, despite this polypeptide structure containing two highly flexible ACP domains, 





Figure 4.2  SAXS Models of Polyketide Synthase Modules. a) SAXS density for individual 
domains in DEBS M3 fits well to determined high resolution structures, although the KS didomain 
appears as though the slight bend towards the pre-KS docking domain could be caused by crystal 
contacts. b) The three conformations of DEBS M3+TE proposed by Edwards et al. c) Superposition of 
these conformations over the determined SAXS envelope reveals a poor fit, with a lot of unaccounted 
density. d) SAXS interrogation of the virginiamycin PKS M5 reveals an arch-shaped structure, with 









In addition to the studies outlined above, differences between the mammalian FAS structure 
determined by Maier et al.,152 and mPKS structures were revealed by Zheng et al.140 This study 
reported the first high resolution structure of an ER domain from the spinosyn PKS, which 
reveals a marked difference in the protein-protein interactions between the ER and KR do-
mains, as compared to their FAS equivalents. In order to crystallise the ER domain, the team 
purified a didomain consisting of the KR and ER subunits. This revealed that the constituent 
domains adopted a side-by-side arrangement, as opposed to the end-to-end organisation seen 
in FAS. This significant disparity further casts doubt on the viability of using available FAS 
structures as a proxy for mPKSs. 
 
4.1.3  Cryo-EM based PKS Module Structures 
The only cryo-EM derived structure determined to date is that of PikAIII (Figure 1.7, Figure 
4.3). This reveals a remarkably different domain organisation to that reported by Edwards et 
al., and is in much better agreement with that reported for M5 of the trans-AT virginiamycin 
PKS.141 The PikAIII  structure, resolved to 7.9 Å, was used as a template in which to dock high 
resolution crystal structures and homology models of individual mPKS yielding a complete 
pseudo-atomic model. Whilst not a high resolution description of an intact mPKS module, 
(none have been determined to date), it is a much more detailed model than that formulated by 
Edwards et al. The high resolution structure of the DEBS M5 didomain was dissected into a 
KS dimer and AT monomer, and complimented with atomic resolution structures of a KR do-
main and ACP domain, also from DEBS. The high degree of similarity necessary to create a 
convincing pseudo-atomic model in this way makes it unlikely that DEBS and the pikromycin 
PKSs adopt radically different structures in solution.  
 
4.1.4  ACP Binding Sites 
The ACP domain within canonical mPKS modules is universally located after the condens-
ing and reducing domains. This means that a long flexible linker is needed for the ACP to 
interact with the AT, receiving its -CoA extender unit; then the KS, catalysing chain extension; 
and subsequently ferry the growing polyketide chain between reducing domains, before finally 
interacting with the downstream KS or TE. This has led to the identification of a number of 




from DEBS allowed Tang et al. to identify an ACP docking domain situated in the cleft between 
the KS and AT domains.114 Docking the NMR structure of the ACP from M3 onto the KS-AT 
didomain crystal structure, they showed that it was able to interact with both the AT and KS 
simultaneously, whilst the upstream ACP from M2137 interacted more closely with the KS, but 
was shown to adopt a very similar position to the cognate ACP (Figure 4.3a). In the SAXS 
models constructed by Edwards et al.,143 the location of the ACP could not be determined, 
although they positioned them diagrammatically, bound to the TE domains. In contrast, the 
structural model determined by Dutta et al.141 shows the ACP present in two distinct locations, 
in a roughly 1:1 ratio. The ACP is shown to associate strongly with both the AT-KS interface 
and the KR domain (Figure 4.3b and c). In the arch-shaped conformation adopted by PikAIII 
the cleft identified by Tang et al. no longer exists, with the bend in the KS-AT interface obscur-
ing this region. Consequently, the cylindrical ACP is observed to engage with the AT domain 
via an extended interaction interface, with the end of the a-helices presenting the key serine 
residue necessary to bind the methylmalonyl-CoA extender unit and the growing polyketide 
chain pointing inwards towards the KS dimer. In the same study, Dutta et al. were also able to 
obtain structures of PikAIII M5 complexed to the upstream ACP domain from PikAII M4. This 
revealed a previously unidentified ACP-KS interaction domain on the top of the arch, separate 
from the M5 reaction chamber. Based on the identification of these two binding sites, either 
side of the KS active site (Figure 4.3d and e), they proposed a hypothesis for chain transfer 
between modules. This configuration provides a clear structural basis for the principal of vec-
toral biosynthesis mPKS assembly lines, where ACPs from different modules would never bind 
in the same location, allowing the KS to clearly discriminate between the two. Intriguingly, the 
ACP from M4 would only bind to the KS of M5 when a polyketide analogue, similar to the 
natural growing chain, was bound. These data imply that the presence of substrate drives con-
formational changes necessary for protein-protein interaction. Thus, to structurally observe any 
inter-module interactions in mPKS systems, polyketide analogues will need to be synthesised 
and loaded onto relevant ACP domains. 
In a companion paper, Whicher et al. were able to determine mid-resolution cryo-EM struc-
tures for PikAIII M5 locked into a series of different states within the catalytic cycle.142 These 
were accessed by incubating PikAIII M5 with different substrates and analogues thereof. The 
resulting structures identified a number of crucial structural rearrangements necessary for ca-
talysis to proceed. With the natural pentaketide substrate bound to the KS dimer via an active 




hypothesised to lead to a slight shift in the AT, obscuring the side entrance through which the 
upstream ACP delivers the polyketide chain. The ACP is brought into close contact with the 
AT domain, and appears to be conformationally aligned to accept an AT-loaded methylmalonyl 
extender unit (Figure 4.3f). The largest conformational change is reserved for the KR domain, 
which flips end-to-end in a roughly 180° rotation. This large conformational change, precipi-
tated by substrate binding, is another example for why rigid body fitting should be avoided 
wherever possible when modelling mPKS structures. Chain extension leads to the ACP dock-
ing close to the cleft between the AT and KR domains (Figure 4.3g). With the natural reduced 
hexaketide substrate bound to the ACP, a further conformational change is observed. The ACP 
now re-locates to one of three positions beneath the KR and is ejected out of the module reac-
tion chamber (Figure 4.3h). This would allow it to interact with the downstream module, form-
ing a transient interaction with the apex of the M6 KS domain, passing the elongated polyketide 
chain onto this neighbouring module. Presumably the module would then return to one of the 
conformations observed by Dutta et al., revealing the active site channel on top of the arch, 





Figure 4.3  ACP Location and Movement in Different PKS Models. a) ACP docking site 
determined by Tang et al. The NMR structure of DEBS M2 ACP137 was used to create a homology 
model for DEBS M3 ACP (purple). This was docked into the X-ray crystal structure of DEBS M3 AT-














when no substrates are bound. d) Cryo-EM reconstruction highlighting the docking site for the upstream 
ACP from PikAII M4 (red), on top of the arch shaped structure. This structure does not contain the ACP 
from pikromycin M5. e) Cryo-EM reconstruction of PikAIII with its cognate ACP bound to the AT, 
ready to receive a methylmalonyl extender unit. f) Cryo-EM reconstruction showing the location of 
methylmalonyl-loaded PikAIII M5 ACP at the bottom entrance to the KS active site, ready to receive 
the pentaketide substrate for chain elongation. g) Cryo-EM reconstruction of PikAIII with an unreduced 
hexaketide substrate loaded onto the ACP, which is bound to the KR for NADH coupled reduction. h) 
Cryo-EM reconstructions of the three conformations observed when the ACP of PikAIII is loaded with 
a fully extended and reduced hexaketide product, ready for transfer to PikAIV M6. Figure adapted from 
Tang et al., Dutta et al. and Whicher et al.114,141,142 
 
4.1.5 The Turnstile Mechanism of Vectoral Synthesis 
The cryo-EM structures of PikAIII provide a compelling structural basis for the high-fidelity 
vectoral synthesis employed by mPKSs. Lowry et al.146 provide convincing biochemical evi-
dence for the ACP movement observed by Whicher et al., though due to the two competing 
models for polyketide synthase architecture, there is no mention of either study by Skiniotis 
and co-workers.141,142 The differences observed between the structures of FASs and the PikAIII 
cryo-EM models could be a result of the need to ensure high fidelity vectoral synthesis in multi-
modular PKSs. The explicit need to pass a growing polyketide chain between modules, without 
skipping or premature termination, may be achieved by sequestering each round of chain elon-
gation and reduction within its own catalytic chamber, as formed by the arch shaped confor-
mation. In FAS systems, which do not require the same level of fidelity as they are not multi-
modular in nature,289 a more open configuration of the complex is tolerated due the reduced 
requirement to precisely control protein-protein interactions. One potential benefit of the re-
laxation of high-fidelity regulation is an increase in rate of biosynthesis.  
The structural information also provides rationale for Keatinge-Clay’s proposal to redefine 
the modular architecture.169 Without the highly specific protein-protein interaction between the 
preceding ACP and the downstream KS, the PKS assembly line would stall, locking modules 
in a ‘closed’ conformation, with the active site tunnel on top of each KS occluded by the AT 
domain. Within the enclosed reaction chamber, the specificity required for the protein-protein 
interaction between the ACP and the KS, AT or KR is likely to be decreased, as ACPs from 
other modules will be occluded from binding by their exclusion from the reaction chamber 




4.1.6  The Aim of this Work 
The function of mPKSs is predicated upon precise protein-protein interactions between 
modules, both inter- and intra-polypeptide.91 Attempts to engineer these systems have proved 
challenging due to a lack of detailed understanding about the nature of the interactions neces-
sary for correct function.130,131 The model derived by cryo-EM does not account for the crystal 
structures of the KS-AT didomains,113,114 which have been used to derive a FAS-like architec-
ture of mPKS modules. This itself does not account for the convincing cryo-EM reconstruc-
tions of PikAIII.141,142 The competing structural models proposed for bacterial mPKS architec-
tures are likely to confuse attempts to rationally engineer these assembly lines as different pro-
tein-protein interactions are identified.170 They also lead to different mechanistic interpretations 
and different models for inter-module communication. The work outlined in this chapter seeks 
to resolve the apparent disparities between these conflicting models using a hybrid structural 
biology approach combining X-ray crystallography and cryo-EM. It is hoped that by adopting 
this approach a more comprehensive model for mPKS architecture can be obtained. The test 








4.2.1 Expression and Purification of AbyB3 and AbyB3DACP 
AbyB3 was cloned and expressed according to the method outlined in Chapter 3. A small 
modification was made to the purification protocol, which resulted in enhanced enzyme stabil-
ity. During purification by SEC, AbyB3 was buffer exchanged into XL Buffer (100 mM NaP, 
150 mM NaCl, 1 mM EDTA, 0.02% sodium azide, pH 7.5). If a sample was required for 
NSEM, this material was further buffer exchanged into 50 mM HEPES pH 8.0 prior to use. 
AbyB3DACP was cloned as described in Section 4.3.1. This polypeptide was expressed and 
purified as for AbyB3 with minor modifications as follows: i) HEPES buffers were used 
throughout all purification steps (see Section 3.2.4). ii) Each buffer (Load, Elute and SEC) was 
additionally supplemented with 10 % glycerol to improve the stability of the protein. 
AbyB3DACP was either used immediately or flash frozen in liquid nitrogen and stored at -70 
°C prior to use.  
 
4.2.2 Crystallisation  
Recombinant proteins were purified as described above, following which they were con-
centrated to 10 mg/mL using a vivaspin centrifugal concentrator (Sartorius) with a 50 kDa MW 
cut-off membrane. Concentrated proteins were centrifuged at 19,000 x g for 5 minutes to re-
move any aggregates prior to crystallisation screening. Crystallisation experiments were con-
ducted using commercially sourced screens (PACT premier, Structure Screen 1&2, JCSG-plus, 
MIDASplus, Morpheus and LMB crystallization screen; all from Molecular Dimensions). 
Screens were established using 50 µL of each crystallisation condition placed into the reservoir 
of a 96 well crystallisation plate. Two drops per reservoir were established to enable crystalli-
sation via the sitting drop vapour diffusion method. One drop comprised 0.5 µL reservoir con-
dition and 0.5 µL 10 mg/mL protein, whilst the second comprised 0.75 µL reservoir condition 
and 0.25 µL protein. Plates were stored at 20 °C and monitored periodically for a period of 12 
months. Diffraction quality crystals of AbyB3DACP were grown over a period of two weeks 
in 0.1 M MES, 10 % ethanol, 30 % PAA 5100, pH 6, using 0.5 µL of reservoir and 0.5 µL of 





4.2.3 X-Ray Diffraction Data Collection and Processing 
Crystals grown in the condition described above were manually looped following cryo-pro-
tection by the addition of 25 % glycerol to the sitting drop. They were flash-frozen in liquid 
nitrogen and subjected to X-ray diffraction analysis at Diamond Light Source (Beamline I03). 
Four crystals were interrogated, with the best diffracting to a maximum resolution of 2.36 Å.  
Diffraction data were initially processed on-site, using xia2 dials, and determined to be in 
the space group C1 2 1. The structure was subsequently determined using by molecular re-
placement using the program BALBES,290 employing elements of both DEBS didomains and 
mammalian FAS structures as search models.113,114,136,152 Electron density maps were examined 
and determined to be of good quality. The structure was further refined using the CCP4 suite 
of programs,291 employing multiple iterative rounds of model building in Coot292 and refine-
ment in REFMAC5. The residues 0-32, corresponding to the pre-KS docking domain and res-
idues 888 – 915, corresponding to part of the post-AT linker, were not resolvable due to insuf-
ficient electron density. Residues 280, 457 – 465 and 685 – 694, corresponding to flexible loops 
within the structure, remain unresolved for the same reason. A full complement of water mol-
ecules and ions resolvable within the structure has not yet been determined. 
 
4.2.3 Crystal Structure Analysis 
The structure of AbyB3DACP was analysed using PyMOL.293 Inbuilt functions were used 
to determine the distance between atoms for hydrogen bond and salt bridge identification, and 
for Ca rmsd calculations. 
 
4.2.4 Crosslinking AbyB3 
A variety of commercial crosslinking methods were applied to recombinant AbyB3. Each 
method was performed according to the supplier’s instructions. The most effective crosslinking 
method, using PEG12-SPDP (ThermoFisher Scientific), was carried using the following proto-
col. AbyB3 was purified in XL buffer as previously described. It was then immediately sub-




immediately added to AbyB3 at 5 mg/mL, to give a final concentration of 500 µM. Reactions 
were subsequently incubated at room temperature for 60 minutes. The resulting cross-linked 
material was then passed through a Zeba Spin Desalting column (ThermoFisher Scientific), 
pre-equilibrated with XL buffer. Half of the conjugated AbyB3 was placed on ice, and the other 
half was reduced by the addition of DTT dissolved in acetate buffer (100 mM sodium acetate, 
100 mM NaCl, pH 4.5) to a final concentration of 50 mM. This sample was incubated for 30 
minutes before application to a Zeba Spin Desalting column, pre-equilibrated in XL buffer, to 
remove DTT. The two protein solutions were subsequently mixed and left at 4 °C for 18 h.  
 
4.2.5 Preparation of Cryo-EM Grids 
Cryo-EM grids were prepared within 30 hours of E. coli cell lysis to ensure the sample was 
as fresh as possible. Further details are given in Section 4.4.2. For clarity this method is de-
scribed as follows. Immediately prior to use, grids (apart from those coated in graphene oxide) 
were glow-discharged in air at a pressure of 6 x 10-3 atmospheres using a current of ~15 mA 
for 1 minute. Either a Leica ACE 600 (Leica Microsystems) or an ELMO Glow Discharge 
System (Agar Scientific) was used. A plunge freezer, either a Leica GP (Leica Microsystems) 
or Vitrobot Mk IV (FEI), was pre-cooled to < -170 °C using liquid nitrogen. Liquid ethane was 
subsequently added to fill the cryogen holder. The sample application chamber was typically 
cooled to 4 °C and an atmosphere of 100 % humidity formed. 4 µL of AbyB3 in XL or HEPES 
buffer, typically between 0.1 and 0.2 mg/mL, was applied directly to the grid, which was sus-
pended within the sample application chamber. The grid was then blotted and immediately 
plunged into liquid ethane to ensure vitrification. Grids were subsequently transferred into a 
grid box (Electron Microscopy Sciences) maintained under liquid nitrogen. Grids were then 
either stored in liquid nitrogen until use, or immediately taken forwards for clipping. The grids 
have an inner and outer ring applied by hand, so that they can be manipulated by the autoload-
ing system within the Talos Arctica microscope (FEI). Once clipped, they are either stored or 






4.2.6 Cryo-EM Grid Screening 
Cryo-EM grids were typically screened using a Talos Arctica 200 kV microscope (FEI) 
equipped with a Gatan K2 direct electron detector. The microscope was prepared using both 
direct alignments and software optimisations. Initially, an Atlas image of the grid is acquired, 
before a suitable gridsquare is selected. A eucentric height is then acquired and image shifts 
determined. Quantifoil holes to be imaged were subsequently selected, or a pattern created for 
Lacey Carbon grids. Before data acquisition, direct alignments of the microscope were per-
formed to ensure image quality. The C2 aperture was aligned and stigmated before the beam 
tilts and shifts were adjusted. The diffraction pattern was subsequently focussed, and images 
automatically acquired by the EPU software (FEI). In order to screen each grid, a few micro-
graphs were obtained from a sub-set of gridsquares exhibiting variations in ice thickness. The 
micrographs obtained were then assessed for particle quality and dispersion using Relion 3.0.294 
 
4.2.7 Cryo-EM Data Collection 
Data collection was performed using Lacey Carbon grids found to contain a good concen-
tration and dispersion of particles during screening. The microscope was prepared using a sim-
ilar protocol, but ensuring the conditions outlined in Table 4.4 were specified. 7 gridsquares 
were imaged overnight, collecting a total of 160 micrographs. 138 of these were judged to have 
an adequate contrast transfer function (CTF) as calculated using Relion 3.0, and were taken 




4.3 Results: Structural Interrogation of AbyB3 by X-Ray Crystallography 
To elucidate the structure of the intact AbyB3 module and address current disparities in 
published mPKS structural modules, two primary research objectives were formulated. The 
first of these was to obtain high-resolution structural data of each AbyB3 domain and the sec-
ond was to elucidate the native structure of intact AbyB3.  
The best technique to address the first of these priorities is X-ray crystallography. Due to 
the inherent challenges associated with crystallising intact PKS modules, obtaining crystals of 
a full length AbyB3 module was considered to be unlikely. With this in mind, an AbyB3DACP 
construct was generated, consisting of the pre-KS docking domain, the KS, the KS-AT linker 
and the AT-ACP linker (Figure 4.4a). This construct should not only have a higher chance of 
crystallisation, due to the absence of the highly dynamic ACP domains, but would also provide 
the opportunity to make a direct comparison with the DEBS didomain structures reported pre-
viously.113,114 This would allow us to determine whether the mammalian FAS homology model 
developed by Khosla and co-workers could also be applicable to bacterial mPKSs beyond 
DEBS. 
 
4.3.1  Cloning and Expression of AbyB3DACP 
AbyB3DACP was initially cloned from a pOPINF plasmid containing AbyB3 genomic 
DNA, using AbyB3_pE_Fwd and AbyB3_pE_Rvs primers (Appendix Table A1). PCR amplifi-
cation was completed in one step (Figure 4.4). The construct was inserted into the plasmid 
pOPINE, which contains an ampicillin resistance marker, akin to pOPINF, but differs in that it 
possesses a much shorter, C-terminal, hexa-histidine tag for purification by nickel affinity chro-
matography (Appendix Table A2). This approach was taken in an effort to minimise the impact 







Figure 4.4 Cloning AbyB3DACP. a) Schematic Representation of the Abyssomicin PKS M7 
AT-KS Didomain. A truncated version of AbyB3 was created, including the pre-KS docking domain, 
the KS, the KS-AT linker, the AT and the AT-ACP linker. b) PCR amplification of AbyB3DACP. The 
~2.7 kb gene was amplified using a gradient PCR with temperatures ranging from 60oC to 65oC during 
the annealing step.  
 
AbyB3DACP::pOPINE was transformed into both E. coli BL21 (DE3) and E. coli BL21 
BAP1 cells for expression trials. Although expression was observed in both cell lines, a notable 
increase in expression levels were observed in BAP1 cells. For this reason, BAP1 cells were 
chosen as the cell line of choice for large scale purification attempts. Although AbyB3DACP 
expression was observed at high yields, this polypeptide was found to be much less soluble in 
buffer than AbyB3, with high levels of protein aggregation observed following purification by 
SEC. The addition of 10 % glycerol to the purification buffers used in the production of this 
protein ensured continued solubility and enabled the production of AbyB3DACP to >95 % pu-












Figure 4.5 Expression of AbyB3DACP. An SDS-PAGE gel of purified AbyB3DACP. The 
construct was purified using nickel affinity chromatography and subsequent SEC, all in the presence of 
10 % glycerol to ensure solubility.  
 
4.3.2  Crystallisation and X-ray Diffraction Studies of AbyB3DACP 
Purified AbyB3 and AbyB3DACP, at a concentration of 10 mg/mL, was subjected to crys-
tallisation screening using six commercially available 96-condition screens, employing the sit-
ting drop method of vapour diffusion, as described in Section 4.2.2. Crystallisation attempts 
for AbyB3 yielded no viable crystals. However, a single condition from the MIDASplus screen 
returned small crystals of AbyB3DACP (Figure 4.6a), which formed over a period of four 
weeks. This condition comprised 0.1 M MES, 10% ethanol, 30% PAA 5100, pH 6. Several of 
the crystals present in the drop were subjected to X-ray diffraction at Diamond Light Source. 
Data collection and subsequent processing was performed as described in Section 4.2.3. The 










Figure 4.6 Crystallisation and X-Ray Diffraction of AbyB3DACP. a) Rectangular crystals 
of AbyB3DACP grown in 0.1 M MES, 10% ethanol, 30% PAA 5100, pH 6. b) X-ray diffraction of 







Data Collection Statistics 
Wavelength (Å) 0.98 
Resolution (Å) 2.36 
Reflection (observed / unique) 200817 / 28752 
Completeness (%) 100 (100) 
Multiplicity 7.0 (6.5) 
I/s(I) 3.4 (0.9) 
Rmerge 0.544 (2.474) 
 
Refinement Statistics 
Space Group C121  
Unit Cell Parameters (Å) a = 165.3, b = 86.2, c = 65.7 
Monomers per A.U. 2 
Protein Atoms 11,823 
R-factor 0.246 
R-free 0.321 
RMS Deviations  
Bonds (Å) 0.0070 
Angles (°) 1.69 





Table 4.1 Diffraction and Refinement Data for AbyB3DACP. Statistics in parenthesis are 
for the highest resolution shell. Rmerge= ∑ |#!	 −	〈#〉|/ ∑〈#〉 summed over all observations and 
reflections. Additional cycles of model building and refinement were conducted by Dr. Nicholas Burton 
at the University of Bristol. 
 
4.3.3 X-ray Crystal Structure of AbyB3DACP 
Although the final stages of model building and refinement of the AbyB3DACP are ongoing 
towards a completed crystal structure of this polypeptide; presented herein is our current lead 
model of AbyB3DACP. The remaining required minor modifications of this structure include 
the introduction of alternate conformers and revision of a small number of regions which are 




to 2.36 Å resolution, with our current model well suited for analysis and interpretation (Figure 
4.7). The KS and AT domains of AbyB3DACP are both well defined, as is the KS-AT linker 
region. The KS domains dimerise across a large interface with the KS-AT linker and the AT 
domain stretching horizontally outwards in opposite directions. The AT-ACP linker is partially 
defined, with the final 24 amino acids showing no corresponding density. This region appears 
to wrap around the KS-AT linker and attaches to the bottom of the KS domain, close to the 
ACP docking domain, as identified by Whicher et al. in their cryo-EM structure.142 Unfortu-
nately, no density corresponding to the pre-KS docking domain is visible, indicating flexibility 
in this region.  
  
 
Figure 4.7 The X-Ray Crystal Structure of AbyB3DACP. The structure of dimeric 
AbyB3DACP is depicted using a cartoon representation (left) and a surface representation (right). One 






AT linker regions in light yellow. The one residue distinguishable from the pre-KS docking domain is 
shown in bright yellow and the AT-ACP linker is shown in pink. 
 
4.3.3 Comparison with the Structures of DEBS M3 and M5 
The crystal structure of AbyB3DACP is immediately comparable to those of the DEBS M3 
and M5 didomain structures. Each adopts a similar global fold, which can be readily superim-
posed (Figure 4.8). This analysis reveals small Ca rmsds between the atoms present in each 
structure. AbyB3DACP is more closely structurally related to DEBS M5 with a 3.4 Å Ca rmsd, 
while a larger value of 7.3 Å Ca rmsd is determined between AbyB3DACP and DEBS M3. 
Interestingly, AbyB3DACP can thus be considered to possess greater structural identity to 
DEBS M5 than DEBS M3 (5.1 Å Ca rmsd). Whilst the sequence identities between 
AbyB3DACP and DEBS M3 and M5 are high, 45 % and 48 % respectively, these values are 
lower than between DEBS M3 and M5 (54 %). This serves to highlight the structural conser-
vation between mPKS modules. The major identified differences between these structures are 
attributable to the 27° change in angle between DEBS M3, and both DEBS M5 and 
AbyB3DACP, as previously postulated by Tang et al.114 This is caused by a combination of 
crystal packing constraints and the removal of the pre-KS docking domain, which was ob-





Figure 4.8 Comparison of AbyB3DACP with Didomain Structures from DEBS. The 
structure of AbyB3DACP (red) overlaid with the structure of a) DEBS M5 (yellow) and b) DEBS M3 
(teal).  
 
4.3.4 Crystal Constraints Imposed on AbyB3DACP 
In order to investigate these proposals further, the crystal packing arrangement observed for 
AbyB3DACP was explored. As with the structure of the DEBS M5 AT-KS didomain, signifi-
cant inter-dimer contacts are observed (Figure 4.9a). With each dimer forming an ‘S’ confor-
mation, individual protomers are able to stack closely together, potentially stabilising the linear 
structure. These sheets of interlocking ‘S’ conformations do not, however, stack directly on top 
of each other. Instead, the AT domains from dimers in the plane above sit in the cleft created 
by the KS-AT linker (Figure 4.9b). This results in the formation of a cavity above the KS do-
mains, in between the AT domains from the dimers on the above plane. This provides free space 
for the flexible pre-KS docking domains to be accommodated, though the absence of compel-






are in contrast to the packing constraints imposed in the crystallisation of DEBS M5, where 
the pre-KS docking domain sits in the cleft created by the KS-AT linker region, thereby stabi-
lising it and allowing its resolution (Figure 4.1). Whilst the presence of significant packing 
constraints does not preclude the pre-KS linker having a significant effect on the structure of a 
didomain, it does show that both hypotheses have merit.  
  
 
Figure 4.9 Crystal Packing Constraints for AbyB3DACP. Each AbyB3DACP dimer forms 
significant contacts with other dimers within the crystalline lattice. a) On a single plane the dimers stack 
together, with the AT domain from one dimer resting between the KS and AT of another dimer. b) These 
contacts also exist both above and below the dimer. Shown are two monomers which illustrate the cavity 







4.3.5 Analysis of Individual Domains in AbyB3DACP 
The KS domain of AbyB3DACP adopts a five-layered ababa fold, as seen in previous KS 
structures, including those from type I and type II PKSs, and trans-AT PKSs, as well as in 
homologous condensing domains from FASs.99,113,114,295,296 The KS dimerisation interface is 
extensive, stretching 50.4 Å from corner to corner and is dominated by hydrophobic interac-
tions and hydrogen bonds. The core of each KS monomer is composed of five antiparallel b-
sheets. Across the dimerisation domain the two five-membered b-sheets are joined by back-
bone hydrogen bonds, creating a ten-membered anti-parallel b-sheet structure (Figure 4.10a). 
Whilst this is a common feature to previously studied KS domains,99,295,297 specificity is con-
ferred by two salt bridges between arginine 190 and glutamic acid 313 (Figure 4.10b). This 
pair of charged residues reside at the top two corners of the dimer interface, a notable difference 
from DEBS M3, which lacks salt bridges, and DEBS M5, where two salt bridges form at the 
base of the dimerisation interface. The conservation between the structure of distinct KS do-
mains is demonstrated by a 1.31 Å rmsd between all Ca atoms in the DEBS M5 and AbyB3 





Figure 4.10 Identification of the KS Dimerisation Domains. a) Identification of backbone 
hydrogen bonds formed between two antiparallel b-sheets in opposing monomers, as well as a couple 
of surrounding hydrogen bonds. b) The salt bridge formed between R190 and D313. These salt bridges 
are formed at the top two corners of the dimerisation interface. Distances given are in Angstroms.  
 
The active site in both the KS and AT domains of AbyB3DACP can be identified using both 
sequence and structural homology to published didomain structures. The active site in the KS 
domain houses a highly conserved catalytic triad consisting of cysteine 200, histidine 335 and 
histidine 373 (Figure 4.11a). This triad faces downwards and towards the dimerisation inter-
face. Whilst Cys200 binds the polyketide chain, the two histidine residues have been shown to 
play a key role in the decarboxylation of the ACP-bound extender unit.298 The AT domain con-
sists of a ferredoxin-like fold fused to a larger a/b-hydrolase sub-domain, that forms the central 
core of the AT (Figure 4.11b). The active site resides at the interface of these two structural 




















elements, and houses the proposed critical residue serine 637. Whilst the structural identity 
between AbyB3 AT and DEBS M5 AT is high, with a 3.4 Å rmsd between Ca atoms, these 
domains are noticeably more structurally differentiated than their respective KS domain part-
ners. 
The KS-AT linker region of AbyB3DACP closely mirrors that of both DEBS didomains, 
with two anti-parallel b-sheets sitting between three a-helices (Figure 4.11c). The b-sheets are 
flanked on one side by two additional a-helices in the DEBS structures, one belonging to the 
AT and one to the AT-ACP linker. In the AbyB3DACP structure the a-helix belonging to the 
AT-ACP linker is only comprised of one full turn, raising the possibility that, when the ACP 
domain is attached, this helix could dissociate into a flexible loop, enabling a conformational 







Figure 4.11 Visualising the KS and AT Domain Active Sites and the KS-AT Linker 
Region in Detail. a) The KS active site is highlighted, with the catalytic triad of Cys200, His335 and 
His373 shown in orange. b) The AT domain with the catalytic Ser637 residue highlighted in orange. 
The ferredoxin-like fold resides at the bottom of the image. c) The KS-AT linker region is shown in 
light yellow, with an interacting a-helix belonging to the AT domain shown in green, and the loop of 











4.4 Results: Structural Analysis of AbyB3 by EM and Cryo-EM 
In order to determine the structure of the intact minimal module of AbyB3, thereby investi-
gating what conformational constraints are imposed on the linear didomain structure by the 
addition of the ACP domain, single particle cryo-EM was used. The multiple structures ob-
tained by Dutta et al. and Whicher et al.141,142 leave significant room for resolution improve-
ment and provide limited information about what an intact minimal module might look like. 
The previously determined DEBS didomain structures113,114 are far closer in terms of sequence 
to a minimal module than PikAIII. The 90 amino acids that comprise the AbyB3 ACP domain 
represent roughly 10 % of the intact polypeptide, whereas an additional KR domain, and linker, 
as is present in PikAIII, equates to a > 30 % increase in module molecular weight.  
 
4.4.1  Crosslinking AbyB3 
In an attempt to obtain as high a resolution structure of AbyB3 as possible, a number of 
crosslinking methods were investigated to bias the formation of the AbyB3 tetramer seen in 
solution (Figure 3.9). This work was undertaken as, when solving cryo-EM structures, larger 
proteins are easier to work with and deliver higher contrast in the resulting image, leading to 
increased resolution. Additional axes of symmetry also enable structures to be solved at a 
higher resolution. This work was to be undertaken whilst simultaneously attempting to solve a 
structure of the modular dimer, as shown in the studies of PikAIII and DEBS modules.91,114,141–
143  
Although multiple crosslinkers were investigated, including BS3, glutaraldehyde (both link-
ing two primary amine groups) and Sulfo-SBED (linking a primary amine with any other amino 
acid functional group), the best results were seen when crosslinking AbyB3 with PEG12-SPDP, 
a multifunctional crosslinker with a 54.1 Å linker length (Figure 4.12). This required binding 
PEG12-SPDP to AbyB3 via a primary amine, before reducing the disulphide bond in the linker 
with DTT. This reveals an activated sulfhydryl group that could either bind directly to other 
sulfhydryl groups or link to another activated subunit of AbyB3, hence fusing two primary 
amines via a 108.2 Å linker. Although PEG12-SPDP is a long, non-specific linker, this was 
deemed preferable to generating new constructs capable of being linked specifically, both to 




   
 
Figure 4.12  Crosslinking the AbyB3 Tetramer. a) Non-reducing SDS-PAGE gel of AbyB3 
crosslinking by PEG12-SPDP. 1) Native AbyB3, with no crosslinking performed. 2) PEG12-SPDP 
conjugated AbyB3, designed to link an amine sidechain with the thiol group on a cysteine residue. 3) 1 
and 2 incubated together for 18 hours. 4) PEG12-SPDP conjugated AbyB3 is then reduced by DTT, 
revealing a sulfhydryl moiety attached to AbyB3 via an amine sidechain. This is then mixed with 
unreduced PEG12-SPDP-conjugated AbyB3 for 18 h to form an amine-amine linkage. b) Native PAGE 
gel of crosslinked AbyB3. The reaction from 4 is separated by size using analytical SEC and 5) early 
peak and 6) late peak fractions identified by UV-vis spectroscopy of the eluent are analysed by native 
PAGE. c) The PEG12-SPDP crosslinker, with the orange sphere representing AbyB3. 
 
Once crosslinked AbyB3 was subsequently visualised by NSEM (Figure 4.13). This re-

























Figure 4.13 Negative Stain Electron Microscopy of PEG12-SPDP crosslinked AbyB3. 
AbyB3 is conjugated by PEG12-SPDP, linking two amine residues together. The protein multimers are 
visualised as white on a dark grey background. 
 
4.4.2  Screening AbyB3 Cryo-EM Conditions 
A range of conditions were explored in an attempt to analyse native and crosslinked AbyB3 




cryo-EM. Major obstacles were encountered in attempts to generate monodisperse particles in 
the layer of ice situated within a quantifoil hole. Both the native and crosslinked proteins ad-
hered to the carbon support around the quantifoil holes, minimising their accumulation within 
the holes themselves. In an attempt to mitigate this, and to stabilise the protein complexes, R 
2/2 grids coated with an ultrathin carbon support were employed. Unfortunately, the small size 
of AbyB3, even when crosslinked, prevented sufficient contrast from being generated against 
the support film. In addition, it was feared that the majority of particles were still adhering to 
the thicker carbon support around the quantifoil holes. To address both of these issues, R 2/2 
grids coated in graphene oxide were further treated for use with 1 M magnesium chloride so-
lution. Graphene oxide, because it can be added in a film one atom thick, enables significantly 
higher contrast for single particle analysis.299 In order to reduce the hydrophobic nature of 
standard grids, they are glow discharged, that is, gently ionised at low pressures. When this 
occurs in air, the carbon supports are given a negative charge.300 The addition of MgCl2 to 
graphene oxide coated grids reverses the charge present on the grid, from negative to positive, 
ideally resulting in an even dispersal of particles. This approach can be used to reduce sample 
adherence to the negatively charged carbon support. Unfortunately, this did not appear to re-
solve the issue. Some larger aggregated particles were observed when the solution of cross-
linked AbyB3 was incubated on the grid for two minutes, but homogenous monodisperse par-
ticles were not observed. Issues with the quality of commercially applied graphene oxide coat-
ings also impeded progress. Some grids were completely uncoated, and others appeared to have 
had large sections of compromised coating. These issues only came to light after application 
with protein solution, freezing, clipping and attempted cryo-EM analysis. 
Due to these unsuccessful attempts at cryo-EM analysis, a full dataset of negative stain im-
ages was acquired for crosslinked AbyB3. 438 micrographs were obtained on an FEI Technai 
T20 microscope. These were processed using Relion 3.0294 and particles were picked using a 
Laplacian of Gaussian difference detector, which is well suited to identifying high contrast 
negatively stained particles. This yielded a total of ~65,000 particles which were subsequently 
subjected to multiple rounds of reference free 2D classification. Despite a number of attempts 
and the use of various strategies, for instance using very large or small boxes to extract the 
particles and provide them with a localised CTF estimation, or iteratively filtering the particles 
based on metadata scores determined by Relion, no reliable 2D classes could be generated. 
This was hypothesised to be because crosslinking AbyB3 with PEG12-SPDP did not generate 





The AbyB3 dimer, which was previously disfavoured due to its lower contrast against the 
carbon and graphene support films used, was subsequently investigated by cryo-EM using 
Lacey Carbon grids (Figure 4.14a and b). These grids consist of randomly sized and placed 
holes within a carbon support stretched between the copper mesh. This delivers a combination 
of very small and very large holes within the grid; the smallest holes tend to possess extremely 
thick ice and the largest possess no ice at all. The irregular nature of these grids means that they 
are not optimised for automated data collection, and it is difficult to obtain datasets large 
enough to determine high resolution structures by cryo-EM. The automated data collection 
software is not able to verify its location using the regularly spaced and well-defined quantifoil 
holes (Figure 4.14c). This results in very small image alignment differences multiplying with 
every movement of the stage and imaging plane, leading to a highly heterogenous set of mi-



























AbyB3 XL Leica 100 0 1 N/A 4 No 
No protein visible in quantifoil 
holes 
R2 / 2 None AbyB3 & AbyB3 XL 
Leica & 
Vitrobot 80 - 100 0 1, 2 1, 2 4, 10 No 
No protein visible in quantifoil 
holes 
R2 / 2 Ultrathin Carbon AbyB3 XL Vitrobot 95 0 1 1 4 No Background contrast too high 
R2 / 2 Graphene Oxide AbyB3 XL 
Leica & 
Vitrobot 80 - 100 0, 120 
0.5, 1, 2, 
3 
0.5, 1, 
3, 5 4, 8, 10 No 
Background contrast too high / 
no protein in quantifoil holes 
Lacey 
Carbon None AbyB3 Vitrobot 100 0 0.5, 1 1, 3 4 Yes 
Protein only visible in thinnest 
ice far from Carbon edges 
 
Table 4.2 Cryo-EM Screening Conditions Investigated. All grids, apart from those coated in graphene oxide, were glow discharged immediately 
prior to use at full power (15 – 19 mA) for one minute. 4 µL of protein sample, 0.05 – 0.5 mg/mL, was applied to each grid. Grids were plunge-frozen on either 







 Figure 4.14 Cryo-EM Atlas and Gridsquare Images. Images acquired on a Talos Arctica 
Cryo-TEM (FEI). a) Overview of the entire Lacey Carbon grid used to collect a small dataset. 






Carbon gridsquare. The brightest holes are empty and do not contain any ice. Images were taken 
throughout each selected gridsquare using a computer generated pattern with a 1.5 µm spread between 
them, deleting selections near carbon support. c) An R 2/2 quantifoil gridsquare.  
 
After monodispersed AbyB3 dimers were observed in some of the initial micrographs ob-
tained on the Lacey Carbon grids, a number of different concentrations of AbyB3, blotting 
times and blot forces were trialled. These aimed to determine the optimal ice thickness and 
concentration of AbyB3 needed to observe high-density, yet still monodisperse, particles. The 
particles appeared to prefer the regions of thinnest ice, as far away from the carbon support as 
is possible (Figure 4.15). An optimal AbyB3 concentration of 0.12 mg / mL, or 1.12 µM, pro-
vides a high density of monodisperse particles within these regions. In order to collect a small 
dataset of images, a grid was prepared using the conditions outlined in Table 4.3.  
  
Grid Preparation 
Protein / Grid Type AbyB3 / Lacey Carbon 
Glow Discharge 1 min, 19 mA 
Protein Sample Concentration (mg / mL) 0.12  
Protein Sample Volume (µL) 4  
Plunge Freezer Vitrobot Mk IV (ThermoScientific) 
Humidity (%) 100  
Temperature (°C) 4  
Pre-Blot Incubation (s) 0  
Blot Time (s) 1  
Blot Force 1 
 






Figure 4.15 Screening AbyB3 Cryo-EM Grids. A motion corrected and CTF adjusted 
micrograph displaying particle preference for thin ice, far away from carbon support. The particles can 
only be distinguished in the top right hand corner of the micrograph, displaying a small, triangular 
shape. 
 
4.4.3 AbyB3 Dataset Collection  
A dataset of 213 micrographs from the prepared Lacy Carbon grid was acquired overnight 
on an FEI Talos Arctica Cryo-EM microscope (Figure 4.16). The data collection statistics are 
presented in Table 4.4. Unfortunately, halfway through the overnight run, a camera malfunction 
resulted in the bottom ~100 nm of the remaining micrographs becoming corrupted and lower-




cropped out (Figure 4.16b) and does not impact on downstream processing of particles as ex-











Figure 4.16 Representative Cryo-EM Micrographs of AbyB3. Each micrograph was 
obtained on a Talos Arctica Cryo-TEM (FEI). a) A high contrast micrograph obtained at -2.6 µm 















AbyB3 Data Collection 
Hardware 
Microscope Talos Arctica 
Detector (Mode) GATAN K2 (Counted) 
Accelerating Voltage (keV) 200  
Cs (mm) 2.7 
Illumination 
Spot Size 6 
C2 intensity (%) 39.59 
C2 Aperture (µm) 1.8 
Dose 
Magnification 130,000 x 
Pixel Size (Å) 1.05 
Square Pixel (Å2) 1.1025 
Dose Rate (electrons pixel-1 s-1) 5.973 
Dose Rate (electrons Å -1 s-1) 5.377 
Exposure Time (s) 11 
Total Dose (electrons (Å2)-1) 59.147 
Number of Fractions 55 
Total Dose per Fraction (electrons (Å2)-1) 1.075 
Data Collection 
Objective Aperture (µm) 70 
Defocus Range (µm) -1, -1.4, -1.8, -2.2, -2.6 
Autofocus Frequency (µm) 6 
Delay after Image Shift (s) 3 
Delay after Stage Shift (s) 6 
Energy Slit Width (eV) 20 
 
Table 4.4  Data Collection Statistics for Cryo-EM Microscopy Analysis of AbyB3. 
 
4.4.4 Processing AbyB3 Cryo-EM Data 
The dataset of 213 micrographs was manually sorted, excluding i) those micrographs con-
taining large sections of carbon support; ii) those primarily containing empty holes; and iii) 
those without discernible AbyB3 particles. This left 38 micrographs, each containing 80 – 714 
AbyB3 particles. These particles were picked by hand, as autopicking software is unable to 
correctly distinguish the small, low contrast, AbyB3 particles in the highly heterogenous Lacey 




and a soft circular mask of 100 Å. The dataset was processed using multiple rounds of refer-
ence-free 2D classification, with a soft circular mask of 80 Å and a resolution limit of 15 Å. 
Particles not conforming to the best classes generated with each iteration were discarded. The 
particles were further sorted according to the Relion metadata ParticleSelectZScore which pro-
vides a reliable way to discard particles with the least homology to the class averages generated. 
Eventually a dataset of 2978 particles was obtained, each of which fit into a 2D class average 
displaying clear structural properties (Figure 4.17a). Some of these classes did, however, still 
possess spikes within the solvent region. These spikes are the result of fitting artefacts and sub-
classification of these individual classes was performed to remove them (Figure 4.17b). The 
2D class averages obtained are derived from a small dataset, and as such, should be treated 





Figure 4.17 Reference-Free 2D Class Averages of AbyB3. The micrographs obtained from 
the Lacey Carbon grids were manually sorted and particles picked by hand. These were then subjected 
to multiple rounds of reference-free 2D classification until a) a dataset of 2978 particles displaying clear 
secondary structure was obtained. b) Further sub-classification of 2D class averages displaying peaks 
within the surrounding solvent (numbered 1 – 5) provided improved class averages. N.B. These class 
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averages are taken from a small dataset and should not be considered appropriate for the generation 
of a high-resolution model. 
 
4.4.5 Analysis of AbyB3 Cryo-EM Data 
As class averages were obtained with a relatively small numbers of particles (as shown in 
Figure 4.16), the clear structural features that would be expected from a large publication qual-
ity dataset are less evident. Nevertheless, the class averages generated can be compared to those 
generated during the refinement of the PikAIII model determined by Dutta et al.,141 and the 
crystal structure of AbyB3DACP. The minimal AbyB3 module is expected to be a significantly 
smaller construct than PikAIII due to a lack of a KR domain. In the PikAIII structure the KR 
domain is observed at the bottom of the arch shaped structure, creating a large central reaction 
chamber (Figure 4.3). This would mean that, if AbyB3 adopted a similar structure, it would be 
expected to primarily consist of the top of the arch observed in PikAIII, potentially forming a 
triangular shape as observed in the motion corrected micrographs of AbyB3 (Figures 4.15 and 
4.16). If, however, AbyB3 adopted a conformation similar to that observed in mammalian 
FAS152 and analogous to that observed for AbyB3DACP, a more linear shape would be ob-
served in the class averages if only one KS subunit was in view, or an S shaped conformation 
if two KS subunits were visible.  
The low resolution class averages obtained from this initial dataset appear to be in good 
accordance with those generated by Dutta et al. (Figure 4.18). The triangular shape observed 
in the raw micrographs is representative of the KS and AT domains within PikAIII, when the 
structure is viewed in a front on arch conformation. Likewise, other 2D class averages match 
up with those from PikAIII that display a more circular or squashed architecture as a result of 





Figure 4.18 Comparison of AbyB3 Cryo-EM 2D Class Averages with PikAIII. AbyB3 
does not contain a KR domain, which is situated at the bottom of the arch structure displayed by PikAIII. 
AbyB3 is therefore observed to form a smaller shape, consistent with the top of the PikAIII arch 
conformation. 
 
The particles adhering to the reference-free 2D class averages obtained (Figure 4.17a) were 
subsequently used to generate an ab initio model of AbyB3 (Figure 4.19). This process typi-
cally takes a subset of 400 particles and uses them to generate a very low resolution model of 
the structure. This is an unbiased process using a sphere the size of the soft circular mask em-
ployed when processing the data as a starting point. This initial model immediately indicates 










structure of AbyB3DACP, and is far more representative of the structure exhibited by the KS 
and AT domains in the cryo-EM structure of PikAIII.  
 
 
Figure 4.19 Generating an Ab Initio Model of AbyB3. The dataset of 2978 particles were 
used to generate an initial model from an unbiased starting conformation. 300 iterations of refinement 
yielded a convincing initial model displaying the triangular shape observed in the micrographs. 
 
Although the dataset collected is too small to determine reliable, high resolution, 3D class 
averages, or to formulate a definitive model, it did yield a number of 3D class averages, under 
different processing conditions, resembling the 3D class average shown in Figure 4.20a. The 
initial model and the 3D class averages allow a hypothetical structure of AbyB3 to be proposed, 
based on that determined by Dutta et al. (Figure 4.20b). This shows a closer homology to the 
3D class average than the structure of AbyB3DACP, although the dataset is not large enough 









Figure 4.20 A Hypothetical Model for AbyB3. a) A 3D class average generated after 
processing the small dataset shown in Figure 4.17a. A resolution cut-off of 12 Å was imposed and it 
was generated from 541 particle projections. b) A possible AbyB3 model, constructed in Pymol out of 
the AbB3DACP crystal structure and the structure of the DEBS M2 ACP, using the published structure 







The abyssomicin C synthase module 7 from M. maris has been structurally characterised 
using both X-ray crystallography and cryo-EM. This structural information is considered crit-
ical in providing insight into the mechanism employed by bacterial mPKSs and the molecular 
details of vectoral biosynthesis. Such studies also provide information about the inter- and 
intra-module protein-protein interactions that are known to be critical for mPKS function. 
 
4.5.1 Analysis of the Structure of AbyB3DACP 
The AbyB3DACP structure presented herein represents the first high-resolution mPKS 
didomain structure outside of the DEBS system. Our structure indicates that architectures of 
these respective mPKS didomains is highly conserved. Although there are differences between 
the two structures, such as in the placement of salt bridges, or in some of the flexible loop 
regions, these structures are readily super-imposable. This implies that their mechanism of ca-
talysis is likely to be highly similar, and consistent with that of PikAIII. The AbyB3DACP  
structure sheds light on the structural conservation between bacterial polyketide synthases of 
diverse species, with M. maris and S. erythraea sharing only 13.3 % identity by DNA-DNA 
hybridization.301 The location of the  AT-ACP linker domain that can be discerned is perhaps 
surprising in that it is identical to the AT-KR linker domain in both DEBS modules. This 
demonstrates that the association first with the KS-AT linker region, and then with the KS, is 
likely to be highly specific, with a non-discernible flexible linker then providing the connection 
to the downstream domain. The relative disorder of the AT-ACP linker domain’s interaction 
with the KS-AT linker could provide some insight as to a possible mechanism by which con-
formational changes are relayed through the module. The addition of a downstream domain 
could provide the tension to cause this partial a-helix to dissociate, triggering a rearrangement 
in the linker region causing the AT domains to bend round, into the arch conformation seen by 
Dutta et al. Specific interactions in this region, influenced by the location of the ACP or the 
orientation of the KR domain, which Whicher et al. showed to be highly variable depending 
on status of the catalytic cycle, could then result in the movement of the AT-KS linker to ob-
scure the top-most channel to the KS active site, preventing the premature insertion of a polyke-




4.5.2 Analysis of the Preliminary Cryo-EM Structure of AbyB3 
Although a full dataset of AbyB3 cryo-EM images is yet to be acquired, the preliminary 
data presented in this thesis does provide a number of important insights. A significant period 
of time was needed to investigate a wide range of sample preparation conditions, with the im-
aging of AbyB3 proving intractable by more conventional EM approaches. A combination of 
its tendency to adhere to carbon supports, its low contrast, and preference for very thin ice 
means that most traditional grids proved unsuitable. This presents another possible reason why 
no cryo-EM structures of polyketide synthase modules have been reported since 2014, as im-
aging is likely to entail a large resource and time commitment. The successful acquisition of a 
small dataset does, however, provide significant hope for the future. R 2/1 grids are thought to 
present the best chance of successful data acquisition using easy-to-process quantifoil grids. 
Although rarely used for single particle cryo-EM and recommended for the visualisation of an 
entire cell,302 the quantifoil holes are spaced more closely together than R 2/2 grids, removing 
excess carbon support. Larger quantifoil holes are also available, with R 3.5/1 grids an alterna-
tive if R 2/1 grids are not suitable. Non-specific crosslinking attempts have been unsuccessful, 
and future efforts should be concentrated on determining the dimeric structure, despite its 
smaller size, lower oligomeric number and lower contrast. 
The 2D class averages obtained to date are a convincing replication of those obtained by 
Dutta et al. The observation of a triangularly shaped structure in both the 2D class averages 
and initial model, which are both obtained in a completely unbiased reference-free manner, is 
a significant departure from the linear or ‘S’ shaped conformations observed in the structure of 
AbyB3DACP. Although preliminary, the 3D models generated bare good resemblance to what 
might be expected if an arch shaped conformation was adopted. These models are, however, 
currently too small to accurately fit in individual domains from the structure of AbyB3DACP. 
This is likely due to a preference for AbyB3 to adopt a face on conformation on the grid, dis-
playing a triangular shape. The small dataset will disfavour any but the most common orienta-
tions observed and means that the model generation software is unable to accurately determine 





4.5.3 Comparison of the Structures of AbyB3 and AbyB3DACP 
The structure of AbyB3 with and without the ACP appears to differ significantly. The 
didomain adopts a highly distinctive linear or ‘S’ conformation that is in good agreement with 
the prior art. However, the cryo-EM and negative stain analyses preclude this as being the 
native conformation. AbyB3DACP is ~150 Å from the end of one AT domain to the end of the 
other. Even when crosslinked, distinct particles do not appear to reach this size on a negative 
stain grid, whilst both negative stain and cryo-EM grids of the non-crosslinked AbyB3 fail to 
display any particles, even coming close to this size or exhibiting a highly recognisable ‘S’ 
configuration. Once processed, the cryo-EM class averages reveal small, mostly triangular, 
species. Again, none of these class averages resemble the didomain structure and all fit within 
an 80 Å circular mask. One explanation for the size of these particles could be that the dimer 
dissociates into monomers upon plunge freezing and vitrification, although this is unlikely. The 
large KS dimerisation interface, with many hydrogen bonds and two salt bridges is likely to be 
extremely stable. The close resemblance to the 2D class averages generated by Dutta et al.,141 
as well as the negative stain micrographs, where a method of fixing the particles is employed 
and is unlikely to precipitate any dissociation events, also indicate that the dimer is observed. 
An alternative explanation is that the ACP domain, thought to be solely a flexible vector for 
shuttling the growing polyketide chain between multiple active sites,151,303 in fact exerts an 
outsized and unexpected influence on the structure of bacterial mPKSs. The presence of a 
structurally conserved post-AT linker indicates that this region may serve to transmit structural 
rearrangements from later domains back to the KS and AT domains, revealing and obscuring 
the upper entrance to the KS active identified by Dutta et al. The inability of the same authors 
to create stable ACP4-KS5-AT5-KR5 constructs without the inclusion of some of the sequence 
of the ACP from M5 also points to a role in structural integrity for the ACP and the post-ACP 
linker.  
Initial studies on AbyB3 and AbyB3DACP using SAXS have also shed light onto their re-
spective structures (Figure 4.21). Although these results are still highly preliminary, they do 
show that, for AbyB3DACP, a dimer conformation is exhibited in solution, and that the overall 
density map generated initially fits well to the ‘S’ shape observed in the crystal structure. The 
density map for AbyB3, however, fits far less well to the ‘S’ shaped dimer it is modelled with, 




Work is underway to model in each structure with the flexible regions present, as well as with 
individual domains. 
 
Figure 4.21 Preliminary SAXS Analysis of AbyB3DACP and AbyB3. Dr. Ash Winter at the 
University of Bristol has been able to conduct preliminary SAXS analysis of a) AbyB3DACP and b) 
AbyB3 using the initial structure of AbyB3DACP for map determination and analysis.  
 
These results show that the structure of a minimal module mPKS should not be predicated 
on the structure of a didomain. In order to accurately interrogate the structures of modular and 
multi-modular systems, as well as the highly complex web of structural rearrangements that 
govern them, they need to be examined as a whole, without any preconceived bias. They also 
demonstrate, for the first time, the high level of structural homology between mPKS systems 
from diverse species, and show that there is highly likely to be one overriding structure for 
mPKS systems. The highly specific protein-protein interactions required for correct vectoral 




The work outlined in this chapter constitutes the first comparative structural study between 





study, although incomplete, is the first structural analysis of a polyketide synthase minimal 
module, and the second reported of any bacterial PKS module studied by cryo-EM. The two 
studies both show consistency to the studies that have given rise to two contradictory models 
for bacterial mPKS structure.113,141,143,148 Whilst the cryo-EM work remains incomplete, it does 
provide significant evidence that the addition of the ACP domain precipitates a large structural 
reorganisation of the module, and casts significant doubt on any model predicting mPKS mod-
ules to be structurally homologous to those found in mammalian FASs. This work further ex-
emplifies that, using modern techniques, studies on large, complex biosynthetic machinery 





Delineation of the Complete Reaction Cycle of 
the b-Barrel Diels-Alderase AbyU  
5.1 Introduction 
5.1.1 The Diels-Alder Reaction 
The DA reaction was originally described by Otto Diels and Kurt Alder in 1928, who iden-
tified the two products formed by the reaction of cyclopentadiene with quinone. The develop-
ment of this reaction, a [4 + 2] cycloaddition, was immediately postulated by Diels and Alder 
as a potential route to the “synthesis of complex compounds related to or identical with natural 
products such as terpenes, sesquiterpenes, perhaps even alkaloids”. Their work would eventu-
ally lead to the award of a Nobel prize in Chemistry in 1950.304,305 It wasn’t until the award of 
this Nobel prize, however, that the DA reaction began to be used regularly in synthetic chem-
istry, perhaps due to Diels and Alder’s exhortation in their 1928 paper that others were not to 
use the reaction for the synthesis of NPs. This reaction has since been used extensively in or-
ganic synthesis, being used in > 400 syntheses in 2019 alone.306  
The DA reaction occurs between a 1,3-diene and a dienophile (usually an alkene), to form 
a cyclohexene (Figure 5.1a). Formal DA reactions proceed concertedly, that is each of the two 
new carbon-carbon bonds are formed at the same time. This is achieved due to the overlap of 
the electron orbital fields in the diene and the dienophile. The highest occupied molecular or-
bital (HOMO) present on the diene overlaps with the lowest unoccupied molecular orbital 
(LUMO) of the dienophile, allowing electrons to flow between the two (Figure 5.1b & 5.1c).307 
In order for this to happen, electrons are donated by the nucleophilic diene to the electrophilic 




bonds, and so proceeds in an enthalpically favourable manner.308 However, in most chemical 
systems the diene and the dienophile do not have a sufficient electronic interaction for the 
reaction to proceed, necessitating the presence of electron withdrawing groups on the dieno-
phile, or donating groups on the diene. If these are absent, a catalyst must be used, such as a 
Lewis acid, which can accept a pair of non-bonding electrons. The Lewis acid (any chemical 
moiety that can accept a pair of non-bonding electrons) is thereby used to increase the with-
drawing nature of the dienophile. These measures strengthen the HOMO-LUMO overlap, al-
lowing the forward reaction to occur. There are also inverse electron demand DA reactions, 
where the diene becomes the electrophile and the dienophile the nucleophile.309 The pericyclic 
reaction remains the same, and likewise has a lack of an energy minimum in the transition state.  
 
 
Figure 5.1 The Diels-Alder reaction. a) The simplest DA reaction possible, between buta-1,3-
diene and ethene to form cyclohexene. The reaction proceeds in a synchronous concerted manner with 
a single transition state. b) Reaction of the unhybridised P orbitals in the sp2 hybridised ethene and but-
1,3-diene. c) Overlap of the HOMO and LUMO electron orbitals between a diene and a dienophile 



















Early progress in the application of DA reactions to synthesis was made using intramolecu-
lar reactions, asymmetric variants and hetero-DA reaction,310,311 as well as in identifying the 
secondary electronic orbitals that influence the reaction progression.312,313 More recently, in-
vestigations have focussed on the potential applications of the DA reaction in areas such as 
natural product chemistry and the synthesis of bioactive compounds.314–317 The DA reaction 
has also attracted attention as a ‘green chemistry’ reaction, as there are no by-products pro-
duced, and toxic catalysts are typically not needed.318 The ability of chemists to catalyse this 
reaction has also been furthered, with the canonical Lewis acid catalysts often used to control 
the reaction and product stereochemistry recently complemented by novel techniques such as 
the application of electrostatic fields, shown to drive electron flow from the dienophile to the 
diene in an inverse system.304,319 As a result of this extensive theoretical and experimental re-
search, a number of different [4 + 2] cycloaddition transition states have been determined, 
ranging from synchronous concerted to biradical (Figure 5.2).307 It has become accepted that 
for a [4 + 2] cycloaddition reaction to proceed via a formal DA mechanism, there must be a 
concerted bond formation, as well as the formation of a stereospecific product.320 In this way, 
a DA reaction must be a pericyclic reaction that proceeds via a single transition state.  
 
Figure 5.2 Possible [4 + 2] Cycloaddition Transition States. Synchronous and 
asynchronous transition states form bonds in a concerted manner, whereas biradical and biradicaloid 


































5.1.2 The Diels-Alder Reaction in Industry 
Advances in the understanding, control and application of the DA reaction have not, how-
ever, translated into the use of this reaction in industrial settings. In 2010 only one marketed 
drug and two generic drugs in the top 200 approved for use in the USA used the DA reaction 
in their synthesis.311,321 This paucity of use is reflected throughout industrial chemical reac-
tions, with the only industry to regularly use the DA reaction in synthesis being the fragrance 
industry.322 It is thought that there are two key reasons for the lack of DA adducts in industry. 
The first is that the substrates are often difficult to work with, and frequently unstable. This not 
only impacts the ability of chemists to use this reaction at scale, but also comes with a number 
of safety concerns.311 Secondly, without using catalysts, it is often difficult to precisely control 
the stereochemistry of the reaction. For example, in the reaction of methyl acrylate to cyclo-
pentadiene, the products formed are a mixture of endo and exo species. The addition of a Lewis 
Acid catalyst, such as aluminium chloride, is sufficient to drive the reaction from an 82:18 to 
99:1 endo:exo ratio.323 Therefore, if the catalyst used to control the reaction isn’t compatible 
with the rest of the industrial process, or is too expensive or toxic, the DA reaction can yield 
too great a diversity in product stereochemistry for use in highly stereo-sensitive applications, 
such as pharmaceutical manufacture.  
The simplicity, utility and functional practicality of a reaction that is capable of generating 
sp3 rich cyclic systems without any waste, means that, from the 1970s onwards, research 
groups have been actively searching for enzymes that have naturally evolved to catalyse DA 
reactions.307 Not only would these enzymes be intrinsically valuable in biosynthetic NP path-
ways, most of which produce cyclised products, but they also might offer a biocatalytic route 
to producing highly stereoselective DA adducts, without the need to add metal catalysts in bulk. 
These biocatalysts would likely be far more selective, without potential off-target effects, fa-
cilitating the use of the DA reaction more broadly in pharmaceutical and allied applications.  
 
5.1.3 Early Enzymatic Diels-Alder Catalysts 
Whilst the synthetic DA reaction is dated to 1928, it was a full 67 years before the first 
potential enzymatic catalyst for this reaction was identified. Oikawa et al. successfully showed 




reaction in the formation of solanapyrone.324 Although they were not able to identify the en-
zyme capable of performing this reaction, or purify it from the extract, they showed that it 
could precisely control the stereochemistry of the DA adduct formed. They also showed, how-
ever, that the same enzyme to catalyse the cycloaddition reaction functioned as an oxidase, 
preparing the prosolanpyrone precursor for cyclisation. This result was followed up by studies 
showing that lovastatin nonaketide synthase (a fungal iPKS) was also capable of cyclising a [4 
+ 2] cycloaddition reaction in the polyketide intermediate it produces, forming a decalin ring 
system.325 Macrophomate synthase was hypothesised to catalyse a DA reaction as part of a 
five-step catalytic process in the formation of Benzoates.  
At a similar time to these discoveries a number of other biomolecules were being investi-
gated as putative DA catalysts. These included antibodies326 and ribozymes,327 but the charac-
terisation of an enzyme exclusively evolved to catalyse a DA reaction, a standalone DAase, 
still eluded researchers. Much like the study of PKSs, the identification and characterisation of 
putative DAases has been almost entirely enabled by gene sequencing technology. This enabled 
the characterisation of the components BGCs, a key step towards detailed biochemical interro-
gation of prospective DAases. In some cases, such as that of macrophomate synthase, further 
studies showed that the enzyme, despite initial encouraging data,328 was not a DAase, but rather 
a cyclase.329 It was shown to create the cyclohexene via a Michael addition reaction, followed 
by an aldol reaction (Figure 5.3a).330 In other cases, such as in the biosynthesis of the solanap-
yrones, further studies identified the enzyme Sol5 as the [4 + 2] cyclase necessary to form the 
bicyclic ring system (Figure 5.3b), however, an additional oxidation reaction was shown to be 
necessary for the creation of a potent enough dienophile to facilitate cyclisation. It wasn’t until 
the characterisation of SpnF in 2011 as a standalone [4 + 2] cyclase by Kim et al., that we could 
say for certain that enzymes had evolved to promote the formation of cyclohexenes in NP bio-
synthesis.331 Heterologous expression of a number of tailoring enzymes in the spinosyn A bio-
synthetic pathway showed that SpnF was capable, in isolation, of forming a stereoselective 
cyclohexene (Figure 5.3c). 
There were, however, still a number of outstanding questions with regards to DAases. The 
primary question is whether these enzymes can really be called DAases at all. As studies of 
macrophomate synthase had shown, and although somewhat semantic, many felt that unless it 
could be shown that the reaction proceeded in a concerted manner, the enzymes identified 




from a biosynthetic and industrial point of view, others would argue that if the desired product 
is produced, the transition states necessary to achieve this are of secondary importance. A fur-
ther important question is how, if these reactions do proceed via a formal DA reaction, is ca-
talysis promoted? Do the enzymes function akin to a Lewis acid catalyst, increasing the with-
drawing nature of the dienophile, or do they employ an alternative catalytic mechanism? The 
length of the search and the high level of interest meant that the 2015 characterisation of three 
more “elusive and irresistible”307 putative DAases precipitated the publication of no fewer than 
7 reviews into enzyme mediated [4 + 2] cyclisation between 2015 – 2016.307,320,332–336 These 
enzymes, VstJ from the versipelostatin NP biosynthetic pathway, and PyrE3 and PyrI4 from 
the pyrroindomycin biosynthetic pathway were all identified as stand-alone [4 + 2] cyclases.  
 
5.1.4  Recent Characterisation of Putative Diels-Alderases 
VstJ was successfully purified heterologously in E. coli and shown to enable the stereose-
lective [4 + 2] cycloaddition reaction necessary to create the macrocycle in versipelostatin 
(Figure 5.3d).337 The entire BGC was transferred into Streptomyces albus for the creation of a 
DVstJ knockout strain which produced an accumulation of the cycloaddition precursor. The 
purification of this precursor and subsequent incubation with VstJ created the formation of the 
putative DA adduct. Tian et al. successfully interrogated some of the final tailoring steps in the 
formation of the glycosylated and halogenated spirotetramate antibiotic pyrroindomycin B.338 
Within this BGC they identified two stand-alone [4 + 2] cyclases, which act in sequence to 
create a pentacyclic compound from a linear spirotetramate chain (Figure 5.3e). The first en-
zyme to act, PyrE3, was identified as an FAD-dependent cyclase. The enzyme was not, how-
ever, characterised to work in a typical redox fashion, instead it was determined to use the FAD 
cofactor purely to stabilise its conformational shape. It was somewhat surprising to find that it 
could perform catalysis in the absence of NADPH or NADP, especially considering that the 
enzyme used for homology modelling, OxyS from the oxytetracycline BGC,339 functions as a 
typical reductase, hydroxylating at two positions in the presence of NADPH. PyrI4, was, like 
PyrE3, identified as a [4 + 2] cyclase by homologous expression in E. coli and incubation with 
substrate purified from knockout versions of the host producer, Streptomyces rugosporus. Alt-
hough no initial characterisation of PyrI4 was presented, the same group published the crystal 




revealed a rare b-barrel structure, with the active site within the centre of the barrel. The prod-
uct was complexed within the barrel and enclosed by an active site capping loop. This loop 
was shown to be essential for catalysis through mutagenesis experiments. The inside of the 
barrel was shown to be hydrophobic, with a negatively charged outer surface. The hydropho-
bicity was hypothesised to facilitate the entry of the substrate into the active site, whilst the 
positively charged acidic amino acid side chains were postulated to form a more electron with-
drawing environment, facilitating the movement of charge from the diene to the dienophile. 
Whilst together, these two papers from the Liu lab formed the most complete analysis of a 
hypothetical DAase, it was not until the characterisation of AbyU by Byrne et al. in 2016 that 
any direct evidence of a concerted reaction mechanism was presented.224  
 





Figure 5.3 NP biosynthetic reactions hypothesised to be enzyme catalysed DA [4 + 2] 































































































































cascade of [4 + 2] cycloaddition reactions performed in the biosynthesis of the pyrroindomycins. c) The 
oxidation and then [4 + 2] cycloaddition steps performed by Sol5 in the biosynthesis of the 
solanapyrones. d) Cycloaddition reaction performed by VstJ in the versipelostatin biosynthetic pathway. 
e) Multiple reactions catalysed by macrophomate synthase (MPS) in the biosynthesis of macrophomate. 
The hypothesised and incorrect DA mechanism is shown in blue. MPS performs a decarboxylation of 
oxaloacetate (not shown) followed by a Michael-Aldol reaction. The final step in the biosynthesis of 
macrophomate involves a decarboxylation and simultaneous dehydration. Inset) The DA reaction 
catalysed by AbyU in the biosynthesis of abyssomicin C. 
 
5.1.5 Characterisation of AbyU 
AbyU, similarly to other putative DAases, was heterologously expressed in E. coli and 
shown to perform a [4 + 2] cycloaddition reaction in vitro by analysis of reactants and products 
using high-pressure liquid chromatography (HPLC), mass spectrometry and NMR.224 In con-
trast, however, this study was performed using synthetic analogues of the natural linear chain 
5 (Figure 5.5). This removed the need for large batch fermentation of the slow-growing M. 
maris, but was only feasible due to the relatively simple nature of 9 (Figure 5.5). AbyU, like 
PyrI4, does not share any sequence identity with non-spirotetronate/tetramate cyclases. It does, 
however, exhibit the same b-barrel and active site structure as PyrI4 (Figure 5.4). Although 
Race and co-workers were unable to determine the structure of AbyU in complex with either 
the substrate or the product, they were able to use computational methods to investigate sub-
strate binding and the mechanism of catalysis. The authors determined 4 possible docked poses 
of the substrate within the active site. Molecular dynamics showed that this binding occurred 
in a stable conformation. These poses were then subjected to quantum mechanics/molecular 
mechanics (QM/MM) simulations to determine the correct pose and the mechanism of the re-
action. The authors determined two potentially productive binding conformations, of which 
one was favoured in both docking and QM/MM simulations (position A, Figure 5.26). The 
QM/MM simulations of the substrate bound in this conformation showed that the reaction pro-
ceeded in a concerted, asynchronous manner, as would be expected for a DA reaction involving 
a non-symmetrical diene.307 Higher-level density functional theory calculations were then used 






Figure 5.4 Comparison of the structures of AbyU and PyrI4. a) PyrI4 and b) AbyU. The 
active sites at the centre of the b-barrel in each monomer are marked with a star. Both PyrI4 and AbyU 
exist as a homodimer in solution, although AbyU dimerises in a parallel orientation, with the entrances 
to the active site adjacent to one another whereas PyrI4 dimerises in an antiparallel orientation with the 







Figure 5.5 Natural and Non-Natural Substrates Cyclised by AbyU. Natural abyssomicin 
C precursors 5 and 6 and their synthesised analogue 9, as well as the biosynthesised analogue 10, created 
upon incubation with AbyU. 
 
5.1.6 Mechanistic Interrogation of SpnF 
Following this discovery, a number of further experimental and theoretical studies of SpnF 
were reported. Patel et al. initially investigated the reaction mechanism using QM/MM meth-
ods.189 They hypothesised that the reaction proceeds via two distinct intermediates. The first 
possible intermediate is that of an asynchronous concerted DA reaction, confirming an earlier 
theoretical study by Hess and Smentek.340 In contrast, however, Patel et al. identified an alter-
native pathway, believed to be more energetically favourable than a DA reaction. They identi-
fied a bis-pericyclic (BPC) reaction intermediate where two cyclic orbital systems stabilise 
each other and can give rise to two separate cycloaddition products; in this case, a [6 + 4] 
cycloadduct was formed in addition to a [4 + 2] cycloadduct (Figure 5.6). The [6 + 4] adduct 
then undergoes a rapid Cope rearrangement to form the [4 + 2] adduct. They concluded that 





























reaction for this system, but that the dominant reaction route, according to their simulations, 
was via a [6 + 4] cycloaddition reaction and Cope rearrangement. Medvedev et al., in apparent 
competition with Patel et al., then took this theoretical analysis further.341 They also investi-
gated the possible direct DA and BPC reaction paths, as well as a biradicaloid pathway and an 
alternative DA reaction pathway. Although Medvedev et al. determined that these additional 
two pathways were not energetically favourable, they were also able to analyse 376 potential 
BPC and DA transition states. They determined that the BCP transition states were more stable 
than the DA transitions states, and, in general, possessed shorter inter-bond distances. Svitanko 
and co-workers also identified the BPC transition state analysed by Patel et al. as a relative 
outlier with a comparatively low energy level.341 In addition, they modelled the reaction of the 
substrate in water, showing an 83% predominance for a BPC [6 + 4] non-enzymatic cycload-
dition reaction over a DA reaction.  
The first experimental interrogation of the mechanism of SpnF was undertaken by Jeon et 
al.,342 who used individually deuterated substrates to monitor the secondary kinetic isotope 
effect (KIE) during cyclisation. In these complex experiments the authors analysed the rate of 
formation of each bond in both the enzymatic and non-enzymatic reactions. They were able to 
deuterate at each a-carbon involved in the putative [4 + 2] cycloaddition reaction (not at all 
BPC reaction coordinates), and investigate the change in reaction time for the formation of 
each bond. This was achieved through reaction quenching at specific time points and analysis 
of the fraction of the reaction that had proceeded during that time. With the heavier deuterium 
isotopes contributing to longer bond formation times, this enables identification of the rate 
limiting bond formation step. For a concerted DA reaction, the KIE should be equal for all four 
deuterated carbon analogues. Liu and co-workers, however, found that, for both the non-enzy-
matically catalysed and enzymatically catalysed reactions, the reaction proceeds via a stepwise 
mechanism, with the formation of an intermediate.343 Although this provided no evidence ei-
ther for or against the existence of a [6 + 4] cycloadduct intermediate, it did reinforce the find-
ings of the theoretical studies, showing that SpnF is a complex cyclase, but not, principally at 
least, a DAase. All the studies do agree, even if not on the precise mechanism and transition 
state, that the enzyme is able to function as a catalyst by sterically constricting the substrate in 






Figure 5.6 Comparison of Transition States During SpnF-Catalysed Cyclisation. Patel 
et al.189 identified multiple possible transition states during SpnF catalysed cycloaddition of 7 to form 
8. The reaction was found to either proceed via a concerted DA reaction, or via a BPC transition state, 
which could either lead to DA cycloaddition or to [6 + 4] cycloaddition, followed by a Cope 
rearrangement.  
 
Houk and co-workers were then able to further investigate the theoretical catalysis of 7 to 
form 8 within the active site of SpnF.343 This time QM/MM simulations were used to show that 
SpnF is able to constrain the substrate in a conformation that biases a DA reaction, raising the 
ratio of DA adduct to [6 + 4] adduct from 1:1 in the gas phase to 11:1 in the enzyme-catalysed 
reaction. They were also able to theoretically calculate the KIE results obtained by Jeon et al., 
and find that their results overlapped with good agreement.  
 
5.1.7 The Continuing Excitement of Putative Diels-Alderases 
This extensive analysis into the mechanism of one enzyme190,340–343 demonstrates the high 
level of interest in the mechanism of putative DAases. The 2019 characterisation of two novel 
[4 + 2] cyclases by Houk, Smith, Sherman, Williams and co-workers in Nature Chemistry fur-









































pathway using a combination of synthetic and biosynthetic approaches. They characterised and 
crystallised the two putative DA homologues MalC and PhqE, revealing a new structural fold 
for [4 + 2] enzymatic catalysis. MalC was identified as a bifunctional reductase and DAase, 
although the reaction intermediate has not been thoroughly interrogated, and so the bona fide 
DA nature of the enzyme is still in question. They determined, as is the case with SpnF, PyrI4 
and AbyU, that spatial confinement of the substrate leads to catalysis. 
 
5.1.8 The Aim of this Work 
Despite the high level of interest around the mechanism of putative DAases, there remains 
significant ambiguity as to the precise mechanisms employed by enzymes that catalyse DA 
reactions. Even in the case of SpnF, and despite the high level theoretical analysis performed, 
this enzyme has, to date, not been subjected to a complete biochemical and kinetic characteri-
sation. Although the steady-state kinetic parameters for SpnF, AbyU, VstJ, PyrE3, PyrI4 and 
MalC have all been reported, these results, often obtained through reaction quenching and 
HPLC or liquid chromatography – mass spectrometry (LCMS), are by no means a complete 
study. Although single turnover and burst phase kinetics have been used extensively to deter-
mine the kinetic parameters and reaction mechanism for enzymes as diverse as T7 DNA poly-
merase,345,346 DNA topoisomerase I,347 HIV reverse transcriptase,348 tryptophan hydroxylase349 
and Toluene /o-Xylene monooxygenase,350 there has been, to date, no extensive kinetic char-
acterisation of a [4 + 2] cyclase or DAase. In order to interrogate the kinetic profile and catalytic 
mechanism of these systems, this chapter reports a comprehensive single turnover and burst 
phase kinetic analysis of the bona fide b-barrel DAase AbyU. This system represents an ideal 
case study for the kinetic mechanism of putative DAases due to the ability to heterologously 
express AbyU in E. coli and the accessibility of synthetic diketone 9.224 Recent studies have 
revealed AbyU to be a robust enzyme capable of performing catalysis in a number of different 
industrially relevant conditions, such as at high concentrations of solvent and high tempera-
tures.351 This study aims to present a complete kinetic analysis of the system both to provide a 
new level of insight into [4 + 2] cyclases, particularly those with a b-barrel fold, as well as to 
provide a rational basis for the mutagenesis and engineering of AbyU, enabling it to become a 
more attractive industrial biocatalyst. These studies also seek to provide a template for those 





AbyU was cloned previously according to the method laid out by Byrne et al. 224 AbyU was 
subsequently expressed and purified according to the general method outlined in Chapter 2 
Section 3.2.  
 
5.2.1 Synthesis of Substrate 9 and Product 10 
Synthesis was carried out by Ms. Sbusisiswe Mbatha, University of Bristol according to the 
protocol outlined by Byrne et al.  
 
5.2.1 Spectrophotometric Analysis of Substrate 9 
A Cary 60 UV-Vis spectrophotometer (Agilent) was used to determine the absorbance pro-
file of both substrate 9 and product 10, as well as their respective extinction coefficients. 9 and 
10, prepared synthetically as a powder, were individually diluted in 100 % acetonitrile to form 
a 10 mM stock solution. This stock solution was stored at -70 °C to prevent spontaneous cy-
clisation, and kept on dry ice when taken out for use. This was further diluted to a 1 mM stock 
solution on each day of use. The use of more dilute stock solutions was not possible due to 
increasing rates of spontaneous cyclisation at lower concentrations. To determine the absorb-
ance spectra of each compound, a 100 µM solution was prepared in SF buffer (150 mM NaCl, 
20 mM Tris-HCl, 10% acetonitrile, pH 7.5), creating a final concentration of 10 % acetonitrile. 
120 µL of each solution was added to a 100 µL cuvette (Hellma) and the absorbance spectra 
recorded between 200 – 600 nm.  
The largest differential between the absorbance profiles of 9 and 10 was determined to be 
at 325 nm. In order to calculate extinction coefficients at this wavelength, the absorbance pro-
file of a series of concentrations was determined for each compound. The same 100 µL cuvette 
was used, filled with 120 µL solution to ensure air bubbles did not interfere with the reading. 
Each substrate concentration was prepared immediately before use, using a 10 or 25 µL Ham-






5.2.2 Dynamic Light Scattering Protocol 
Dynamic Light Scattering (DLS) experiments were conducted on a Malvern Zetasizer Nano 
ZSP (Malvern Panalytical). 110 µL 9 was prepared in a 100 µL absorbance cuvette (Hellma) 
at a variety of concentrations, diluted in 100 % acetonitrile. A monochromatic light source at 
250 nm was used to determine scattering properties of the solution.  
 
5.2.3 AbyU Stopped-Flow Experiments 
Stopped-flow (SF) experiments were performed using a Hi-Tech Scientific KinetAsyst 
Stopped-Flow System spectrophotometer (TgK Scientific, Bradford on Avon, UK). Both sy-
ringe 1 and 2 were washed with ddH2O and SF buffer. 10% acetonitrile was maintained in both 
syringes at all times to ensure solubility of the substrate. The stop-flow was zeroed and refer-
ences were taken using SF buffer in each syringe for burst phase kinetics. AbyU, in SEC buffer 
following purification by SEC, was diluted to create a final concentration of 800 µM AbyU 
and 10 % acetonitrile. This solution of AbyU was present in syringe 1 to obtain references for 
the single turnover experiments. For the multiple turnover experiments, AbyU was added to 
syringe 1 at a concentration of 2 µM, diluted in SF buffer. Likewise, substrate 9 was diluted in 
SF buffer to double the reaction concentration and added to syringe 2. 50 µL from each syringe 
was injected into the mixing chamber and measurement immediately commenced.  
Reactions were observed using a logarithmic timebase over either 1000 s or 10 s. For the 
1000 s experiments, the timeframe was split into 15 cycles, each with 200 points, each of which 
was distributed in a logarithmic manner. This ensured a high number of readings in the first 
seconds of the experiment. It did not prove tractable to measure each reaction over 1000 s as 
over this timeframe, 9 can undergo significant background cyclisation to form 10, rendering 
the rest of the syringe useless. This was compounded by the slight affinity of substrate 9 for 
the plastic components in the SF system, rendering it impossible to precisely replicate the con-
centration of 9 in the reaction chamber over multiple syringes. To measure the uncatalysed rate 
of substrate cyclisation, the stop flow was zeroed and references were taken using SF buffer in 
both syringes. Varying concentrations of substrate 9 were added to syringe 2 and measurements 





5.2.4 Fitting and Analysis of the Stopped-Flow Transients 
Results were fit using Graphpad Prism. Data obtained before 2 ms was discarded. The burst 
phase raw kinetic data were fit to two exponentials with a sloping baseline (Equation 5). This 
fit did not, however, reliably determine the angle of the slope observed in the single turnover 
10 s experiments due to the shallow nature of the slope and bias introduced by the exponential 
phases. To circumvent this, the data between 3 s and 10 s were separately fit to a straight line 
to determine the initial rate of kobs3 (Equation 1). Further fitting details are described in the text. 
In order to fully analyse the change in the reaction with respect to the concentration of 9, 3-
6 transients at each substrate concentration were taken and the rate and amplitude parameters 
derived from the fit appropriate for each transient, as is outlined in Chapter 5, Section 3. The 
background rate of reaction was removed from the steady-state reaction and from the linear 
portion of kobs3. The other exponential phases were too quick for the background rate of reaction 
to have an appreciable effect. The amplitude of the change in absorbance was converted to 
concentration using the following measured absorbance coefficient for substrate 9: e325 nm = 
13200 M-1 cm-1 and the following measured absorbance coefficient for product 10: e325 nm = 
1085 M-1 cm-1. The rate and amplitude parameters were averaged across all transients from the 
same concentration of 9, before plotting against the initial concentration of substrate. Initial 
concentrations of substrate 9 were calculated from the absorbance at t = 0, to account for un-
catalysed substrate turnover, and the tendency of the substrate to have a loose affinity with 
plastic present in the stop-flow apparatus. Once plotted the data were subsequently fit as is 
outlined in Chapter 5, Section 3.  
In order to calculate the rate of spontaneous cyclization by 2, the transients were each fit to 
a straight line (Equation 1). The slope of the line was determined for each substrate concentra-
tion and averaged over 3 – 5 repeats.  
 
5.2.5 Stopped-Flow Experiments Conducted at 5 °C 
Experiments were conducted in a similar manner to the 1000 s single turnover experiments 




with a T-Pod (also TgK Scientific), which allows individual sets of stopped-flow injections to 
be incubated at either very high or low temperatures prior to injection. In this case, the reaction 





5.2.6 A List of Equations Used  
Equation 1: 
Y = mX + C 
 
Equation 2: 
Y = Y = A! + A" × exp(−." × X) + 0# × exp(−.# × X) 
 
Equation 3: 
Y = Y = A! + A" × exp(−." × X) + 0# × exp(−.# × X)
+ 0$ × exp(−.$ × X) 
 
Equation 4: 
Y = Y = A! + A" × exp(−." × X) + 0# × exp(−.# × X)
+ 0$ × exp(−.$ × X) + 0% × exp(−.% × X) 
 
Equation 5: 
Y = A! + A" × exp(−." × X) + 0# × exp(−.# × X) + (Slope × X) 
 
Equation 6: 
Y = A! + A" × exp(−." × X) + (Slope × X) 
 
Equation 7: 
Y = A! + A" × exp(−." × X) + 0# × exp(−.# × X)










.*+, = .$_./[S] + .$_.00 
 
Equation 10: 
Y = 01)& × X5& + X  
 
Equation 11: 

















6.1 .*+, = 1 28 (=– ?) 
6.2 = = .+#_./" × [S] + .+#_.00" + .+#_./# + .+#_./# 
6.3 ? = @=#– 4B 
6.4 B	 = .+#_./" × [C] × .+#_./# + .+#_.00" × .+#_.00# + .+#_./" × [C] × .+#_.00# 
 
Equation 14:  







5.3 Results: Characterisation of the AbyU Substrate Analogue 
In order perform an extensive characterisation of the kinetic parameters relating to the DA 
reaction catalysed by AbyU, it was first essential to properly characterise the substrate ana-
logue, 9. In order to monitor the reaction of interest, the cyclisation of  substrate 9 via a the DA 
route to product 10 (Figure 5.7a), the spectrophotometric profile of both 9 and 10 were obtained 
(Figure 5.7b). This revealed significant differences in absorption profiles, and hence the oppor-
tunity to measure the progress of the reaction spectrophotometrically. 9 was found to exhibit a 
peak at ~325 nm, in an absorbance profile between 200 – 400 nm. The absorbance of 10 gave 






Figure 5.7 AbyU Catalysed Reaction and Absorbance Spectra. a) The AbyU catalysed DA 
reaction to be investigated. The catalytically relevant AbyU monomer is shown with the capping loop 
highlighted. b) Absorbance spectra of the AbyU substrate analogue 9 and the pre-abyssomicin product 
analogue 10. The change in absorbance measured at 325 nm due to cyclisation of 9 is shown by an 
arrow. 
 
Based on these data, it was considered that the progression of 9 to 10 would be best moni-
tored by following the loss of substrate at 325 nm, as this provides the largest change in ab-

































extinction coefficients at 325 nm (e325 nm) were determined as e325 nm = 13231 M-1 cm-1 for 9 
and e325 nm = 1085 M-1 cm-1 for 10 (Figure 5.8). Difficulties working with substrate 9 quickly 
became apparent. Obtaining consistent repeats was difficult and led to extensive testing, with 
the 6 – 7 most closely related repeats for each concentration shown in Figure 5.8a. These dif-
ficulties appeared to be due to the mild affinity of 9 for plastic and the propensity for 9 to 
cyclise spontaneously at a far greater rate when diluted in buffer. This meant that the establish-
ment of stock solutions of 9 was not feasible, and small, microlitre quantities were added to 
the cuvette/syringe, as appropriate for the experiments conducted, using a Hamilton syringe. 
In addition, previous reports from the lab had identified reactions with a higher concentration 
of substrate as being unable to proceed (unpublished results). 
 
 
Figure 5.8 Extinction Coefficients for the AbyU Substrate and Product. a) Calculation 
of the extinction coefficient for 9. Each point is the average of 6 - 7 repeats and the error bars are 
standard deviation from the mean b) Calculation of the extinction coefficient for 10. Each point is an 
average of 3 repeats and the error bars are standard deviation from the mean. 
 
5.3.1 Dynamic Light Scattering Analysis 
The propensity of 9 to undergo more rapid spontaneous cyclisation when diluted in buffer 
was further investigated by DLS. These experiments were motivated by the rationale that 9 
chemically resembles a lipid or detergent molecule, with a hydrophobic tail and a hydrophilic 
head group. It was hence hypothesised that at high concentrations 9 may be able to self-










































assemble into vesicle-like structures. DLS experiments were used to establish the presence of 
higher-order micellular structures that may be formed by 9 in solution (Figure 5.9). These re-
sults showed that substrate 9 indeed forms large, regularly sized, structures at concentrations > 
500 µM. In the interpretation of DLS results, the identification of a discrete peak is required to 
ascertain the formation of consistent particles within the solution. The appearance of multiple, 
randomly dispersed, peaks provides evidence of sample heterogeneity, or the presence of too 
few particles of a size large enough to scatter light beyond the signal to noise ratio.354 For 
concentrations between of 100 – 400 µM 9, multiple dispersed peaks are observed consistent 
with sample heterogeneity and the absence of multimeric assemblies. Although the intensity 
records the presence of larger molecules, the volume distribution implies that these particles 
are not representative of the entire sample. At concentrations > 500 µM the presence of discrete 
particles with an average diameter of 160 nm are observed (Figure 5.10). Here the volume, 
intensity and number peaks are well aligned, implying sample homogeneity. As the concentra-
tion of 9 increases up to 30 mM we see an increase in the Z-average size355 to 329 nm. As might 
be expected, the size of the multimeric assemblies being formed increases with increasing con-
centration. For comparison, the globular protein thyroglobulin, with a molecular weight (MW) 







Figure 5.9 Dynamic Light Scattering of the AbyU Substrate Analogue. The potential for 
9 to form higher order structures was investigated by DLS. Concentrations ranging from 100 µM to 30 
mM were investigated. Concentrations of 500 µM and above show evidence for the formation of 
multimeric structures when measured by Number weighted distribution, Volume weighted distribution 
and Intensity weighted distribution.  
 
These results clearly show that substrate 9 is capable of forming large, disperse, multimeric 
constructions in solution. Whether these constructs are the result of polymerisation or the for-
mation of vesicle-like structures is unknown. These structures are significantly larger than 
AbyU, with a monomer of AbyU likely to measure in the region of 2 nm (carbonic anhydrase, 
MW = 29 kDa, diameter = 2.37; Aprotinin, MW = 6.5 kDa, diameter = 1.82 nm;354 AbyU 
monomer, MW = 17.7 kDa) formations of 9 at 30 mM are around 160 times the size of AbyU. 
They imply that any work undertaken with substrate concentrations > 400 µM are likely to give 
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aberrant readings, as AbyU is unlikely to be able to engage substrate molecules which are se-
questered within high-order assemblies in solution. There may also be associative effects below 
this threshold, hence substrate concentrations should be kept as low as possible. It should be 
noted, however, that these associative effects are likely to protect the substrate from spontane-




Figure 5.10 Z-Average Size of AbyU Substrate Analogue Multimers. The Z-average size 
is an intensity-weighted measurement for the mean size of particles present and gives a good estimate 
for the size of particles present, with any noise removed. Results for 0.1 – 0.4 mM were inconclusive 
and hence are not shown. 
 
5.3.2 Spontaneous Cyclisation of the AbyU Substrate Analogue 
In complementary studies, the rate of spontaneous cyclisation of 9 in SF buffer was deter-
mined (Figure 5.11). These results were obtained by SF to ensure the quality of the data and to 
mimic the experimental conditions as closely as possible. Spontaneous cyclisation reactions 
produced a linear decrease in absorbance during each 10 s experiment, with a linear corre-
spondence between the rate of spontaneous turnover and the concentration of substrate, 




















equating to a non-enzymatically catalysed rate of 0.001255 µM s-1. This rate was subtracted 
from all relevant experiments. 
 
Equation 1: 
D = 	E;	 + 	F 
 
 
Figure 5.11 The Rate of Spontaneous Cyclisation of the AbyU Substrate Analogue. The 
rate of spontaneous cyclisation of 9 to form 10 was determined in SF buffer. The trend is fit to a line of 
Equation 1, where m = (1.26 × 10!" ± 2 × 10!#), and *	 = 	0. 
 
  




















5.4 Results: Interrogating the Catalytic Mechanism of AbyU 
5.4.1  Purification of AbyU 
In order to probe the kinetics of the conversion of 9 to 10 by AbyU, the enzyme was ex-
pressed in recombinant form in E. coli and purified to homogeneity using a combination of 
nickel affinity chromatography and SEC, as described in Section 2.3.1 (Figure 5.12). Purified 
protein was routinely recovered in high quantity and at high purity.  
 
Figure 5.12 SDS-PAGE Analysis of Purified Recombinant AbyU. AbyU was purified in SF 
buffer and estimated to be of > 95 % purity. 
 
5.4.2 Single Turnover Experiments Monitoring the AbyU Catalysed Conversion of 9 to 
10 over 1000 s 
 
To probe the reaction mechanism of the AbyU catalysed DA reaction (Figure 5.7), two com-
plementary transient experimental methods were used. SF spectroscopy, which has been used 







far greater understanding of enzyme mechanism than steady-state kinetic studies alone.356 The 
AbyU catalysed conversion of 9 to 10 was monitored in a SF apparatus both in burst phase, 
where the concentration of 9 exceeded the concentration of AbyU; and under single turnover 
conditions, where the concentration of AbyU was greatly in excess of that of 9. The single 
turnover experiments were performed to probe the AbyU reaction in a system where each en-
zyme active site binds and cyclises a maximum of one molecule of substrate. In order to ensure 
AbyU was significantly in excess of the substrate, a final concentration of 400 µM enzyme was 
used. Reaction progress was monitored spectrophotometrically at 325 nm for 1000 s (Figure 
5.13). Resulting absorbance traces indicated the presence of multiple reaction transients, indic-
ative of an unanticipatedly more complex reaction cycle than was previously predicted.24 The 
reaction progresses rapidly during the first 0.5 s, proceeding more slowly beyond this point for 
the entirety of the 1000 s measurement period. This is characterised by the observation of a 






Figure 5.13 Transients of the reaction of AbyU with 25 µM substrate 9 over 1000 s. The 
reaction was monitored spectrophotometrically at 325 nm. Transients are presented against absorbance 
as both the product and substrate absorb at 325 nm. a) A transient of the reaction between 400 µM AbyU 
and 25 µM 9 displayed on a logarithmic scale. b) The same transient displayed on a linear scale.  
In order to fully characterise the observed reaction transients, kinetic data were fit to three 
different exponential equations and the quality of data fitting assessed (Figure 5.14). A two 
exponential fit (Equation 2, Figure 15a), poorly satisfied the initial 0.1 s of the reaction, and a 
significant non-linear trend can be observed in the residual function. A three exponential fit 
(Equation 6, Figure 15b) is observed to fit the transient much more accurately, with the adjusted 
R2 value increasing towards 1. A four exponential fit (Equation 7, Figure 15c) was observed to 
resolve a slight mis-fitting at the end of the curve, but as this mis-fit would be likely resolved 
in a 3 exponential fit with additional data points, and because there was no overall significant 
increase in the fitting statistics, it was decided that the reaction was best fit to an equation with 
three exponential terms. There were, however, a number of practical difficulties associated with 







































measuring the reaction over 1000 s. Over this timeframe, 9 is able to undergo significant spon-
taneous cyclisation to 10, whilst held at temperature in the syringe of the stop-flow apparatus. 
This means that subsequent runs from the same syringe were not comparable as repeats. The 
issues obtaining precise repeats of substrate concentration (as discussed previously) meant that 
this was not a viable method to investigate the reaction in relation to 9. 
 
Equation 2: 
Y = Y = A! + A" × exp(−." × X) + 0# × exp(−.# × X) 
Equation 3: 
Y = Y = A! + A" × exp(−." × X) + 0# × exp(−.# × X)
+ 0$ × exp(−.$ × X) 
Equation 4: 
Y = Y = A! + A" × exp(−." × X) + 0# × exp(−.# × X)






Figure 5.14 Fitting analysis for the reaction of 25 µM Substrate 9 with 400 µM AbyU over 
1000 s. The residual plots are inset and the adjusted R2 value given below the transients. a) The reaction 
transient fitted to a biphasic equation (Equation 2). b) The reaction transient fitted to a triphasic equation 
(Equation 6). c) The reaction transient fitted to an equation with four exponential terms (Equation 7).  

















Adj. R2 = 0.9991




























Adj. R2 = 0.9870




























Adj. R2 = 0.9995

















5.4.3 Single Turnover Studies of the AbyU Catalysed Conversion of 9 to 10 Over 10 s 
As the majority of the AbyU reaction occurs within 0.5 s, it was decided that the reaction 
should be monitored over 10 s to obtain an understanding of how the AbyU catalysed conver-
sion of 9 to 10 is influenced by varying substrate concentration (Figure 5.15). 
 
 
Figure 5.15 Transients for the reaction of 30 µM substrate 9 with 400 µM AbyU over 
10 s. The reaction was measured spectrophotometrically at 325 nm for 10 seconds. a) The transient 
displayed on a logarithmic scale. b) The same transient displayed on a linear scale, with the first 0.1 s 
shown over a linear scale inset.  
Reaction transients observed over this shorter time period were found to be in good agree-
ment with those identified in longer duration experiments. However, the final exponential 
phase observed appears linear over this shorter timeframe. Data fitting analysis (Figure 5.16) 
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was performed using equations incorporating an additional term for a straight line, to account 
for the initial long, slow exponential phase. On this occasion an equation consisting of two 
exponential terms and a straight line (Equation 5) was found to best fit the experimental data, 
with a single exponential plus slope (Equation 6) introducing significant bias into the calculated 
residuals. No significant improvement was observed in the fitting data following the addition 
of a third exponential term (Equation 7). The three exponential phases observed over the longer 
time frame indicate three separate reaction conformations are formed during the AbyU cata-
lysed conversion of 9 to 10. These conformations are not observed in the spontaneous reaction, 
implying that they are specific to the enzyme catalysed reaction. 
 
Equation 5: 
Y = A! + A" × exp(−." × X) + 0# × exp(−.# × X) + (Slope × X) 
Equation 6: 
Y = A! + A" × exp(−." × X) + (Slope × X) 
Equation 7: 
Y = A! + A" × exp(−." × X) + 0# × exp(−.# × X)






Figure 5.16 Fitting Analysis for the Reaction of 30 µM Substrate 9 with 400 µM AbyU 
Over 10 s. The residual plots are inset and the adjusted R2 values are given below the transients. a) 
The reaction transient fitted to Equation 6. b) The reaction transient fitted to Equation 5. c) The reaction 
transient fitted to Equation 7. 
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5.4.4 Interpretation of Single Turnover Reaction Transients 
The complex multiphasic transients observed during the single turnover experiments allow 
determination of three distinct rates of reaction, kobs1, kobs2, and kobs3, corresponding to the fast-
est, intermediate and slowest exponential phases observed over 1000 s. These are atypical re-
action transients not predicted for a cofactor independent enzyme with one active site, acting 
on a single substrate to yield a single product. For reactions of this nature one would  typically 
expect to observe a single exponential curve consistent with first order kinetics.357,358 Single 
turnover experiments can be used to simplify the interpretation of multiple-turnover data, as 
they enable direct interrogation of the rate of the chemical step of a reaction.359 The appearance 
of three distinct phases within the AbyU single turnover experiment indicates the formation of 
three distinct species during a single catalytic cycle. In other transient kinetic analyses, multi-
phasic single turnover transients are usually indicative of a reaction proceeding via a stable 
transition state or multiple chemical reactions.349,360,361 However, in this case, the detection of 
any viable transition state, according to the QM/MM data presented by Race and co-workers,224 
would not be feasible due to the femtosecond timescale observed during the asynchronous 
concerted DA reaction. Irrespective of this, the detection of intermediates in any of the hypo-
thetically possible reaction pathways, whether concerted, biradicaloid or stepwise, would not 
be feasible due the timescales involved. Typical neutral [4 + 2] cycloaddition reactions can be 
observed both experimentally and theoretically to produce products in approximately 1 µs, 
whilst slower, ionic reactions are observed to produce products in under 1 ms,362 with this latter 
rate still too quick for delineation by SF methods. Given that this reaction proceeds in a neutral 
system, that the diene is asymmetric, and asymmetric reactions typically proceed orders of 
magnitude faster363 than the symmetric DA reactions described by Rivero et al.,362 and the 
preceding QM/MM calculations, it can be safely determined that the three phases observed 
cannot be attributed to chemical transition states. Given that these distinct reaction species 
cannot, therefore, be attributed to transition state intermediates, two possible explanations re-
main. The first of these is that the enzyme substrate complex undergoes a large conformational 
change during the catalytic cycle. Such events are well documented in enzyme systems, for 
example in catalysis by uracil-DNA glycosylase amongst others.364,365 In this instance however, 
this seems highly unlikely, as QM/MM simulations reveal very little conformational change in 
AbyU upon substrate binding,224 or throughout the catalytic possess, and the robust b-barrel 




The third possible explanation for a multiphasic transient in a single turnover reaction be-
tween two distinct species, is the adoption of multiple substrate binding conformations within 
a single enzyme active site. This is a phenomenon that has been observed, albeit infrequently, 
through the inspection of substrate bound enzyme complex structures,366 by comparison of 
chemical shift data by NMR methods,367 or during mutagenesis of enzyme active sites.359 This 
later case is elegantly illustrated by studies of  Morphinone reductase, where a single active 
site mutation, removing a hydrogen bond to the substrate, facilitated the binding of NADH in 
multiple alternative conformations. This led to the detection of four separate binding confor-
mations, equating to four discernible reaction rates during catalysis. Docking studies performed 
in the original AbyU paper show four potential docked poses of the substrate within the enzyme 
active site, of which one was postulated to be non-productive, one moderately productive and 
two highly productive, but with one pose possessing a higher energy barrier to reaction than 
the other. Given these data, one plausible explanation for the observed transients is that there 
are multiple binding conformations of 9 within the active site of AbyU. There is evidence in 
these transients of at least three different binding conformations, although there may be more 
which are not distinguishable, with rate constants needing to be roughly an order of magnitude 
in difference to be distinguished by SF.359 Given the mechanism for enzyme catalysed DA 
reactions appears to be predicated on conformational restriction of the substrate (hypothesised 
for SpnF, MalC, AbyU, PyrI4), this lack of specificity is perhaps unsurprising and would not 
necessarily be expected to significantly hinder catalysis. 
 
5.4.5 Single Turnover Studies of the AbyU Catalysed conversion of 9 to 10 With Respect 
to Substrate Concentration 
In order to further investigate the catalytic mechanism of AbyU, multiple kinetic transients 
were obtained at a variety of concentrations of 9, which was measured retrospectively using 
the starting absorbance recorded and the measured extinction coefficient for this substrate. 
Each syringe volume of reactants in the stopped-flow apparatus enabled the collection of 4 – 7 
kinetic transients at each concentration of 9. By fitting each transient to Equation 5, the rate of 
kobs1 and kobs2 with respect to [9], as well as the rate of the final linear phase, corresponding to 
a rough approximation of kobs3, could be determined. Additionally, the amplitude of the faster 





In order to analyse the change in kobs1 with respect to [9], each set of repeats was plotted 
against [9] and the linear trend determined (Figure 5.17a, Equation 1). The same process was 
repeated for kobs2 (Figure 5.17b). In this case the data were fit to a substrate inhibition curve 
(Equation 8). In addition, the rate of reaction observed in the initial linear phase of kobs3 can be 
seen to increase in a linear manner with respect to [9] (Figure 5.18). This relationship can be 




Y = 4&'( × X
5& + X × G1 + X 5)8 H
 
Equation 9: 









Figure 5.17 Analysis of the rate constants observed during a single turnover of 
substrate 9 by AbyU. Each data point is an average of 3-6 repeats and the error bars are standard 
deviation from the mean. a) The change in kobs1 with respect to the concentration of 9. The data are fitted 
to a straight line (Equation 1). b) The change in kobs2 with respect to the concentration of 9. The data are 















































Figure 5.18 Substrate Turnover in the Final Phase of a Single Turnover Reaction. Each 
data point is an average of 3 – 6 data points and the error bars are standard errors from the mean. The 
initial rate of kobs3 is fit to a straight line, the background rate of reaction removed, and plotted against 
the concentration of substrate 9. The data are then fit to Equation 9, where kobs3_on = 0.6 ± 0.04 mM-1 s-
1 and kobs3_off = 0.007 ± 0.002 s-1. 
 
The amplitude of each phase as a function of substrate concentration can also be investi-
gated. This allows the determination of the binding constants associated with each phase, as 
well as the quantity of substrate needed to saturate a given binding conformation. The change 
in A1 in relation to [9] was determined and the resulting data fit to a rectangular hyperbola 
(Equation 10, Figure 5.19a). The change in A2 in relation to [9] was also determined. It was not 
possible to reach a concentration of substrate sufficient to saturate this binding conformation, 
but the data available fit best to a sigmoidal curve (Equation 11, Figure 5.19b). Intriguingly, if 
the amplitudes in the fast phase and the slow phase are combined and then plotted as a function 
of [9], we see that they fit to a linear regression that comprises ~68 % of the total substrate 
present in the reaction (Figure 5.19c). It appears as though the A2, almost non-existent at very 
low concentrations of 9, compensates for A1 as it begins to saturate, and A2 begins to predom-


















Y = 01)& × X57 + X  
Equation 11: 











Figure 5.19 Analysis of the amplitude change observed in each phase during a single turnover 
of substrate 9 by AbyU. Each data point is an average of 3-6 repeats and the error bars are standard 
deviation from the mean. a) The change in A1 with respect to the concentration of 9. The data are fitted 
to a rectangular hyperbola (Equation 10). b) The change in A2 with respect to the concentration of 9. 
The data are fitted to a sigmoidal curve (Equation 11). c) A1 and A2, along with the amplitudes of A1 
and A2 added together, and fit to Equation 1, on the same graph for direct comparison. 












































5.4.6 Interpretation of the Single Turnover Rates and Amplitudes as a Function of Sub-
strate Concentration. 
Analysis of kobs1 and kobs2 as a function of substrate concentration reveals a further layer of 
complexity. As the concentration of 9 increases, the rates of kobs1 and kobs2 unexpectedly de-
crease. This is a strong indication that within each observable phase there exists multiple dif-
ferent binding conformations. As the concentration of 9 increases, weaker, less productive, 
binding conformations are manifest, giving the appearance of a slowing of the reaction rate; 
this occurs because it is only possible to isolate rates that differ by at least an order of magnitude 
by stopped-flow. Consequently, it is not possible to extract intrinsic rate constants for each 
binding conformation. We are, however, able to ascertain the relative binding affinities ob-
served for two different binding conformations contained within kobs2. The Km, 13.2 ± 3.2 µM, 
gives us a measure of the binding affinity for the quicker conformation, whilst the Ki, 54.9 ± 
14.5 µM, represents the binding affinity for a less productive conformation which only be-
comes apparent at higher concentrations of 9. These different binding conformations, which 
only begin to saturate at higher substrate concentrations, do not necessarily represent com-
pletely unique poses, as demonstrated by Byrne et al., but could also represent a need for small 
rearrangements to occur in the enzyme active site prior to the adoption of a catalytically com-
petent state. The standard deviations observed in such analyses are routinely high, due to the 
inherent level of complexity within the system.  
Analysis of A1 and A2 again reveals layers of complexity. Whilst the relationship between 
A1 and the concentration of substrate fits well to a classical rectangular hyperbola (Equation 
10) and produce an observable Kd of 62.5 ± 3.9 µM and an Alim of 38.8 ± 1.2 µM; it is known 
from analysis of kobs1 that these values represent an average for all binding conformations 
adopted in the single extractable phase. A2 cannot be saturated under the experimental condi-
tions and instead exhibits a sigmoidal relationship, although the data is insufficiently compre-
hensive to confidently verify this. What is clear, however, is that the sum of A1 and A2 is a 
consistent proportion of the substrate present in the reaction. The slope of the line reveals that 
67.8 ± 0.6 % of the substrate is converted to product in the phases represented by kobs1 and kobs2. 
This leaves approximately one third of the substrate available to bind in the conformation(s) 
represented by kobs3. The constant nature of this binding conformation reveals that it likely 




substrate 9 adopts in solution. Given the previously discussed ability of individual molecules 
of 9 to self-associate, and the highly flexible nature of 9, one possible explanation is that inter- 
or intra-molecular interactions preclude ~1/3 of the substrate from binding in a productive 
conformation within the enzyme active site. Analysing the portion of kobs3 measurable over 10 
s (Figure 5.18) enables determination of an over-estimated approximation of the rate of binding 
and dissociation for substrate in this conformation. This reveals an approximate kobs3_on rate of 
0.6 ± 0.04 mM-1 s-1 and kobs3_off rate of 0.007 ± 0.002 s-1. Although we are unable to extract 
reliable rate constants for kobs1 and kobs2, determining an approximate kobs1_off rate of 150 s-1 
would conservatively indicate affinity of over 4 orders of magnitude higher in kobs1 as compared 
to kobs3. Mechanistically, two potential outcomes are likely when substrate is bound in this non-
productive conformation. The first is the slow conversion of 9 to 10 within the AbyU active 
site before release. Alternatively, the substrate may be required to dissociate before re-binding 
in a productive conformation. This would mean that the substrate is capable of acting as com-
petitive inhibitor of self, binding in a conformation that is essentially unproductive. Such be-
haviour is also observed in dihydrofolate reductase, for example.367  
 
5.4.7 Burst Phase Kinetic Characterisation of the AbyU Catalysed Conversion of 9 to 
10  
To complement the single turnover experiments outlined above, and to provide additional 
insight into the reaction mechanism employed by AbyU, burst phase kinetic data were obtained 
using SF. These experiments provide information about the enzyme reaction mechanisms in 
the approach to the steady-state equilibrium, as well as the steady-state itself. The behaviour 
of an enzyme during multiple turnover reactions can deviate from that established using single 
turnover experiments. Data obtained using this approach can, however, be more challenging to 
deconvolute.368 Crucially, multiple turnover reactions provide information about product re-
lease, which is often rate limiting.  
SF transients for the AbyU catalysed conversion of 9 to 10 were obtained over 10 seconds 
at 325 nm and analysed on plotted on both logarithmic and linear axes (Figure 5.20). A burst 
phase, approximately stoichiometric to the concentration of AbyU used in the reaction, is 
clearly visible in these data, prior to establishment of a steady-state equilibrium. Fitting analy-




(Figure 5.21). A single exponential did not satisfactorily fit the burst phase data and biased the 
linear portion of the fit resulting in elliptical residuals. Two exponentials provide a good fit to 
the burst phase, and enable the linear portion of the curve to be fit without deviation. Three 
exponentials provide no significant benefit to the fitting statistics and so was deemed to be an 
overfitting of the data. This further underlines the complexity of the reaction, as multiple burst 
phases are rarely observed in experiments of this nature. It also serves to reiterate that the 
delineation of steady-state reaction kinetics in insolation can obscure complex and mechanis-
tically critical information about catalytic processes.  
 
 
Figure 5.20 Transients created by the reaction of 54 µM substrate 9 with 1 µM AbyU 
over 10 s. The reaction was measured spectrophotometrically at 325 nm for 10 seconds. a) The tran-











































Figure 5.21 Fitting analysis for the reaction of 54 µM Substrate 9 with 1 µM AbyU over 
10 s. The residual plots are inset and the adjusted R2 values are given below the transients. a) The 
reaction transient fitted Equation 6. b) The reaction transient fitted Equation 5. c) The reaction transient 
fitted to Equation 7. 
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5.4.8 Analysis of Burst Phases with Respect to Substrate Concentration 
As was the case with the single turnover experiments, the behaviour of the two burst phases 
and the linear steady-state phase were investigated as a function of substrate concentration. 
Burst phase kinetic transients were obtained at different concentrations of [9], repeated 3 – 6 
times, and the rates observed for the fast exponential phase, kb1, and slow exponential phase, 
kb2, extracted. These results were then be plotted as a function of [9]. Due to the stoichiometric 
nature of these burst phases, the most likely explanation for origin is that product release is the 
rate limiting step, causing a population of [EP] complexes to rapidly accumulate before the 
steady-state is observed. For this reason, kb1 has been fitted to a one-step binding equation 
(Figure 5.22a, Equation12), whilst the kb2 data, which is representative of a two-step binding 
mechanism, was fit to Equation 13 (Figure 5.22b). The binding constants for each of these burst 
phases were then determined and are reported in Table 5.1.  
 
Equation 12: 
.*+, = .4"_./[S] + .4"_.00 
Equation 13: 
13.1 .*+, = 1 28 (=– ?) 
13.2 = = .4#_./" × [S] + .4#_.00" + .4#_./# + .4#_./# 
13.3 ? = @=#– 4B 






Figure 5.22 Relationship Between the Rate Constants Observed and the Concentration 
of Substrate 9. Each data point is an average of 3-6 repeats and the error bars are standard deviation 
from the mean. a) The change in kb1 with respect to the concentration of 9. The data are fitted to a one-
step binding model (Equation 12). b) The change in kb2 with respect to the concentration of 9. The data 

















































Table 5.1 Experimentally Determined Binding Constants for the Burst Phases 
Exhibited in the Turnover of 9 by AbyU. kb1 is fit to Equation 12 and kb2 is fit to Equation 13.  
 
5.4.9 Origin of Burst Phase Kinetic Transients 
A small stoichiometric burst phase, as observed for the AbyU catalysed conversion of 9 to 
10, is often the result of the formation of a catalytic intermediate during an enzyme catalysed 
reaction. This means an intermediate must saturate before the steady-state can predominate. 
For the AbyU catalysed reaction, as it is possible to discern two distinct burst phases, there 
must be two distinct catalytic intermediates formed. As discussed previously, a large confor-
mational change in AbyU during the catalytic step, or the formation of a chemical intermediate, 
are both implausible. The mechanistic implication of these data is thus that product release is 
rate limiting. This is perhaps unsurprising as the conformationally constricted product must by 
necessity dissociate from an enclosed, hydrophobic active site. This process is further regulated 
by lid opening, or the movement of the capping loop sequestering the product (highlighted in 
Figure 5.8). This loop region has been shown to be important in catalysis in this class of en-
zyme,158 and so it is not surprising that it would play a central role in the catalytic cycle. 
The presence of two distinguishable burst phases gives further credence to the hypothesis 
that multiple binding conformations are observed during catalysis. The faster of the two burst 
phases observed, kb1, likely represents substrate binding in the amalgamation of subtly different 
conformations detected in kobs1. The data fit well to a one-step binding model, allowing us to 
extract on and off rates for this conformation in a competitive environment, as reported in Table 
5.1. The rates observed in kb2, however, fit to a two-step binding model. This likely represents 
 kb1 kb2 
kb_on1 (µM-1 s-1) 0.88 ± 0.03 0.36 ± 0.46 
kb_off1 (s-1) 3.4 ± 0.71 0.71 ± 0.62 
kb_on2 (s-1) - 1.37 ± 2.38 




substrate binding in the conformations represented by kobs2, and the two-step behaviour could 
be a consequence of the substrate undergoing a modest conformational rearrangement within 
the active site before adoption of a catalytically competent pose is adopted. The burst phase 
kinetic transients obtained (Figure 5.20) also enable the determination of the Michaelis con-
stants for the AbyU catalysed reaction (Figure 5.23; Table 2). These data provide information 
on substrate specificity and the rate of catalysis under equilibrium conditions. Steady-state val-
ues obtained can be complex functions comprised of multiple contributing steps.359  
 
Equation 14: 
Y = 4&'( × X5& + X  
 
These analyses yield a kcat of 6.94 ± 0.30 min-1 and Km of 9.9 ± 1.1 µM. These values deviate 
from those previously reported by Byrne et al.224 Although this discrepancy is not easily re-
solved, the experiments performed previously were conducted using a questionable protocol. 
The kcat determined here is ~230 times slower than the initial rate of kb1, giving a measure of 







Figure 5.23 The steady-state reaction between AbyU and substrate 9. The data are fit to a 
Michaelis-Menten curve (Equation 14). Each data point is the average of 3-6 repeats and the error bars 
are standard deviation from the mean. 
 
Michaelis constant Value 
kcat (min-1) 6.94 ± 0.30 
Km (µM) 9.9 ± 1.1 
kcat / Km (µM-1min-1) 0.70 ± 0.11 
 
Table 5.2 Steady-state kinetic parameters for the reaction of AbyU and substrate 9. 
 














5.4.10 Preliminary Investigations into the Effect of Temperature on the AbyU-Catalysed 
Cycloaddition reaction 
Further investigation into the catalytic mechanism employed by AbyU could entail perform-
ing an analysis of the single turnover reaction at different temperatures. Preliminary analysis 
at 5 °C reveals a fourth extractable exponential phase present in the transient (Figure 5.24), 
corroborating the prior hypothesis that the extractable rates actually contain a multiplicity of 
catalytic conformations. This additional extractable phase appears to come out of kobs2, and 
likely corresponds to the second phase with a binding affinity similar to that of the measured 
Ki for kobs2 at 22 °C. Intriguingly, we are also able to observe a significant increase in the pro-
portion of substrate turned over by AbyU in 1000 s compared to what is seen at 22 °C (Figure 
5.24c and Figure 5.25). Although the rates observed for kobs1, kobs2 and kobs3 appear to decrease, 
as would be expected, the amplitudes observed in each phase increase. This corresponds to an 
additional 33 % turnover over the full timescale and enables all the substrate present in the 
reaction to be cyclised. Mechanistically, this implies that the substrate has more chance to bind 
correctly and is less likely to bind in an inhibitory manner. This raises the interesting possibility 
that AbyU could be a more effective catalyst in cold environments, something that is not en-






Figure 5.24 Transients and fitting statistics for a single turnover of 9 by AbyU at 5°C. 
a) The reaction transient fitted to Equation 4. b) The same reaction transient fitted to the same equation 
with three exponential terms used to fit the transients obtained at 22 oC (Equation 3). In comparison to 
experiments performed at room temperature an additional phase is observed, becoming apparent around 
kobs2. c) A comparison of transients obtained at 22 oC and 5 oC over 1000 s.  




























































Adj. R2 = 0.9985

























Figure 5.25 The proportion of 9 turned over in 1000 s at 22°C and 5°C. A comparison between 
the turnover observed in each extractable exponential phase observed at both 22°C and 5°C, and in the 
total turnover over 1000 s. A2 at 5 °C is a composite of the amplitude observed in both phases extractable 
between A1 and A3. Each bar is an average of 6 results at 5°C and 3 results at 22°C. 
 
  






















5.5.1 Analysis of AbyU’s Synthesised Substrate Analogue 9 
During this study, substrate 9 was found to present a number of challenges when used in in 
vitro enzyme assays. In contrast to other putative DA substrates, 9 is a tractable synthetic target. 
However, the potential for polymerisation of this compound during its preparation necessitates 
the introduction of a tetronate ring methyl protecting group to stabilise this compound in solu-
tion. 9 was also found to be challenging to work with at lower concentrations due to an inability 
to produce stable and appropriately concentrated stock solutions, and the propensity of 9 to 
adhere to plastic labware. These issues translate into significant errors during handling. Fortu-
nately, however, during the experiments outlined herein, appropriate handling protocols were 
established to circumvent these effects. DLS analysis of 9 does demonstrate that this compound 
can self-assemble into micellular like structures at concentrations > 500 µM, however, this is 
above the threshold required to conduct the experiments described in this thesis.  
 
5.5.2 Mechanistic Insights into AbyU Catalysis 
Together, the single turnover and burst phase kinetic data present herein represent the first 
detailed mechanistic investigation into the AbyU catalysed cyclisation of 9, and indeed the first 
such analysis of a [4 + 2] cyclase. These data reveal a minimum of three distinct binding con-
formations of substrate within the enzyme, as established from the single turnover data. Anal-
ysis of the rates of kobs1 and kobs2 with respect to substrate concentration reveal an additional 
layer of complexity. Decreasing rates of reaction imply that these phases comprise multiple 
binding conformations, with slower reacting conformations becoming more prevalent at higher 
concentrations of 9. In order to further investigate the apparent multiplicity of binding confor-
mations, computational simulations were performed by Mr. Samuel Johns at the University of 
Bristol (Figure 5.26). The substrate was docked into the active site in a variety of conformations 
and molecular dynamics (MD) simulations were performed to ascertain the most representative 
pose for each docked structure. This revealed four possible general conformations of the sub-
strate within the active site (A-D), which are consistent with the findings previously presented 
by Byrne et al. MD was then used to determine binding energies for each pose, and QM/MM 




distinct binding poses with relatively similar binding energies (A, B and D). Whilst substrate 
bound in conformations A and B have relatively similar activation free energies, the reaction 
free energy required in conformation D is significantly larger. An additional small free energy 
penalty is expected for substrate bound in conformation B because of the longer distances be-
tween the diene and dienophile observed in MD simulations. This corresponds well to the three 
distinguishable binding conformations represented by kobs1, kobs2 and kobs3, with substrate bound 
in conformation D experiencing a significant barrier to catalysis that is possibly too great to 
overcome.  
The burst phase kinetic data provides additional insight into the catalytic mechanism of 
AbyU and corroborates the single turnover and simulation data. These data provide evidence 
for multiple catalytic binding conformations in the burst phases, with two distinct reaction in-
termediates forming prior to the steady-state. The accumulation of these intermediates indicates 
that product release is rate limiting, a conclusion that makes mechanistic sense when the struc-
ture of the enzyme is considered. The fit of kb2 to a two-step binding model is most revealing 
aspect of the burst phases. This implies that substrate binding in this conformation is undergo-
ing a significant rearrangement in the active site before catalysis can proceed. Whilst the MD 
simulations performed have precluded the possibility of the substrate flipping about a horizon-
tal axis, i.e. a transition from C or D to A or B, only a minor dissociation would be required for 
the substrate to rotate about a vertical axis. With this in mind, the most likely hypothesis for 
the existence of a two-step binding model is that substrate binding in conformation B is, in fact, 
undergoing a slight dissociation and re-binding in conformation A prior to catalysis.  
One intriguing question is as to why there is no manifestation of substrate bound in confor-
mation D, that is those conformations represented by kobs3. The rate of reaction in kobs3 is so 
slow that cyclisation in this conformation would not necessarily be evident over the timeframes 
used in this study. However, if we were to assume that ~1/3 of the substrate would bind in 
conformation D in each reaction cycle, as shown in the single turnover experiments, the AbyU 
active sites would rapidly become inhibited and the steady-state rate would be an approxima-
tion of kobs3. Although they do not necessarily agree with the binding energies determined for 
each pose, the calculated approximations of the kobs3_on and kobs3_off rates of 0.6 ± 0.04 mM-1 s-
1 and 0.007 ± 0.002 s-1, respectively, provide further insight. Despite being determined in a non-
competitive single turnover environment, they are around three orders of magnitude smaller 




turnover, scenario, binding in the conformations represented by kobs3 would be outcompeted by 
substrate binding in conformations A and B. The modelling data only take into account the 
affinity for the pose once it is inside the active site.  
 
Figure 5.26 MD and QM/MM Classification of Different Substrate Binding Conformations. 
a) The representative structures from molecular dynamics (MD) simulations of substrate 2 in each of 
the 4 binding modes obtained from docking. b) Average binding energy for each mode (as calculated 
using the MM-GBSA approach using 1000 snapshots of each mode taken from 10 independent MD 
runs). c) Predicted Diels-Alder activation free energies for each pose (obtained from 10 independent 
QM/MM umbrella sampling molecular dynamics simulations using DFTB/ff14SB, with a 7.32 
kcal/mole correction for each to M06-2X/6-31+(d,p) level). Standard deviations are indicated for 
binding and activation free energies. Figure and Figure Legend courtesy of Mr. Samuel Johns, 
University of Bristol.  
The kinetic transients obtained at 5 °C appear to support the theory that, at 22 °C, substrate 
is rapidly bound in non-viable conformations. Although the initial rate of turnover at 5 °C is 
slower than that observed at 22 °C, the amplitudes are increased, particularly with respect to 
kobs2. This appears to show that by slowing the rate of binding, AbyU is able to more effectively 
rearrange the substrate into a productive conformation before the substrate is fully bound 
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9 and the loop region and / or the initial residues in the cavity of the barrel act to ensure correct 
turnover of the substrate under physiological conditions. For an enzyme isolated from a bacte-
rium found at the bottom of the ocean, this could well be much closer to 5 °C than 22 °C. These 
initial findings need to be verified through further experiments before concrete conclusions can 
be drawn. 
The combination of the transient approaches applied during this study, coupled with in silico 
analysis, enables the construction of a reaction scheme for AbyU catalysis (Scheme 1). Within 
this scheme the three different observable binding conformations are represented by ES1, ES2 
and ES3. These correspond to the binding conformations identified in Figure 5.24 as A, B and 
D, respectively. Molecules of substrate forming an ES complex are able to undergo rapid ca-
talysis, yielding an enzyme-product complex, EP. The product 10 is then held within the active 
site, enclosed within the hydrophobic pocket by the capping loop, before being slowly released. 
Substrate binding to form ES2, likely in conformation B, is in fact rearranged to form ES, before 
cyclisation occurs. Substrate binding to form ES3 experiences a large barrier to catalysis mean-
ing that most substrate is likely to slowly dissociated prior re-binding in a productive confor-
mation. Simultaneously, free substrate will undergo spontaneous cyclisation to form product at 
rate kspont. The combination of burst phase kinetic data and an overestimated approximation for 
the on and off rates for substrate binding in a non-productive mode, as illustrated by binding 
mode D, from the single turnover experiments allow us to determine binding constants for ES1, 
ES2 and ES3 (Table 5.3). It is important, however, to recognise that this scheme is likely to 
represent a simplification of the actual reaction mode. The single turnover experiments reveal 
that each of ES and ES2 represent an average of multiple, subtly different, substrate binding 
conformations, and hence the on and off rates depicted are a composite of a multitude of dif-
ferent rates with closely related affinities. The steady-state rate provides an approximation for 







Scheme 5.1 Proposed reaction scheme for the AbyU catalysed intramolecular DA reaction. 
There are three sets of binding conformations that can be distinguished experimentally, denoted ES, 
ES2 and ES3. The	intrinsic	rate	constants	calculated	are	given	in	Table 5.3. 
 
Parameter Rate Constant 
k1 (µM–1 s–1) 0.88 ± 0.03 
k-1 (s–1) 3.41 ± 0.71 
k2 (µM–1 s–1) 0.36 ± 0.46 
k-2 (s–1) 0.71 ± 0.62 
k3 (µM–1 s–1) ≈	5.7 x10–4 ± 3.8 x10–5 
k-3 (s–1) ≈	6.9 x10–3 ± 1.9 x10–3 
k4 (s–1) 1.37 ± 2.38 
k-4 (s–1) 0.90 ± 2.29 
k5 (s–1) N.D. (very quick) 
k6 (s–1) ≈ 0.12 ± 0.05 
kspont (µM–1 s–1) 1.25 x10–3 ± 1.7 x10–5 
K1 (µM) 3.86 ± 0.94 
K2 (µM) 1.97 ± 4.24 
K3 (µM) ≈	1.2 x10–5 ± 4.1 x10–6 
K4 0.66 ± 2.81 
Kapp (µM) 1.3 ± 8.4 
 






















5.5.3 Consequences for the Exploitation of DA Biocatalysis 
The unexpected level of complexity uncovered by the studies of AbyU reported herein has 
significant consequences for the development of an industrially relevant DAases. Attempts at 
engineering this class of enzyme should take into account the multiple binding conformations 
observed, as mutations within the barrel or the loop region could have the unintended conse-
quence of impacting substrate binding affinity, particularly in orientations C and D. Increasing 
the specificity for optimally bound substrate could, however, be one opportunity for engineer-
ing attempts. The highly significant rate-limiting step in the catalytic cycle, the opening of the 
lid-like loop region allowing the release of product 10, is a barrier to optimal catalytic profi-
ciency and presents another opportunity for rational engineering. Whilst removal of the loop 
region in its entirety is not likely to provide benefit,158 mutagenesis could increase the in vitro 
catalytic rate. The work further describes possible reaction limits imposed by substrates in this 
type of system. Enzymatic catalysis cannot optimally occur at high substrate concentrations, 
with the large higher order structures observed by DLS likely to seriously inhibit anything apart 
from small scale, low concentration catalysis.  
 
5.5.3 Summary 
This work constitutes the first investigation of its kind into the mechanism of a [4 + 2] 
cyclase, and similarly the first detailed kinetic analysis of a b-barrel enzyme of any description. 
The results show that this class of enzyme, presumed to function via a simple catalytic mech-
anism of conformational restriction, is, in fact, a deceptively complex biocatalytic system. This 
work shows that the current practice of characterising putative DAases using steady-state meth-
ods is likely to conceal a number of catalytic nuances which must be understood before efforts 






Mechanistic and Biophysical Studies of AbyU at 
High Pressure 
6.1 Introduction 
6.1.1 Determining the Effect of Pressure on Proteins 
The effect of pressure on biomolecular systems has been studied since P. W. Bridgeman 
published a short article about the effect of high pressure (HP) regimes upon Albumin, specif-
ically that pressure drives coagulation.369 The effect of pressure on enzyme structure and func-
tion is still not fully understood, despite pressure being a ubiquitous thermodynamic property. 
The effect of pressure on the stability and activity of several model enzymes was studied from 
the 1960s to 1990s.370–374 In general, these studies sought to determine the basic influences of 
pressure on proteins. The development of HP UV-vis spectroscopy facilitated many of these 
investigations, allowing the in-situ determination of pressure induced protein denaturation. For 
example, Zipp and Kauzmann were able to determine the conditions for the denaturation of 
sperm whale metmyoglobin in relation to a combination of temperature and pressure.375  
Many of the early studies into the effects of pressure upon proteins were hindered by a 
requirement for access to expensive specialist equipment and were mostly of limited scope. 
Nevertheless, several significant advances were made. In the 1970s it was determined that high 
pressure regimes could cause multimeric enzyme complexes to dissociate, thereby inhibiting 
their function,373 whilst the effect of pressure upon the folding landscape of enzymes was first 
discussed by Walter Kauzmann in Nature in 1987.372 Similarly, the effect of pressure on more 
complex biological systems was also investigated, for example, Robb and Clark’s study of the 
growth of hyperthermophiles at HP. This study demonstrated significant benefits to culturing 
these microorganisms at HP environments, postulated to be due to enzyme adaptation to pres-
sures in the deep sea.370 Together, these investigations established that pressure has the poten-




macromolecular systems. Pressures relevant to cells, proteins and biochemical reactions are 
generally thought to be in the range of 1 bar – 10 kbar, whilst it is accepted that pressures up 
to 20 kbar do not impact the primary structure of biological molecules such as proteins, pep-
tides and lipids.376 For context, the deepest point in the ocean, the Mariana trench, which rep-
resents the point of highest pressure on earth, has a maximum depth of 11,000 m, equating to 
a pressure of 1,100 bar.  
 More recently, detailed molecular level studies of the influence of pressure on enzyme 
structure and mechanism have been largely restricted a small number of research groups inter-
nationally. These studies have generally used specialised biophysical techniques, including 
high pressure nuclear magnetic resonance (HP-NMR) spectroscopy, pressure jump studies and, 
most recently, high pressure stop-flow (HP-SF).377 Kremer et al. have been able to use pressure 
to stabilise excited protein folding states and then interrogate them using HP-NMR.378 Hay et 
al. were able to interrogate electron transfer in redox proteins via HP-SF, sampling electron 
transfer rates in different protein folding states stabilised by HP regimes.379 High pressure re-
gimes have, of course, been far more extensively studied within synthetic chemistry, and have 
frequently been shown to have a catalytic effect, driving many synthetic chemical processes, 
as well as promoting isomerisation and selective polymerisation.380,381  
 
6.1.2 The Effect of Pressure on Enzymatic Catalysis 
HP enzyme catalysis studies have largely focused on well characterised model biocatalysts, 
including a-chymotrypsin,382–384 and human cytochrome P450 by Hay et al.379 These studies 
seek to investigate and explain the fundamental rules determining what effect pressure elicits 
upon an enzyme’s catalytic performance and structural integrity.383,385,386 These studies have 
shown that, generally, HP serves to strengthen hydrogen bonds within biomolecules, whilst 
destabilising hydrophobic reactions.387 The secondary structure composition of an enzyme, and 
the structure-function relationships necessary for catalytic competency, have been shown to 
play a major role in defining the capability of enzymes to recover after pressurisation. For 
example, Araujo et al. showed that whilst Hsp70 is not impeded as an ATPase, the application 
of pressure to 3000 bar completely inhibits its ability to refold heat-denatured luciferase.386 




vulnerable to pressure-induced denaturation, preventing the restoration of function following 
pressurisation. 
 
6.1.3 The Effect of Pressure on Enzyme-Catalysed Chemical Reactions 
HP regimes have been shown to decrease available reaction volume. This means that, in a 
synthetic context, HP drives reactions in the direction of bond formation, as this decreases the 
volume required by the individual reactants, thus decreasing the overall volume of the sys-
tem.376,380,381 More broadly, if a reaction transition state has a smaller volume than that of the 
reactants, HP tends to promote the reaction rate. This provides an explanation as to why high 
pressure regimes are often used to drive Diels-Alder reactions, with a net reduction in product 
volume vs. that of the reactants. This is consistent for both inter- and intra-molecular pro-
cesses.388 The effect of pressure on enzyme-catalysed chemical reactions is decidedly more 
complex, as illustrated by the work of Butz et al., who investigated the reversible conversion 
of fumarate to L-malate by fumarase.389 When fumarase binds these substrates, this results in 
a decrease in the volume of the reaction transition state, but an increase in the volume of the 
enzyme-fumarate or enzyme-malate complex. Binding further displaces water molecules 
bound to catalytic side chains, thus increasing the reaction volume. Thus, a volume minimum 
is observed during binding of either fumarate or malate, and a maximum observed as the chem-
ical intermediate forms, as water is displaced, but prior to bond formation. Similarly, the pro-
teolysis of ubiquitin by a-chymotrypsin has been investigated at HP. Even though proteolysis 
results in the breaking of bonds and a subsequent increase in reaction volume, the rate of a-
chymotrypsin-catalysed proteolysis is greatly enhanced by a HP regime.384 As ubiquitin may 
adopt a proteolysis-resistant folded form, or a highly susceptible unfolded form,390 it is postu-
lated to be readily unfolded by the application of pressure, as disordered proteins have a much 
smaller volume than ordered proteins. This enables a highly increased rate of reaction, despite 
subsequent volume increases as a result of proteolysis.  
Broadly speaking there are three reasons an enzyme’s activity may be enhanced by a HP 
regime. HP may drive a conformational change within the enzyme, or within the target protein 
itself (such as ubiquitin) that drives catalysis. HP may also affect the reaction mechanism by 
driving conformational changes that decrease the volume of the enzyme. This can result in both 




HP can initiate a change in either the solvent, such as the pH or viscosity, or in the substrate, 
by modulating solubility or inter-molecule associations, thereby affecting either the enzyme or 
the chemical reaction.391 When the effect of temperature on enzymatic catalysis is also taken 
into account, another set of considerations emerge. For example, HP regimes used to be thought 
to only have enhancing effects on monomeric enzymes, as the application of HP drives multi-
mer disassembly in the majority of cases. This decreases the volume of the system by exposing 
hydrophobic surfaces.376 It has since been shown, however, that some multimeric enzymes are 
stabilised or enhanced at high pressure, particularly at temperatures high enough to otherwise 
dissociate the protomer complex.391,392 The ability of HP regimes to stabilise enzymes at HP 
comes about due to heat denaturation, and subsequent aggregation, which acts to increase the 
relative volume occupied by the biomolecule. This is a direct consequence of the formation of 
multiple, non-specific, interactions.376 Enzyme catalysis, which is often accelerated by temper-
ature increases, can therefore be accelerated further by a combination of high temperature and 
HP.377  
More detailed mechanistic studies have made use of the HP-SF system developed by TgK 
Scientific. These studies have been used to both to investigate the model enzymes previously 
highlighted, and to explore enzyme catalysed hydrogen tunnelling.393,394 Studies of model sys-
tems have yielded important insights; they are, however, limited in scope and generality, fo-
cussing predominantly on hydrolases and oxidoreductases.391  
 
6.1.4 Investigating Protein Folding Using High Pressure 
Although not the focus of this study, it is worth discussing, briefly, some of the studies that 
have successfully used HP-NMR to investigate protein folding and to identify intermediate 
folding states in proteins.395,396 This technique enables the chemical shifts observed in individ-
ual main chain amide groups to be studied, thus providing information about any rearrange-
ments occurring due to the HP regime. A sigmoidal, and therefore cooperative, relationship 
between individual groups is often observed and correlates to a conformational transition, or 
the movement of the folded state to a new, preferential minima within the protein energy land-
scape. This approach can be used to bias the formation of little seen yet physiologically relevant 
folding intermediates. For example, HP-NMR has been used to study the folding of prion pro-
teins that are capable of propagating in a species-specific manner.397 These experiments do, 




of small, globular and previously well characterised enzymes, such as ubiquitin.398 It can also 
be extremely challenging to identify how macromolecular changes impact the secondary and 
tertiary structure of proteins, particularly if there has been no significant enhancement of an 
alternative conformer. 
High pressure Fourier transform infra-red spectroscopy (HP-FTIR), provides far greater in-
sight to the changes in secondary structure composition instigated by HP regimes. It has, how-
ever, only been sparingly used to study, for example DNA, or the formation of amyloid fibrils. 
This is due to the practical complexities of this technique.385,399 It requires highly concentrated 
protein samples, or, ideally, a film such as is found in amyloidosis. D2O is mandatory as a 
solvent at HP regimes, and diamond anvil windows are sub-optimal for FTIR spectroscopy due 
to similar spectral characteristics to amide regions.400 High pressure synchrotron radiation cir-
cular dichroism (HP-SRCD) is also capable of determining secondary structural changes in situ 
at HP. This technique possesses its own drawbacks, including the requisition of a synchrotron. 
Solvation in more benign phosphate-based buffers is possible, however, as is the use of less 
concentrated samples than in HP-FTIR, where samples concentrated up to 10 % are sometimes 
required.399 Studies using this technique have, to date, been extremely limited, although it has 
been used to monitor excited folded states of myoglobin.401 
 
6.1.5 Alternative Applications of High Pressure Enzymology 
HP regimes and their effect on enzyme function have also been investigated by food scien-
tists, and their findings are worth briefly outlining here. These studies have sought to determine 
catalytic function following high pressure processing (HPP), a technology emerging in the food 
industry as an alternative to commercial thermal processing techniques which are widely 
adopted. These studies have sought to apply a HP regime to an enzyme and then to observe 
structure and function when the enzyme has returned to ambient pressures, with in situ charac-
terisation of little relevance.402–404 These studies have confirmed that whilst some enzymes can 
be denatured by HPP, others can be moderately enhanced by it., including some antioxidant 
enzymes relied upon by the food industry to preserve some food stuffs. The lack of either in 
situ, or comprehensive, biochemical analysis, means that these studies are of limited value, 




6.1.6 Industrially Relevant High Pressure Enzymology 
Limited information is available on the effect of pressure on enzymes that are not model 
systems, such as those that have recently been isolated or have been shown to catalyse non-
classical chemical reactions. To date, no investigation into the effects of HP on enzyme medi-
ated catalysis have been performed upon enzymes involved in the biosynthesis of natural prod-
ucts. The complex chemistry involved in these pathways simultaneously drives intense interest, 
and often precludes the use of highly specialised equipment with its necessary limitations.  
 
6.1.7  The Aim of this Work 
The paucity of information pertaining to the effect of pressure on NP biosynthetic enzymes, 
in particular those isolated from marine microorganisms recovered from extreme pressures, 
represents a substantial knowledge gap. The isolation of M. maris and the subsequent charac-
terisation of AbyU, coupled with the well reported effects of pressure on a synthetic Diels-
Alder reaction,388 makes the AbyU-catalysed DA reaction an excellent target for investigation. 
Such a study would help to inform our knowledge of the effect of pressure on a wider variety 
of enzymatic processes and architectures, as to date b-barrel enzymes have not yet been sub-
jected to characterisation under HP regimes. For these reasons the purpose of the work reported 
in this chapter was to undertake a detailed molecular level characterisation of the effect of HP 
on AbyU. To achieve this, a combination of HP-SF and HP-SRCD were used. These techniques 
allow us to observe overall conformational change and stability, as well as the kinetic profile 






6.2.1 Cloning and Expression of AbyU 
AbyU was cloned and expressed as previously described, with the exception that SEC puri-
fication was performed using a GE Healthcare 16/60 S75 column, pre-equilibrated in CD buffer 
(10 mM sodium phosphate, pH 7.5). Fractions were analysed by absorbance at 280 nm and 
SDS-PAGE. AbyU was found to be stable in this buffer. Purified protein was concentrated to 
500 µM and flash frozen in liquid nitrogen or stored at 4 °C for a maximum of 14 days.  
 
6.2.2 The High Pressure SRCD System 
A high-pressure cell (HP-200) (ISS), designed for fluorescence and absorption studies, was 
used for all HP-SRCD experiments. The cell was interfaced to beamline B23, at Diamond Light 
Source, Oxfordshire UK. The cell is made from a stainless-steel alloy and can withstand pres-
sure of up to 2000 bar with MgF2 windows (ISS). The windows, 10 mm in diameter and 8.5 
mm thick, are mounted into the cell via a Poulter type configuration with 10 mm clear aperture. 
During the experiment, N2 was blown over the windows to clear any water leakage from the 
windows. Aqueous samples were loaded into custom made circular quartz cells (ISS) of diam-
eter 8 mm and stoppered with a rubber cap, expelling all air. The cuvette was placed in a holder 
and then positioned into the HP cell. The interior of the cell was subsequently filled so that the 
sample cell was completely surrounded by the pressurising medium, clean, degassed, de-ion-
ised water. The pressure cell is mounted onto the beamline within a blackout box to prevent 
any light from interfering with the signal. The pressure cell is connected, via flexible tubing, 
to a manually operated hydrostatic pressure pump. Two valves are included in the pressure 
system which allow the pump to be isolated from the reservoir and or the high-pressure cell. 
The reservoir, pump and tubing are filled with degassed and deionized water and cleared of 
any air bubbles prior to use. 
 
6.2.3 Circular Dichroism Spectroscopy of AbyU at High Pressure 
Far-UV CD spectra were recorded using an AbyU protein solution of 1.5 µM in CD buffer 




were collected from CD buffer supplemented with the relevant organic solvent at a range of 
pressures up to 2000 bar. Baselines were subtracted from the relevant AbyU CD spectra ob-
tained at the same pressures. Samples containing AbyU were equilibrated for 120 seconds at 
pressure before readings were taken. Four repeats of CD spectrum were collected and averaged 
between 190 – 260 nm. Data were initially processed by the subtraction of the relevant baseline, 
and the removal of results where the high-tension voltage (HT) exceeded 700 V. Results were 
plotted using Graphpad Prism. Secondary structure analysis was performed using BestSel.405  
 
6.2.4 High Pressure Stopped-Flow Experiments 
HP-SF experiments were performed using a Hi-Tech Scientific HPSF-56 high-pressure 
stopped-flow spectrophotometer (TgK Scientific, Bradford on Avon, UK). The stopped-flow 
spectrometer was zeroed and references taken using ddH2O. For data collection, Syringe 1 
contained a final concentration of 40 µM AbyU, in 10 mM phosphate buffer. Syringe 2 con-
tained substrate 9 diluted into 10 mM phosphate buffer with 20% acetonitrile. Syringes were 
placed within the pressure cell and equilibrated briefly at increasing pressures before 50 µL 
from each syringe was injected into the mixing chamber and measurement immediately com-
menced. Data were measured at 325 nm using a logarithmic timebase for 5 seconds. All reac-
tions were performed at 22 oC, and 3 – 5 transients were averaged for all data points. Results 
were fit using Graphpad Prism. Initial concentrations of substrate 9 were calculated from the 
absorbance at t = 0, to account for uncatalysed substrate turnover, as well as the tendency of 
the substrate to stick within the apparatus. Data obtained before 2 ms was discarded. The data 
were subsequently fit to Equation 7. Measured amplitude changes in absorbance were con-
verted to concentration using the measured absorbance coefficients for the substrate and prod-
uct described previously. Data for the rate of background turnover of 9 were also recorded at 
325 nm. 10 mM Sodium Phosphate buffer in syringe 1 was mixed with 50 mM Substrate 9 in 
10 mM Phosphate buffer supplemented with 20% acetonitrile, and the data were fit to a single 
exponential (Equation 15). The first 0.5 seconds of each run were discarded due to mixing 
effects generated by the presence of acetonitrile in syringe 2 but not syringe 1. 
Equation 15: 




6.3 Results: Structural Stability of AbyU at High Pressure 
Given that AbyU was isolated from a deep-sea marine microorganism, it was hypothesised 
that it could have developed to function at HP. This hypothesis is particularly appealing as HP 
environments are known to drive DA reactions synthetically. This may be of relevance in the 
context of employing AbyU in high pressure industrial processes, with related investigations 
into the compatibility of this DA biocatalyst in the presence of high organic solvent concentra-
tions recently undertaken.351 Studies conducted under HP regimes may also serve to provide 
further insight into the kinetic behaviour of AbyU. In order to probe this hypothesis, a combi-
nation of structural and transient kinetic studies, using both HP-SF and HP-SRCD, were per-
formed at a range of HP regimes and in the presence of a variety of solvents. 
 
6.3.1 Probing Structural Changes in AbyU Induced by High Pressure in the Presence of 
Organic Solvents 
In order to gain insight into pressure induced structural changes in AbyU, it was necessary 
to monitor any the behaviour of this enzyme in response to high pressure in situ, as this gives 
considerably more insight than simply determining the point at which AbyU is denatured by 
pressure. This necessitated the use of a state-of-the-art HP-SRCD system. HP-SRCD is a novel 
technique, which to date has only been used once in the study of enzyme structure.401 This 
technique uses the extra intensity of a synchrotron radiation to penetrate the water used as a 
pressurising medium, facilitated by the use of custom MgF2 windows of 8.5 mm thickness.  
AbyU was incubated within the HP-SRCD cell with either 10 % acetonitrile, 10 % methanol 
or 40 % methanol. These solvents are often used within industrial process, and are required to 
ensure the solubility of substrate 9, a synthetic analogue of AbyU’s natural substrate. These 
conditions are, therefore, far more relevant to study from a practical point of view, although 
the solvents do prevent high-quality data from below 200 nm from being obtained. HP-SRCD 
data reports on the overall structural integrity of the target protein, in this case AbyU, and re-
veals changes in secondary structure composition. These changes can be monitored at any dis-
crete pressure up to 2000 bar (200 MPa). The sample is then returned to atmospheric pressure, 




Initially, structural changes in AbyU at HP were monitored in the presence of 10 % acetoni-
trile (Figure 6.1). This revealed that AbyU retains an intrinsically folded conformation at all 
pressures investigated up to 2000 bar. The HP-SRCD transients were subsequently interpreted 
as a function of secondary structure composition, as calculated using the program BestSel.405 
This program uses a comparison between secondary structure elements observed by X-ray 
crystallography and the CD spectrum of the equivalent parent polypeptide to determine a pre-
diction of the secondary structure composition from a CD spectrum. This analysis is consistent 
with AbyU being principally composed of a b-strands. At increased pressures the small pro-
portion of a-helix present in the structure appears to be lost at HP, whilst the proportion of 
loops and flexible regions decreases slightly. This contrasts with a significant increase in the 
proportion of b-strand content, which rises from ~ 40 % to > 50 %. This additional b-sheet 






Figure 6.1 HP-SRCD of AbyU in the Presence of 10 % Acetonitrile. a) HP-SRCD spectra 
of AbyU at pressures between 1 and 2000 bar. HP-SRCD spectra were also obtained whilst returning 
the sample to atmospheric pressure from 2000 bar. These data are labelled 1500 bar return, 1000 bar 
return and 1 bar return respectively, and are indicated by dotted lines. b) A prediction of the secondary 
structure composition of AbyU at pressures between 1 and 2000 Bar. The prediction was performed by 
BestSel using the HP-SRCD spectrum between 200-250 nm for AbyU at the corresponding pressure. 
Secondary structure predictions labelled ‘Return’ indicate the prediction for the secondary structure 



































































once the sample has had the pressure decreased to that value from 2000 Bar, and are indicated by dashed 
bars. 
In order to further investigate the structural stability of AbyU, a harsher solvation medium 
was used. Although increasing the concentration of acetonitrile present in the medium was 
initially explored, this did not allow reliable HP-SRCD results to be obtained, as the solvent 
interferes with the passage of polarised light through the cuvette. As methanol interferes less 
strongly with polarised light, and because AbyU has already been shown to be stable in its 
presence, this solvent was also trialled. Initially, 10 % methanol was used at pressures up to 
1000 bar (Figure 6.2). In order to conserve the MgF2 window, which becomes damaged by 
extensive exposure to the highest pressure regimens, HP-SRCD data was not obtained for pres-
sures between 1000 – 2000 bar. Following data analysis using BestSel, a small increase in b-
strand content at pressures up to 750 bar was identified, although at 1000 bar, the b content of 
the polypeptide was seen to decrease slightly. The results obtained during a return to atmos-
pheric pressure indicate that this drop is likely to be within the constraints of experimental 
error.  
The highest possible concentration of methanol that still allowed HP-SRCD data to be col-
lected (40 %) was subsequently used in an attempt to destabilise the structural integrity ob-
served at the highest pressures (Figure 6.3). This was ultimately unsuccessful, with AbyU re-
taining structural integrity at all pressures up to 2000 bar. An increased level of noise is ob-
served in the spectra due to the higher concentration of methanol. Nevertheless, following data 
deconvolution in BestSel, an increasing trend in the proportion of b-content is observed. The 
higher solvent content also appears to have disrupted the small proportion of helical content, 






Figure 6.2 HP-SRCD of AbyU in the Presence of 10 % Methanol. a) HP-SRCD spectra 
of AbyU at pressures between 1 and 1000 bar. HP-SRCD spectra were also obtained whilst returning 
the sample to atmospheric pressure from 2000 bar. These data are labelled 1500 bar return, 1000 bar 
return and 1 bar return respectively, and are indicated by dotted lines. b) A prediction of the secondary 
structure composition of AbyU at pressures between 1 and 1000 Bar. The prediction was performed by 
BestSel using the HP-SRCD spectrum between 200-250 nm for AbyU at the corresponding pressure. 
Secondary structure predictions labelled ‘Return’ indicate the prediction for the secondary structure 
once the sample has had the pressure decreased to that value from 1000 Bar, and are indicated by dashed 
bars. 






























































Figure 6.3 HP-SRCD of AbyU in the Presence of 40 % Methanol. a) HP-SRCD spectra 
of AbyU at pressures between 1 and 2000 bar. HP-SRCD spectra were also obtained whilst returning 
the sample to atmospheric pressure from 2000 bar. These data are labelled 1500 bar return, 1000 bar 
return and 1 bar return respectively, and are indicated by dotted lines. b) A prediction of the secondary 
structure composition of AbyU at pressures between 1 and 2000 Bar. The prediction was performed by 
BestSel using the HP-SRCD spectrum between 200-250 nm for AbyU at the corresponding pressure. 
Secondary structure predictions labelled ‘Return’ indicate the prediction for the secondary structure 
once the sample has had the pressure decreased to that value from 2000 Bar, and are indicated by dashed 
bars. 
 












































































Together, these data demonstrate that AbyU maintains overall structural integrity at pres-
sures up to 2000 bar and in the presence of all the solvents tested. Although no major global 
structural changes were observed, the HP regime investigated did raise the percentage of b-
content significantly; by an average of 32 %, between 1 and 1000 bar (Figure 6.4). The pro-
portion of b-strand then stabilises at around 60 %, though small increases may still be occurring 
up to 2000 bar. Some retention of elevated b-structure is observed once the sample is depres-
surised. This elevation is likely due to the HP environment strengthening existing hydrogen 
bonds and potentially driving the formation of new ones.387 The backbone hydrogen bonds 
between each b-strand in the barrel of AbyU are therefore strengthened, and residues at either 
end of each strand may be incorporated. 
 
Figure 6.4 The Influence of Pressure on the Proportion of b-Sheet Structure Observed 
in AbyU. The average up to 1000 bar consists of data obtained in the presence of 10 % and 40 % 
methanol as well as 10 % acetonitrile. The average from 1500 bar to 2000 bar consists of data obtained 





































6.4 Results: AbyU Reaction Kinetics at High Pressure  
Whilst CD data are generally considered less informative for the study of predominantly b- 
structures, these data do show that attempts to disrupt the structural integrity of AbyU via a HP 
regime, serves to increase the proportion of b-content and decrease the proportion of loops and 
turns. Higher concentrations of solvent may also contribute to this effect.  
In tandem with studies of the impact of HP on AbyU structure, it was also important to 
explore the impact of different HP regime on the kinetic performance of this enzyme. Due to 
the well-documented relationship between protein folding states and functional states,406 it was 
hoped that the relationship between the HP-SRCD data and HP kinetic data would allow further 
mechanistic insight to be derived. The data would also enable assessment of the potential for 
using AbyU as an industrial catalyst at HP. As shown previously, AbyU possesses a complex 
reaction mechanism. Substrate 9 can be bound in at least three different conformations, with 
small reorganisations within the active site often necessary for catalysis. A number of practical 
complexities also prevented easy characterisation of the kinetic parameters of AbyU with re-
spect to pressure. These included the propensity for 9 to cyclise spontaneously, and the need to 
incubate enzyme and substrate together for between 2 – 5 minutes in a static cell before the 
correct pressure regime was reached. The mechanistic and practical complexities together pre-
vented the use of steady-state kinetics to investigate the effect of pressure on AbyU-catalysed 
cyclisation of 9 to form 10. In light of these issues experiments were chosen to be performed 
using a HP-SF system, which removes the need to incubate the substrate and enzyme together 
prior to data collection. It also allows closer inspection of the effect of HP on the mechanism 
of AbyU. Traditional approaches to determining the effect of pressure on the catalytic effi-
ciency of an enzyme, such as taking measurements before and after the application of a HP 
regime, were considered to be of limited value when assessing AbyU’s catalytic performance 
under HP. 
 
6.4.1 High-Pressure Stopped-Flow Transients of AbyU-Catalysed Cyclisation 
Although the HP-SF characterisation of AbyU is only interpretable once the mechanism 
employed during catalysis has been deciphered, it was these experiments that first revealed the 




lack of immediate access to HP-SF equipment, some of the experimental parameters used are 
now considered sub-optimal. They do, however, still provide important insight into the effect 
of pressure and the increase in b-strand structure on the catalytic mechanism of AbyU.  
HP-SF experiments were performed by mixing 20 µM AbyU rapidly with 9, with in-situ 
burst phase kinetic data collected at pressures between 1 bar and 1000 bar. The kinetic transi-
ents generated bare good resemblance to those obtained at atmospheric pressure (Section 
5.3.7). These were analysed and fit to Equation 7 (Figure 6.5). Although a fit consisting of three 
exponentials and a slope was previously deemed an overfit in the presence of 1 µM AbyU, the 
increased concentration of enzyme used in these experiments induced the manifestation of a 
third burst phase. As the size of the burst phase is approximately stoichiometric with the con-
centration of AbyU in the reaction, this is likely to represent a third binding conformation. The 
manifestation of this additional phase in kb2, the slower of the two exponentials, indicates that 
it may represent the second, weaker, binding conformation identified in kobs2 during single 
turnover analysis.  
 
Equation 7: 
Y = A! + A" × exp(−." × X) + 0# × exp(−.# × X)






Figure 6.5 An Example Transient and Fitting Statistics for AbyU-Catalysed 
Cyclisation at HP. This transient was produced by the turnover of 83 µM substrate 4 by 20 µM AbyU 
at 750 bar. a) Fit to Equation 6. b) Fit to Equation 5. c) Fit to Equation 7. Adjusted R2 values are shown 
beneath the transients. The residual plots generated are shown inset for comparison.  
 






































Adj. R2 = 0.9992
Adj. R2 = 0.9998
Adj. R2 = 0.9913



































































6.4.2 Spontaneous Cyclisation of 9 at High Pressure 
The next goal was to investigate the effect of pressure on the rate of spontaneous cyclisation 
of 9 to 10 (Figure 6.6). Similarly to other Diels-Alder reactions, the cyclisation of 9 in the 
absence of enzyme is driven at an increasing rate by increasing pressures. Interestingly, the 
spontaneous turnover of 9 at HP occurs in an exponential manner, whilst the rate of reaction at 
atmospheric pressure remains linear. This indicates an increased level of cooperation between 
substrate molecules at HP. One possibility is that, at HP, the reaction volume is decreased, 
leading to an increased proliferation of the higher order structures observed by DLS (Section 
5.2.1). Injection into the reaction chamber of the stopped-flow subsequently halves the con-
centration leading to the disassembly of the higher order structures and an increased initial rate 
of spontaneous cyclisation. The rate of spontaneous cyclisation of 9 increases by around 10 % 
of the initial rate for every 100 bar increase in pressure (Figure 6.6b). Due to the necessity of 
filling two large syringes with reactants and then progressively increasing the pressure on those 
reactants prior to injection, the quantity of starting material decreased at a rate proportional to 
the pressure and concentration of substrate 9 present in the syringe (Figure 6.7). This means 
that not only is it impossible to realistically obtain multiple repeats of data with the same start-
ing concentration at different pressures, but that the concentration of starting material in the 








Figure 6.6 Pressure Dependence of the Rate of Spontaneous Cyclisation of 9. a) 
Example transient for the spontaneous turnover of Substrate 9 at 500 bar. Data were fit to a single 
exponential and the rate k derived for each replicate. b) The rate of spontaneous cyclisation as a function 














































Figure 6.7 The Initial Concentration of Substrate 9 at Increasing Pressures. Each run 
was initiated from the same syringe, which is incubated at increasing pressures before injection. The 
concentration was calculated from the initial absorbance and the measured extinction coefficient, and 
then fit to Equation 11.  
 
6.4.3 Determining a Concentration Dependence at Atmospheric Pressure 
In order to account for the decrease in the concentration of 9 with increasing pressure, a full 
concentration dependent dataset for the reaction of 20 µM AbyU with substrate 9 was obtained 
at atmospheric pressure. The individual transients were analysed and fit to Equation 7 (Figure 
6.8). The rate and amplitude of each phase within the reaction was determined and plotted with 
respect to the concentration of substrate (Figure 6.9). This allows us to extract the three dis-
cernible burst phases under these reaction conditions, determining their rates, kb1 – kb3, and 
their amplitudes, Ab1 – Ab3. The relationship between the concentration of substrate and the 
three phases of the reaction could then be determined. The parameters for the equations linking 































Figure 6.8 An Example Transient for the Incubation of 102 µM Substrate 9 with 20 
µM AbyU at Atmospheric Pressure. The same transient is shown on both a logarithmic and linear 






















































Figure 6.9 Kinetic Data Derived from the Reaction of 20 µM AbyU with Varying 
Concentrations of Substrate. a) The relationship between kb1, kb2 and kb3 and the concentration of 
substrate present in the reaction. Each relationship is fit to a straight line (Equation 1). b) The amplitude 
of each of the three burst phases, Ab1, Ab2 and Ab3, and their change with respect to substrate 
concentration. Whilst Ab2 and Ab3 have a linear relationship to substrate concentration and are fit to 
Equation 1, Ab1 is fit to a rectangular hyperbola (Equation 10). c) The rate of the steady-state reaction 

























































Phase Slope (µM-1) Y-intercept (µM) 
kb1 0.19 ± 0.015 24.9 ± 1.7 
kb2 -0.025 ± 0.0020 8.34 ± 0.23 
kb3 -0.00079 ± 0.00014 0.30 ± 0.016 
Steady-State 0.0039 ± 0.00022 0.15 ± 0.025 
Ab2 -0.025 ± 0.0045 10.50 ± 0.52 
Ab3 0.060 ± 0.0020 3.35 ± 0.22 
 Alim (µM) Kd (µM) 
Ab1 42.71 ± 1.8 56.66 ± 6.4 
 
Table 6.1 Parameters for the Concentration Dependence of a Reaction with 20 µM 
AbyU.  
 
6.4.4 The Effect of Pressure on Concentration Independent AbyU Catalysis 
Data acquired from AbyU HP-SF experiments do not constitute a formal kinetic interroga-
tion of AbyU, as the concentration of enzyme present is too high to ensure pseudo-first order 
kinetics. The data do, however, allow us to establish the effect that a decrease in substrate 
concentration has on the rate and amplitude of each phase observed in the HP experiments. The 
parameters given in Table 6.1 were used to account for the effect of the varying substrate con-
centration on each transient generated at HP. The expected change in rate or amplitude for each 
phase due to the decreasing concentration of substrate was determined. The HP transients were 
subsequently analysed with these expected changes taken into account. This allowed the deter-
mination of a concentration independent pressure effect on the cyclisation of substrate 9 by 
AbyU (Figure 6.12). The relationship between pressure and the rate and amplitude of each 
phase was determined. This provided further insight into the enzyme mechanism and also the 
limits placed by HP regimes on catalysis.  
Unfortunately, it was not possible to conduct the same analysis for the enzyme independent 
reaction, due to the changing nature of the transient observed. It should therefore be noted that 
the background rate of reaction has not been corrected for the variation in initial substrate con-
centration. It is not anticipated that this will have had any bearing on the results obtained from 




The rate of reaction observed in each of the three burst phases increases with increasing 
pressure. This is possibly due to the smaller reaction volume present at HP causing an increase 
in the rate of collisions. This is likely to account for the small increases observed in kb2 and kb3, 
as the amplitudes corresponding to these phases remain unaffected by a change in pressure. 
Ab1, however, decreases by roughly 2/3 over the pressures analysed. This reduction in ampli-
tude represents fewer molecules of 9 binding in this conformation and successfully cyclising 
before the rate-limiting product release step occurs. Given that Ab2 and Ab3 remain unaffected, 
and there are no major structural rearrangements occurring, we can infer that the increased 
rigidity of the AbyU b-barrel prevents small rearrangements of the substrate from taking place 
upon binding. This in turn leads to an increase in the number of substrate molecules binding in 
a non-productive conformation, such as D, as opposed to the most productive conformation, 
A. However, with rearrangement unable to occur, those molecules that do successfully bind in 
are able to cyclise significantly faster, with the rate of reaction in this phase increasing by 2-
fold. 
Although the reaction conditions do not saturate the steady-state rate of reaction, they still 
evidence the effect of HP regimes on AbyU. Up to ~500 bar, AbyU is still able to catalyse the 
cyclisation of 9 with the same efficiency. Beyond 750 bar, however, a drastic decrease in the 
rate of the steady-state reaction is observed, until, at 1250 bar, the rate of enzyme-catalysed 
reaction does not exceed the background rate of reaction. Given that the rate of reaction has 
been adjusted for the decrease in initial substrate concentration, there are two more possible 
hypotheses for this catalytic inhibition. The first of these is that the enzyme active sites are 
each rapidly inhibited by non-productively bound substrate. The sigmoidal shape of the curve, 
however, suggests that the pressure at which catalysis can no longer occur effectively is reached 
suddenly, and is not a linear process. When fit to Equation 11, the hill coefficient of -5.4 ± 2.4 
(which increases to -8.8 ± 2.7 if the fit is constrained to 0 on the bottom) indicates a very high 
degree of cooperativity between pressure and the rate of reaction. A K0.5 of 917 ± 110 provides 
us with an upper limit for the pressure regime AbyU can effectively function within. The con-
cept that active sites might suddenly be unable to bind substrate in a productive conformation 
does not agree with the burst phase data, or the mechanistic understanding developed so far. 
Although non-productively bound substrate doubtless contributes to the decrease in rate, the 
burst phase data show that enzymatic catalysis does still occur, and that substrate is still able 




enzymatic inhibition is the rate-limiting product release step. If the capping loop is no longer 
dissociating from the active site to allow product release, the product would become trapped 
inside the b-barrel, creating a permanently inhibited EP complex. Another possibility is that, 
around 920 bar, the AbyU dimer dissociates, leading to an inactive population of monomers. 
There is no mechanistic or structural information to support the assumption that monomeric 
AbyU is inactive, however, so this theory should be discounted.  
 
Equation 11: 








Figure 6.10 The Concentration Independent Effect of Pressure on AbyU-Catalysed 
Cyclisation. a) The rate of reaction in the three extractable burst phases in relation to pressure. The 
change in rate in relation to pressure is fitted to Equation 1 and the results shown in table 2. b) The 
effect of pressure upon the amplitude of each exponential phase in the reaction. The results are all fit to 
Equation 1 and the results are shown in table 2. c) The effect of pressure on the steady-state. The trend 





























































The parameters for the relationship between pressure and the AbyU catalysed cyclisation of 
9 are given in Table 6.2. kb3, along with Ab2 and Ab3, remain largely unaffected by the HP 
regimes investigated. kb1 and kb2 increase by around 10 % of their starting rate with every 100 
bar increase in pressure. Ab1, however, decreases by roughly 6 % of its starting amplitude over 
100 bar. The steady-state shows a high degree of cooperativity between pressure and catalysis, 
with AbyU unable to efficiently catalyse substrate conversion at pressures > 920 bar. 
 
Phase Slope (µM per 100 bar) Y-intercept (µM) 
kb1 4.2 ± 0.4 43.8 ± 2.5 
kb2 1.3 ± 0.2 10.6 ± 1.3 
kb3 0.015 ± 0.022 0.64 ± 0.13 
Ab1 -1.74 ± 0.13 28.53 ± 0.7 
Ab2 0.00 ± 0.002 0.12 ± 0.009 
Ab3 -0.08 ± 0.04 5.06 ± 0.2 
 K0.5 (µM) Hill Coefficient 
Steady-State 832 ± 36.8 -8.2 ± 2.3 
 
Table 6.2 Parameters for the Pressure Dependence of AbyU-Catalysed Cyclisation 








Whilst the experiments undertaken during this chapter do not represent a complete study of 
a model system and its function in a high pressure environment, they do provide a valuable 
insight into the effect of pressure on enzyme-mediated catalysis. They have also proven im-
portant in informing the design of subsequent experiments focused on exploring the effect of 
HP on enzyme systems.  
The HP-SRCD data reported herein show that there are no major structural rearrangements 
within AbyU at pressures up to 2000 bar, in the presence of different solvents and concentra-
tions of solvent. The stability exhibited by AbyU under these pressures is perhaps surprising 
given its sizeable active site cavity. Roche et al. demonstrate that staphylococcal nuclease, a 
protein containing a small b-barrel fold within its structure, begins to denature at pressures as 
low as 500 bar.407 This study showed that the cavity within this b-barrel was the principal driver 
behind pressure dependent denaturation, due to its significant internal volume. Furthermore, 
the data also show that a moderate increase in pressure can promote b-strand formation within 
AbyU. Although HP-NMR would be required to determine whether this is the result of com-
paction or conformational transition to a higher energy state, HP-SRCD does give a wider, and 
more easily interpreted, overview of the structural state of AbyU at high pressure. The newly 
developed HP-SRCD technique exploited here provides the ability to observe the enzyme in 
its entirety, as opposed to the individual 15N and 1H shifts observed in HP-NMR. As such, these 
data are the first example of HP driving an overall increase in b-sheet architecture within an 
enzyme, and provide further evidence that HP can favour hydrogen bond formation within 
macromolecular structures.  
The kinetic data obtained by HP-SF, when interpreted in combination with the structural 
data obtained by HP-SRCD, provide a unique insight into the reaction mechanism employed 
by AbyU. The increased rigidity of the b-barrel, brought about by increased numbers of short-
ened backbone hydrogen bonds, appears to prevent conformational rearrangement of the sub-
strate within the active site. As discussed in Chapter 5, kobs1 contains multiple slightly different 
binding conformations, some of which must undergo minor rearrangements until the substrate 
is poised for cyclisation in pose A, as identified by MD simulations (Figure 5.24). The decrease 




occurring during the burst phase. Optimally oriented substrate is still able to bind, with the 
increased rate of reaction at high pressure reflecting a lower manifestation of less productive 
orientations. Binding in conformations B and D is not affected by the increase in pressure. 
Increased rates of reaction in these burst phases is likely due to the smaller reaction volume for 
the ES complex. 
Steady-state kinetic studies reveal the effect of pressure on the rate-limiting product release 
step of the reaction. We see a highly cooperative relationship between pressure and the rate of 
reaction, indicating that, at ~920 bar, product release is no longer able to occur. As product 
release increases the reaction volume, this process will be naturally inhibited to some degree 
by increasing pressure. We would, however, expect this process to be linear in nature. The 
initial mechanistic interpretation is that the capping loop, which needs to dissociate from the 
top of the barrel to permit product release, is no longer able to open, preventing product release 
and trapping the EP complex. In this enzyme the substrate can enter the active site in a variety 
of conformations and at a variety of rates. In the same way that a lower temperature can give 
the substrate time to rearrange and accurately bind within the active site, a lower pressure can 
increase the flexibility of the active site. Whilst the rates of binding and turnover are slower 
under these conditions, this appears to allow the substrate the time required to bind produc-
tively.  
This study showcases the mechanistic information that can be gained through the study of 
pressure perturbation on enzyme catalysts. We see that the robust b-barrel architecture is capa-
ble of withstanding pressurisation, despite its large internal cavity, and that the active site of 
AbyU can be locked shut under HP regimes. This information not only increases the basic 
understanding of the effects that pressure can have on macromolecules, but it also provides 
crucial information about protein folds that remain stable under adverse conditions and how 







7.1 The Abyssomicin Biosynthetic Pathway 
Although abyssomicin C is one of the smallest and most simple of the tetronate antibiot-
ics,198 the biosynthetic machinery used to make it consists of a multitude of enzymes capable 
of performing complex chemical catalysis (Figure 1.13). Following synthesis, the polyketide 
chain is liberated as a linear molecule, without the use of a TE domain, by a rare combination 
of three enzymes, AbyA1 – A3. This simultaneously creates the tetronate moiety that gives this 
class of natural products their name. The acetate-lyase AbyA5 performs a little seen chemical 
reaction, preparing the dienophile required for the DA cyclisation to occur in the next step.225 
The elimination of acetate without the production of hydrolysis product, along with the later 
enzymatic insertion of an epoxide before the creation of the active antimicrobial product, are 
two more unusual examples of enzymatic catalysis. This means that virtually every step in the 
biosynthesis of abyssomicin C represents a rarely characterised or not yet understood enzymat-
ically catalysed reaction. This relatively short and simple biosynthetic pathway is an exemplary 
model of the catalytic and structural complexity that can be accessed thanks to advances in 
gene sequencing and synthesis.51  
The bona fide natural DAase AbyU is an excellent example of this catalytic complexity.224 
Not only has it been shown to be a remarkably stable, industrially relevant, catalyst,351 but it 
has also been revealed here as a deceptively complex catalyst with great potential for rational 
engineering, now that the catalytic complexities are more conclusively understood.  
Although polyketide synthases, their mechanism and products have been studied exten-
sively over the last two and a half decades,99,108,141,142,151,170,258,266,408 a number of questions 
about the complex web of structural and functional relations that guides vectoral synthesis re-
main unanswered.149 The type I bacterial mPKS genes present in the abyssomicin biosynthetic 
pathway have been shown to present a tractable alternative for investigation to the two proto-




pathways.107,409 The abyssomicin polyketide synthase genes allow us to study a minimal mod-
ule, from which basic structural and mechanistic understanding can be built up, as well as the 
opportunity to study an unusual module containing two inactive domains.  
 
7.2 The Abyssomicin Polyketide Synthase Genes 
7.2.1 Cloning and Heterologous Expression 
Although successful expression of AbyB2 remained elusive, the cloning and assembly pro-
tocol devised provides an alternative and more modern method for working with these large 
and repetitive genes. The ability to rapidly assemble biosynthetic genes into multiple vectors 
for analysis in multiple expression strains is essential for future studies of the many unique 
natural products discussed, and for future attempts to engineer these modular enzymes in a 
directed manner. 
The successful expression of AbyB3 does, however, highlight the strain that an E. coli host 
is put under through the successful expression of polyketide synthase modules. Minor varia-
tions in culture conditions proved to completely eliminate protein expression, whilst multiple 
unsuccessful expression trials for both AbyB2 and AbyB3 show a need to develop a more ro-
bust polyketide synthase production host in the future. With improved genetic techniques, the 
ability to rapidly shuttle genes between hosts and vectors should make this task far more 
achievable.  
 
7.2.2 AbyB3 Structural Studies 
The structural studies of AbyB3 go a long way towards reconciling the differing modular 
architectures observed in mammalian FASs, intact mPKS modules and mPKS KS-AT 
didomains. The crystal structure of AbyB3DACP reveals a very high level of sequence and 
structural homology between mPKS didomains found in different bacterial species. This fur-
ther points towards one dominant modular architecture within this diverse class of enzymes 
and makes the reconciliation of the different postulated architectures a necessity. The intricate 




example in the binding site of the ACP to the KS and AT,114,142 depend entirely on the structural 
model used for study. This in turn biases any attempt to re-engineer these modular assembly 
lines and represents a huge bottleneck in our ability to develop them for the production of 
designer polyketides. 
This study, although not yet concluded, points towards a significant rearrangement of the 
modular polyketide structure upon the addition of the ACP domains. Although the 
AbyB3DACP structure is highly similar to those observed in DEBS, the AbyB3 2D class aver-
ages, and, indeed, the micrographs themselves, bare a high resemblance to the 2D class aver-
ages obtained during the reconstruction of a cryo-EM map for the arched PikAIII.141 Crucially, 
no particles are observed close to the size of the 150 Å long didomain structure solved by x-
ray crystallography. The smaller, ~75 Å, arch shaped particles are good evidence that a signif-
icant conformational rearrangement has been precipitated by the addition of the ACP domains, 
and points to a major, and as yet unidentified, role in structural fidelity for mPKS ACP domains. 
The structurally conserved post-AT linker region could play a significant and unidentified role 
in the transmission of structural rearrangements throughout the module, ensuring vectoral syn-
thesis. Interactions of the post-AT linker with the KS-AT linker could also enable the structural 
rearrangements necessary for the creation of the enclosed reaction chamber created by the cat-
alytic arch conformation. Hydrophobic contacts observed to stabilise the linear conformation 
of the KS and AT domains in the didomain structures,114 and in FAS structures,152 as well as 
the hydrogen bonding observed between the post-AT linker, the KS domain and the AT domain 
and their linker,114 could all be disrupted by the movement of the post-AT linker, for instance 
upon the addition of a downstream domain.  
 
7.3 AbyU 
7.3.1 The Catalytic Mechanism of AbyU 
The DA reaction holds great potential as a tool in synthetic chemistry, facilitating the crea-
tion of cyclohexenes with up to four new stereocentres and two new carbon-carbon bonds in a 
single step, whilst creating no waste products. It is, however, difficult to catalyse and control 
and remains sparsely used in synthesis. Although, until recently, there were no enzymes char-




five years has seen a number of them identified. Whilst VstJ, PyrE3, PyrI4, AbyU, SpnF, MalC 
and PhqE have all been characterised to different levels, mechanistic understanding for all but 
SpnF remains non-existent.224,331,337,338,344 Whilst the mechanism of SpnF has been investigated 
in more detail, mostly through theoretical studies,340–343 the possible [6 + 4] reaction mecha-
nism makes it unique amongst those [4 + 2] cyclases characterised to date, and hence a bad 
model system. Although PyrI4 is the only other [4 + 2] cyclase to possess a b-barrel fold, each 
of the enzymes characterised to date have been identified to enable catalysis through the steric 
restriction of their substrate. The simplicity of mechanism that this statement engenders belies 
the highly complex reaction mechanism that has been shown to exist beneath the surface.  
The work described herein evidences a number of complex interactions between the sub-
strate and the hydrophobic core of the active site. Multiple subtly different binding confor-
mations can be grouped into three or four distinct substrate orientations within the active site, 
each with different binding energies and energy barriers towards catalysis. Rearrangements 
within the active site are sometimes necessary to facilitate catalysis, whilst mis-binding can be 
seen to create a catalytically incompetent enzyme substrate complex. Whilst these mechanistic 
observations might directly apply to PyrI4, they also show that the structural and steady-state 
kinetic characterisations performed so far on putative DAases are likely to hide significant 
complexities. These should be determined to enable engineering attempts and directed muta-
genesis to proceed in a rational manner.  
 
7.3.2 The Influence of Pressure and Temperature on AbyU-Catalysed Cycloaddition 
The catalytic mechanism of AbyU, as well as its ability to function in a hostile industrial 
environment, was further probed at high pressures and cold temperatures. High pressure in-
creases the rigidity of AbyU’s b-barrel structure. The proportion of b-sheet secondary archi-
tecture is increased as the backbone hydrogen bonds connecting the antiparallel strands are 
strengthened. Mechanistically, this both prevents substrate rearrangements and adjustments 
from occurring within the active site and increases the rate of collisions, decreasing the time 
AbyU has to ensure correct substrate binding. This results in a decrease the amplitude observed 
in the most catalytically competent phase of the reaction. At pressures above 600 bar, there is 
a rapid and cooperative decrease in the rate of the steady-state reaction. Given that there is no 




pressure upon the rate limiting product release step. The obvious mechanistic conclusion, 
which is now supported by MD simulations, is that the active site capping loop becomes locked 
shut at high pressures, underlining the importance of this loop to the overall catalytic cycle. 
Initial results from experiments conducted at 5 °C appear to corroborate these findings. The 
low temperatures will decrease the rate of collisions and decrease the rate of substrate binding 
within the active site. This allows AbyU the necessary time to ensure correct substrate binding, 
allowing cyclisation to reach 100 % over 1000 s.  
 
7.4 Future Work 
7.4.1 Polyketide Structural Studies 
The first priority should be to screen quantifoil grids with a decreased proportion of the grid 
dedicated to carbon support, such as R 2/1 grids. As the concentration of sample and correct 
freezing conditions have already been determined, it should be possible to rapidly collect a full 
sized cryo-EM dataset of AbyB3. Once processed an assessment can be made as to whether 
any additional information is required or an attempt to bias additional particle orientations must 
be made. Given the results presented here, a high-resolution structure of AbyB3 is within reach 
and should be obtainable within a reasonable timeframe. If the theories presented here are con-
firmed, this would enable a detailed study into the modular architecture of mPKS enzymes as 
well as the complex protein-protein interactions that facilitate vectoral synthesis.  
Once that is complete, further efforts can be made to study the multimodular mPKS enzymes 
AbyB1 and AbyB2. Efforts to express these constructs in heterologous hosts closer in identity 
to M. maris, such as S. coelicolor, could be made. Additionally, the two modules present in 
AbyB2 could be separated for expression, and then re-joined in vitro for biochemical and struc-
tural analysis. This would enable the structures of polyketide synthase modules containing all 
three commonly occurring reducing enzymes, as well as one containing inactive KR and DH 






Future work on AbyU can build on the detailed mechanistic understanding developed here. 
Attempts to engineer AbyU as a multifunctional DA biocatalyst can now proceed in a directed 
manner. One of the first possible approaches should be to create small mutations in the loop 
region, aiming to increase the rate of catalysis by effecting the rate limiting step. These muta-
tions may enable us to develop a better understanding of the rearrangements necessary to en-
sure the substrate binds in the correct conformation, further building a detailed mechanistic 
understanding of this deceptively complex enzyme. In silico modelling should be exploited to 
speed and direct experimental work, with the MD and QM/MM studies performed to date 
providing a good basis from which to build.  
 
7.5 Conclusion 
Two key enzymes within the abyssomicin C biosynthetic pathway have been further char-
acterised using structural and mechanistic studies. This work provides a strong basis from 
which attempts to engineer enzymes within this pathway and analogous enzymes from other 
systems can proceed. The structural studies of AbyB3 allow us to reconcile the apparent struc-
tural differences seen in different mPKS modules. It enables the creation of one mPKS archi-
tectural blueprint for use in future work developing and rationally engineering polyketide syn-
thase modules for the creation of designer polyketides. The mechanistic understanding of elu-
sive [4 + 2] cyclases has been increased, with the transient methods described within the first 
example of their application to this class of enzyme. Understanding the complexities involved 
allow us to direct future attempts to develop industrial DA biocatalysts, as well as attempts to 
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A.1 Primers and Plasmids Used in This Project 
A.1.1 Primers Used 
 
Primer Name Protein Primer Sequence 5’-3’ Primer function 
B2_pET28_Fwd AbyB2 tgggtcgcggatccgaattcATGAC-CACACCGAGCAAAGG Insertion into pET28 
B2_pET28_Rvs AbyB2 caagcttgtcgacggagctcTTAAC-CTGCGTCAACTTCTTGATAATC Insertion into pET28 
B2_pF_Fwd (B2_1F) AbyB2 aagttctgtttcagggcccgATGAC-CACACCGAGCAAAGG 
Insertion into pOPINF, 
sequencing 
B2_pF_Rvs (B2_6R) AbyB2 atggtctagaaagctttaTTAAC-CTGCGTCAACTTCTTGATAATC 
Insertion into pOPINF, 
sequencing 
B2_1CF AbyB2 GGCAGAATATGGTCAGGGTC Sequencing & assembly verification 
B2_1CR AbyB2 AACAGTTCCGGTGTGGC Sequencing  
B2_1R AbyB2 ACGCAGTGACCAATCCACATG Sequencing 
B2_2F AbyB2 GATTGGTCACTGCGTGCAG Sequencing  
B2_2CF AbyB2 GTCTGGGTGCCGTTGG Sequencing & assembly verification 
B2_2CR AbyB2 ACGACGACGATCACCTTC Sequencing & assembly verification 
B2_2R AbyB2 ACCATCAGGTTCTGCCAGAC Sequencing  
B2_3F AbyB2 GCAGAACCTGATGGTCCGC Sequencing  
B2_3CF AbyB2 GCCTGACCGCAATTGAAC Sequencing & assembly verification 
B2_3CR AbyB2 GCTCACCAGACCTAAACGA Sequencing & assembly verification 
B2_3R AbyB2 GCTCAGAACGGTGGCACC Sequencing  
B2_4F AbyB2 GCCACCGTTCTGAGCAATC Sequencing 
B2_4CF AbyB2 GAAGAAGCCCTGCGTCG Sequencing  
B2_4CR AbyB2 GTGCTGCCGGATTTGCT Sequencing & assembly verification 
B2_4R AbyB2 CAGTGCTGTCAGAAAACGACG Sequencing 
B2_5F AbyB2 TTTCTGACAGCACTGGCCG Sequencing  
B2_5CF AbyB2 GGTTACCAGCACCATTGC Sequencing & assembly verification 




B2_5R AbyB2 AATCAGAACACGTTCACCTGGAC Sequencing 
B2_6F AbyB2 GAACGTGTTCTGATTCATAGCGC Sequencing  
B2_6CF AbyB2 GGGTCGTATTGAACGTGGT Sequencing  
B2_6CR AbyB2 GGAACGGCTGCCAGAAC Sequencing & assembly verification 
abyB2_frag1_FW AbyB2 CCGGTCGGTCTCTCTGGATGACCACACCGAGCAAAG Type IIs assembly 
abyB2_frag1_RV AbyB2 AGGGCAGGTCTCGAGTGACCAATCCACATGAGGAGC Type IIs assembly 
abyB2_frag2_FW AbyB2 CGACTGGGTCTCCCACTGCGTGCAGTTCTGGCA Type IIs assembly 
abyB2_frag2_RV AbyB2 AACAATGGTCTCCCGGACCATCAGGTTCTGCCAGA Type IIs assembly 
abyB2_frag3_FW AbyB2 GCCAACGGTCTCTTCCGCGTCAGGTTGTTGTTGCAC Type IIs assembly 
abyB2_frag3_RV AbyB2 TCGACCGGTCTCTTGCTCAGAACGGTGGCACCA Type IIs assembly 
abyB2_frag4_FW AbyB2 TCCAAAGGTCTCCAGCAATCCGGATATTTTTGTTGGTTTT Type IIs assembly 
abyB2_frag4_RV AbyB2 TCCTGAGGTCTCCGCCAGTGCTGTCAGAAAACGACGA Type IIs assembly 
abyB2_frag5_FW AbyB2 TCACCGGGTCTCGTGGCCGAAGCATATGTGACCGGT Type IIs assembly 
abyB2_frag5_RV AbyB2 TGCCGCGGTCTCCGAACACGTTCACCTGGACGCA Type IIs assembly 
abyB2_frag6_FW AbyB2 CATTTCGGTCTCCGTTCTGATTCATAGCGCAGCCG Type IIs assembly 







Insertion into pOPINE, 
sequencing 















Insertion into pOPINF, 
sequencing 
AbyB3_pF_Rvs AbyB3 atggtctagaaagctttaTCAC-GTCCGCGCG 




























B3_F4_seq AbyB3 GCCGTTTCGTGGAGGTC Sequencing 
AbyU_pF_Fwd AbyU aagttctgtttcagggcccgATGACTGAGCGACTGGAG Insertion into pOPINF 
AbyU_pF_Rvs AbyU atggtctagaaagctttaTCAC-TCGCCGAGCAG Insertion into pOPINF 
T7 (Eurofins)  TAA TAC GAC TCA CTA TAG GG Sequencing 
T7term (Eurofins)  CTA GTT ATT GCT CAG CGG T Sequencing 
 
Table A.1 List of primers used in this project  
Each primer was designed on BenchlingTM to have a Tm as close to 62oC as possible under the 
conditions used by CloneAmp HiFi PCR premix (Takara, Japan), apart from GeneArt type IIs assembly 
primers, which were designed using the Type IIs primer design tool (Thermofisher UK). Lowercase 
letters encode plasmid overlap sequences for insertion via homologous recombination. BsaI recognition 
sites are highlighted in grey. 
 
A.1.2 Plasmids Used 
 
Plasmid Resistance Marker Promoter Tag Sequence Tag Location 
pOPINF Ampicillin T7 MAHHHHHHSSGLEVLFQGP  N-terminal 
pOPINE Ampicillin T7 KHHHHHH  C-terminal 
pET28a Kanamycin T7 GSSHHHHHHSSGLVPR N-terminal 
 






A.2 Nucleotide and Amino Acid Sequences  
A.2.1 A Comparison of the Native and Codon Optimised AbyB2 Genes 
AbyB2              1 atgaccacaccgagcaaggggacggacagcattgccgaccagcagaagct     50 
                     |||||||||||||||||.||.||.||.||||||||.||.||||||||.|| 
AbyB2_CodonOp      1 atgaccacaccgagcaaaggcaccgatagcattgcagatcagcagaaact     50 
 
AbyB2             51 gcgcgagtacctccggcgggtcaccgacgacctgctgcggacccgccggc    100 
                     |||.||.||.||.||.||.||.|||||.||.||||||||.|||||.||.| 
AbyB2_CodonOp     51 gcgtgaatatctgcgtcgtgttaccgatgatctgctgcgtacccgtcgtc    100 
 
AbyB2            101 gcctgaccgaggtggagtcggccgaccgggagccggtggccatcgtctcg    150 
                     |.||||||||.||.||....||.||.||.||.|||||.||.||.||.... 
AbyB2_CodonOp    101 gtctgaccgaagttgaaagcgcagatcgtgaaccggttgcaattgttagc    150 
 
AbyB2            151 atggcctgccgcttccccggcggggtggcttcgccggaggacctgtggca    200 
                     |||||.||.||.||.||.||.||.||.||....|||||.||.|||||||| 
AbyB2_CodonOp    151 atggcatgtcgttttccaggtggtgttgcaagtccggaagatctgtggca    200 
 
AbyB2            201 gctggtggcgtccggcaccgacgcgatcagcgggttccccgatgaccggg    250 
                     ||||||.||...|||||||||.||.||.|||||.||.||.|||||.||.| 
AbyB2_CodonOp    201 gctggttgcaagcggcaccgatgcaattagcggttttccggatgatcgtg    250 
 
AbyB2            251 gctggccactggacgagctgtacgacccggacccggagcacccgggcacg    300 
                     |.|||||.|||||.||.|||||.||.||.||.|||||.||.|||||.||. 
AbyB2_CodonOp    251 gttggcctctggatgaactgtatgatcctgatccggaacatccgggtaca    300 
 
AbyB2            301 tccaccacccggcaggggggtttcctgcacgacgccgccgacttcgaccc    350 
                     ..||||||.||.||.||.|||||.|||||.||.||.||.||.||.||||| 
AbyB2_CodonOp    301 agcaccacacgtcaaggtggttttctgcatgatgcagcagattttgaccc    350 
 
AbyB2            351 ggagttcttcgggatcagcccccgtgaggcgttgaccatcgacccgcagc    400 
                     |||.||.||.||.||.||.||.|||||.||..|||||||.||.||||||| 
AbyB2_CodonOp    351 ggaattttttggtattagtccgcgtgaagcactgaccattgatccgcagc    400 
 
AbyB2            401 agcggctgctgttggagaccgcctgggaggcggtggagcgggccgggatc    450 
                     ||||.||||||||.||.|||||.|||||.||.||.||.||.||.||.||. 
AbyB2_CodonOp    401 agcgtctgctgttagaaaccgcatgggaagcagttgaacgtgcaggtatt    450 
 
AbyB2            451 gcaccggactcgctgcgtggcagccggaccggcgtgttcgccggggtcat    500 
                     ||||||||....||||||||.|||||.|||||.||.||.|||||.||.|| 
AbyB2_CodonOp    451 gcaccggatagcctgcgtggtagccgtaccggtgtttttgccggtgttat    500 
 
AbyB2            501 gtacggcgactacggtgcccgcctgcgcccgatcccggcgggcttcgagg    550 
                     |||.||.||.||.|||||.||.|||||.|||||.|||||.||.||.||.| 
AbyB2_CodonOp    501 gtatggtgattatggtgcacgtctgcgtccgattccggcaggttttgaag    550 
 
AbyB2            551 ggtacatgggcaccggcagcgcgggcagcgtggccaccggccggatcgcg    600 
                     |.||.|||||||||||.|||||.||.|||||.||||||||.||.||.||. 
AbyB2_CodonOp    551 gttatatgggcaccggtagcgcaggtagcgttgccaccggtcgtattgca    600 
 
AbyB2            601 tacaccctcggcctggaggggccggcggtgagcgtcgacacggcgtgct-    649 
                     ||.|||||.||..|.||.||.|||||.||.|||||.||.||.||.||..  
AbyB2_CodonOp    601 tataccctgggtttagaaggtccggcagttagcgttgataccgcatgtag    650 
 
AbyB2            650 cgtcgtcgctggtggcgctgcacctcgcggcgcaggcgctgcggcgcggc    699 
                     |..|..| |||||.||.|||||.||.||.||.|||||.|||||.|||||. 
AbyB2_CodonOp    651 cagcagc-ctggttgccctgcatctggcagcacaggcactgcgtcgcggt    699 
 
AbyB2            700 gagtgcgacctggcgctggccggcggcgtgacggtcatcgccacgccgga    749 
                     ||.||.||.|||||.|||||.|||||.||.||.||.||.|||||.||||| 
AbyB2_CodonOp    700 gaatgtgatctggcactggcaggcggtgttaccgttattgccacaccgga    749 
 




                     .|||||.||.||.||.|||||.|||||.||..||...|||||.||.||.| 
AbyB2_CodonOp    750 actgtttgttgaatttagccgtcagcgtggtctgagtccggatggtcgtt    799 
 
AbyB2            800 gcaaggcattcgcggcctcggccgacggcacgggctgggccgagggcgtc    849 
                     |.||.|||||.||.|||...||.||.||.||.||.|||||.||.||.||. 
AbyB2_CodonOp    800 gtaaagcatttgcagccagcgcagatggtacaggttgggcagaaggtgtt    849 
 
AbyB2            850 ggcctggtgcttgtcgaacggctcgccgacgcccgccgcaacggtcaccc    899 
                     ||.|||||.||.||.|||||.||.||.||.||.||.||.||.|||||.|| 
AbyB2_CodonOp    850 ggtctggttctggttgaacgtctggcagatgcacgtcgtaatggtcatcc    899 
 
AbyB2            900 ggtgctcgcgctgctgcgcggcagcgccgtcaaccaggacggccgcagca    949 
                     |||.||.||.||||||||.||....||.||.||.|||||.||.||||||| 
AbyB2_CodonOp    900 ggttctggccctgctgcgtggttcagcagttaatcaggatggtcgcagca    949 
 
AbyB2            950 gccagctctccgcgcccaacggcccggcgcagcggcgggtcatccgggcg    999 
                     |||||||...|||.||.||.||.|||||.|||||.||.||.||.||.||. 
AbyB2_CodonOp    950 gccagctgagcgcaccgaatggtccggcacagcgtcgtgtgattcgtgca    999 
 
AbyB2           1000 gcgctggccagtgccggcctggagcccgccgaggtcgacctggtggaggc   1049 
                     ||.|||||.||.||.||.|||||.||.||.||.||.||.|||||.||.|| 
AbyB2_CodonOp   1000 gcactggcaagcgcaggtctggaaccggcagaagttgatctggtagaagc   1049 
 
AbyB2           1050 acacggcaccggcacccggctcggtgacccgatcgaggcccaggcactgc   1099 
                     |||.||.||.||||||||.||.|||||.|||||.||.||||||||.|||| 
AbyB2_CodonOp   1050 acatggtacgggcacccgtctgggtgatccgattgaagcccaggcgctgc   1099 
 
AbyB2           1100 tggccgagtacgggcaggggcgcacggagccgctctggctgggctcgctc   1149 
                     ||||.||.||.||.|||||.||.||.||.|||||.|||||||| |.||.. 
AbyB2_CodonOp   1100 tggcagaatatggtcagggtcgtaccgaaccgctgtggctggg-tagcct   1148 
 
AbyB2           1150 aagtcg-aacatcgggcacacccaggcggcggccggcgtcggcggggtga   1198 
                     .|...| ||.||.||.||.||||||||.||.|||||.||.||.||.||.| 
AbyB2_CodonOp   1149 gaaaagcaatattggtcatacccaggcagcagccggtgttggtggtgtta   1198 
 
AbyB2           1199 tcaaggtggtgcaggccatgcggcacgggctcctgcccgccaccctgcac   1248 
                     |.||.||.||.|||||.|||||.||.||.||.|||||.||.||.|||||. 
AbyB2_CodonOp   1199 ttaaagttgttcaggcaatgcgtcatggtctgctgccagcaacactgcat   1248 
 
AbyB2           1249 gccgacgaggccaccccgcacgtcgactggagcgtcggtgacgtccgtct   1298 
                     |||||.||.|||||.|||||.||.||.||||||||.|||||.||.||||| 
AbyB2_CodonOp   1249 gccgatgaagccacaccgcatgttgattggagcgttggtgatgttcgtct   1298 
 
AbyB2           1299 gctcaccgaggcccgcgactggccggcgcgggagcggccccggcgggcgg   1348 
                     |||.||.||.||.||.||.|||||.||.||.||.||.||.||.||.||.| 
AbyB2_CodonOp   1299 gctgacggaagcacgtgattggcctgcacgtgaacgtccgcgtcgtgcag   1348 
 
AbyB2           1349 ccgtgtcctccttcggcatcagcggcaccaacgcgcacgtgatcctggag   1398 
                     ||||...|..|||.||.||....||||||||.||.||.||.||.|||||. 
AbyB2_CodonOp   1349 ccgttagcagctttggtatttcaggcaccaatgcacatgttattctggaa   1398 
 
AbyB2           1399 gagggcgaccccgacggggtcgccgacgcgccaccggacgacgtgctcgc   1448 
                     ||||||||.||.||.||.||.|||||.||.||.||.||.||.||.||.|| 
AbyB2_CodonOp   1399 gagggcgatccggatggcgtggccgatgcaccgcctgatgatgttctggc   1448 
 
AbyB2           1449 gcgcaagccggtgccggtggtgctgtcggcgcacaccgcgtcggctctcg   1498 
                     .||.||.|||||.|||||.||.|||...||.||.|||||....||.||.| 
AbyB2_CodonOp   1449 acgtaaaccggttccggttgttctgagtgcacataccgcaagcgcactgg   1498 
 
AbyB2           1499 ggccgcaggcggcccggctccgcgcgcacctcgacgcccaccccgacctc   1548 
                     |.||||||||.|||||.||.||.||.||.||.||.||.||.||.||.||. 
AbyB2_CodonOp   1499 gtccgcaggcagcccgtctgcgtgcacatctggatgcacatcctgatctg   1548 
 
AbyB2           1549 acggtggccgacgtcgcgcactcgctggccaccacccgtaccccgctcgc   1598 
                     ||.||.||.||.||.||.||....|||||.|||||.|||||.|||||.|| 
AbyB2_CodonOp   1549 accgttgcagatgttgcacatagcctggcaaccacacgtacaccgctggc   1598 
 




                     |||.||.|||||.||.||.||.|||||.||.|||||.|||||.|||||.| 
AbyB2_CodonOp   1599 cgaacgtgccgttctggtggcagccgatctggacgaactgcgtaccgcac   1648 
 
AbyB2           1649 tggacgccgtcgcggacggcgacgagccgccggtgcgcggcacggccggg   1698 
                     ||||.||.||.||.||.||.||.||.|||||.||.||.|||||.||.||. 
AbyB2_CodonOp   1649 tggatgcagttgccgatggtgatgaaccgcctgttcgtggcaccgcaggt   1698 
 
AbyB2           1699 caccccggcggggtcgtgttcgtcttccccggccagggcgcccagtgggc   1748 
                     ||.||.||.||.||.||.||.||.||.||.||||||||.||.|||||||| 
AbyB2_CodonOp   1699 catcctggtggtgtggtttttgtttttccaggccagggtgcacagtgggc   1748 
 
AbyB2           1749 gggcatggccctggacctgtaccgcgaggacgaggtgttccgcgcggcgc   1798 
                     .||.|||||||||||.|||||.||.||.||.||.||.||.|||||.||.| 
AbyB2_CodonOp   1749 aggtatggccctggatctgtatcgtgaagatgaagtttttcgcgcagccc   1798 
 
AbyB2           1799 tggacgactgcgagcgggccctggccccgcacgtcgactggtcgctgcgg   1848 
                     ||||.||.||.||.||.||||||||.||.||.||.||.|||||.|||||. 
AbyB2_CodonOp   1799 tggatgattgtgaacgtgccctggctcctcatgtggattggtcactgcgt   1848 
 
AbyB2           1849 gccgtgctggccgacgccgacgccctcggacgcgtcgacgtcgtccagcc   1898 
                     ||.||.|||||.||.||.||.||.||.||.||.||.||.||.||.||||| 
AbyB2_CodonOp   1849 gcagttctggcagatgcagatgcactgggtcgtgttgatgttgttcagcc   1898 
 
AbyB2           1899 cgccctgtgggcggtgatggtgtcactggcggcgctgtggcagcaccacg   1948 
                     .||.||||||||.||.|||||....|||||.||.|||||||||||.||.| 
AbyB2_CodonOp   1899 tgcactgtgggcagttatggttagcctggcagcactgtggcagcatcatg   1948 
 
AbyB2           1949 gcgtgacccccgacgcggtcgtcggccactcccagggcgagatcgccgcc   1998 
                     |.||.||.||.||.||.||.||.||.||...||||||.||.||.||.||. 
AbyB2_CodonOp   1949 gtgttacaccggatgcagttgttggtcatagccagggtgaaattgcagca   1998 
 
AbyB2           1999 gcctgtgtcgcgggtgccctgtcgctggagcaggccgcggccgtggtggc   2048 
                     ||.|||||.||.|||||.|||...|||||.|||||.||.|||||.||.|| 
AbyB2_CodonOp   1999 gcatgtgttgccggtgcactgagcctggaacaggcagcagccgttgttgc   2048 
 
AbyB2           2049 gctgcgggcgcgggccatcaccgccgtcgcgggtcgcggtgccatggcgt   2098 
                     .|||||.||.||.|||||.|||||.||.||.|||||.|||||.|||||.. 
AbyB2_CodonOp   2049 cctgcgtgcacgtgccattaccgcagttgcaggtcgtggtgcaatggcaa   2098 
 
AbyB2           2099 cggtttctgtgcccgcacagcagatcaccgagcggtggggcgaccggatc   2148 
                     ..|||...||.||.|||||||||||.|||||.||.|||||.||.||.||. 
AbyB2_CodonOp   2099 gcgttagcgttccggcacagcagattaccgaacgttggggtgatcgtatt   2148 
 
AbyB2           2149 accgtggccgtgacgaactccgccgacgcgacggtcgtcgccggtgaacc   2198 
                     |||||.||.||.||.||...|||.||.||.||.||.||.||.|||||||| 
AbyB2_CodonOp   2149 accgttgcagttaccaatagcgcagatgcaaccgtggttgcgggtgaacc   2198 
 
AbyB2           2199 agaggccgtcgccgaggtggtcgccgcgtacgacgccgagggagtccggg   2248 
                     .||.|||||.|||||.||.||.||.||.||.||.|||||.||.||.||.| 
AbyB2_CodonOp   2199 ggaagccgttgccgaagttgttgcagcatatgatgccgaaggtgttcgtg   2248 
 
AbyB2           2249 cccgggtcctgccggtggactacgcctcccactcggcgcacgtg--gagc   2296 
                     ||||.||.||||||||.||.||.||...|||  ..||||||.||  ||.| 
AbyB2_CodonOp   2249 cccgtgttctgccggttgattatgcaagcca--tagcgcacatgttgaac   2296 
 
AbyB2           2297 ccgtgcgggagccgatcctcgacgcgctgcgcgacctcaccccgaccgag   2346 
                     |.|||||.||.|||||.||.||.||.|||||.||.||.|||||||||||. 
AbyB2_CodonOp   2297 cggtgcgtgaaccgattctggatgcactgcgtgatctgaccccgaccgaa   2346 
 
AbyB2           2347 gcccgggtcccgttccactccaccgtcaccggtgcggagttcgacacccg   2396 
                     ||.||.||.|||||.||...||||||.||||||||.||.||.||.||||| 
AbyB2_CodonOp   2347 gcacgtgttccgtttcatagcaccgttaccggtgcagaatttgatacccg   2396 
 
AbyB2           2397 gggcctgaccgccgactactggtacaccaacctgcgcagcaccgtccggt   2446 
                     .||.||||||||.||.||.|||||.||.||.|||||.||||||||.||.| 
AbyB2_CodonOp   2397 tggtctgaccgcagattattggtatacaaatctgcgtagcaccgtgcgtt   2446 
 




                     |.||.|||||.||.|||||.||.||.||||||||.||.||.||.||.||. 
AbyB2_CodonOp   2447 ttgatcaggcagttacccgtctgcgtgaacagggtcatcgtatttttgtt   2496 
 
AbyB2           2497 gagatcagcccgcatccggtactgacgccggtgctcggcgagggcgcgtt   2546 
                     ||.||.||.|||||||||||.|||||.|||||..|.||.||.||.||.|| 
AbyB2_CodonOp   2497 gaaattagtccgcatccggttctgacaccggttttaggtgaaggtgcatt   2546 
 
AbyB2           2547 cggcacgctgcgccgcgacgagggcgaccgtcgacgtttcatcacgtcac   2596 
                     .|||||.|||||.||.||.||.||.||.|||||.|||||.||.||....| 
AbyB2_CodonOp   2547 tggcaccctgcgtcgtgatgaaggtgatcgtcgtcgttttattaccagcc   2596 
 
AbyB2           2597 tgggtgcggtgcatgccgtgggcgtaccggtggactggtccgccgcgatc   2646 
                     |||||||.||.|||||.||.||.||.||||||||.|||..|||.||.||. 
AbyB2_CodonOp   2597 tgggtgcagttcatgcagttggtgttccggtggattggagcgcagcaatt   2646 
 
AbyB2           2647 ggcccggcgcgccgtgtgcccctgccgacgtacgccttccagcggtcccg   2696 
                     ||.|||||.||.|||||.||.||||||||.||.||.||.|||||...||| 
AbyB2_CodonOp   2647 ggtccggcacgtcgtgttccgctgccgacctatgcatttcagcgtagccg   2696 
 
AbyB2           2697 ctactggctggacgcgcccgcgcggaccggcgacgcatccggggtggggg   2746 
                     .||.||||||||.||.||.||.||.|||||.||.|||..|||.||.||.| 
AbyB2_CodonOp   2697 ttattggctggatgctccggctcgtaccggtgatgcaagcggtgttggtg   2746 
 
AbyB2           2747 tgggcccgaccgaccacccgctgctcggcggtgccgtcgacgtggccggc   2796 
                     |.||.||||||||.||.||||||.|.||.|||||.||.||.||.|||||. 
AbyB2_CodonOp   2747 ttggtccgaccgatcatccgctgttaggtggtgcagttgatgtagccggt   2796 
 
AbyB2           2797 gacggcacgctggtgctcaccgggcggctggtgcccggagcggaccgggc   2846 
                     ||.||.||.|||||.||.|||||.||.|||||.||.||.||.||.||.|| 
AbyB2_CodonOp   2797 gatggtacactggttctgaccggtcgtctggttccgggtgcagatcgtgc   2846 
 
AbyB2           2847 cgccgccgagctgcgggtcggcggcgtacccgtgctgtccggcaccgcgc   2896 
                     .|||||.||.|||||.||.||.||.||.||.||||||..|||||||||.| 
AbyB2_CodonOp   2847 agccgcagaactgcgtgttggtggtgtgccggtgctgagcggcaccgcac   2896 
 
AbyB2           2897 tgctcgacctcgccctacgggcgggcgagctggccggtctgggtgcggtc   2946 
                     ||||.||.||.||.||.||.||.||.||.|||||.|||||||||||.||. 
AbyB2_CodonOp   2897 tgctggatctggctctgcgtgccggtgaactggcaggtctgggtgccgtt   2946 
 
AbyB2           2947 ggcgagttcagcgtggagacgcctttggtgctgtccgccaccgccggttg   2996 
                     ||.||.||.|||||.||.||.||..||||.|||||.||.|||||.||||| 
AbyB2_CodonOp   2947 ggtgaatttagcgttgaaacaccgctggttctgtcagcaaccgcaggttg   2996 
 
AbyB2           2997 gttgcaggtcgtggtggcgccggccggcgccgacggcgaccgggagatcg   3046 
                     |.|||||||.||.|||||.|||||.|||||.||.||.||.||.||.||.| 
AbyB2_CodonOp   2997 gctgcaggttgttgtggcaccggcaggcgcagatggtgatcgtgaaattg   3046 
 
AbyB2           3047 gcgtgtacgcccggcccgaccacgaggcgccctggacccggcacggtcac   3096 
                     |.||.||.||.||.||.||.||.||.||.||.|||||.||.||.|||||. 
AbyB2_CodonOp   3047 gtgtttatgcacgtccggatcatgaagcaccgtggacacgtcatggtcat   3096 
 
AbyB2           3097 ggtgtgctcgtcccggccacggcgcaggacctcccgccgcaccggccggt   3146 
                     ||||||||.||.||.|||||.||.|||||.||.||.|||||.||.||||| 
AbyB2_CodonOp   3097 ggtgtgctggttccagccaccgcacaggatctgcctccgcatcgtccggt   3146 
 
AbyB2           3147 gccgggcgcaccgctcgccccggacgaggcggtggagcggctcgccgcgg   3196 
                     |||.||.||||||||.||.|||||.||.||.||.||.||.||.||.||.| 
AbyB2_CodonOp   3147 gcctggtgcaccgctggcaccggatgaagcagttgaacgtctggcagcag   3196 
 
AbyB2           3197 ccggtgtggaactggcctcggcgcccacggcggtgtccggcgacgccgac   3246 
                     |.|||||.|||||||||...||.||.||.||.||...|||.||.|||||. 
AbyB2_CodonOp   3197 cgggtgttgaactggccagcgcaccgaccgcagttagcggtgatgccgat   3246 
 
AbyB2           3247 gggtacgtcgccgacctcgcgtcgccgccggagggacgcttcacgctgca   3296 
                     ||.||.||.||.||.||.||....||.|||||.||.||.||.||.||||| 
AbyB2_CodonOp   3247 ggttatgttgcagatctggcaagccctccggaaggtcgttttaccctgca   3296 
 




                     .||.||||||||.||.||.||||||.|.||.||.||.|||||.||.||.| 
AbyB2_CodonOp   3297 tcctgcgctgctggatgcagccctgttaccggcatttggccgtggtgatg   3346 
 
AbyB2           3347 cccggctgccgagccggtggcgcggggtacggctgccgcagccggacggc   3396 
                     |.||.|||||||||||.|||||.||.||.||.|||||.||||||||.||. 
AbyB2_CodonOp   3347 cacgtctgccgagccgttggcgtggtgttcgtctgcctcagccggatggt   3396 
 
AbyB2           3397 cagccgacccgcgcgtcggtacgccgccgcgacggcgactcgtgggccgt   3446 
                     ||||||||.||.||....||.||.|||||.||.||.||....|||||.|| 
AbyB2_CodonOp   3397 cagccgacacgtgcaagcgtgcgtcgccgtgatggtgatagctgggcagt   3446 
 
AbyB2           3447 gtcgctgaccgactccgccggtgcgccggtggtcgagatcgccgaggtgg   3496 
                     |...||||||||...|||.||.||.||||||||.||.||.||.||.||.| 
AbyB2_CodonOp   3447 gagcctgaccgatagcgcaggcgcaccggtggttgaaattgcggaagttg   3496 
 
AbyB2           3497 tgctgggtccggtgccggtggtgtcggccgccgggcaccacgaccccctg   3546 
                     ||||||||||.||.|||||.||....||.||.||.||.||.||.||.||| 
AbyB2_CodonOp   3497 tgctgggtcctgttccggttgttagcgcagcaggtcatcatgatcctctg   3546 
 
AbyB2           3547 ttcacgctggagtgggcccccgtggcccggccccggggtgccgccgcaac   3596 
                     ||.||.|||||.|||||.||.||.||.||.||.||.|||||.||.||.|| 
AbyB2_CodonOp   3547 tttaccctggaatgggcacctgttgcgcgtccgcgtggtgcagcagccac   3596 
 
AbyB2           3597 cgagccggtgccgcacgagctgcccggcgacgccggtcccgccgcgctgg   3646 
                     |||.||.||.|||||.||..|.||.||.||.||.|||||.||.||.|||| 
AbyB2_CodonOp   3597 cgaacctgttccgcatgaattaccgggtgatgcgggtcctgcagcactgg   3646 
 
AbyB2           3647 ccgtgcttcgcggcgggctggccgagccggacgggccgcgccaggtggtg   3696 
                     ||||.||.||.||.||.|||||.||.||.||.||.|||||.|||||.||. 
AbyB2_CodonOp   3647 ccgttctgcgtggtggtctggcagaacctgatggtccgcgtcaggttgtt   3696 
 
AbyB2           3697 gtggcccgcggggcgggcacggtgacgggtctggtccggtgcgcgcaact   3746 
                     ||.||.||.||.||.|||||.||.||.||||||||.||.||.||.||.|| 
AbyB2_CodonOp   3697 gttgcacgtggtgcaggcaccgttaccggtctggttcgttgtgcacagct   3746 
 
AbyB2           3747 ggaggagcccgggcgggtcggcctcgtcgagtgggacgggcgcgacgccg   3796 
                     |||.||.||.||.||.||.||.||.||.||.|||||.||.||.||.||.| 
AbyB2_CodonOp   3747 ggaagaaccgggtcgtgttggtctggttgaatgggatggtcgtgatgcag   3796 
 
AbyB2           3797 acgcgctgcgcgacgccgtggccgccgggctgccgcaggtggcggtccat   3846 
                     |.||.|||||.||.|||||.||.||.||.|||||||||||.||.||.||| 
AbyB2_CodonOp   3797 atgcactgcgtgatgccgttgcagcaggtctgccgcaggttgcagttcat   3846 
 
AbyB2           3847 ggtgcggagctgcgtacgccccggctcgcgccgctcaccgcgccgggccg   3896 
                     |||||.||.||||||||.||.||.||.||.|||||.|||||.||.||.|| 
AbyB2_CodonOp   3847 ggtgcagaactgcgtacaccgcgtctggcaccgctgaccgcacctggtcg   3896 
 
AbyB2           3897 ccccgtcgagttggacggcacggccctgatcgtcggggaggccggagcgc   3946 
                     .||.||.||..||||.|||||.||.|||||.||.||.||.|||||.|||| 
AbyB2_CodonOp   3897 tccggttgaactggatggcaccgcactgattgttggtgaagccggtgcgc   3946 
 
AbyB2           3947 tgcgcgacgccgtgctgcgcacgctggcgcgccacggcgtggaccggctg   3996 
                     ||||.|||||.||.|||||.||.|||||.||.||.||.||.||.||.||| 
AbyB2_CodonOp   3947 tgcgtgacgcggttctgcgtaccctggcacgtcatggtgttgatcgtctg   3996 
 
AbyB2           3997 gtggtggtggacgtggacggcacggcaccagccgacgtgggcgtacccac   4046 
                     ||.|||||.||.||.||.||.||.|||||.||.||.||.||.||.||.|| 
AbyB2_CodonOp   3997 gttgtggttgatgttgatggtacagcaccggcagatgttggtgttccgac   4046 
 
AbyB2           4047 cgaggtgctcaccggtgatcccaccgaccgtgccgtgctcgccgaggcgg   4096 
                     |||.||.||.|||||||||||.||.||.|||||.||.||.|||||.||.| 
AbyB2_CodonOp   4047 cgaagttctgaccggtgatccgacagatcgtgcagttctggccgaagccg   4096 
 
AbyB2           4097 tccaccgcgccgcgaacctgcgcacggtcgtgcacgccgtgcagcccacg   4146 
                     |.||.||.||.||.||.||||||||.||.||.||.||.||.|||||.||. 
AbyB2_CodonOp   4097 ttcatcgtgcagcaaatctgcgcaccgttgttcatgcagttcagccgaca   4146 
 




                     |||||.||.||||||||.||.|||||.||.||.||.||.||.||.||||| 
AbyB2_CodonOp   4147 gccgatgcaccgctggcagcactgagtccggaagatctgacagcactggt   4196 
 
AbyB2           4197 cgagcggatcgtggcgccggcccggcacctgcacgaactgaccgcgcacc   4246 
                     .||.||.||.||.||.|||||.||.||.||||||||||||||.||.||.| 
AbyB2_CodonOp   4197 tgaacgtattgttgcaccggcacgccatctgcacgaactgacagcccatc   4246 
 
AbyB2           4247 tgccgctgacccggttcgtgctgtccggctcggcggcgggtgtgctgggc   4296 
                     ||||||||||.||.||.||.|||..|||....||.||.|||||..|.||. 
AbyB2_CodonOp   4247 tgccgctgacacgttttgttctgagcggtagcgcagccggtgttttaggt   4296 
 
AbyB2           4297 ggcatcgggcaggccgccgtggcggcggccaccaccgggttgggcgcgct   4346 
                     ||.||.||.|||||.||.||.||.||.||.|||||.||..||||.||.|| 
AbyB2_CodonOp   4297 ggtattggtcaggcagcagttgcagccgcaaccacaggtctgggtgcact   4346 
 
AbyB2           4347 cgcggcccgccgtcgcgccgacgggctgcccgcccaggtcgtcgcctggg   4396 
                     .||.|||||.|||||.|||||.||.|||||.||.|||||.||.||.|||| 
AbyB2_CodonOp   4347 ggcagcccgtcgtcgtgccgatggtctgcctgcacaggttgtggcatggg   4396 
 
AbyB2           4397 gtccgtcggccggcacccgccggctcgggctggtgtccctcgacgacgcc   4446 
                     |||||...||.||||||||.||..|.||.||||||..|||.||.||.||. 
AbyB2_CodonOp   4397 gtccgagcgcaggcacccgtcgtttaggtctggtgagcctggatgatgct   4446 
 
AbyB2           4447 cgcctggccgcactgttcgcgcaggtcttggcgcacgacgtcgacgtggt   4496 
                     ||||||||.||.|||||.||.|||||..||||.||.||.||.||.||.|| 
AbyB2_CodonOp   4447 cgcctggcagcgctgtttgcccaggttctggcacatgatgtggatgttgt   4496 
 
AbyB2           4497 ggccgcgcccctggtccgggcggggctgcgggggcaggcgcgggcgggca   4546 
                     .|||||.||.|||||.||.||.||.|||||.||.||.||.||.||.||.| 
AbyB2_CodonOp   4497 tgccgctccgctggttcgtgccggtctgcgtggtcaagcacgtgcaggta   4546 
 
AbyB2           4547 cgctgcccgtggcgctgcgggccctcgtgccggcgctgcccggcggtgcc   4596 
                     |.|||||.||.||.|||||.||.||.||.|||||.|||||.||.|||||. 
AbyB2_CodonOp   4547 cactgccggttgctctgcgtgctctggttccggcactgcctggtggtgca   4596 
 
AbyB2           4597 accggcctggcggcccggctggccggcgcctcccccgccgaggggcgccg   4646 
                     ||.||..|.||.||.||.|||||.|||||....||.||.||.||.||.|| 
AbyB2_CodonOp   4597 actggtttagcagcacgtctggcaggcgcaagtccggcagaaggtcgtcg   4646 
 
AbyB2           4647 tctgctgctggacaccatccgtacccatgtcgccggggtgctgggccacg   4696 
                     ||||||||||||.|||||.|||||||||||.|||||.||.|||||.||.| 
AbyB2_CodonOp   4647 tctgctgctggataccattcgtacccatgttgccggtgttctgggtcatg   4696 
 
AbyB2           4697 acgacgccagcggcatcgacgagcgccgcgccttcaaggacctcgggttc   4746 
                     |.||.||.|||||.||.||.||.||.||.||.||.||.||.||.||.||. 
AbyB2_CodonOp   4697 atgatgcaagcggtattgatgaacgtcgtgcatttaaagatctgggtttt   4746 
 
AbyB2           4747 gactcgctcaccgccatcgagctgcgcaaccgtctcaacaccgcgctggg   4796 
                     ||....||.|||||.||.||.||||||||.|||||.||.|||||.||||| 
AbyB2_CodonOp   4747 gatagcctgaccgcaattgaactgcgcaatcgtctgaataccgcactggg   4796 
 
AbyB2           4797 gcggaccctgcccgcgacgctgatcttcgaccaccccagtcccggcgctc   4846 
                     .||.||||||||.||.||.|||||.||.||.||.||.|||||.||.||.| 
AbyB2_CodonOp   4797 tcgtaccctgcctgcaacactgatttttgatcatccgagtccgggtgcgc   4846 
 
AbyB2           4847 tggccgaacacctgcgcgacgacctgctcggccgtgccgccgtggccgct   4896 
                     ||||||||||.|||||.||.||.|||||.||.|||||.|||||.|||||. 
AbyB2_CodonOp   4847 tggccgaacatctgcgggatgatctgctgggtcgtgcagccgttgccgca   4896 
 
AbyB2           4897 gccccggtggcggtcgccagcgacgaaccgatcgccatcgtcgcgatggg   4946 
                     ||.|||||.|||||.||....||.||||||||.||.||.||.||.||||| 
AbyB2_CodonOp   4897 gcaccggttgcggttgcatcagatgaaccgattgcaattgttgcaatggg   4946 
 
AbyB2           4947 ctgccgctatccgggcggcatcgccgaccccgaggcgttgtggcaggcgg   4996 
                     .||.||.|||||.||.|||||.||.||.||.||.||..||||||||||.| 
AbyB2_CodonOp   4947 ttgtcgttatcctggtggcattgcagatccggaagcactgtggcaggcag   4996 
 




                     |.||....||.||.||.||.||.||.|||||.||.|||||.||.||.||| 
AbyB2_CodonOp   4997 ttgttagcgagctggatgcagttggtccgtttcctaccgatcgtggttgg   5046 
 
AbyB2           5047 ccggcggacctgtacgaccccgacccggaggccaccggccgcacgtacgc   5096 
                     ||.||.||.|||||.||.||.||.||.||.||.|||||.||.||.||.|| 
AbyB2_CodonOp   5047 cctgcagatctgtatgatcctgatcctgaagcaaccggtcgtacctatgc   5096 
 
AbyB2           5097 gcgtgagggcggcttcctctacgacgccgccgggttcgacccggaattct   5146 
                     .|||||.||.||.||.||.||.|||||.||.||.||.||.||||||||.| 
AbyB2_CodonOp   5097 acgtgaaggtggttttctgtatgacgcagcaggttttgatccggaatttt   5146 
 
AbyB2           5147 tcggcatcagcccccgcgaggccaccggcatggacccgcagcagcggctg   5196 
                     |.||.||.||.||.||.||.||||||||.|||||.|||||||||||.||| 
AbyB2_CodonOp   5147 ttggtattagtccgcgtgaagccaccggtatggatccgcagcagcgtctg   5196 
 
AbyB2           5197 ctgctgcagaccggctgggaggtgttcgagcgggccgggatcgaccccac   5246 
                     .|.|||||||||||.|||||.||.||.||.||.||.||.||.||.||.|| 
AbyB2_CodonOp   5197 ttactgcagaccggttgggaagtttttgaacgtgcgggtattgatccgac   5246 
 
AbyB2           5247 ggcgctgcgcggcagccgtaccggggtcttcgcgggggtcgtctacaccg   5296 
                     .||..|.||.||.|||||||||||.||.||.|||||.||.||.||.|||| 
AbyB2_CodonOp   5247 cgcattacgtggtagccgtaccggtgtgtttgcgggtgttgtttataccg   5296 
 
AbyB2           5297 actacggctcccgggccgacccgatccccgccgacctggagggatacctc   5346 
                     |.||.||.||.||.|||||.|||||.||.||.||.|||||.||.||..|. 
AbyB2_CodonOp   5297 attatggttcacgtgccgatccgattccggcagatctggaaggttattta   5346 
 
AbyB2           5347 ggcatcggcagcgccggcagcatcgcctccggccgcatcgcctacaccct   5396 
                     ||.||.||.||.||.||.|||||.||...|||.||.||.||.||.||||| 
AbyB2_CodonOp   5347 ggtattggtagtgcaggtagcattgcgagcggtcgtattgcatataccct   5396 
 
AbyB2           5397 cggcctggagggcccggcggtcaccgtggacaccgcgtgct-cctcgtcg   5445 
                     .||..|.||.||.|||||.||.|||||.||.|||||.||.. |..|..|  
AbyB2_CodonOp   5397 gggtttagaaggtccggcagttaccgttgataccgcatgtagcagcagc-   5445 
 
AbyB2           5446 ctggtggcgctgcacctggccgtgcagtcgctgcgccgcggcgagtgcga   5495 
                     |||||.||.|||||.|||||.||.|||...|||||.||.||.||.||.|| 
AbyB2_CodonOp   5446 ctggttgcactgcatctggcagttcagagcctgcgtcgtggtgaatgtga   5495 
 
AbyB2           5496 cctggccctggcgggcggtgcgacggtgctgtccaacccggacatcttcg   5545 
                     .|||||..|.||.||.|||||.||.||.|||..|||.|||||.||.||.| 
AbyB2_CodonOp   5496 tctggcattagccggtggtgccaccgttctgagcaatccggatatttttg   5545 
 
AbyB2           5546 tcggcttctcgcgccagcggggcctgtccccggacagccgttgcaaggcg   5595 
                     |.||.||....||.|||||.||.|||...|||||.||||||||.||.||. 
AbyB2_CodonOp   5546 ttggttttagccgtcagcgtggtctgagtccggatagccgttgtaaagca   5595 
 
AbyB2           5596 ttcgccgccgccgccgacggcaccgccttcgccgagggtgtcggcctgct   5645 
                     ||.||.||.||.|||||.||||||||.||.|||||.|||||.||.||||| 
AbyB2_CodonOp   5596 tttgcagcagcagccgatggcaccgcatttgccgaaggtgttggtctgct   5645 
 
AbyB2           5646 gctggtgcagcggctcgccgacgcgcggcgcgatggtcggccggtgctgg   5695 
                     ||||||.|||||.||.||.||.||.||.||.||||||||.|||||.|||| 
AbyB2_CodonOp   5646 gctggttcagcgtctggcagatgcacgtcgtgatggtcgtccggttctgg   5695 
 
AbyB2           5696 ccgtcatccggggcaccgccatcaaccaggacggcgcgtccaacgggctc   5745 
                     |.||.||.||.|||||||||||.||.|||||.||.||...|||.||.||. 
AbyB2_CodonOp   5696 cagttattcgtggcaccgccattaatcaggatggtgcaagcaatggtctg   5745 
 
AbyB2           5746 accgcacccaacgggccgtcgcagcagcgggtcatcctgggtgcgctggc   5795 
                     ||||||||.||.||.|||...||||||||.||.||.||||||||.||||| 
AbyB2_CodonOp   5746 accgcaccgaatggtccgagccagcagcgtgttattctgggtgcactggc   5795 
 
AbyB2           5796 cgacgcggggctgcgcccgtccgacgtcgacgtggtggaggcgcacggca   5845 
                     |||.||.||.|||||.|||...||.||.||.||.||.||.||.||.|||| 
AbyB2_CodonOp   5796 cgatgcaggtctgcgtccgagtgatgttgatgttgttgaagcacatggca   5845 
 




                     ||||.||.||||||||.||.|||||.||.||.|||||.||.||.||.||| 
AbyB2_CodonOp   5846 ccggtacaaccctgggtgatccgattgaagcccaggcaattattgcaacc   5895 
 
AbyB2           5896 tacgggcagggccgcgacgagccgctgctgctcggctcgctgaagtcgaa   5945 
                     ||.||.|||||.||.||.||.|||||||||.|.||....|||||....|| 
AbyB2_CodonOp   5896 tatggtcagggtcgtgatgaaccgctgctgttaggtagcctgaaaagcaa   5945 
 
AbyB2           5946 catcggccacacccaggccgcagccggtgtcggcggcgtgatcaagatgg   5995 
                     .||.||.||.||||||||.||.||.||.||.||.||.|||||.||.|||| 
AbyB2_CodonOp   5946 tattggtcatacccaggcagccgcaggcgttggtggtgtgattaaaatgg   5995 
 
AbyB2           5996 tcgccgccatgcgacacgggctggtgccccggaccctgcacgtcgacgag   6045 
                     |.||.||.|||||.||.||.|||||.||.||.||.|||||.||.||.||. 
AbyB2_CodonOp   5996 ttgcagcaatgcgtcatggtctggttccgcgtacactgcatgtggatgaa   6045 
 
AbyB2           6046 ccgaccccgcacgtggactggtcggcgggtgcggtccggctggtcaccga   6095 
                     |||||.|||||.||.||.|||...||.|||||.||.||.|||||.||||| 
AbyB2_CodonOp   6046 ccgacaccgcatgttgattggagtgccggtgcagttcgtctggttaccga   6095 
 
AbyB2           6096 ggcgcggccctggccggagtcgaaccggccgcgccgcgccggggtgtcct   6145 
                     .||.||.||.|||||.||....||.||.|||||.||.|||||.||...|. 
AbyB2_CodonOp   6096 agcacgtccgtggccagaaagcaatcgtccgcgtcgtgccggtgttagca   6145 
 
AbyB2           6146 cgttcggcatgagcggcacgaacgcccacgtcgtcgtcgagcagggcgac   6195 
                     ..||.||.|||||||||||.||.||.||.||.||.||.||.||||||||. 
AbyB2_CodonOp   6146 gctttggtatgagcggcaccaatgcacatgttgttgtggaacagggcgat   6195 
 
AbyB2           6196 ccgctcgaggtgccgccggtgcgcgccggccgcctcgtaccggtgccggt   6245 
                     |||||.||.||.|||||.||.||.||.||.|||||.||.|||||.||||| 
AbyB2_CodonOp   6196 ccgctggaagttccgcctgttcgtgcaggtcgcctggttccggttccggt   6245 
 
AbyB2           6246 gtccgccgccaacccggcggcgctgcgccgacaggccgcccgtctgctcc   6295 
                     |..|||.||.||.|||||.||.|||||.||.|||||.||.||||||||.| 
AbyB2_CodonOp   6246 gagcgcagcaaatccggcagcactgcgtcgtcaggcagcacgtctgctgc   6295 
 
AbyB2           6296 ccgccgtggccgaccggcatcccgccgacgtggcccgtaccctcgcggcc   6345 
                     |.||.||.||.||.||.|||||.||.||.||.||.||||||||.||.||| 
AbyB2_CodonOp   6296 cagcagttgcagatcgtcatccggcagatgttgcacgtaccctggcagcc   6345 
 
AbyB2           6346 cgcacctccctcgccacccgggccgtcgtgctcgcggacgacgccgacga   6395 
                     ||.|||..|||.||.|||||.||.||.||.||.|||||.||.||.||.|| 
AbyB2_CodonOp   6346 cgtaccagcctggcaacccgtgcagttgttctggcggatgatgcagatga   6395 
 
AbyB2           6396 gctggccgagggcctacgggcgctggacgacgcgacgttcaccggtccgg   6445 
                     .||||||||.|||||.||.||.|||||.||.||.||.||.|||||||||| 
AbyB2_CodonOp   6396 actggccgaaggcctgcgtgcactggatgatgccacctttaccggtccgg   6445 
 
AbyB2           6446 tgggcgacgccgacgagccgggcaaggtggtcttcgtcttccccgggcag   6495 
                     |.||.||.||||||||.|||||.||.||.||.||.||.||.||.||.||. 
AbyB2_CodonOp   6446 ttggtgatgccgacgaaccgggtaaagttgtttttgtttttcctggtcaa   6495 
 
AbyB2           6496 ggcgggcagtggaccggcatggctctggacctgtaccgcgacgagcccac   6545 
                     ||.||.|||||||||||.|||||.|||||.|||||.||.||.|||||.|| 
AbyB2_CodonOp   6496 ggtggtcagtggaccggtatggcactggatctgtatcgtgatgagccgac   6545 
 
AbyB2           6546 cttccgcgagtccctggacgcctgcgccgccgcgctggcaccgcacgtgg   6595 
                     |||.||.||...||||||.||.||.||.||.||.||||||||.||.|||| 
AbyB2_CodonOp   6546 ctttcgtgaaagcctggatgcatgtgcagcggcactggcacctcatgtgg   6595 
 
AbyB2           6596 actgggcgttgctcgacgtgctcgccgacgaggaggccctgcggcgggtg   6645 
                     |.|||||..||||.||.||.||.||||||||.||.||||||||.||.||. 
AbyB2_CodonOp   6596 attgggcactgctggatgttctggccgacgaagaagccctgcgtcgcgtt   6645 
 
AbyB2           6646 gacgtcgtgcagcccgcgctctgggcggtgatggtgtcggtggcccggct   6695 
                     ||.||.||.|||||.||.||.|||||.||.|||||....||.||.||.|| 
AbyB2_CodonOp   6646 gatgtggttcagcctgcactgtgggcagttatggttagcgttgcacgcct   6695 
 




                     .||||||||.||.||.||.||.||.||.|||||.||.||.||...||||| 
AbyB2_CodonOp   6696 gtggcagcatcatggtgttacaccggatgcggttgtgggtcatagccagg   6745 
 
AbyB2           6746 gtgagatcgccgccgcccacgtggccggcgcgctcagcctggccgacgcc   6795 
                     ||||.||.||.||.|||||.||.|||||.|||||.||||||||.||.||| 
AbyB2_CodonOp   6746 gtgaaattgcagctgcccatgttgccggtgcgctgagcctggctgatgcc   6795 
 
AbyB2           6796 gccgccgtggtggcgctgcgggccagggcgatcacggcgatcgccgggac   6845 
                     ||.||.||.||.||.|||||.|||.|.||.||.||.||.||.||.||.|| 
AbyB2_CodonOp   6796 gcagcagttgttgcactgcgtgcccgtgcaattaccgcaattgcaggcac   6845 
 
AbyB2           6846 cggcggcatggcctcggtcgcactcggtgtcggagaggtcacccggcgct   6895 
                     |||.||.|||||....||.|||.|.|||||.||.||.||.|||||.||.| 
AbyB2_CodonOp   6846 cggtggtatggcaagcgttgcattaggtgtgggtgaagttacccgtcgtt   6895 
 
AbyB2           6896 ggggccacacggtggccgtcgccgcgaccaacggtccggacaccgcggtg   6945 
                     ||||.||.||.||.||.||.|||||.||.||.||||||||.|||||.||. 
AbyB2_CodonOp   6896 ggggtcataccgttgcagttgccgcaacaaatggtccggataccgcagtt   6945 
 
AbyB2           6946 atcgccggcgacccgggcgtgctggaccacatcgccgccacgtgtgccgc   6995 
                     ||.|||||.||.|||||.||.|||||.||.||.||.||.||.|||||.|| 
AbyB2_CodonOp   6946 attgccggtgatccgggtgttctggatcatattgcagcaacctgtgcagc   6995 
 
AbyB2           6996 cgaggaggtccgggtgaagatcctgccggtcgactacgcctcacactccg   7045 
                     .||.||.||.||.||.||.||.||||||||.||.||.||....||...|| 
AbyB2_CodonOp   6996 agaagaagttcgcgttaaaattctgccggttgattatgcaagccatagcg   7045 
 
AbyB2           7046 cgcacgtggaggcactgcgtgaggaactgctggctgcgttggagaccgtg   7095 
                     |.||.|||||.||.||||||||.||||||.|.||.||..||||.|||||. 
AbyB2_CodonOp   7046 cacatgtggaagcgctgcgtgaagaactgttagccgcactggaaaccgtt   7095 
 
AbyB2           7096 caaccccgggccgccgagatcgcgttctgttccacggtcaccgccgaggc   7145 
                     ||.||.||.||.|||||.||.||.||.|||..|||.||.|||||.||.|| 
AbyB2_CodonOp   7096 cagcctcgtgcagccgaaattgcattttgtagcaccgttaccgcagaagc   7145 
 
AbyB2           7146 gctggacaccaccacgctcacggccgactactggtacacgaacctgcgca   7195 
                     .|||||.||||||||.||.||.||.||.||.|||||.||.||.|||||.| 
AbyB2_CodonOp   7146 actggataccaccacactgacagcagattattggtatacaaatctgcgta   7195 
 
AbyB2           7196 gcaccgtgcgctacgacgagacggtccgccggctgcacgccgaggggcac   7245 
                     |.|||||.||.||.||.||.||.||.||.||.|||||.||.||.||.||. 
AbyB2_CodonOp   7196 gtaccgtccgttatgatgaaaccgtgcgtcgtctgcatgcggaaggtcat   7245 
 
AbyB2           7246 cgcacctttctggagatgagccctcacccggtgctgaccaccgtcaccga   7295 
                     ||.|||||||||||.|||||||||||.|||||||||||||||||.||.|| 
AbyB2_CodonOp   7246 cgtacctttctggaaatgagccctcatccggtgctgaccaccgttacaga   7295 
 
AbyB2           7296 gcaggtcaccggggcggtcgcgctgggcacgctgcgccgggacgagggcg   7345 
                     .|||||.|||||.||.||.||.|||||.||||||||.||.|||||.||.| 
AbyB2_CodonOp   7296 acaggtgaccggtgccgttgcactgggtacgctgcgtcgtgacgaaggtg   7345 
 
AbyB2           7346 accgccgccgcttcctcaccgcgctggccgaggcgtacgtgaccggcgtg   7395 
                     |.||.||.||.||.||.||.||.||||||||.||.||.||||||||.||. 
AbyB2_CodonOp   7346 atcgtcgtcgttttctgacagcactggccgaagcatatgtgaccggtgtt   7395 
 
AbyB2           7396 gcggtggactggcgtccggccgtgggcgccgacgcacggctggtggacct   7445 
                     ||.||.||.|||||||||||.||.||.||.||.|||||.|||||.||.|| 
AbyB2_CodonOp   7396 gcagttgattggcgtccggcagttggtgcagatgcacgtctggttgatct   7445 
 
AbyB2           7446 gcccacgtatgcgttcgccagcgaccgctactggctcgacgcgacgacgc   7495 
                     |||.||.|||||.||.||.|||||.||.||.|||||.||.||.||.||.| 
AbyB2_CodonOp   7446 gccgacctatgcatttgcaagcgatcgttattggctggatgcaaccacac   7495 
 
AbyB2           7496 ggccggtcgacgccaccgggctcgggctggctgccaccgcgcacccactg   7545 
                     |.|||||.||.||.|||||.||.||..|.||.||.|||||.||.||.||| 
AbyB2_CodonOp   7496 gtccggtggatgcgaccggtctgggtttagcagcaaccgcacatccgctg   7545 
 




                     ||.||.||.|||||.||.|||||.||.||.||.||.||.|||||.||||| 
AbyB2_CodonOp   7546 ctgggtgcagccgttgatctggcagatgatgaaggtgttctgctgaccgg   7595 
 
AbyB2           7596 ccgactgtcgctcgacagccacccgtggctggccgaccacacggtggcgg   7645 
                     .||.|||...||.||.|||||.|||||||||||.||.||.||.||.||.| 
AbyB2_CodonOp   7596 tcgtctgagcctggatagccatccgtggctggcagatcataccgttgccg   7645 
 
AbyB2           7646 gcgtgccgttgctgccgggcgcggcgttcgtcgagctgtgcgcccaggcc   7695 
                     |.||||||.|||||||.||.||.||.||.||.||.|||||.||.|||||. 
AbyB2_CodonOp   7646 gtgtgccgctgctgcctggtgcagcatttgttgaactgtgtgcacaggca   7695 
 
AbyB2           7696 gcggaggccgccggcgctgccggggtggcggagctgaccctggagacgcc   7745 
                     ||.||.||.|||||.||.||.||.||.||.||.|||||||||||.||.|| 
AbyB2_CodonOp   7696 gccgaagcagccggtgcagcgggtgttgccgaactgaccctggaaacccc   7745 
 
AbyB2           7746 ctgcgtgctgcccgagcgcgggggcgtggacgtgcaggtccaggtccgcg   7795 
                     .||.||.|||||.||.||.||.||.||.||.||.|||||.|||||.||.| 
AbyB2_CodonOp   7746 gtgtgttctgccggaacgtggtggtgttgatgttcaggttcaggtgcgtg   7795 
 
AbyB2           7796 acggcgggctgcgcgtgtactcgcgcagcgtcggcgacgcctgggtacgc   7845 
                     |.||.||.|||||.||.||....||.|||||.||.||.||.|||||.||. 
AbyB2_CodonOp   7796 atggtggtctgcgtgtttatagccgtagcgttggtgatgcatgggttcgt   7845 
 
AbyB2           7846 aacgcctccggcgtcctgcttcccaccgagccgcccgcgccggccggttg   7895 
                     ||.||...|||.||.|||||.||.|||||.||.||.||.|||||.||||| 
AbyB2_CodonOp   7846 aatgcaagcggtgtactgctgccgaccgaacctccggcaccggcaggttg   7895 
 
AbyB2           7896 gggcgcctggccgccacccggggcgcaggccgtcgacgtcgagggcctgt   7945 
                     |||.||.|||||.||.||.||.||||||||.||.||.||.||.||.|||| 
AbyB2_CodonOp   7896 gggtgcatggcctcctccgggtgcgcaggcagttgatgttgaaggtctgt   7945 
 
AbyB2           7946 acccgcagctggccgcgtccggctacgggtacggcccggccttccggggg   7995 
                     |.|||||||||||.||...|||.||.||.||.||.|||||.||.||.||. 
AbyB2_CodonOp   7946 atccgcagctggcagcaagcggttatggttatggtccggcatttcgtggc   7995 
 
AbyB2           7996 ctgcgggccgcctggcggcgcggcgaggaggtcttcgccgaggtccggct   8045 
                     |||||.||.||||||||.||.||.||.||.||.||.||.||.||.||.|| 
AbyB2_CodonOp   7996 ctgcgtgcagcctggcgtcgtggtgaagaagtttttgcagaagttcgcct   8045 
 
AbyB2           8046 gcccgagggcctcgaaccggaggggtacggtctgcacccggcgctgctcg   8095 
                     |||.||.||.||.||||||||.||.||.||.|||||.|||||.|||||.| 
AbyB2_CodonOp   8046 gccggaaggtctggaaccggaaggttatggcctgcatccggcactgctgg   8095 
 
AbyB2           8096 acgcggccctgcacgcgctggcgttcggggacttcctcggcgcgggtgtc   8145 
                     |.||.||.|||||.||.|||||.||.||.||.||..|.||.||.|||||. 
AbyB2_CodonOp   8096 atgccgcactgcatgcactggcatttggtgattttttaggtgccggtgtt   8145 
 
AbyB2           8146 cgcctgccgttcgccttcaccggcgtacgggtgttcgccaccggcgccga   8195 
                     ||.||||||||.||.||.|||||.||.||.||.||.||.|||||.||.|| 
AbyB2_CodonOp   8146 cgtctgccgtttgcatttaccggtgtgcgtgtttttgcaaccggtgcaga   8195 
 
AbyB2           8196 catcctgcgcgtacggctcagcccgcggggcgaggacaccgtggcggtgg   8245 
                     .||.|||||.||.||.||.||.|||||.|||||.||.||||||||.||.| 
AbyB2_CodonOp   8196 tattctgcgtgtgcgtctgagtccgcgtggcgaagataccgtggcagttg   8245 
 
AbyB2           8246 cgctggcggactccaccggggcaccggtcgccgagatcgagtcgctggtg   8295 
                     |.|||||.||...|||.||.||||||||.||.||.||.||....|||||. 
AbyB2_CodonOp   8246 ccctggcagatagcacaggtgcaccggtggcagaaattgaaagcctggtt   8295 
 
AbyB2           8296 ctgcgcgcggcaccgtccctggaggccaccgcgccgcacgcccccgacgt   8345 
                     |||||.||.||||||..||||||.||.||.||.|||||.||.||.||.|| 
AbyB2_CodonOp   8296 ctgcgtgccgcaccgagcctggaagcgacagcaccgcatgcaccggatgt   8345 
 
AbyB2           8346 gctggtcctcgactggaccccactggccctgccggacaccccggtgaccg   8395 
                     .|||||.||.||.|||||.||.|||||.||||||||.||.|||||.|||| 
AbyB2_CodonOp   8346 tctggttctggattggacaccgctggcactgccggatacaccggttaccg   8395 
 




                     |||||||.||||||||.||.||||||...|||||.||.||.|||||.||. 
AbyB2_CodonOp   8396 aaccggatctgctggttgttgcaccgagtgatgcacatgatccggttgca   8445 
 
AbyB2           8446 gccaccggccggctggtgacgtccacgatcgccgaactcgccggccggct   8495 
                     ||||||||.||.|||||.||...|||.||.||.|||||.||.||.||.|| 
AbyB2_CodonOp   8446 gccaccggtcgcctggttaccagcaccattgcagaactggcaggtcgtct   8495 
 
AbyB2           8496 ggccgacgaccggggcgcggtcgtcgtgacccgcgacgcggtggccgtgc   8545 
                     ||||||.||.||.||.||.||.||.||.|||||.||.||.||.||.||.| 
AbyB2_CodonOp   8496 ggccgatgatcgtggtgcagttgttgttacccgtgatgcagttgcagttc   8545 
 
AbyB2           8546 gccccggcgatcctgccgccgacctggcgcacgccgccctgtggggcctg   8595 
                     |.||.||.||||||||.||.||.|||||.||.||.||.||||||||.||| 
AbyB2_CodonOp   8546 gtccgggtgatcctgcagcagatctggcacatgcagcactgtggggtctg   8595 
 
AbyB2           8596 ctgcgcagcgcgcagacggagaacccggaccggttcacgctcgtcgacac   8645 
                     |||||.||.||.|||||.||.||.|||||.||.||.||.||.||.||.|| 
AbyB2_CodonOp   8596 ctgcgtagtgcacagaccgaaaatccggatcgttttaccctggttgatac   8645 
 
AbyB2           8646 cgacgggcggcccgagtcggcagccgtggtggcggcggccgtggcgaccg   8695 
                     |||.||.||.||.||....|||||.||.|||||.||.||.||.||.||.| 
AbyB2_CodonOp   8646 cgatggtcgtccggaaagcgcagcagttgtggcagccgcagttgcaacag   8695 
 
AbyB2           8696 gagagccgcagatcgccgtccgcgagggacgcgggtacgtgccgcgcctg   8745 
                     |.||.||||||||.|||||.||.||.||.||.||.||.||.|||||.||| 
AbyB2_CodonOp   8696 gtgaaccgcagattgccgttcgtgaaggtcgtggttatgttccgcgtctg   8745 
 
AbyB2           8746 gcccgcgccgccgccaaccggggcctcgtcccgccgccgggcgcctggcg   8795 
                     ||.||.||.||.||.||.||.||.||.||.|||||.||.|||||.||||| 
AbyB2_CodonOp   8746 gcacgtgcggcagcaaatcgtggtctggttccgcctcctggcgcatggcg   8795 
 
AbyB2           8796 gctggaggcggccggcaccactgtggacgagctgcgcctgacggaggtga   8845 
                     .|||||.||.||.||||||||.||.||.||.|||||.|||||.||.||.| 
AbyB2_CodonOp   8796 tctggaagcagcaggcaccaccgttgatgaactgcgtctgaccgaagtta   8845 
 
AbyB2           8846 ccgaagcgccgctgccggccgggcacgtccgggtcgcggtacgcgcctgc   8895 
                     |||||||.||||||||.||.||.||.||.||.||.|||||.||.||.||. 
AbyB2_CodonOp   8846 ccgaagcaccgctgcctgcaggtcatgttcgtgttgcggttcgtgcatgt   8895 
 
AbyB2           8896 gggctgaacttccgcgacgtgctggccaccctgggcgtcgtaccccgcga   8945 
                     ||.|||||.||.||.||.||||||||.||||||||.||.||.||.||.|| 
AbyB2_CodonOp   8896 ggtctgaattttcgtgatgtgctggcaaccctgggtgttgtgcctcgtga   8945 
 
AbyB2           8946 cgccccgctgggcgcggagggtgcgggcgtggtggtcgaggtcggcgtcg   8995 
                     .||.||||||||.||.||.|||||.|||||.||.||.||.||.||.||.| 
AbyB2_CodonOp   8946 tgcaccgctgggtgccgaaggtgcaggcgttgttgtggaagttggtgttg   8995 
 
AbyB2           8996 gtgtcaccggcttcgcccccggtgaccgggtgtacggcttcctccagggc   9045 
                     ||||.|||||.||.||.||.|||||.||.||.||.||.||.||.|||||. 
AbyB2_CodonOp   8996 gtgttaccggttttgcacctggtgatcgtgtttatggttttctgcagggt   9045 
 
AbyB2           9046 gccatcggcccgcgcgccgtcgtggacgcgcggctgctcgcccacctgcc   9095 
                     ||.||.||.|||||.|||||.||.||.||.||.|||||.||.||.||||| 
AbyB2_CodonOp   9046 gcaattggtccgcgtgccgttgttgatgcccgtctgctggcacatctgcc   9095 
 
AbyB2           9096 cgccggatggtccttcgcgcaggcggccacagcgccggcggtctgcacca   9145 
                     .|||||.|||..|||.||.|||||.||.||.||.||.||.||.||.|||| 
AbyB2_CodonOp   9096 tgccggttggagctttgcccaggcagctaccgcaccagcagtttgtacca   9145 
 
AbyB2           9146 ccgcctactacgcgctggtcaccctggcggacctgcgccccggggagcgg   9195 
                     ||||.||.||.||.|||||.||||||||.||.|||||.||.||.||.||. 
AbyB2_CodonOp   9146 ccgcatattatgcactggttaccctggccgatctgcgtccaggtgaacgt   9195 
 
AbyB2           9196 gtgctgatccactccgccgccggcggggtcggtctggccgccgggcacct   9245 
                     ||.|||||.||...|||.|||||.||.||.||||||||.||.||.||.|| 
AbyB2_CodonOp   9196 gttctgattcatagcgcagccggtggtgttggtctggcagcaggtcatct   9245 
 




                     .||.||.||.|||||.||.||.||.||.|||||.||.||.|||||.||.| 
AbyB2_CodonOp   9246 ggcacgtcatctgggtgcagaagtttttggcaccgcaagtccggcaaaat   9295 
 
AbyB2           9296 gggcggcgctggacctggacgaggcgcacctggcgt-cgtcgcggaacac   9344 
                     ||||.||.|||||.|||||.||.||.||.|||||.. |..| ||.||.|| 
AbyB2_CodonOp   9296 gggcagcactggatctggatgaagcacatctggcaagcagc-cgtaatac   9344 
 
AbyB2           9345 cgacttcgccgaccggttcggcccggtcgacgtggtgctcaactcgctga   9394 
                     |||.||.||.||.||.||.||.|||||.||.||.||.||.||....|||| 
AbyB2_CodonOp   9345 cgattttgcagatcgttttggtccggttgatgttgttctgaatagcctga   9394 
 
AbyB2           9395 ccggggagttcatcgacgcgtccctgcgcctgctgggtccgggcggtcgg   9444 
                     ||||.||.||.||.||.||...||||||.|||||.|||||.||.|||||. 
AbyB2_CodonOp   9395 ccggtgaatttattgatgcaagcctgcgtctgcttggtcctggtggtcgt   9444 
 
AbyB2           9445 ttcgtggagatgggtgtggcggacctgcggtcgtc-cgagcagatgccca   9493 
                     ||.||.||.||||||||.||.||.|||| ||.|.. ||||||||||||.| 
AbyB2_CodonOp   9445 tttgttgaaatgggtgttgccgatctgc-gtagcagcgagcagatgccga   9493 
 
AbyB2           9494 ccggcgtcgactaccacgcgttcgagctgctcgacctggcccccgcgcgg   9543 
                     ||||.||.||.||.||.||.||.||.|||||.||||||||.||.||.||. 
AbyB2_CodonOp   9494 ccggtgttgattatcatgcatttgaactgctggacctggcaccggcacgt   9543 
 
AbyB2           9544 gtgggcgagctgttcgccgaggtggtccggctgatcgaccagggggtctt   9593 
                     ||.||.||.|||||.|||||.||.||.||.|||||.||.|||||.||.|| 
AbyB2_CodonOp   9544 gttggtgaactgtttgccgaagttgttcgtctgattgatcagggtgtttt   9593 
 
AbyB2           9594 tccgccgctgccggtcaccgcctgggacgtccggcgggcgccggaggcgc   9643 
                     ||||||.||||||||.|||||.|||||.||.||.||.||.|||||.||.| 
AbyB2_CodonOp   9594 tccgcctctgccggttaccgcatgggatgttcgtcgtgcaccggaagcac   9643 
 
AbyB2           9644 tgcgctacttcagccaggcccggcagatcggcaagatcgccctgaccgcc   9693 
                     ||||.||.||....|||||.||.|||||.||.||.||.||.||||||||. 
AbyB2_CodonOp   9644 tgcgttatttttctcaggcacgtcagattggtaaaattgcactgaccgca   9693 
 
AbyB2           9694 ccggtcccgctcgacccgaacggcacggtcctggtcaccggcggcacggg   9743 
                     |||||.|||||.||.|||||.|||||.||.|||||.|||||.||.||.|| 
AbyB2_CodonOp   9694 ccggttccgctggatccgaatggcaccgttctggttaccggtggtacagg   9743 
 
AbyB2           9744 cagcctcggcggcctcgtcgcccggcacctggcgcgcgcccacggggtac   9793 
                     .|||.|.||.||.||.||.||.||.||||||||.||.||.||.||.||.| 
AbyB2_CodonOp   9744 tagcttaggtggtctggttgcacgccacctggcacgtgcacatggtgttc   9793 
 
AbyB2           9794 gtcacctgctgctggtcagccggtccggtccggccgcgcccggcgcgacg   9843 
                     ||||.|||||||||||.|||||...|||||||||.||.||.||.||.||. 
AbyB2_CodonOp   9794 gtcatctgctgctggttagccgtagcggtccggcagcaccgggtgcaacc   9843 
 
AbyB2           9844 gagctggtcggtgagttgacctccctggacgtacgggtggacgtggtggc   9893 
                     ||.|||||.|||||..|||||..||||||.||.||.||.||.|||||.|| 
AbyB2_CodonOp   9844 gaactggtgggtgaactgaccagcctggatgtgcgtgttgatgtggttgc   9893 
 
AbyB2           9894 ggccgacctggccgaccgggcggcggtcgccggggtgttggcggcggtgc   9943 
                     .||.||.|||||.||.||.||.||.||.|||||.||..||||.||.||.| 
AbyB2_CodonOp   9894 agcagatctggcagatcgtgcagcagttgccggtgttctggcagccgttc   9943 
 
AbyB2           9944 cgccggagcacccgctcaccgccgtcgtgcacactgccggtgtcctggac   9993 
                     ||||.||.||.|||||.|||||.||.||.||.||.||.||.||.|||||. 
AbyB2_CodonOp   9944 cgcctgaacatccgctgaccgcagttgttcataccgcaggcgttctggat   9993 
 
AbyB2           9994 gacggcgtcctggagtcgttgaccccgcagaagatcgcccgggtgctcgc  10043 
                     ||.||.||.|||||.....||||.||||||||.||.|||||.|||||.|| 
AbyB2_CodonOp   9994 gatggtgtgctggaaagcctgacaccgcagaaaattgcccgtgtgctggc  10043 
 
AbyB2          10044 accgaaggtagacgccgcgtggcacctgcacgagctgacccgggacctgg  10093 
                     ||||||.||.||.||.||.|||||.||||||||.||||||||.||.|||| 
AbyB2_CodonOp  10044 accgaaagttgatgcagcatggcatctgcacgaactgacccgtgatctgg  10093 
 




                     |.|||...||.||.||||||||...|...||....||||||.|.||.||| 
AbyB2_CodonOp  10094 atctgagcgcatttctgctgtttagcagcgcaagcggtctgttaggtggt  10143 
 
AbyB2          10144 gcggggcaggccaactacgcggcggccaatgcgttcctggacgcgctggc  10193 
                     ||.||.|||||.||.||.||.||.||.|||||.||.|||||.||.||||| 
AbyB2_CodonOp  10144 gcaggtcaggcaaattatgcagcagcaaatgcctttctggatgcactggc  10193 
 
AbyB2          10194 cacggcgcggcgccgcgccggcctgcccgccgtgtcgctggcctggggca  10243 
                     .||.||.||.||.||.|||||.|||||.||.||....|||||.|||||.| 
AbyB2_CodonOp  10194 aaccgcacgtcgtcgtgccggtctgcctgcagttagcctggcatggggta  10243 
 
AbyB2          10244 tgtgggcgcgggccaccggcctgaccgcccacctgggcggcacggacctg  10293 
                     |||||||.||.||.|||||.|||||.||.||..|.||.||.|||||.||| 
AbyB2_CodonOp  10244 tgtgggcacgtgcgaccggtctgacagcacatttaggtggtacggatctg  10293 
 
AbyB2          10294 ggccgcatcgaacgcggcggcctgctgccgatgaccgacgagcagggcct  10343 
                     ||.||.||.|||||.||.||.|||||||||||||||||.||.||.||.|| 
AbyB2_CodonOp  10294 ggtcgtattgaacgtggtggtctgctgccgatgaccgatgaacaaggtct  10343 
 
AbyB2          10344 ggctttgttcgacgccacctggacggccgaccgtccggtgctggtgccgg  10393 
                     |||..||||.||.|||||||||||.||.||.||||||||||||||.|||| 
AbyB2_CodonOp  10344 ggcactgtttgatgccacctggaccgcagatcgtccggtgctggttccgg  10393 
 
AbyB2          10394 cgccgctgcgcctggaccggggccgcaccggatccggtgtggtgccggcc  10443 
                     |.||||||||.|||||.||.||.||.|||||...||||||.||.|||||. 
AbyB2_CodonOp  10394 caccgctgcgtctggatcgtggtcgtaccggtagcggtgttgttccggca  10443 
 
AbyB2          10444 gtgctgcgcgcgctggtgcggccggtgcgccgggtggcccgctcggcggg  10493 
                     ||.|||||.||.|||||.||.|||||.||.||.||.||.||....||.|| 
AbyB2_CodonOp  10444 gttctgcgtgcactggttcgtccggttcgtcgcgttgcacgtagcgcagg  10493 
 
AbyB2          10494 gacggcgtcgccggactcgctgcgcgagcggctgctgccgctgtccccga  10543 
                     .||.||.||.|||||....|||||.|||||.||||||||||||..||||| 
AbyB2_CodonOp  10494 caccgcatcaccggatagtctgcgtgagcgcctgctgccgctgagcccga  10543 
 
AbyB2          10544 cggagcgcacggccctgctggtggacctggtccgtacacaggtcgcggcg  10593 
                     |.||.||.||.||.||||||||.||.|||||.|||||.|||||.||.||. 
AbyB2_CodonOp  10544 ccgaacgtaccgcactgctggttgatctggttcgtacccaggttgccgca  10593 
 
AbyB2          10594 gtcctgggccacaccgacaccgacgccgtggtggtggaccgggcgttcaa  10643 
                     ||.|||||.||.|||||.|||||.||.||.||.||.||.||.||.||.|| 
AbyB2_CodonOp  10594 gttctgggtcataccgataccgatgcagttgttgttgatcgtgcatttaa  10643 
 
AbyB2          10644 ggacagcggtttcgactcgttgacggcggtggagctgcgcaaccgggtgt  10693 
                     .||.||||||||.||.||..||||.||.||.||.|||||.||.||.||.. 
AbyB2_CodonOp  10644 agatagcggttttgattcactgacagcagttgaactgcgtaatcgtgtta  10693 
 
AbyB2          10694 cccgcgccaccgggctgcggctgccacccaccgtggtgttcgaccgcccc  10743 
                     .|||.||.||.||.|||||.|||||.||.|||||.|||||.||.||.||. 
AbyB2_CodonOp  10694 gccgtgcaacaggtctgcgcctgcctccgaccgttgtgtttgatcgtccg  10743 
 
AbyB2          10744 acgccggcggagttggccgcgcaccttctcgaccagctcgtgccgcctgc  10793 
                     ||.|||||.||..||||.||.||.||.||.||.|||||.||.||.||.|| 
AbyB2_CodonOp  10744 acaccggcagaactggcagcccatctgctggatcagctggttcctccggc  10793 
 
AbyB2          10794 cgacgggccggccggcgcggcgacgcccgcccgcaagacccgaaagcaac  10843 
                     .||.||.||.|||||.||.||.||.||.||.||.||.|||||.||.||.| 
AbyB2_CodonOp  10794 agatggtcctgccggtgcagcaactccggcacgtaaaacccgtaaacagc  10843 
 
AbyB2          10844 tcgactcggccacggtcgaggagatcttcgacttgatcgactcccagctc  10893 
                     |.||....||.||.||.||.||.||.||.||..|||||||...||||.|. 
AbyB2_CodonOp  10844 tggatagcgcaaccgttgaagaaatttttgatctgatcgatagccagtta  10893 
 
AbyB2          10894 ggccgggggtctcgcagcgactatcaggaggtcgacgccgggtga  10938 
                     ||.||.||....||.||.||.|||||.||.||.|||||.||.|.| 





A.2.2  AbyB2 Amino Acid Sequence 
       1 MTTPSKGTDS IADQQKLREY LRRVTDDLLR TRRRLTEVES ADREPVAIVS MACRFPGGVA  
      61 SPEDLWQLVA SGTDAISGFP DDRGWPLDEL YDPDPEHPGT STTRQGGFLH DAADFDPEFF  
     121 GISPREALTI DPQQRLLLET AWEAVERAGI APDSLRGSRT GVFAGVMYGD YGARLRPIPA  
     181 GFEGYMGTGS AGSVATGRIA YTLGLEGPAV SVDTACSSSL VALHLAAQAL RRGECDLALA  
     241 GGVTVIATPE LFVEFSRQRG LSPDGRCKAF AASADGTGWA EGVGLVLVER LADARRNGHP  
     301 VLALLRGSAV NQDGRSSQLS APNGPAQRRV IRAALASAGL EPAEVDLVEA HGTGTRLGDP  
     361 IEAQALLAEY GQGRTEPLWL GSLKSNIGHT QAAAGVGGVI KVVQAMRHGL LPATLHADEA  
     421 TPHVDWSVGD VRLLTEARDW PARERPRRAA VSSFGISGTN AHVILEEGDP DGVADAPPDD  
     481 VLARKPVPVV LSAHTASALG PQAARLRAHL DAHPDLTVAD VAHSLATTRT PLAERAVLVA  
     541 ADLDELRTAL DAVADGDEPP VRGTAGHPGG VVFVFPGQGA QWAGMALDLY REDEVFRAAL  
     601 DDCERALAPH VDWSLRAVLA DADALGRVDV VQPALWAVMV SLAALWQHHG VTPDAVVGHS  
     661 QGEIAAACVA GALSLEQAAA VVALRARAIT AVAGRGAMAS VSVPAQQITE RWGDRITVAV  
     721 TNSADATVVA GEPEAVAEVV AAYDAEGVRA RVLPVDYASH SAHVEPVREP ILDALRDLTP  
     781 TEARVPFHST VTGAEFDTRG LTADYWYTNL RSTVRFDQAV TRLREQGHRI FVEISPHPVL  
     841 TPVLGEGAFG TLRRDEGDRR RFITSLGAVH AVGVPVDWSA AIGPARRVPL PTYAFQRSRY  
     901 WLDAPARTGD ASGVGVGPTD HPLLGGAVDV AGDGTLVLTG RLVPGADRAA AELRVGGVPV  
     961 LSGTALLDLA LRAGELAGLG AVGEFSVETP LVLSATAGWL QVVVAPAGAD GDREIGVYAR  
    1021 PDHEAPWTRH GHGVLVPATA QDLPPHRPVP GAPLAPDEAV ERLAAAGVEL ASAPTAVSGD  
    1081 ADGYVADLAS PPEGRFTLHP ALLDAALLPA FGRGDARLPS RWRGVRLPQP DGQPTRASVR  
    1141 RRDGDSWAVS LTDSAGAPVV EIAEVVLGPV PVVSAAGHHD PLFTLEWAPV ARPRGAAATE  
    1201 PVPHELPGDA GPAALAVLRG GLAEPDGPRQ VVVARGAGTV TGLVRCAQLE EPGRVGLVEW  
    1261 DGRDADALRD AVAAGLPQVA VHGAELRTPR LAPLTAPGRP VELDGTALIV GEAGALRDAV  
    1321 LRTLARHGVD RLVVVDVDGT APADVGVPTE VLTGDPTDRA VLAEAVHRAA NLRTVVHAVQ  
    1381 PTADAPLAAL SPEDLTALVE RIVAPARHLH ELTAHLPLTR FVLSGSAAGV LGGIGQAAVA  
    1441 AATTGLGALA ARRRADGLPA QVVAWGPSAG TRRLGLVSLD DARLAALFAQ VLAHDVDVVA  
    1501 APLVRAGLRG QARAGTLPVA LRALVPALPG GATGLAARLA GASPAEGRRL LLDTIRTHVA  
    1561 GVLGHDDASG IDERRAFKDL GFDSLTAIEL RNRLNTALGR TLPATLIFDH PSPGALAEHL  
    1621 RDDLLGRAAV AAAPVAVASD EPIAIVAMGC RYPGGIADPE ALWQAVVSEL DAVGPFPTDR  
    1681 GWPADLYDPD PEATGRTYAR EGGFLYDAAG FDPEFFGISP REATGMDPQQ RLLLQTGWEV  
    1741 FERAGIDPTA LRGSRTGVFA GVVYTDYGSR ADPIPADLEG YLGIGSAGSI ASGRIAYTLG  




    1861 SRCKAFAAAA DGTAFAEGVG LLLVQRLADA RRDGRPVLAV IRGTAINQDG ASNGLTAPNG  
    1921 PSQQRVILGA LADAGLRPSD VDVVEAHGTG TTLGDPIEAQ AIIATYGQGR DEPLLLGSLK  
    1981 SNIGHTQAAA GVGGVIKMVA AMRHGLVPRT LHVDEPTPHV DWSAGAVRLV TEARPWPESN  
    2041 RPRRAGVSSF GMSGTNAHVV VEQGDPLEVP PVRAGRLVPV PVSAANPAAL RRQAARLLPA  
    2101 VADRHPADVA RTLAARTSLA TRAVVLADDA DELAEGLRAL DDATFTGPVG DADEPGKVVF  
    2161 VFPGQGGQWT GMALDLYRDE PTFRESLDAC AAALAPHVDW ALLDVLADEE ALRRVDVVQP  
    2221 ALWAVMVSVA RLWQHHGVTP DAVVGHSQGE IAAAHVAGAL SLADAAAVVA LRARAITAIA  
    2281 GTGGMASVAL GVGEVTRRWG HTVAVAATNG PDTAVIAGDP GVLDHIAATC AAEEVRVKIL  
    2341 PVDYASHSAH VEALREELLA ALETVQPRAA EIAFCSTVTA EALDTTTLTA DYWYTNLRST  
    2401 VRYDETVRRL HAEGHRTFLE MSPHPVLTTV TEQVTGAVAL GTLRRDEGDR RRFLTALAEA  
    2461 YVTGVAVDWR PAVGADARLV DLPTYAFASD RYWLDATTRP VDATGLGLAA TAHPLLGAAV  
    2521 DLADDEGVLL TGRLSLDSHP WLADHTVAGV PLLPGAAFVE LCAQAAEAAG AAGVAELTLE  
    2581 TPCVLPERGG VDVQVQVRDG GLRVYSRSVG DAWVRNASGV LLPTEPPAPA GWGAWPPPGA  
    2641 QAVDVEGLYP QLAASGYGYG PAFRGLRAAW RRGEEVFAEV RLPEGLEPEG YGLHPALLDA  
    2701 ALHALAFGDF LGAGVRLPFA FTGVRVFATG ADILRVRLSP RGEDTVAVAL ADSTGAPVAE  
    2761 IESLVLRAAP SLEATAPHAP DVLVLDWTPL ALPDTPVTEP DLLVVAPSDA HDPVAATGRL  
    2821 VTSTIAELAG RLADDRGAVV VTRDAVAVRP GDPAADLAHA ALWGLLRSAQ TENPDRFTLV  
    2881 DTDGRPESAA VVAAAVATGE PQIAVREGRG YVPRLARAAA NRGLVPPPGA WRLEAAGTTV  
    2941 DELRLTEVTE APLPAGHVRV AVRACGLNFR DVLATLGVVP RDAPLGAEGA GVVVEVGVGV  
    3001 TGFAPGDRVY GFLQGAIGPR AVVDARLLAH LPAGWSFAQA ATAPAVCTTA YYALVTLADL  
    3061 RPGERVLIHS AAGGVGLAAG HLARHLGAEV FGTASPAKWA ALDLDEAHLA SSRNTDFADR  
    3121 FGPVDVVLNS LTGEFIDASL RLLGPGGRFV EMGVADLRSS EQMPTGVDYH AFELLDLAPA  
    3181 RVGELFAEVV RLIDQGVFPP LPVTAWDVRR APEALRYFSQ ARQIGKIALT APVPLDPNGT  
    3241 VLVTGGTGSL GGLVARHLAR AHGVRHLLLV SRSGPAAPGA TELVGELTSL DVRVDVVAAD  
    3301 LADRAAVAGV LAAVPPEHPL TAVVHTAGVL DDGVLESLTP QKIARVLAPK VDAAWHLHEL  
    3361 TRDLDLSAFL LFSSASGLLG GAGQANYAAA NAFLDALATA RRRAGLPAVS LAWGMWARAT  
    3421 GLTAHLGGTD LGRIERGGLL PMTDEQGLAL FDATWTADRP VLVPAPLRLD RGRTGSGVVP  
    3481 AVLRALVRPV RRVARSAGTA SPDSLRERLL PLSPTERTAL LVDLVRTQVA AVLGHTDTDA  
    3541 VVVDRAFKDS GFDSLTAVEL RNRVSRATGL RLPPTVVFDR PTPAELAAHL LDQLVPPADG  





A.2.3  AbyB3 Amino Acid Sequence 
       1 MSETREEKLV EYLKWVTGEL QETKAQLARA RAEREPIAIV SAACRLPGDV HSPEDLWRVV  
      61 VDGVDAIGDV PTDRGWAVHE VYADAPAHRP LGGFLSDAAG FDAAFFGIGP HEATAMDPQH  
     121 RLLLESSWEA VERAGIDPTT LRGSATGVYA GLVSQNYAAY GTPPELNGHL MTGTATSVAS  
     181 GRIAYLLGLR GPAVTLDTAC SSSLVALHLA AQALRRGECD LALAGGATVM ATPALLAEFV  
     241 TQGGLSPDAR CKAFAAAADG TGFAEGVGVL VLERLADARR HHRRVLAVLR GSAVNQDGAS  
     301 NGLTAPSGPA QEEVIRAALA DAGLRPSDVD HVEAHGTGTR LGDPIEAAAL LATYGQDRAE  
     361 PLWLGSVKSN IGHTQTAAGV AGVIKVIEAL RHERLPRTLH VDEPTPHVDW AAGKVRLLTE  
     421 EQPWPRGKRR RVAGVSSFGI SGTNAHVLIE EGDPEPPPTP PTPSAHPVAW LLGAKTDSAL  
     481 RAQAARLRQR FAVASHDPLD VAVALATTRT AFDRRAAVVA ADHDGLLRGL DALAAGETTP  
     541 GRAVRGPTAF LFSGQGSQRV GMGTELRRVF PAFRDAWREV ADEVDRHLDQ PLDRVLADED  
     601 LLLRTEYAQP ALFTLEVALV RLLGGWGLRP DLLLGHSLGE LVAAHVAGVL DLPDAVALVA  
     661 ARGAAMQAAP AEGAMVAIRA AADEVRASLA GREHEVSVAA VNGPRSTVVS GDAGAVQEVA  
     721 AHWAATGHRT SRLRVSHAFH SPHLDGVLDG FRAVAAGVRH HPPSIPVVSN LTGTVVEAFT  
     781 AEHWVRHVRQ EVRFAAGVSA LTSAGVRRFV EVGPDAVLAA LAGENAPGTP VVATLRRDES  
     841 EALTVVRALA ASHVTGARVD WRAFHDERTA AVPLPTYPFE HRRYWVSPPT GPAPTAPPPV  
     901 ADEPPRESTP HEERLLDLVR THAAAVLGHD TPESVGPDDN FVEIGLSSFT ALEVRNRLCE  
     961 GTGLELSPLA LFEHPTPAAL AEHLRAVRAA RT  
 
A.2.4  AbyB3DACP Amino Acid Sequence 
       1 VSETREEKLV EYLKWVTGEL QETKAQLARA RAEREPIAIV SAACRLPGDV HSPEDLWRVV  
      61 VDGVDAIGDV PTDRGWAVHE VYADAPAHRP LGGFLSDAAG FDAAFFGIGP HEATAMDPQH  
     121 RLLLESSWEA VERAGIDPTT LRGSATGVYA GLVSQNYAAY GTPPELNGHL MTGTATSVAS  
     181 GRIAYLLGLR GPAVTLDTAC SSSLVALHLA AQALRRGECD LALAGGATVM ATPALLAEFV  
     241 TQGGLSPDAR CKAFAAAADG TGFAEGVGVL VLERLADARR HHRRVLAVLR GSAVNQDGAS  
     301 NGLTAPSGPA QEEVIRAALA DAGLRPSDVD HVEAHGTGTR LGDPIEAAAL LATYGQDRAE  
     361 PLWLGSVKSN IGHTQTAAGV AGVIKVIEAL RHERLPRTLH VDEPTPHVDW AAGKVRLLTE  
     421 EQPWPRGKRR RVAGVSSFGI SGTNAHVLIE EGDPEPPPTP PTPSAHPVAW LLGAKTDSAL  
     481 RAQAARLRQR FAVASHDPLD VAVALATTRT AFDRRAAVVA ADHDGLLRGL DALAAGETTP  
     541 GRAVRGPTAF LFSGQGSQRV GMGTELRRVF PAFRDAWREV ADEVDRHLDQ PLDRVLADED  
     601 LLLRTEYAQP ALFTLEVALV RLLGGWGLRP DLLLGHSLGE LVAAHVAGVL DLPDAVALVA  




     721 AHWAATGHRT SRLRVSHAFH SPHLDGVLDG FRAVAAGVRH HPPSIPVVSN LTGTVVEAFT  
     781 AEHWVRHVRQ EVRFAAGVSA LTSAGVRRFV EVGPDAVLAA LAGENAPGTP VVATLRRDES  
     841 EALTVVRALA ASHVTGARVD WRAFHDERTA AVPLPTYPFE HRRYWVSPPT GPAPTAPPPV  
     901 ADEPPRESTP HE 
 
A.2.5  AbyU Amino Acid Sequence 
              1 MTERLETRPQ ALLIKVPTEI VVKVVDDVDV AAPAVGQVGK FDDELYDEAG AQIGTSSGNF  
      61 RIEYVRPTDG GLLTYYQEDI TLSDGVIHAE GWADFNDVRT SKWVFYPATG VSGRYLGLTG  
     121 FRQWRMTGVR KSAEARILLG E  
 
A.3 Sequence Alignment of mPKS KS-AT Didomains 
AbyB3DACP was aligned with the sequences of both didomains solved by x-ray crystallog-
raphy from the DEBS polyketide synthases. A high level of sequence identity is observed, with 
AbyB3DACP displaying 48 % sequence identity to each of DEBS M3 and M5, which, in turn, 
display 57 % sequence identity to each other.  
Small hydrophobic residues are coloured red, acidic residues coloured blue, basic amino 
acids are coloured in magenta and hydroxly, sulfhydryl, and amine residues are coloured green. 
The KS active site cysteine and the AT active site serine residues are highlighted in yellow. 
 
AbyB3DACP       ---VSETREEKLVEYLKWVTGELQETKAQLA-RARAEREPIAIVSAACRLPGDVHSPEDL 56 
DEBS_M3         ---------------------------------MELESDPIAIVSMACRLPGGVNTPQRL 27 
DEBS_M5         MSGDNGMTEEKLRRYLKRTVTELDSVTARLREVEHRAGEPIAIVGMACRFPGDVDSPESF 60 
                                                  .   :*****. ***:**.*.:*: : 
 
AbyB3DACP       WRVVVDGVDAIGDVPTDRGWAVHEVYADAPA-----HRPLGGFLSDAAGFDAAFFGIGPH 111 
DEBS_M3         WELLREGGETLSGFPTDRGWDLARLHHPDPDNPGTSYVDKGGFLDDAAGFDAEFFGVSPR 87 
DEBS_M5         WEFVSGGGDAIAEAPADRGWEP------DPD------ARLGGMLAAAGDFDAGFFGISPR 108 





AbyB3DACP       EATAMDPQHRLLLESSWEAVERAGIDPTTLRGSATGVYAGLVSQNYAAYG--TPPELNGH 169 
DEBS_M3         EAAAMDPQQRLLLETSWELVENAGIDPHSLRGTATGVFLGVAKFGYGEDTA-AAEDVEGY 146 
DEBS_M5         EALAMDPQQRIMLEISWEALERAGHDPVSLRGSATGVFTGVGTVDYGPRPDEAPDEVLGY 168 
                ** *****:*::** *** :*.** ** :***:****: *: . .*.     :  :: *: 
 
AbyB3DACP       LMTGTATSVASGRIAYLLGLRGPAVTLDTACSSSLVALHLAAQALRRGECDLALAGGATV 229 
DEBS_M3         SVTGVAPAVASGRISYTMGLEGPSISVDTACSSSLVALHLAVESLRKGESSMAVVGGAAV 206 
DEBS_M5         VGTGTASSVASGRVAYCLGLEGPAMTVDTACSSGLTALHLAMESLRRDECGLALAGGVTV 228 
                  **.* :*****::* :**.**::::******.*.***** ::**:.*..:*:.**.:* 
 
AbyB3DACP       MATPALLAEFVTQGGLSPDARCKAFAAAADGTGFAEGVGVLVLERLADARRHHRRVLAVL 289 
DEBS_M3         MATPGVFVDFSRQRALAADGRSKAFGAGADGFGFSEGVTLVLLERLSEARRNGHEVLAVV 266 
DEBS_M5         MSSPGAFTEFRSQGGLAADGRCKPFSKAADGFGLAEGAGVLVLQRLSAARREGRPVLAVL 288 
                *::*. :.:*  * .*: *.*.* *. .*** *::**. :::*:**: ***. : ****: 
 
AbyB3DACP       RGSAVNQDGASNGLTAPSGPAQEEVIRAALADAGLRPSDVDHVEAHGTGTRLGDPIEAAA 349 
DEBS_M3         RGSALNQDGASNGLSAPSGPAQRRVIRQALESCGLEPGDVDAVEAHGTGTALGDPIEANA 326 
DEBS_M5         RGSAVNQDGASNGLTAPSGPAQQRVIRRALENAGVRAGDVDYVEAHGTGTRLGDPIEVHA 348 
                ****:*********:*******..*** ** ..*:. .*** ******** ******. * 
 
AbyB3DACP       LLATYGQDR--AEPLWLGSVKSNIGHTQTAAGVAGVIKVIEALRHERLPRTLHVDEPTPH 407 
DEBS_M3         LLDTYGRDRDADRPLWLGSVKSNIGHTQAAAGVTGLLKVVLALRNGELPATLHVEEPTPH 386 
DEBS_M5         LLSTYGAERDPDDPLWIGSVKSNIGHTQAAAGVAGVMKAVLALRHGEMPRTLHFDEPSPQ 408 
                ** *** :*    ***:***********:****:*::*.: ***: .:* ***.:**:*: 
 
AbyB3DACP       VDWAAGKVRLLTEEQPWPRGKRRRVAGVSSFGISGTNAHVLIEEGDPEPPPTPPTPSAHP 467 
DEBS_M3         VDWSSGGVALLAGNQPWRRGERTRRAAVSAFGISGTNAHVIVEEAPEREHRETTAHDGRP 446 




                ::*  * * :::  : *  *:* * *.**:**********::**.         : .. * 
 
AbyB3DACP       VAWLLGAKTDSALRAQAARLRQRFAVA-SHDPLDVAVALATTRTAFDRRAAVVAADHDGL 526 
DEBS_M3         VPLVVSARSTAALRAQAAQIAELLE-RPDADLAGVGLGLATTRARHEHRAAVVASTREEA 505 
DEBS_M5         VPLVLSGRDEQAMRAQAGRLADHLAREPRNSLRDTGFTLATRRSAWEHRAVVV-GDRDEA 526 
                *  ::..:   *:****.:: : :      .  .... *** *:  ::**.** . ::   
 
AbyB3DACP       LRGLDALAAGETTPGRAVR-------GPTAFLFSGQGSQRVGMGTELRRVFPAFRDAWRE 579 
DEBS_M3         VRGLREIAAGAATADAVVEGVTEVDGRNVVFLFPGQGSQWAGMGAELLSSSPVFAGKIRA 565 
DEBS_M5         LAGLRAVADGRIADRTATG--QARTRRGVAMVFPGQGAQWQGMARDLLRESQVFADSIRD 584 
                : **  :* *  :   ..          ..::* ***:*  **. :*     .* .  *  
 
AbyB3DACP       VADEVDRHLDQPLDRVLA---DEDLLLRTEYAQPALFTLEVALVRLLGGWGLRPDLLLGH 636 
DEBS_M3         CDESMAPMQDWKVSDVLRQAPGAPGLDRVDVVQPVLFAVMVSLAELWRSYGVEPAAVVGH 625 
DEBS_M5         CERALAPHVDWSLTDLLS---GARPLDRVDVVQPALFAVMVSLAALWRSHGVEPAAVVGH 641 
                    :    *  :  :*    .   * *.: .**.**:: *:*. *  . *:.*  ::** 
 
AbyB3DACP       SLGELVAAHVAGVLDLPDAVALVAARGAAMQAAPAEGAMVAIRAAADEVRASLAGREHEV 696 
DEBS_M3         SQGEIAAAHVAGALTLEDAAKLVVGRSRLMRSLSGEGGMAAVALGEAAVRERLRPWQDRL 685 
DEBS_M5         SQGEIAAAHVAGALTLEDAAKLVAVRSRVLRRLGGQGGMASFGLGTEQAAERIGRFAGAL 701 
                * **:.******.* * **. **. *.  ::   .:*.*.:.  .   .   :      : 
 
AbyB3DACP       SVAAVNGPRSTVVSGDAGAVQEVAAHWAATGHRTSRLRVSHAFHSPHLDGVLDGFRAVAA 756 
DEBS_M3         SVAAVNGPRSVVVSGEPGALRAFSEDCAAEGIRVRDIDVDYASHSPQIERVREELLETTG 745 
DEBS_M5         SIASVNGPRSVVVAGESGPLDELIAECEAEAHKARRIPVDYASHSPQVESLREELLTELA 761 
                *:*:******.**:*: * :  .  .  * . :.  : *.:* ***::: : : :    . 
 




DEBS_M3         DIAPRPARVTFHSTVESRSMDGTELDARYWYRNLRETVRFADAVTRLAESGYDAFIEVSP 805 
DEBS_M5         GISPVSADVALYSTTTGQPIDTATMDTAYWYANLREQVRFQDATRQLAEAGFDAFVEVSP 821 
                .:      : . *.  .  ::   : : :*  ::*: ***  ..  *:.:*   *:**.* 
 
AbyB3DACP       DAVLAALAGE-------NAPGTPVVATLRRDESEALTVVRALAASHVTGARVDWRAFHDE 867 
DEBS_M3         HPVVVQAVEEAVEEADG-AEDAVVVGSLHRDGGDLSAFLRSMATAHVSGVDIRWDVALPG 864 
DEBS_M5         HPVLTVGIEATLDSALPADAGACVVGTLRRDRGGLADFHTALGEAYAQGVEVDWSPAFAD 881 
                . *:.               .: **.:*:** .    .  ::. ::. *. : *       
 
AbyB3DACP       RTAAVPLPTYPFEHRRYWVSPPTGPAPTAPPPVADEPPRESTPHE- 912 
DEBS_M3         -AAPFALPTYPFQRKRYWLQPAAPAAASD------ELAYRSSSVDK 903 
DEBS_M5         -ARPVELPVYPFQRQRYWLPIPTGGRARDEDD---DWRYQ------ 917 
                 :  . **.***:::***:   :            :   .       
 
